IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

Abstract: Corticotropin releasing factor (CRF) antagonists of formula (I) and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.

Description: TITLE IMIDAZOPYRIMIDINES AND IMIDAZOPYRIDINES FOR THE TREATMENT. OF NEUROLOGICAL DISORDERS FTFT.D OF THE TNVF.NTTON The present invention relates to novel compounds, compositions, and methods for the treatment of psychiatric disorders and neurological diseases, including major depression, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders, as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress. In particular, the present invention relates to novel imidazopyrimidines and imidazopyridines, pharmaceutical compositions containing such compounds and their use in treating psychiatric disorders, neurological diseases, immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress. BACKGROUND OF THE INVENTION Corticotropin releasing factor (herein referred to as CRF) , a 41 amino acid peptide, is the primary physiological regulator of proopiomelanocortin (POMC) -derived peptide secretion from the anterior pituitary gland [J. Rivier et al., Proc. Nat . Acad. Sci . (USA) 80:4851 (1983); W. Vale et al., Science 213:1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in brain [W. Vale et al., Rec. Prog. Horm. Res . 39:245 (1983); G.F. Koob, Persp. Behav. Med. 2:39 (1985); E.B. De Souza et al., J. Neurosci . 5:3189 (1985)]. There is also evidence that CRF plays a significant role in integrating the response of the immune system to physiological, psychological, and immunological stressors [J.E. Blalock, Physiological Reviews 69^1 (1989); J.E. Morley, Life Sci . 41:527 (1987)]. Clinical data provide evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis as they relate to the dysfunction of CRF neurons in the central nervous system [for review see E.B. De Souza, Hosp. Practice 23:59 (1988)]. In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals [CB. Nemeroff et al., Science 226:1342 (1984); CM. Banki et al., Am. J. Psychiatry 144:873 (1987); R.D. France et al., Biol . Psychiatry 28:86 (1988); M. Arato et al., Biol Psychiatry 25:355 (1989)]. Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF [CB. Nemeroff et al., Arch. Gen . Psychiatry 45:577 (1988)]. In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients [P.W. Gold et al., Am J. Psychiatry 141:619 (1984); F. Holsboer et al., Psychoneuroendocrinology 9:147 (1984); P.W. Gold et al., New Eng. J. Med. 314:1129 (1986)]. Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen in human depression [R.M. Sapolsky, Arch. Gen. Psychiatry 46:1047 (1989)]. There is preliminary- evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of CRF receptors in brain [Grigoriadis et al., Neuropsychopharmacology 2:53 (1989) ] . It has also been postulated that CRF has a role in the etiology of anxiety-related disorders. CRF produces anxiogenic effects in animals and interactions between benzodiazepine / non-benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models [D.R. Britton et al., Life Sci . 31:363 (1982); C.W. Berridge and A.J. Dunn Regul . Peptides 16:83 (1986)]. Preliminary studies using the putative CRF receptor antagonist a-helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrate that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines [C.W. Berridge and A.J. Dunn Horm. Behav. 21:393 (1987), Brain Research Reviews 15:71 (1990) ] . Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics, providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF in both the conflict test [K.T. Britton et al., Psychopharmacology 86:170 (1985); K.T. Britton et al . , Psychopharmacology 94:306 (1988)] and in the acoustic startle test [N.R. Swerdlow et al., Psychopharmacology 88:147 (1986)] in rats. The benzodiazepine receptor antagonist (Rol5-1788), which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose- dependent manner while the benzodiazepine inverse agonist (FG7142) enhanced the actions of CRF [K.T. Britton et al., Psychopharmacol ogy 94:306 (1988)]. It has been further postulated that CRF has a role in immunological, cardiovascular or heart-related diseases such as hypertension, tachycardia and congestive heart failure, stroke, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus and colonic hypersensitivity associated with psychopathological disturbance and stress. The mechanisms and sites of action through which the standard anxiolytics and antidepressants produce their therapeutic effects remain to be elucidated. It has been hypothesized however, that they are involved in the suppression of the CRF hypersecretion that is observed in these disorders. Of particular interest is that preliminary studies examining the effects of a CRF receptor antagonist (a -helical CRF9-41) in a variety of behavioral paradigms have demonstrated that the CRF antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines [for review see G.F. Koob and K.T. Britton, In: Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide, E.B. De Souza and CB. Nemeroff eds., CRC Press p221 (1990)]. DuPont Merck PCT application US94/11050 describes corticotropin releasing factor antagonist compounds of the formula: and their use to treat psychiatric disorders and neurological diseases. Included in the description are fused pyridines and pyrimidines of the formula: where : V is CR la or N; Z is CR 2 or N; A is CR 3 0 or N; and D is CR 28 or N. Other compounds reported to have activity as corticotropin releasing factors are disclosed in WO 95/33750, WO 95/34563 and WO 95/33727. SUMMARY OF THE INVENTION In accordance with one aspect, the present invention provides novel compounds which bind to corticotropin releasing factor receptors, thereby altering the anxiogenic effects of CRF secretion. The compounds of the present invention are useful for the treatment of psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals. According to another aspect, the present invention provides novel compounds of formula (I) (described below) which are useful as antagonists of the corticotropin releasing factor. The compounds of the present invention exhibit activity as corticotropin releasing factor antagonists and appear to suppress CRF hypersecretion. The present invention also includes pharmaceutical compositions containing such compounds of formula (I) , and methods of using such compounds for the suppression of CRF hypersecretion, and/or for the treatment of anxiogenic disorders . According to yet another aspect, the present invention provides novel compounds, pharmaceutical compositions and methods which may be used in the treatment of affective disorder, anxiety, depression, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal disease, anorexia nervosa or other feeding disorder, drug or alcohol withdrawal symptoms, drug addiction, inflammatory disorder, fertility problems, disorders, the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic, phobias, obsessive-compulsive disorder; post- traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer, human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases such as ulcers, irritable bowel syndrome, Crohn's disease, spastic colon, diarrhea, and post operative ilius and colonic hypersensitivity associated by psychopathological disturbances or stress; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH) ; obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g. , cerebral ischemia such as cerebral hippocampal ischemia) ; excitotoxic neuronal damage; epilepsy; cardiovascular and hear related disorders including hypertension, tachycardia and congestive heart failure; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g.. stress induced fevers, porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human- animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions (e.g. , dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs) ; drug and alcohol withdrawal- symptoms; osteoporosis; psychosocial dwarfism and hypoglycemia in mammals. According to a still further aspect of the invention, the compounds provided by this invention (and especially labelled compounds of this invention) are also useful as standards and reagents in determining the ability of a potential pharmaceutical to bind to the CRF receptor. DETAILED DESCRTPTTON OF INVENTION [1] Thus, in a first embodiment, the present invention provides a novel compound of formula I: (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; provided that at least one of the groups A and B is N; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0 , 1 or 2 ; R 1 is selected from the group Cι_ιo alkyl, C2-10 alkenyl, C2-10 alkynyl, C3_8 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C1-4 alkoxy-Cι-4 alkyl, -SO2-C1-10 alkyl, -S0 2 -R la , and -S0 2 -R lb ; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b / -COR 13a , -C0 2 R 13a , -NR 15a C0R 13a , -N(C0R 13 ) 2 / -NR 15a CONR 13 R 16a , -NR 15a C0 2 R 1 b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C3-8 cycloalkyl, wherein 0-1 carbon atoms in the C4-8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , C0R 14b and S0 2 R 1 b ; R 1 is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C1- 6 alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C1-4 haloalkyl, -OR 13a , -NR 13a R 16a , C1-4 alkoxy-Cι_ alkyl, and C3-8 cycloalkyl which is substituted with 0- 1 R 9 and in which 0-1 carbons of C4-8 cycloalkyl is replaced by -0-; provided that R 1 is other than: (a) a cyclohexyl- (CH 2 ) - group; (b) a 3-cyclopropyl-3-methoxypropyl group; (c) an unsubstituted- (alkoxy) methyl group; and, (d) a 1-hydroxyalkyl group; also provided that when R 1 alkyl substituted with OH, then the carbon adjacent to the ring N is other than CH 2 ; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 -6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17 R 19 ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl, benzoxazolyl , isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 -6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19 , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -C0NR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , C0R 14b and S0 2 R 14b ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C1- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C1-4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b / -C0R 13a , -OC(0)R 1 b , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13 R 16a , -NR 15 C0 2 R 14b , -NR 13a R 16a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R ,13a C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any sυ is optionally monooxidized or dioxidized; provided that R 1 is other than a - (CH ) 1 - 4 -aryl, - (CH 2 ) 1 - 4 -heteroaryl, or - (CH 2 ) 1 - 4 -heterocycle, wherein the aryl, heteroaryl, or heterocycle group is substituted or unsubstituted; R 2 is selected from the group C 1 - 4 alkyl, C 3 -. 8 cycloalkyl, C 2 _ 4 alkenyl, and C _ 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 F 5 ; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 -4 alkyl, C3-8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 -4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl ) amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C1-4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, C 1 - 4 alkylthio, C 1 -4 alkyl sulfinyl, C 1 -4 alkylsulfonyl, C 1 - 6 alkylamino and (C 1 - 4 alkyl) 2 amino; provided that when R 1 is unsubstituted Cι- 10 alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 -4 alkyl, C 3 _ 6 cycloalkyl-Cι- 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 -4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, aryl, aryl (C 1 - 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 -. 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cχ- 4 alkyl, C 3 - 6 cycloalkyl, C3- 6 cycloalkyl-Cι- 6 alkyl, aryl, aryl(Cι-4 alkyl)-, heteroaryl and heteroaryl (C 1 -. 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 14 is selected from the group C 1 - 4 alkyl, C 1 -4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C3-6 cycloalkyl-Cι- 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; p i4 b i s selected from the group C 1 - 4 alkyl, C 1 -. 4 haloalkyl, C 1 -4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, Cι_ 4 alkoxy, C1-. 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C1-4 alkyl, C 3 -7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 is selected at each occurrence from the group H, Ci-β alkyl, C3-10 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C 1 - 2 alkoxy-Cι_ 2 alkyl, C 1 - 4 haloalkyl, R 14 S (0) n -Cι- 4 alkyl, and R 17b R 19b N-C 2 - alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, Ci-β alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C1-4 haloalkyl; alternatively, in an NR 7 R 9 moiety, R and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; alternatively, in an NR 17b R 19b moiety, R 17b and R 19b taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-C1- 6 alkyl and C 1 -4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R lδ \ -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 C0R 17 , -N(C0R 17 ) 2 , -NR 15 C0NR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 and up to 1 phenyl, each phenyl substituent being, substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, Cι_ 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , S0Me and acetyl; heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl , benzothiazolyl , benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 / -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(C0R 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 14a , COR 14a and S0 2 R 14a ; and, provided that when D is imidazole or triazole, R 1 is other than unsubstituted Cι_ 6 linear or branched alkyl or C 3 - 6 cycloalkyl. [2] In a preferred embodiment, the present invention provides a novel compound of formula la: (la). [2a] In a more preferred embodiment, the present invention provides a novel compound of formula la, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, and C 3 - 8 cycloalkyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 1 b , -COR 13a , -C0 2 R 13a , and C 3 _ 8 cycloalkyl, wherein 0-1 carbon atoms in the C4_s cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NC0R 14b - and -NS0 2 R 14b -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C -β alkenyl, C 2- . 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -OR 13a , -NR 13a R 16a , C 1 - 2 alkoxy-Cι- 2 alkyl, and q C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C1-4 alkyl, C3-6 cycloalkyl, Br, Cl, F, C1-4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R 1 , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C1-4 alkyl, C3-6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group τ -,15a ^ - ^ π 14b ^1ΛT-1 14b -, _,._ τ- > 14b R , C0 R , COR and S0 2 R ; provided that R 1 is other than a - (CH 2 ) 1-4-aryl or - (CH 2 ) 1-4-heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group C1-4 alkyl, C 2 _4 alkenyl, and C 2 _4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C1-4 alkoxy; R 3 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, -CN, C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, NH 2 , C1-4 alkylamino, and (C1-4 alkyl) 2-amino; R 9 is independently selected at each occurrence from the group H, C1-4 alkyl and C3-8 cycloalkyl; R 13 is selected from the group Cι_4 alkyl, C1-2 haloalkyl, C1-2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι- 2 alkyl, aryl(Cι_ alkyl)-, and heteroaryl (C1-2 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C1-6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C1-2 alkoxy-Cι- 2 alkyl, C3-6 cycloalkyl-Cι_ alkyl, aryl (C 1 - 2 alkyl)-, and heteroaryl (Cι_ 2 alkyl)-; R 1 a is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C1- 2 alkoxy-Cι_ 2 alkyl, and C 3 -6 cycloalkyl-Cι_ alkyl; R 14b is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι- 2 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι- 2 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 -. 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C 1 - 4 haloalkyl, C 1 -4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 -6 cycloalkyl-Ci-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 -.1 0 cycloalkyl, C 3 _ 6 cycloalkyl-Cι-6 alkyl, Cι_ alkoxy-Cι_ 2 alkyl, and C 1 - 4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 17 and R 19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and SO 2 R 14 ; R 17a and R I9a are independently selected at each occurrence from the group H, Ci-β alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Ci_6 alkyl and C1-. 4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -NR 15 C0R 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 ; and, heteroaryl is independently selected at each occurence froirr the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl , benzoxazolyl, isoxazolyl, tetrazolyl, indazolyl, 2,3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι-6 alkyl, C3_e cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 C0R 17 , -N(C0R 17 ) 2 / -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 and each heteroaryl being substituted on any nitrogen atom 15 with 0-1 substituents selected from the group R , C0 2 R 14a , C0R 14a and S0 2 R 1 a . [2b] In an even more preferred embodiment, the present invention provides a novel compound of formula la, wherein: X is selected from the group 0, S and a bond; R 1 is substituted Cι- 6 alkyl; R is substituted with 0-1 substituents selected from the group -CN, -Cθ 2 R 13a , and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ and -NR 13a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, Br, Cl, F, CF 3 , -OR 13a , -NR 13a R 16a , C 1 - 2 alkoxy-Cι- 2 alkyl, and C 3 _ 6 cycloalkyl which is substituted with 0-1 CH 3 and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2- group; R la is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , 0CH(CH 3 ) 2 / OCH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2/ CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C ( 0 ) N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, i idazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , 0CH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0CH 3 ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 ) 1 - 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CHCH 3 , CH(CH 3 ) 2 , and CH2CH2CH3 ; R 3 and R 8 are independently selected at each occurrence from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CHCHCH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 )2/ -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 )2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and S0 2 CH 3 . [2c] In a still more preferred embodiment, the present invention provides a novel compound of formula la, wherein: R 1 is substituted Ci; R is substituted with 0-1 substituents selected from the group -CN, -C0 2 CH 3 , and -C0CH 2 CH 3 ; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , F, CF 3 , cyclopropyl, CH 3 -cyclopropyl, cyclobutyl, CH 3 - cyclobutyl, cyclopentyl, CH 3 -cyclopentyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 )ι-4-heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CHCH 3 , and CH(CH 3 ) ; R 3 and R 8 are independently selected at each occurrence from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH3, SO2CH3, -NH 2 , -NHCH3, -N(CH 3 ) 2 -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 . [2d] In a further preferred embodiment, the present invention provides a novel compound of formula la, wherein: R 1 is substituted (cyclopropyl) -Ci alkyl or (cyclobutyl) -Ci alkyl; R 1 is substituted with 0-1 -CN; R is also substituted with 0-1 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCHCH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, and pyrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [2e] In another further preferred embodiment, the present invention provides a novel compound of formula la, wherein: R 1 is (cyclopropyl )Cι alkyl or (cyclobutyl) -Ci alkyl substituted with 1 substituent independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , Cl, F, and CF 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, and isoxazolyl, each heteroaryl being substituted on 0-2 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , OCH 3 , Cl, F, and CF 3 . [2f] In an even further preferred embodiment, the present invention provides a novel compound of formula la, wherein: R 1 is selected from the group (cyclopropyl)CH-CH 3 , (cyclopropyl ) CH-CH 2 CH 3 , (cyclopropyl) CH-CH 2 OCH 3 , (cyclopropyl) CH-CH 2 CH 2 CH 3 , (cyclopropyl) CH-CH 2 CH 2 OCH 3 , (cyclopropyl ) 2 CH, phenyl (cyclopropyl)CH, furanyl (cyclopropyl) CH, thienyl (cyclopropyl) CH, isoxazolyl (cyclopropyl) CH, (CH 3 - furanyl) (cyclopropyl )CH, (cyclobutyl)CH-CH 3 , (cyclobutyl)CH-CH 2 CH 3 , ( cyclobutyl )CH-CH 2 OCH 3 , (cyclobutyl ) CH-CH 2 CH 2 CH 3 , (cyclobutyl ) CH-CH 2 CH 2 OCH 3 , (cyclobutyl ) 2 CH, phenyl (cyclobutyl ) CH, furanyl (cyclobutyl ) CH, thienyl (cyclobutyl) CH, isoxazolyl (cyclobutyl)CH, and (CH 3 - furanyl ) (cyclobutyl ) CH; [2g] In another further preferred embodiment, the present invention provides a novel compound of formula la, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [2h] In another further preferred embodiment, the present invention provides a novel compound of formula la, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [2i] In another preferred embodiment, the present invention provides a novel compound of formula la, wherein the compound is selected from the group: 3- (1-cyclopropylpropyl) -7- (2, 4-dichlorophenyl) -2-ethyl-3H- imidazo [4, 5-b] pyridine; 3- (l-cyclopropylpropyl)-7- (2, 4-dichlorophenyl) -2-methoxy-3H- imidazo[4, 5-b] pyridine; 3- (1-cyclopropylpropyl) -7- (2,4-dichlorophenyl) -2- (methylsulfanyl) -3H-imidazo[4, 5-b] pyridine; 7- [2-chloro-4- (trifluoromethyl) phenyl] -3- (1- cyclopropylpropyl ) -2-ethyl-3H-imidazo[4, 5-b] pyridine; 7- [2-chloro-4- (trifluoromethyl) phenyl] -3- (1- cyclopropylpropyl) -2-methoxy-3H-imidazo[4, 5-b] pyridine; 7- [2-chloro-4- (trifluoromethyl) phenyl] -3- (1- cyclopropylpropyl) -2- (methylsulfanyl) -3H-imidazo[4, 5- b] pyridine; 3- (1-cyclopropylpropyl) -2-ethyl-7- [2-methyl-4- (trifluoromethyl) phenyl] -3H-imidazo[4, 5-b] pyridine; 7- (2-chloro-4-methoxyphenyl) -3- (1-cyclopropylpropyl) -2-ethyl- 3H-imidazo[4, 5-b]pyridine; 7- (2-chloro-4-methoxyphenyl) -3- (1-cyclopropylpropyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 3- (1-cyclopropylpropyl) -2-ethyl-7- (4-methoxy-2,5- dimethylphenyl) -3H-imidazo[4, 5-b] pyridine; 3- (1-cyclopropylpropyl) -2-methoxy-7- (4-methoxy-2, 5- dimethylphenyl) -3H-imidazo [4, 5-b] pyridine; 7- (2-chloro-4-methoxyphenyl) -3- (1-cyclopropylpropyl) -2-ethyl- 3H-imidazo [4, 5-b] pyridine; 7- (2-chloro-4-methoxyphenyl) -3- (1-cyclopropylpropyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 7- (2-chloro-5-fluoro-4-methoxyphenyl) -3- (1-cyclopropylpropyl) - 2-ethyl-3H-imidazo [4, 5-b] pyridine; 7- (2-chloro-fluoro-4-methoxyphenyl) -3- (1-cyclopropylpropyl) -2- methoxy-3H-imidazo [4, 5-b] yridine; 7- (2-chloro-5-fluoro-4-methylphenyl) -3- (1-cyclopropylpropyl) - 2-ethyl-3H-imidazo[4, 5-b] yridine; 7- (2-chloro-fluoro-4-methylphenyl) -3- (1-cyclopropylpropyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 3- (1-cyclopropylpropyl) -2-ethyl-7- (2,4, 5-trimethylphenyl) -3H- imidazo[4, 5-b] pyridine; 3- (1-cyclopropylpropyl) -2-methoxy-7- (2,4, 5-trimethylphenyl) - 3H-imidazo [4 , 5-b] pyridine; 3- (1-cyclopropylpropyl) -2-ethyl-7- (2,5, 6-trimethyl-3- pyridinyl) -3H-imidazo[4, 5-b] pyridine; 3- (1-cyclopropylpropyl) -2-methoxy-7- (2,5, 6-trimethyl-3- pyridinyl)-3H-imidazo [4, 5-b] yridine; 3- (1-cyclopropylpropyl) -7- (2, 6-dimethyl-3-pyridinyl) -2-ethyl- 3H-imidazo[4, 5-b] pyridine; 3- (1-cyclopropylpropyl) -7- (2, 6-dimethyl-3-pyridinyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 3- (1-cyclopropylpropyl) -7- (2, 6-dimethoxy-3-pyridinyl) -2-ethyl- 3H-imidazo[4, 5-b] pyridine; 7- (2, 4-dichlorophenyl) -2-ethyl-3- (1-ethylpropyl) -3H- imidazo [4, 5-b] pyridine; 7- (2, 4-dichlorophenyl) -3- (1-ethylpropyl) -2-methoxy-3H- imidazo [4, 5-b] pyridine; 7- [2-chloro-4- (trifluoromethyl ) phenyl] -2-ethyl-3- (1- ethylpropyl) -3H-imidazo[4, 5-b]pyridine; 7-[2-chloro-4- (trifluoromethyl) phenyl] -3- (1-ethylpropyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 7- [2-chloro-4- (methylsulfonyl) henyl] -2-ethyl-3- (1- ethylpropyl) -3H-imidazo[4, 5-b] pyridine; 7- [2-chloro-4- (methylsulfonyl) henyl] -3- (1-ethylpropyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 2-ethyl-3- (1-ethylpropyl) -7- (4-methoxy-2, 5-dimethylphenyl) -SHimidazo [4, 5-b] pyridine; 3- (1-ethylpropyl) -2-methoxy-7- (4-methoxy-2, 5-dimethylphenyl) - 3H-imidazo [4, 5-b] pyridine; 7- (2-chloro-4-methoxyphenyl) -2-ethyl-3- (1-ethylpropyl) -3H- imidazo [4 , 5-b] pyridine; 7- (2-chloro-4-methoxyphenyl) -3- (1-ethylpropyl) -2-methoxy-3H- imidazo[4, 5-b] pyridine; 2-ethyl-3- (1-ethylpropyl) -7- [4-methoxy-2- (trifluoromethy1) phenyl] -3H-imidazo [4, 5-b] pyridine; 3- (1-ethylpropyl) -2-methoxy-7- [4-methoxy-2- (trifluoromethyl) phenyl] -3H-imidazo[4,5-b]pyridine; 7- (2, 6-dimethoxy-3-pyridinyl) -2-ethyl-3- (1-ethylpropyl) -3H- imidazo [4 , 5-b] yridine; 7- (2, 6-dimethyl-3-pyridinyl) -2-ethyl-3- (1-ethylpropyl) -3H- imidazo[4, 5-b] pyridine; 2-ethyl-3-(l-ethylpropyl)-7-(2,5,6-trimethyl-3-pyridinyl)-3H- imidazo[4, 5-b] pyridine; 2-ethyl-3- (1-ethylpropyl) -7- (5-fluoro-4-methoxy-2- methylphenyl) -3H-imidazo [4, 5-b] pyridine; 3- (1-ethylpropyl) -7- (5-fluoro-4-methoxy-2-methylphenyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 3-chloro-4-[2-ethyl-3-(l-ethylpropyl)-3H-imidazo[4,5- b] pyridin-7-yl] benzonitrile; 3-chloro-4- [3- (1-ethylpropyl) -2-methoxy-3H-imidazo[4, 5- b] pyridin-7-yl] benzonitrile; l-{3-chloro-4-[2-ethyl-3-(l-ethylpropyl)-3H-imidazo[4,5- b] pyridin-7-yl] phenyl} -1-ethanone; l-{3-chloro-4-[3- (1-ethylpropyl) -2-methoxy-3H-imidazo[4, 5- b] pyridin-7-yl] phenyl} -1-ethanone; 3- (dicyclopropylmethyl)-2-ethyl-7- (5-fluoro-4-methoxy-2- methylphenyl) -3H-imidazo [4, 5-b] pyridine; 3- (dicyclopropylmethyl) -7- (5-fluoro-4-methoxy-2-methylphenyl) - 2-methoxy-3H-imidazo[4, 5-b] pyridine; 7- (2-chloro-4-methoxyphenyl) -3- (dicyclopropylmethyl) -2-ethyl- 3H-imidazo [4 , 5-b] pyridine; 7- (2-chloro-4-methoxyphenyl) -3- (dicyclopropylmethyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 7- (2, 4-dichlorophenyl) -3- (dicyclopropylmethyl) -2-ethyl-3H- imidazo [4, 5-b] pyridine; 7- (2 , 4-dichlorophenyl) -3- (dicyclopropylmethyl) -2-methoxy-3H- imidazo [4, 5-b] pyridine; 7- [2-chloro-4- (trifluoromethyl) phenyl] -3- (dicyclopropylmethyl) -2-ethyl-3H-imidazo[4, 5-b] pyridine; 7- [2-chloro-4- (trifluoromethyl) phenyl] -3- (dicyclopropylmethyl) -2-methoxy-3H-imidazo [4, 5-b] pyridine; 7- (2, 4-dichlorophenyl) -2-ethyl-3- (l-ethyl-3-methoxypropyl) -3H- imidazo [4 , 5-b] pyridine; 7- (2,4-dichlorophenyl) -3- (l-ethyl-3-methoxypropyl) -2-methoxy- 3H-imidazo [4 , 5-b] yridine; 7- [2-chloro-4- (trifluoromethyl) phenyl] -2-ethyl-3- (l-ethyl-3- methoxypropyl ) -3H-imidazo[4, 5-b] pyridine; 7- [2-chloro-4- (trifluoromethyl) phenyl] -3- (l-ethyl-3- methoxypropyl) -2-methoxy-3H-imidazo [4, 5-b] pyridine; 7- (2-chloro-4-methoxyphenyl) -2-ethyl-3- (l-ethyl-3- methoxypropyl ) -3H-imidazo [4, 5-b]pyridine; 7- (2-chloro-4-methoxyphenyl) -3- (l-ethyl-3-methoxypropyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 7- (2-chloro-5-fluoro-4-methoxyphenyl)-2-ethyl-3- (l-ethyl-3- methoxypropyl) -3H-imidazo [4, 5-b]pyridine; 7- (2-chloro-5-fluoro-4-methoxyphenyl) -3- (l-ethyl-3- methoxypropyl) -2-methoxy-3H-imidazo [4, 5-b] pyridine; 2-ethyl-3- (l-ethyl-3-methoxypropyl) -7- (4-methoxy-2, 5- dimethylphenyl ) -3H-imidazo [4 , 5-b] pyridine; 3- (l-ethyl-3-methoxypropyl) -2-methoxy-7- (4-methoxy-2, 5- dimethylphenyl) -3H-imidazo[4, 5-b]pyridine; 2-ethyl-3- (l-ethyl-3-methoxypropyl) -7- (5-fluoro-4-methoxy-2- methylphenyl ) -3H-imidazo [4, 5-b] yridine; 3- (l-ethyl-3-methoxypropyl) -7- (5-fluoro-4-methoxy-2- methylphenyl ) -2-methoxy-3H-imidazo [4, 5-b] yridine; 7-(2-chloro-5-fluoro-4-methylphenl)-2-ethyl-3-(l-ethyl-3- methoxypropyl ) -3H-imidazo [4 , 5-b] pyridine; 7- (2-chloro-5-fluoro-4-methylphenyl) -3- (l-ethyl-3- methoxypropyl) -2-methoxy-3H-imidazo [4, 5-b] pyridine; 7- [2-chloro-4- (methylsulfonyl) phenyl] -2-ethyl-3- (l-ethyl-3- methoxypropyl) -3H-imidazo [4, 5-b] pyridine; 7- [2-chloro-4- (methylsulfonyl) phenyl] -3- (l-ethyl-3- methoxypropyl) -2-methoxy-3H-imidazo[4, 5-b] pyridine; l-{3-chloro-4- [2-ethyl-3- (l-ethyl-3-methoxypropyl) -3H- imidazo [4, 5-b] pyridin-7-yl] phenyl} -1-ethanone; l-{3-chloro-4- [3- (l-ethyl-3-methoxypropyl) -2-methoxy-3H- imidazo[4, 5-b]pyridin-7-yl] henyl}-l-ethanone; 1- {5- [2-ethyl-3-( l-ethyl-3-methoxypropyl )-3H-imidazo [4, 5- b] yridin-7-yl] -6-methyl-2-pyridinyl}-l-ethanone; l-{5- [3- (l-ethyl-3-methoxypropyl)-2-methoxy-3H-imida t zo[4,5- b]pyridin-7-yl] -6-methyl-2-pyridinyl }-l-ethanone; 2-ethyl-3- (l-ethyl-3-methoxypropyl) -7- (6-methoxy-2-methyl-3- pyridinyl) -3H-imidazo [4, 5-b] pyridine; 3- (1-ethyl-3-methoxypropyl) -2-methoxy-7- (6-methoxy-2-methyl-3- pyridinyl) -3H-imidazo [4, 5-b] pyridine; 7- (2, 6-dimethoxy-3-pyridinyl) -2-ethyl-3- (l-ethyl-3- methoxypropyl) -3H-imidazo [4, 5-b] pyridine; 7- (2, 6-dimethoxy-3-pyridinyl) -3- (l-ethyl-3-methoxypropyl) -2- methoxy-3H-imidazo[4, 5-b] pyridine; 7- (2, 6-dimethyl-3-pyridinyl) -2-ethyl-3- (l-ethyl-3- methoxypropyl ) -3H-imidazo[4, 5-b] pyridine; 7- (2, 6-dimethyl-3-pyridinyl) -3- (l-ethyl-3-methoxypropyl) -2- methoxy-3H-imidazo [4, 5-b] pyridine; 2-ethyl-3- (1-ethyl-3-methoxypropyl) -7- (2, 5, 6-trimethyl-3- pyridinyl) -3H-imidazo [4, 5-b] pyridine; 3- (l-ethyl-3-methoxypropyl) -2-methoxy-7- (2,5, 6-trimethyl-3- pyridinyl) -3H-imidazo [4, 5-b] pyridine; 7- (2,4-dichlorophenyl) -2-ethyl-3- [1- (methoxymethyl)propyl] -3H- imidazo[4, 5-b] pyridine; 7- (2, 4-dichlorophenyl) -2-methoxy-3- [1- (methoxymethyl)propyl] - 3H-imidazo [4, 5-b] yridine; 7- [2-chloro-4- (trifluoromethyl ) phenyl] -2-ethyl-3- [1- (methoxymethyl)propyl] -3H-imidazo [4, 5-b]pyridine; 7- [2-chloro-4- (trifluoromethyl) phenyl] -2-methoxy-3- [1- (methoxymethyl)propyl]-3H-imidazo [4, 5-b] pyridine; 7- (2-chloro-5-fluoro-4-methylphenyl) -2-ethyl-3- [1- (methoxymethyl)propyl] -3H-imidazo [4, 5-b] pyridine; 7- (2-chloro-5-fluoro-4-methylphenyl) -2-methoxy-3- [1- (methoxymethyl)propyl] -3H-imidazo[4, 5-b] pyridine; 2-ethyl-7- (4-methoxy-2, 5-dimethylphenyl) -3- [1- (methoxymethyl)propyl] -3H-imidazo [4, 5-b]pyridine; 2-methoxy-7- (4-methoxy-2, 5-dimethylphenyl) -3- [1- (methoxymethyl)propyl] -3H-imidazo [4, 5-b] pyridine; 2-ethyl-7- (5-fluoro-4-methoxy-2-methylphenyl) -3- [1- (methoxymethyl)propyl] -3H-imidazo [4, 5-b] pyridine; 7- (5-fluoro-4-methoxy-2-methylphenyl) -2-methoxy-3- [1- (methoxymethyl)propyl] -3H-imidazo[4, 5-b] pyridine; 2-ethyl-3- [1- (methoxymethyl)propyl] -7- (6-methoxy-2-methyl-3- pyridinyl) -3H-imidazo[4, 5-b]pyridine; 2-methoxy-3- [1- (methoxymethyl)propyl] -7- (6-methoxy-2-methyl-3- pyridinyl) -3H-imidazo [4, 5-b] pyridine; 7- (2, 6-dimethoxy-3-pyridinyl) -2-ethyl-3- [1- (methoxymethyl) ropyl] -3H-imidazo [4, 5-b] pyridine; 7- (2, 6-dimethoxy-3-pyridinyl) -2-methoxy-3- [1- (methoxymethyl ) propyl] -3H-imidazo [4 , 5-b] pyridine; 7- (2, 6-dimethyl-3-pyridinyl) -2-ethyl-3- [1- (methoxymethyl) propyl] -3H-imidazo[4, 5-b] yridine; 7-(2,6-dimethyl-3-pyridinyl)-2-methoxy-3-[l- (methoxymethyl) propyl] -3H-imidazo [4, 5-b] pyridine; 2-ethyl-3- [1- (methoxymethyl) propyl] -7- (2,5, 6-trimethyl-3- pyridinyl) -3H-imidazo [4, 5-b] yridine; 2-methoxy-3- [1- (methoxymethyl) propyl] -7- (2,5, 6-trimethyl-3- pyridinyl) -3H-imidazo [4, 5-b] pyridine; 7- [2-chloro-4- (methylsulfonyl) phenyl] -2-ethyl-3- [1- (methoxymethyl) propyl] -3H-imidazo [4, 5-b] pyridine; and 7- [2-chloro-4- (methylsulfonyl) henyl] -2-methoxy-3- [1- (methoxymethyl) propyl] -3H-imidazo [4, 5-b]pyridine; or a pharmaceutically acceptable salt form thereof. [2j]In another more preferred embodiment, the present invention provides a novel compound of formula la, wherein: R 1 is C 3 - 8 cycloalkyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b -COR 13 , -C0 2 R 13a , -NR 15a COR 13 , -N(COR 13 ) 2 , -NR 15a CONR 13a R 16a , -NR 15a C0 2 R 14b , -C0NR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 4 _ 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -, and wherein N in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b ; and, R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -OR 13 , Cι_ 2 alkoxy-Cι- 2 alkyl, and -NR 13a R 16a . [2k] In another even more preferred embodiment, the present invention provides a novel compound of formula la, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group cyclopropyl, cyclobutyl, and cyclopentyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , and C4-8 cycloalkyl, wherein one carbon atom in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -OR 13a , C 1 - 2 alkoxy-Cι_ 2 alkyl, and -NR 13a R 16a ; R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R 19a , and -C0NR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, i idazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl ,. pyrazolyl , triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -NR 17a R 19a , and -C0NR 1 a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , C0R 14b and S0 2 R 14b ; R 2 is selected from the group C1- 4 alkyl, C 2 - 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C 1 -4 alkoxy; R 9 is independently selected at each occurrence from the group H, Cι_ alkyl and C 3 - 8 cycloalkyl; R 3 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, -CN, C 1 - 4 alkyl, C 3 - 6 cycloalkyl, C 1 - 4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C 1 - 4 alkyl) -amino; R 13 is selected from the group C 1 - 4 alkyl, Cι- haloalkyl, C1-2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (C 1 - 2 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 -.6 cycloalkyl- C 1 - 6 alkyl; R14 i s selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (C 1 - 2 alkyl)-; R 14a is selected from the group C 1 -4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι_ 2 alkyl, and C3-6 cycloalkyl-Cι_ 2 alkyl; R 14b is selected from the group C 1 -4 alkyl, Cι- 2 haloalkyl, Cι_ 2 alkoxy-Cι- 2 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι- alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C1-4 alkyl, Br, Cl, F, C1-4 haloalkyl, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 -1 0 cycloalkyl, C 3 - 6 cycloalkyl-Ci- 6 alkyl, Cι- 2 alkoxy-Cι_ alkyl, and Cι_ 4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 7 and R 9 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0R 14 ; R 17a and R 1 a are independently selected at each occurrence from the group H, Cι- 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and C 1 - 4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -NR 15 C0R 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl, benzoxazolyl, isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -0C(0)R 18 , -NR 15 C0R 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15, C0 2 R 14a , C0R 14a and S0 2 R 14a . [21] In another still more preferred embodiment, the present invention provides a novel compound of formula la, wherein: X is selected from the group 0, S and a bond; R is substituted with 0-1 substituents selected from the group -CN, -CC> 2 R 13a , and C 4 -8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -» and R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 -s alkenyl, C 2 - 8 alkynyl, Br, Cl, F, CF 3 , CF 3 , -0R 13a , -OH, -OCH 3 , -OCH 2 CH 3 , -CH 2 OCH 3 , - CH 2 CH 2 OCH 3 , and -NR 13a R 16a ; R la is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH3 and S0 2 CH 3 ; R 2 is selected from the group CH3, CH2CH3, CH(CH3) 2 , and CH2CH2CH3 ; R 3 and R 8 are independently selected at each occurrence from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH3, OCH2CH3, 0CH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF3, Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl , 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH2CH2CH3, cyclopropyl, OCH3, OCH2CH3, OCH(CH 3 ) 2 , OCH2CH2CH3, OCF3, Br, Cl, F, CF 3 , -CN, SCH3, S0 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH3, C0 2 CH3, COCH3 and S0 2 CH 3 . [2m] In another further preferred embodiment, the present invention provides a novel compound of formula la, wherein: ι R is substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH (CH 3 ) 2 , CH 2 CH 2 CH 3 , - (CH 2 ) 3CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, and CF 3; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 / CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and SO 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH (01 3 ) 2 ; R 3 and R 8 are independently selected at each occurrence from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH2CH3, CH(CH 3 ) 2 / CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 OCH2CH3, OCH(CH 3 ) 2 , OCH 2 CH 2 CH3, OCF3, Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 )2/ -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl. is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 . [2n] In another even further preferred embodiment, the present invention provides a novel compound of formula la, wherein: R is substituted with 0-2 substituents independently selected at each occurrence from the group R l , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH 2 0CH 3 , - CH 2 CH 2 0CH 3 , F, and CF 3 ; and, R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [2o] In a still further preferred embodiment, the present invention provides a novel compound of formula la, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [2p] In another still further preferred embodiment, the present invention provides a novel compound of formula la, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [2q] In another more preferred embodiment, the present invention provides a novel compound of formula la, wherein: R 1 is selected from the group Cι_ιo alkyl, C _ιo alkenyl, C 2 - 10 alkynyl, C 3 - 8 cycloalkyl, C3-6 cycloalkyl-C1-6 alkyl and C 1 - 4 alkoxy-Cι- 4 alkyl; R is substituted with a C 3 - 8 cycloalkyl group, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl group is replaced by a group selected from the group -0-, -S(0) n -/ -NR 13a -, -NC0 2 R 14b -, -NC0R 14b - and -NS0 2 R 14b -; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R l , C 1 - 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -0R 13a , -NR 13 R 16 , Cι_ 2 alkoxy-Cι_ 2 alkyl, and C 3 - 8 cycloalkyl which is substituted with 0- 1 R 9 and in which 0-1 carbons of C 4 -8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH ) 2 - group; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group Ci-β alkyl, C3-6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 / -COR 17 , -0C(0)R 18 , -NR 15a C0R 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17 R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzof ranyl, benzothienyl , benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl , 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane,- each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Ci-β alkyl, C 3 _e cycloalkyl, Br, Cl, F, I, Cι- 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17 R 19a , and -C0NR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , COR 14b and S0 2 R 14b ; and, R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 -. 4 haloalkyl, -CN, nitro, -0R 13 , SH, -S(0) n R 14b / -C0R 13a , -OC(0)R 1 b , -NR 15a C0R 13a , -N(C0R 13a ) 2 , -NR 15a C0NR 13 R 16 , -NR 15a C0 2 R 14b , -NR 13a R 16a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R a , C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized. [2r] In another even more preferred embodiment, the present invention provides a novel compound of formula la, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι- 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, and C 3 - 8 cycloalkyl; R is substituted with a C 3 - 6 cycloalkyl group, wherein 0-1 carbon atoms in the C 4 - 6 cycloalkyl group is replaced by a group selected from the group -0-, -S(0) n -, and -NR 13a - ; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -0R 13a , -NR 13 R 16a , C 1 - 2 alkoxy-Cι-2 alkyl, and C 3 - 6 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C1-. 4 alkyl, C 3 .- 6 cycloalkyl, Br, Cl, F, C1-4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R 9 , and -C0NR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyri idinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -NR 7a R 9 , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R 2 is selected from the group C 1 - 4 alkyl, C 2 _ 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C 1 - 4 alkoxy; R 9 is independently selected at each occurrence from the group H, C 1 - 4 alkyl and C 3 - 8 cycloalkyl; R 3 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, -CN, C 1 - 4 alkyl, C 3 - 6 cycloalkyl, C 1 -4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C 1 - 4 alkyl ) 2 -amino; R 13 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι- 2 alkyl, C 3 - 6 cycloalkyl-Cι- 2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (Cι_ 2 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, Cι_ 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C3-6 cycloalkyl- Cι_ 6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, Cι- 2 haloalkyl, C1-2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (Cι_ alkyl)-; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι- 2 alkyl, and C 3 - 6 cycloalkyl-Cι_ alkyl; R 14b is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, Cι- alkoxy-Cι- 2 alkyl, C3-6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-2 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C 1 - 4 haloalkyl, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, Cχ-6 alkyl, C3-10 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι_2 alkyl, and C 1 - 4 haloalkyl; 17 19 17 19 alternatively, in an NR R moiety, R and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Ci-β alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-C1-6 alkyl and Cι_4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -NR 15 C0R 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl, benzoxazolyl , isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι-6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -0C(0)R 18 , -NR 15 C0R 17 , -N(C0R 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 and each heteroaryl being substituted on any nitrogen atom 15 with 0-1 substituents selected from the group R , 14a C0 2 R COR 14a and S0 2 R 14a . [2s] In another still more preferred embodiment, the present invention provides a novel compound of formula la, wherein: X is selected from the group 0, S and a bond; R 1 is Cι_ 6 alkyl; R is substituted with a C 3 - 6 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 6 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ and -NR a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι- 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, F, CF 3 , -0R 13a , -NR 13a R 16a , -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , and C 3 - 6 cycloalkyl which is substituted with 0-1 CH 3 and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R la is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3/ -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH3, -NH 2 , - NHCH3, -N(CH 3 ) / -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and S0 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , CH(CH3) 2 and CH 2 CH 2 CH 3 ; R 3 and R 8 are independently selected at each occurrence from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2, 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom witϊr 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 . [2t] In another further preferred embodiment, the present invention provides a novel compound of formula la, wherein: R 1 is (cyclopropyl)Cι alkyl or (cyclobutyl)Cι alkyl; R is substituted with 1-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , F, CF 3 , cyclopropyl, CH 3 -cyclopropyl, cyclobutyl, CH 3 - cyclobutyl , cyclopentyl, - CH 3 -cyclopentyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , 0CH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , 0CH 3 , 0CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH(CH 3 ) 2 ; R 3 and R 8 are independently selected at each occurrence from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , 0CH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 . [2u] In another even further preferred embodiment, the present invention provides a novel compound of formula la, wherein: R 1 is (cyclopropyl )Cι alkyl or (cyclobutyl )Cι alkyl; R is substituted with 1-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH (CH 3 ) , -CH≡CH, -CH≡C (CH 3 ) , -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH2CH3, CH(CH 3 )2/ CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, and pyrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , 0CH 2 CH 3 , OCF3, Br, Cl, F, CF 3 , -CN, and SCH 3 . [2v] In another further preferred embodiment, the present invention provides a novel compound of formula la, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF3. [2w] In another further preferred embodiment, the present invention provides a novel compound of formula la, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [3] In another preferred embodiment, the present invention provides a novel compound of formula lb: (lb) [3a] In another more preferred embodiment, the present invention provides a novel compound of formula lb, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, and C 3 - 8 cycloalkyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , and C3-8 cycloalkyl, wherein 0-1 carbon atoms in the C4- 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 1 b -, -NCOR 14b - and -NS0 2 R 14b - ; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , CF2CF 3 , -OR 13 , -NR 13a R 16a , C1-2 alkoxy-Cι- 2 alkyl, and C3- 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH2) 2 - group; R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 -. 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R lδ \ -COR 17 , -NR 17 R 19 , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 -- 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , COR 14b and S0 2 R 14b ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 )ι_ 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group C 1 - 4 alkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C 1 -. 4 alkoxy; R 3 and R 7 are independently selected at each occurrence from the group H, Br, Cl, F, -CN, C 1 - 4 alkyl, C 3 - 6 cycloalkyl, C1- 4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C1-4 alkyl) 2 -amino; R 9 is independently selected at each occurrence from the group H, C 1 - 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group C 1 - 4 alkyl, C1- 2 haloalkyl, C1-2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl(Cι-2 alkyl)-, and heteroaryl (C 1 - 2 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C1-6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C1-2 alkoxy-Cι- 2 alkyl, C 3 - 6 cycloalkyl-Cι_ 2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (Cι_ 2 alkyl)-; R 1 a is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C1-2 alkoxy-Cι_ 2 alkyl, and C3-6 cycloalkyl-Cι-2 alkyl; R 14b is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι_ 2 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-Cι_ 2 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C 1 - 4 haloalkyl, C 1 - 4 alkoxy, C 1 -. 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C3-10 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C 1 - 4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 17 and R 19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , CO 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 -. 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and C 1 - 4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C1-4 haloalkyl, -CN, -S(0) n R 18 -COR 17 , -C0 2 R 17 , -NR 15 COR 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl , benzoxazolyl , isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R , C0 2 R 14a , C0R 14a and S0 2 R 14 . [3b] In another even more preferred embodiment, the present invention provides a novel compound of formula lb, wherein: X is selected from the group 0, S and a bond; R 1 is substituted Ci-β alkyl; R is substituted with 0-1 substituents selected from the group -CN, -C0 2 R 13a , and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -r and -NR 13a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι_ 6 alkyl, C 2 _ 8 alkenyl, C 2 - 8 alkynyl, Br, Cl, F, CF 3 , -OR 13a , -NR 13a R 16 , C 1 - 2 alkoxy-Cι- 2 alkyl, and C 3 - 6 cycloalkyl which is substituted with 0-1 CH 3 and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R l is aryl and is phenyl substituted with 0-1 substituents selected from 0CH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, 0CH 3 , 0CH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , 0CF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and S0 2 CH 3 ; provided that R 1 is other than a - (CH 2 ) ι_ 4 -aryl or - (CH 2 ) 1 -4-heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CHCH 3 , CH(CH 3 ) 2 , and CH2CH2CH3 ; R 3 and R 7 are independently selected at each occurrence from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF3, Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 )2; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2,3-dihydrobenzofuranyl, 2, 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 . [3c] In another still more preferred embodiment, the present invention provides a novel compound of formula lb, wherein: R 1 is substituted Ci; R is substituted with 0-1 substituents selected from the group -CN, -C0 2 CH 3 , and -C0 2 CH 2 CH 3 ; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , F, CF 3 , cyclopropyl, CH 3 -cyclopropyl, cyclobutyl, CH 3 - cyclobutyl, cyclopentyl, CH 3 -cyclopentyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 / CH 2 CH 2 CH 3 , 0CH 3 , 0CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 ; provided that R 1 is other than a - (CH ) ι_ 4 -aryl or - (CH 2 )ι_ 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH(CH 3 ) 2 ; R 3 and R 7 are independently selected at each occurrence from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH3, CH(CH 3 ) 2 CH 2 CH 2 CH 3 , cyclopropyl, OCH3, OCH2CH3, 0CH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF3, Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0) N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C ( 0 ) N ( CH 3 ) 2 . [3d] In another further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: R 1 is substituted (cyclopropyl) -Ci alkyl or (cyclobutyl) -Ci alkyl; R 1 is substituted with 0-1 -CN; R is also substituted with 0-1 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH2CH3, CH(CH 3 ) 2 / CH2CH2CH3, -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), Br, Cl, F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R is also substituted with 0-1 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH (CH 3 ) , -CH≡CH, -CH≡C (CH 3 ) , -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, and pyrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [3e] In another further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: R 1 is (cyclopropyl)Cι alkyl or (cyclobutyl) -Ci alkyl substituted with 1 substituent independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , Cl, F, and CF 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, and isoxazolyl, each heteroaryl being substituted on 0-2 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , OCH 3 , Cl, F, and CF 3 . [3f] In an even further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: R 1 is selected from the group (cyclopropyl)CH-CH 3 , (cyclopropyl ) CH-CH 2 CH 3 , (cyclopropyl) CH-CH 2 OCH 3 , (cyclopropyl) CH-CH 2 CH 2 CH 3 , (cyclopropyl) CH-CH 2 CH 2 OCH 3 , (cyclopropyl) 2 CH, phenyl (cyclopropyl )CH, furanyl (cyclopropyl)CH, thienyl (cyclopropyl)CH, isoxazolyl (cyclopropyl )CH, (CH 3 - furanyl) (cyclopropyl )CH, (cyclobutyl )CH-CH 3 , (cyclobutyl) CH-CH 2 CH 3 , (cyclobutyl ) CH-CH 2 OCH 3 , (cyclobutyl ) CH-CH 2 CH 2 CH 3 , (cyclobutyl ) CH-CH 2 CH 2 OCH 3 , (cyclobutyl) 2 CH, phenyl (cyclobutyl) CH, furanyl (cyclobutyl )CH, thienyl (cyclobutyl )CH, isoxazolyl (cyclobutyl)CH, and (CH 3 - furanyl) (cyclobutyl )CH; [3g] In another further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CHCH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF3, Br, Cl, F, and CF 3 . [3h] In another further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [3i] In another preferred embodiment, the present invention provides a novel compound of formula lb, wherein the compound is selected from the group: 1- (1-cyclopropylpropyl) -4- (2,4-dichlorophenyl) -2-ethyl-lH- imidazo [4,5-c] pyridine; 1- (1-cyclopropylpropyl) -4- (2,4-dichlorophenyl) -2-methoxy-lH- imidazo[4, 5-c] pyridine; 1- (1-cyclopropylpropyl) -2-ethyl-4- [2-methyl-4- (trifluoromethyl) phenyl] -lH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl) phenyl] -1- (1- cyclopropylpropyl ) -2-ethyl-lH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl) henyl] -1- (1- cyclopropylpropyl) -2-methoxy-lH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl) phenyl] -1- (1- cyclopropylpropyl ) -2- (methylsulfanyl) -1H-imidazo [4, 5- c] pyridine; 4- (2-chloro-4-methoxyphenyl) -1- (1-cyclopropylpropyl) -2-ethyl- 1H-imidazo [4 , 5-c] pyridine; 4- (2-chloro-4-methoxyphenyl) -1- (1-cyclopropylpropyl) -2- methoxy-lH-imidazo [4, 5-c] pyridine; 1- (1-cyclopropylpropyl) -2-ethyl-4- (4-methoxy-2, 5- dimethylphenyl ) -lH-imidazo[4, 5-c] pyridine; 1- (1-cyclopropylpropyl) -2-methoxy-4- (4-methoxy-2, 5- dimethylphenyl ) -lH-imidazo[4, 5-c] pyridine; 4- (2-chloro-4-methoxyphenyl) -1- (1-cyclopropylpropyl) -2-ethyl- 1H-imidazo [4 , 5-c] pyridine; 4- (2-chloro-4-methoxyphenyl) -1- (1-cyclopropylpropyl) -2- methoxy-lH-imidazo [4, 5-c] pyridine; 4- (2-chloro-5-fluoro-4-methoxyphenyl) -1- (1-cyclopropylpropyl! 2-ethyl-1H-imidazo [4, 5-c] pyridine; 4- (2-chloro-fluoro-4-methoxyphenyl) -1- (1-cyclopropylpropyl) -2- methoxy-1H-imidazo [4 , 5-c] yridine; 4- (2-chloro-5-fluoro-4-methylphenyl) -1- (1-cyclopropylpropyl) - 2-ethyl-lH-imidazo[4, 5-c] pyridine; 2.4- (2-chloro-fluoro-4-methylphenyl) -1- (1-cyclopropylpropyl) - 2-methoxy-lH-imidazo [4, 5-c] pyridine; 1- (1-cyclopropylpropyl) -2-methoxy-4- (2,4, 5-trimethylphenyl) - 1H-imidazo [4, 5-c] pyridine; 1- (1-cyclopropylpropyl) -2-ethyl-4- (2,4, 5-trimethylphenyl) -1H- imidazo[4, 5-c] pyridine; 1- (1-cyclopropylpropyl) -2-ethyl-4- (2,5, 6-trimethyl-3- pyridinyl) -lH-imidazo [4, 5-c] pyridine 1- (1-cyclopropylpropyl) -2-methoxy-4- (2,5, 6-trimethyl-3- pyridinyl) -lH-imidazo[4, 5-c]pyridine; 1- (1-cyclopropylpropyl) -4- (2, 6-dimethyl-3-pyridinyl) -2-ethyl- 1H-imidazo [4, 5-c] pyridine; 1- (1-cyclopropylpropyl) -4- (2, 6-dimethyl-3-pyridinyl) -2- methoxy-lH-imidazo [4, 5-c] pyridine; 1- (1-cyclopropylpropyl) -4- (2, 6-dimethoxy-3-pyridinyl ) -2-ethyl- 1H-imidazo [4, 5-c] pyridine; 4- (2, 4-dichlorophenyl) -2-ethyl-l- (1-ethylpropyl) -lH- imidazo [4, 5-c] pyridine; 4- (2, 4-dichlorophenyl) -1- (1-ethylpropyl) -2-methoxy-lH- imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl) phenyl] -1- (1-ethylpropyl) -2- methoxy-lH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl ) phenyl] -2-ethyl-l- (1- ethylpropyl) -IH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (methylsulfonyl) phenyl] -2-ethyl-l- (1- ethylpropyl) -IH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (methylsulfonyl) phenyl] -1- (1-ethylpropyl) -2- methoxy-lH-imidazo [4, 5-c] pyridine; 2-ethyl-l- (1-ethylpropyl) -4- (4-methoxy-2, 5-dimethylphenyl) -1H- imidazo[4, 5-c] pyridine; 1- (1-ethylpropyl) -2-methoxy-4- (4-methoxy-2, 5-dimethylphenyl) - IH-imidazo [4, 5-c] pyridine; 4- (2-chloro-4-methoxyphenyl) -2-ethyl-l- (1-ethylpropyl) -1H- imidazo[4, 5-c] pyridine; 4- (2-chloro-4-methoxyphenyl) -1- (1-ethylpropyl) -2-methoxy-lH- imidazo [4, 5-c] pyridine; 2-ethyl-l- (1-ethylpropyl) -4- [4-methoxy-2- (trifluoromethyl) phenyl] -lH-imidazo[4, 5-c] pyridine; 1- (1-ethylpropyl) -2-methoxy-4- [4-methoxy-2- (trifluoromethyl) phenyl] -IH-imidazo [4, 5-c]pyridine; 1- (1-ethylpropyl) -4- (5-fluoro-4-methoxy-2-methylphenyl) -2- methoxy-lH-imidazo [4, 5-c] pyridine; 2-ethyl-l- (1-ethylpropyl) -4- (5-fluoro-4-methoxy-2- methylphenyl ) -IH-imidazo [4 , 5-c] pyridine; 3-chloro-4- [1- (1-ethylpropyl) -2-methoxy-lH-imidazo[4,5- c] pyridin-4-yl] benzonitrile; 3-chloro-4- [2-ethyl-l- (1-ethylpropyl) -IH-imidazo [4, 5- c] pyridin-4-yl] benzonitrile; 1- {3-chloro-4- [2-ethyl-l- (1-ethylpropyl) -IH-imidazo [4,5- c]pyridin-4-yl] phenyl }-l-ethanone; l-{3-chloro-4- [1- (1-ethylpropyl) -2-methoxy-lH-imidazo[4, 5- c] pyridin-4-yl] phenyl} -1-ethanone; 1- (dicyclopropylmethyl) -2-ethyl-4- (5-fluoro-4-methoxy-2- methylphenyl ) -IH-imidazo [4, 5-c] pyridine; 1- (dicyclopropylmethyl) -4- (5-fluoro-4-methoxy-2-methylphenyl) - 2-methoxy-lH-imidazo [4, 5-c] pyridine; 4- (2-chloro-4-methoxyphenyl) -1- (dicyclopropylmethyl) -2-ethyl- 1H-imidazo [4 , 5-c] pyridine; 4- (2-chloro-4-methoxyphenyl) -1- (dicyclopropylmethyl) -2- methoxy-IH-imidazo [4 , 5-c] pyridine; 4- (2, 4-dichlorophenyl) -1- (dicyclopropylmethyl) -2-ethyl-1H- imidazo [4 , 5-c] pyridine; 4- (2 , 4-dichlorophenyl) -1- (dicyclopropylmethyl) -2-methoxy-1H- imidazo[4, 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl) phenyl] -1- (dicyclopropylmethyl) -2-ethyl-lH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl ) phenyl] -1- (dicyclopropylmethyl) -2-methoxy-lH-imidazo [4, 5-c] pyridine; 4- (2, 4-dichlorophenyl) -1- (l-ethyl-3-methoxypropyl) -2-methoxy- IH-imidazo [4, 5-c] yridine; 4- (2, 4-dichlorophenyl) -2-ethyl-l- (l-ethyl-3-methoxypropyl) -lH- imidazo [4 , 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl ) phenyl] -1- (l-ethyl-3- methoxypropyl) -2-methoxy-lH-imidazo[4, 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl) phenyl] -2-ethyl-l- (l-ethyl-3- methoxypropyl ) -lH-imidazo[4, 5-c] yridine; 4- (2-chloro-4-methoxyphenyl) -1- (l-ethyl-3-methoxypropyl) -2- methoxy-lH-imidazo [4, 5-c] pyridine; 4- (2-chloro-4-methoxyphenyl) -2-ethyl-l- (l-ethyl-3- methoxypropyl) -IH-imidazo [4, 5-c] pyridine; 4- (2-chloro-5-fluoro-4-methoxyphenyl) -1- (l-ethyl-3- methoxypropyl) -2-methoxy-lH-imidazo[4, 5-c] pyridine; 4- (2-chloro-5-fluoro-4-methoxyphenyl) -2-ethyl-l- (l-ethyl-3- methoxypropyl ) -lH-imidazo[4, 5-c] pyridine; 1- (l-ethyl-3-methoxypropyl) -2-methoxy-4- (4-methoxy-2, 5- dimethylphenyl ) -IH-imidazo [4, 5-c] pyridine; 2-ethyl-l- (l-ethyl-3-methoxypropyl) -4- (4-methoxy-2, 5- dimethylphenyl) -IH-imidazo [4 , 5-c] pyridine; 2-ethyl-l- (l-ethyl-3-methoxypropyl) -4- (5-fluoro-4-methoxy-2- methylphenyl) -IH-imidazo [4, 5-c] pyridine; 1- (l-ethyl-3-methoxypropyl) -4- (5-fluoro-4-methoxy-2- methylphenyl) -2-methoxy-lH-imidazo [4 , 5-c] pyridine; 4- (2-chloro-5-fluoro-4-methylphenyl) -1- (l-ethyl-3- methoxypropyl) -2-methoxy-lH-imidazo [4, 5-c] pyridine; 4- (2-chloro-5-fluoro-4-methylphenl) -2-ethyl-l- (l-ethyl-3- methoxypropyl) -IH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (methylsulfonyl) phenyl] -1- (l-ethyl-3- methoxypropyl ) -2-methoxy-lH-imidazo[4, 5-c] pyridine; 4- [2-chloro-4- (methylsulfonyl) phenyl] -2-ethyl-l- (l-ethyl-3- methoxypropyl) -lH-imidazo[4, 5-c] pyridine; l-{3-chloro-4- [1- (l-ethyl-3-methoxypropyl) -2-methoxy-lH- imidazo[4, 5-c] pyridin-4-yl] phenyl} -1-ethanone; l-{3-chloro-4- [2-ethyl-l- (l-ethyl-3-methoxypropyl) -1H- imidazo [4 , 5-c] pyridin-4-yl] phenyl} -1-ethanone; l-{5- [1- (l-ethyl-3-methoxypropyl) -2-methoxy-lH-imidazo[4, 5- c]pyridin-4-yl] -6-methyl-2-pyridinyl}-l-ethanone; l-{5- [2-ethyl-l- (l-ethyl-3-methoxypropyl) -lH-imidazo[4, 5- c]pyridin-4-yl]-6-methyl-2-pyridinyl}-l-ethanone; 1- (l-ethyl-3-methoxypropyl) -2-methoxy-4- (6-methoxy-2-methyl-3- pyridinyl )-lH-imidazo [4, 5-c] pyridine; 2-ethyl-l- (l-ethyl-3-methoxypropyl) -4- (6-methoxy-2-methyl-3- pyridinyl) -lH-imidazo[4, 5-c] pyridine; 4- (2, 6-dimethoxy-3-pyridinyl) -2-ethyl-l- (l-ethyl-3- methoxypropyl) -IH-imidazo [4, 5-c] pyridine; 4- (2, 6-dimethoxy-3-pyridinyl) -1- (l-ethyl-3-methoxypropyl) -2- methoxy-IH-imidazo [4, 5-c] pyridine; 4- (2, 6-dimethyl-3-pyridinyl)-l- (l-ethyl-3-methoxypropyl) -2- methoxy-lH-imidazo [4, 5-c] pyridine; 4- (2, 6-dimethyl-3-pyridinyl) -2-ethyl-l- (l-ethyl-3- methoxypropyl) -IH-imidazo [4, 5-c] pyridine; 2-ethyl-l- (l-ethyl-3-methoxypropyl) -4- (2,5, 6-trimethyl-3- pyridinyl) -lH-imidazo[4, 5-c] pyridine; 1- (l-ethyl-3-methoxypropyl) -2-methoxy-4- (2,5, 6-trimethyl-3- pyridinyl) -IH-imidazo [4, 5-c] pyridine; 4- (2, 4-dichlorophenyl) -2-ethyl-l- [1- (methoxymethyl) ropyl] -1H- imidazo[4, 5-c] pyridine; 4- (2,4-dichlorophenyl) -2-methoxy-l- [1- (methoxymethyl) propyl] - IH-imidazo [4, 5-c] yridine; 4- [2-chloro-4- (trifluoromethyl) phenyl] -2-ethyl-l- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (trifluoromethyl) phenyl] -2-methoxy-l- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c] pyridine; 4- (2-chloro-5-fluoro-4-methylphenyl) -2-ethyl-l- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c]pyridine; 4- (2-chloro-5-fluoro-4-methylphenyl) -2-methoxy-l- [1- (methoxymethyl) propyl] -lH-imidazo [4, 5-c] pyridine; 2-methoxy-4- (4-methoxy-2 , 5-dimethylphenyl) -1- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c] pyridine; 2-ethyl-4- (4-methoxy-2, 5-dimethylphenyl) -1- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c]pyridine; 2-ethyl-4- (5-fluoro-4-methoxy-2-methylphenyl) -1- [1- (methoxymethyl) propyl] -lH-imidazo[4, 5-c]pyridine; 4- (5-fluoro-4-methoxy-2-methylphenyl) -2-methoxy-l- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c] pyridine; 2-methoxy-l- [1- (methoxymethyl) propyl] -4- (6-methoxy-2-methyl-3- pyridinyl) -IH-imidazo [4, 5-c] pyridine; 2-ethyl-l- [1- (methoxymethyl) propyl] -4- (6-methoxy-2-methyl-3- pyridinyl) -lH-imidazo [4, 5-c] pyridine; 4- (2, 6-dimethoxy-3-pyridinyl) -2-ethyl-l- [1- (methoxymethyl) propyl] -lH-imidazo[4, 5-c]pyridine; 4- (2, 6-dimethoxy-3-pyridinyl) -2-methoxy-l- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c] pyridine; 4- (2, 6-dimethyl-3-pyridinyl) -2-ethyl-l- [1- (methoxymethyl) propyl] -lH-imidazo[4, 5-c] pyridine; 4- (2, 6-dimethyl-3-pyridinyl) -2-methoxy-l- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c] pyridine; 2-ethyl-l- [1- (methoxymethyl) propyl] -4- (2, 5, 6-trimethyl-3- pyridinyl) -IH-imidazo [4, 5-c] pyridine; 2-methoxy-l- [1- (methoxymethyl) propyl] -4- (2, 5, 6-trimethyl-3- pyridinyl) -IH-imidazo [4, 5-c] pyridine; 4- [2-chloro-4- (methylsulfonyl) phenyl] -2-ethyl-l- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c] pyridine; and 4- [2-chloro-4- (methylsulfonyl) phenyl] -2-methoxy-l- [1- (methoxymethyl) propyl] -IH-imidazo [4, 5-c] pyridine; or a pharmaceutically acceptable salt form thereof. [3j] In another more preferred embodiment, the present invention provides a novel compound of formula lb, wherein: R 1 is C 3 - 8 cycloalkyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13 R 16a , -NR 15a C0 2 R 14b , -C0NR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 4 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ -NR 13a -, -NC0 2 R 14b -, -NC0R 14b - and -NS0 2 R 14b -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , C0R 14b and S0 2 R 14b ; and, R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C 1 - 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -0R 13a , Cι_ alkoxy-Cι_ 2 alkyl, and -NR 13a R 16a . [3k] In another even more preferred embodiment, the present invention provides a novel compound of formula lb, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group cyclopropyl, cyclobutyl, and eye1openty1; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13 , and C4-8 cycloalkyl, wherein one carbon atom in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NC0R 14b - and -NS0 2 R 1 b - ; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -OR 13a , C 1 - 2 alkoxy-Cι_ 2 alkyl, and -NR 13 R 16a ; R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C1-4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17 R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group ,15a 14b C0 2 R COR 14b and S0 2 R 14b ; R 2 is selected from the group C 1 - 4 alkyl, C 2 -4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C 1 - 4 alkoxy; R 9 is independently selected at each occurrence from the group H, C 1 - 4 alkyl and C 3 - 8 cycloalkyl; R 3 and R 7 are independently selected at each occurrence from the group H, Br, Cl, F, -CN, C 1 - 4 alkyl, C 3 - 6 cycloalkyl, C 1 - 4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C 1 - 4 alkyl ) 2 -amino; R 13 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C1-2 alkoxy-Cι- 2 alkyl, C 3 - 6 cycloalkyl-Cι- alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (Cι- 2 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C1-6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C1- 2 haloalkyl, C1-2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (Cι_ 2 alkyl)-; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι- 2 alkyl, and C 3 - 6 cycloalkyl-Cι- alkyl; R 14b is selected from the group C 1 - 4 alkyl, Cι_ 2 haloalkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι_ 2 alkyl; R 15 is independently selected at each occurrence from the group H, Cι_ 4 alkyl, C 3 - 7 cycloalkyl, C 3 -. 6 cycloalkyl- C 1 - 6 - alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C1-4 haloalkyl, Cι_ 4 alkoxy, C 1 -4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 _ 6 cycloalkyl-Cι-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, Ci-β alkyl, C3-10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι- alkyl, and C 1 - 4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0R 14 , COR 14 and S0 2 R 14 ; R 17a and R L9a are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and C1-4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -NR 15 COR 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 ; and, heteroaryl is independently selected at each occurence from " the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 -4 haloalkyl, -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15, C0 2 R 14 , COR 14a and S0 2 R 14a . [31] In another still more preferred embodiment, the present invention provides a novel compound of formula lb, wherein: X is selected from the group 0, S and a bond; 1 R is substituted with 0-1 substituents selected from the group. -CN, -C0 2 R 13 , and C 4 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 _ 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, and -NR 13a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι_ 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , CF 3 , -0R 13a , -OH, -OCH 3 , -0CH 2 CH 3 , -CH 2 0CH 3 , - CH 2 CH 2 0CH 3 , and -NR 13 R 16 ; R la is aryl and is phenyl substituted with 0-1 substituents selected from 0CH 3 , 0CH 2 CH 3 , OCH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CHCH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, 0CH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and S0 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , CH (CH 3 ) 2 , and CH 2 CH 2 CH 3 ; R 3 and R 7 are independently selected at each occurrence from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, 0CH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 / OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 / -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CHCH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 )2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and S0 2 CH 3 . [3m] In another further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: R is substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH2CH3, CH(CH 3 ) 2 , CH2CH2CH3, -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , F, and CF 3 ; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , and 0CF 3 , and 0-2 substituents independently selected at each occurrence from the group CH3, CH 2 CH 3 , CH(CH 3 ) 2 CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 )2/ CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH(CH 3 ) 2 ; R 3 and R 7 are independently selected at each occurrence from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , 0CH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 > 2 , CH 2 CH 2 CH 3 , cyclopropyl, 0CH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 . [3n] In another even further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: 1 R is substituted with 0-2 substituents independently selected at each occurrence from the group R la , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH 2 0CH 3 , - CH 2 CH 2 OCH 3 , F, and CF 3 ; and, R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [3o] In another still further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [3p] In another still further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [3q] In another more preferred embodiment, the present invention provides a novel compound of formula lb, wherein: R 1 is selected from the group Ci-io alkyl, C 2 - 10 alkenyl, C2-10 alkynyl, C3-8 cycloalkyl, C3-6 cycloalkyl-C -6 alkyl and C 1 - 4 alkoxy-Cι- 4 alkyl; 1 R is substituted with a C 3 - 8 cycloalkyl group, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl group is replaced by a group selected from the group -0-, -S(0) n -» -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C 1 - 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -0R 13a , -NR 13a R 16a , Cι_ 2 alkoxy-Cι_ 2 alkyl, and C 3 - 8 cycloalkyl which is substituted with 0- 1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH ) 2 - group; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17 R 19a , and -CONR 17a R 19 ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, Cι_ 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) m R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17 R 19a , -NR 15 C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , COR 14b and S0 2 R 14b ; and, R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b , -COR 13 , -0C(0)R 14b , -NR 15a C0R 13a , -N(C0R 13a ) 2 , -NR 15a C0NR 13a R 16 , -NR 15a C0 2 R 14b , -NR 13a R 16a , and -C0NR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R a , C0 2 R 14b , C0R 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized. [3r] In another even more preferred embodiment, the present invention provides a novel compound of formula lb, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group C 1 - 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C 3 - 8 cycloalkyl; R is substituted with a C 3 - 6 cycloalkyl group, wherein 0-1 carbon atoms in the C 4 - 6 cycloalkyl group is replaced by a group selected from the group -0-, -S(0) n -, and -NR 13a -; 1 R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι_6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -0R 13a , -NR 13 R 16a , C 1 - 2 alkoxy-Cι_ 2 alkyl, and C 3 - 6 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; R l is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group Cι_ 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R 19a , and -C0NR 17 R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 4 alkyl, C - 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -NR 17a R 1 a , and -C0NR 17a R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , C0R 14b and S0 2 R 14b ; R 2 is selected from the group Cι_ 4 alkyl, C 2 _ 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C1- 4 alkoxy; R 9 is independently selected at each occurrence from the group H, Cι_ 4 alkyl and C 3 - 8 cycloalkyl; R 3 and R 7 are independently selected at each occurrence from the group H, Br, Cl, F, -CN, C 1 - 4 alkyl, C 3 - 6 cycloalkyl, C 1 - 4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C 1 - 4 alkyl) 2 -amino; R 13 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C1-2 alkoxy-Cι_2 alkyl, C3-6 cycloalkyl-Cι_2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (C 1 - 2 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 -6 alkyl; R 14 is selected from the group C 1 -4 alkyl, C 1 - 2 haloalkyl, C1-2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (Cι_2 alkyl)-; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι- 2 alkyl, and C3-6 cycloalkyl-Cι-2 alkyl; R 14b is selected from the group C 1 - 4 alkyl, Cι- 2 haloalkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, C 3 - 6 cycloalkyl, and C3-6 cycloalkyl-Cι- 2 alkyl; R 15 is independently selected at each occurrence from the group H, C1-4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- Cι_ 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C 1 - 4 haloalkyl, C 1 - 4 alkoxy, Cι_ 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, Cι- 4 alkyl, C 3 - 7 cycloalkyl, and C 3 _ 6 cycloalkyl-Cι- 6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C3-6 cycloalkyl-Cι_6 alkyl, C1-2 alkoxy-Cι_ 2 alkyl, and C 1 - 4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 17 and R 19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0R 14 ; R 17 and R 19a are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C3-.10 cycloalkyl, C3- 6 cycloalkyl-Cι-6 alkyl and C1-4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 / -COR 17 , -C0 2 R 17 , -NR 15 COR 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl, benzoxazolyl, isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 _ 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 C0R 17 , -N(C0R 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 5 , C0 2 R 14a , COR 14a and S0 2 R 14a . [3s] In another still more preferred embodiment, the present invention provides a novel compound of formula lb, wherein: X is selected from the group 0, S and a bond; R 1 is C 1 - 6 alkyl; 1 R is substituted with a C 3 - 6 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 4 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, and -NR 13a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι_ 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, F, CF 3 , -0R 13a , -NR 13a R 16a , -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , and C 3 - 6 cycloalkyl which is substituted with 0-1 CH 3 and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2- group; R la is aryl and is phenyl substituted with 0-1 substituents selected from 0CH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0 ) N ( CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; R 3 and R 7 are independently selected at each occurrence from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF3, Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 )2; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 37 OCF 3 , Br, Cl, F, CF 3 , -CN, SCH3, SO2CH3, -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH3, CO2CH3, COCH3 and SO2CH3. [3t] In another further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: R 1 is (cyclopropyl )Cι alkyl or (cyclobutyl) Ci alkyl; R is substituted with 1-2 substituents independently selected at each occurrence from the group R la , R lb , CH3, CH2CH3, CH(CH 3 ) 2 , CH2CH2CH3, -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , ■ F, CF3, cyclopropyl, CH3-cyclopropyl, cyclobutyl, CH3- cyclobutyl, cyclopentyl, CH3-cyclopentyl; R la is phenyl substituted with 0-1 substituents selected from OCH3, OCH 2 CH3, and OCF3, and 0-2 substituents independently selected at each occurrence from the group CH3, CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH3, OCH 2 CH 3 , OCF3, Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH3, CO2CH3, COCH3 and SO2CH3; R 2 is selected from the group CH3, CH2CH3, and CH(CH3) 2 ; R 3 and R 7 are independently selected at each occurrence from the group H and CH3; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group. CH 3 , CHCH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 / -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 )2/ -C(0)NH 2 , -C(0)NHCH 3 , and -C ( 0 ) N ( CH 3 ) 2 . [3u] In another even further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: R 1 is (cyclopropyl)Cι alkyl or (cyclobutyl)Cι alkyl; R is substituted with 1-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, and pyrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CHCH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [3v] In another further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH2CH2CH3, OCF3, Br, Cl, F, and CF 3 . [3w] In another further preferred embodiment, the present invention provides a novel compound of formula lb, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [4] In another preferred embodiment, the present invention provides a novel compound of formula Ic: [4a] In another more preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: X is selected from the group 0, S(0) n and a bond; n is 0 , 1 or 2 ; R 1 is selected from the group Cι_ 6 alkyl, C 2 - 6 alkenyl, C _ 6 alkynyl, and C 3 - 8 cycloalkyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -COR 13a , -C0 2 R 13a , and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group --O0--, -S(0) n -/ -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 _ 8 alkenyl, C 2 - 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -0R 13a , -NR 13a R 16a , C 1 - 2 alkoxy-Cι- 2 alkyl, and 9 C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH2) 2- group; R la is aryl and is selected from the- group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 -. 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, Cι_ 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R 19a , and -CONR 17 R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C1- 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -NR 17a R 19 , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , -C0 2 R 14b , COR 14b and S0 2 R 14b ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 ) 1 - 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group C 1 - 4 alkyl, C 2 - 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C 1 - 4 alkoxy; R 3 is selected from the group H, Br, Cl, F, -CN, C 1 -. 4 alkyl, C 3 - 6 cycloalkyl, C 1 - 4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C 1 - 4 alkyl ) 2 -amino; R 9 is independently selected at each occurrence from the group H, Cι_ 4 alkyl and C 3 -. 8 cycloalkyl; R13 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι_ 2 alkyl, C3-6 cycloalkyl-Cι_ 2 alkyl, aryl (Cι_ 2 alkyl)-, and heteroaryl (Cι- 2 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C3- 6 cycloalkyl- C1-6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, Cι- 2 haloalkyl, Cι_ alkoxy-Cι_ alkyl, C 3 - 6 cycloalkyl-Cι_ 2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (Cι- alkyl)-; R 14a is selected from the group C1- 4 alkyl, Cι_ 2 haloalkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, and C 3 - 6 cycloalkyl-Cι- 2 alkyl; R 14b is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, Cι- 2 alkoxy-Cι- 2 alkyl, C 3 -6 cycloalkyl, and C3-6 cycloalkyl-Cι_ alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 _ 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C 1 - 4 haloalkyl, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Ci- 6 alkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, and C 1 - 4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 7 and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, C1- 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and C1-4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C1-4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C1- 4 haloalkyl, -CN, -S(0) n R 18 / -COR 17 , -C0 2 R 17 , -NR 15 COR 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl , benzothiazolyl , benzoxazolyl , isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 -6 cycloalkyl, Br, Cl, F, C 1 -4 haloalkyl, -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom 15 with 0-1 substituents selected from the group R , 14a C0 2 R COR 14a and S0 2 R 14a . [4b] In another even more preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: X is selected from the group 0, S and a bond; R 1 is substituted Cι_ 6 alkyl; R is substituted with 0-1 substituents selected from the group -CN, -Cθ 2 R 13a , and C 3 _β cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ and -NR 13a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C1-6 alkyl, C2-8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF 3 , -OR 13a , -NR 13a R 16a , Cι_2 alkoxy-Cι_ 2 alkyl, and C 3 - 6 cycloalkyl which is substituted with 0-1 CH 3 and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; . provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R la is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH3, CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) / -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH 2 )ι- 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH2CH2CH3 ; R 3 is selected from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , . OCH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH3, S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 . [4c] In another still more preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R 1 is substituted Ci; R is substituted with 0-1 substituents selected from the group -CN, -C0CH 3 , and -C0 2 CH 2 CH 3 ; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 0CH 3 , F, CF 3 , cyclopropyl, CH 3 -cyclopropyl, cyclobutyl, CH 3 - cyclobutyl, cyclopentyl, CH 3 -cyclopentyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCHCH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each - heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 ; provided that R 1 is other than a - (CH 2 ) 1 - 4 -aryl or - (CH )ι- 4 -heteroaryl wherein the aryl or heteroaryl group is substituted or unsubstituted; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH(CH 3 ) 2 ; R 3 is selected from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 / OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH3 , -N (CH 3 ) 2 , -C (0 ) NH 2 , -C (0) NHCH 3 , and -C (0) N (CH 3 ) 2 . [4d] In another further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R 1 is substituted (cyclopropyl) -Ci alkyl or (cyclobutyl )Cι alkyl; R 1 is substituted with 0-1 -CN; R is also substituted with 0-1 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, and pyrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [4e] In another further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R 1 is (cyclopropyl )Cι alkyl or (cyclobutyl) -Ci alkyl substituted with 1 substituent independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , Cl, F, and CF 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, and isoxazolyl, each heteroaryl being substituted on 0-2 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , OCH 3 , Cl, F, and CF 3 . [4f] In an even further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R 1 is selected from the group (cyclopropyl )CH-CH 3 , (cyclopropyl ) CH-CH 2 CH 3 , (cyclopropyl ) CH-CH 2 OCH 3 , (cyclopropyl) CH-CH 2 CH 2 CH 3 , (cyclopropyl) CH-CH 2 CH 2 OCH 3 , (cyclopropyl ) 2 CH, phenyl (cyclopropyl)CH, furanyl (cyclopropyl )CH, thienyl (cyclopropyl) CH, isoxazolyl (cyclopropyl) CH, (CH 3 - furanyl) (cyclopropyl )CH, (cyclobutyl)CH-CH 3 , (cyclobutyl) CH-CH 2 CH 3 , (cyclobutyl) CH-CH 2 OCH 3 , (cyclobutyl ) CH-CH 2 CH 2 CH 3 , (cyclobutyl ) CH-CH 2 CH 2 OCH 3 , (cyclobutyl) 2 CH, phenyl (cyclobutyl) CH, furanyl (cyclobutyl ) CH, thienyl (cyclobutyl ) CH, isoxazolyl (cyclobutyl) CH, and (CH 3 - furanyl) (cyclobutyl) CH; [4g] In another further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF3, Br, Cl, F, and CF3. [4h] In another further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, 0CH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [4i] In another preferred embodiment, the present invention provides a novel compound of formula Ic, wherein the compound is selected from the group: 6- (2, 4-bis (trifluoromethyl) phenyl-9- (dicyclopropylmethyl) -8- ethyl-9H-purine; 6- (2-chloro-4-cyanophenyl) -9- (dicyclopropylmethyl) -8-ethyl-9H- purine; 6- (2-chloro-4-methoxy-5-chlorophenyl) -9- (dicyclopropylmethyl) - 8-ethyl SH-purine; 6- (2-chloro-4-methoxy-5-methylphenyl) -9- (dicyclopropylmethyl) - 8-ethyl -9H-purine; 6- (2-chloro-4-methoxyphenyl) -8-ethyl-9- (2-hexyl) - 9H-purine; 6- (2-chloro-4-methoxyphenyl) -8-ethyl-9- (2-pentyl) -9H-purine; 6- (2-chloro-4-methoxyphenyl) -8-ethyl-9- (3-heptyl) -9H-purine; 6- (2-chloro-4-methoxyphenyl) -8-ethyl-9- (3-hexyl) -9H-purine; 6- (2-chloro-4-methoxyphenyl) -8-ethyl-9- (4-heptyl) -9#-purine; 6- (2-chloro-4-methoxyphenyl) -9- (1-cyclopropylbutyl) -8-ethyl- 9H-purine; 6- (2-chloro-4-methoxyphenyl) -9- (1-cyclopropylpropyl) -8-ethyl- 9H-purine; 6- (2-chloro-4-methoxyphenyl) -9- (dicyclopropylmethyl) -8-ethyl- 9H-purine; 6- (2-chloro-4-methoxyphenyl) -9- (dicyclopropylmethyl) -8- methoxy-9H-purine; 6- (2-chloro-4-methyl-5-fluorophenyl) -9- (dicyclopropylmethyl) - 8-ethyl -9H-purine; 6- (2-chloro-4-methylphenyl) -8-ethyl-9- (2-pentyl) -9H-purine; 6- (2-chloro-4-methylphenyl) -8-ethyl-9- (4-heptyl) -9H-purine; 6- (2-chloro-4-methylphenyl) -9- (1-cyclopropylbutyl) -8-ethyl-9H- purine; 6- (2-chloro-4-methylphenyl) -9- (dicyclopropylmethyl) -8-ethyl- 9H-purine; 6- (2-chloro-4-trifluoromethoxyphenyl) -8-ethyl-9- (2-pentyl) -9H- purine; 6- (2-chloro-4-trifluoromethoxyphenyl) -8-ethyl-9- (3-hexyl) -9H- purine; 6- (2-chloro-4-trifluoromethoxyphenyl) -9- (1-cyclopropylbutyl) - 8-ethyl -9H-purine; 6- (2-chloro-4-trifluoromethoxyphenyl) -9- (1-cyclopropylpropyl) 8-ethyl-9H- urine; 6- (2-chloro-4-trifluoromethoxyphenyl) -9- (dicyclopropylmethyl) 8-ethyl-9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- (l-hexyn-3-yl) 9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- (l-pentyn-3- yl) -9 H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- (l-pentyn-4- yl ) -9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- (l-phenyl-2- butynyl ) -9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- (2-heptyn-4- yl) -9JJ-purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- (2-hexyn-4-yl) 9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- (2-pentyl) -9H- purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- (4-heptyl) -9H- purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- [ (2-furanyl) - cyclopropylmethyl] -9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -8-ethyl-9- [1- (2- furanyl) ropyl] -9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -9- (1-cyclobutylethyl) -8- ethyl-9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -9- (l-cyclopropyl-2- butynyl) -8-ethyl-9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -9- (l-cyclopropyl-2- propenyl) -8-ethyl-9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -9- (1-cyclopropylbutyl) -8- ethyl-9/f-purine; 6- (2-chloro-4-trifluoromethylphenyl) -9- (1-cyclopropylpropyl) - 8-ethyl-9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -9- (dicyclopropylmethyl) - 8-ethyl-9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -9- (dicyclopropylmethyl) - 8-methoxy- 9H-purine; 6- (2-chloro-4-trifluoromethylphenyl) -9- [1-cyclopropyl-l- (2- thienyl) methyl] -8-ethyl-9H-purine; 9- (1-cyclobutylethyl) -6- (2,4-dichlorophenyl) -8-ethyl-9H- purine; 9- [1-cyclopropyl- (3-methylisoxazol-5-yl)methyl] -6- (2,4- dichlorophenyl) -8-ethyl-9H-purine; 9- (1-cyclopropyl-2-butynyl) -6- (2, 4-dichlorophenyl) -8-ethyl-9H- purine; 9- (l-cyclopropyl-2-butynyl) -6- (2,4-dichlorophenyl) -8-ethyl-9H- purine; 9- (l-cyclopropyl-2-propenyl) -6- (2, 4-dichloro-6-methylphenyl) - 8-ethyl-9H-purine; 9- (l-cyclopropyl-2-propenyl) -6- (2, 4-dichlorophenyl) -8-ethyl- 9H-purine; 9- (1-cyclopropyl-2-propynyl) -8-ethyl-6- (2-trifluoromethyl-4- methoxyphenyl) -9H- urine; 9 (l-cyclopropyl-4'-fluorobenzyl) -6- (2,4-dichlorophenyl) -8- ethyl-9H-purine; 9-(l-cyclopropylbenzyl)-6- (2,4-dichlorophenyl) -8-ethyl-9H- purine; 9- (1-cyclopropylbenzyl) -8-ethyl-6- (2-trifluoromethyl-4- methoxyphenyl) -9H-purine; 9- (l-cyclopropylbutyl)-6- (2,4-dichlorophenyl) -8-ethyl-9H- purine; 9- (1-cyclopropylbutyl) -8-ethyl-6- (2 , 4, 6-trimethylphenyl) -9H- purine; 9- (l-cyclopropylbutyl)-8-ethyl-6- (2-methyl-4,5- dimethoxyphenyl) -9H-purine; 9- (1-cyclopropylbutyl) -8-ethyl-6- (2-methyl-4-chlorophenyl) -9H- purine; 9- (1-cyclopropylbutyl) -8-ethyl-6- (2-methyl-4-methoxyphenyl) - 9H-purine; 9- (1-cyclopropylbutyl) -8-ethyl-6- (2-trifluoromethyl-4- chlorophenyl) -9H-purine; 9- (1-cyclopropylbutyl) -8-ethyl-6- (2-trifluoromethyl-4- methoxyphenyl) - 9H-purine; 9- (1-cyclopropylethyl) -6- (2 , 4-dichlorophenyl ) -8-ethyl-9H- purine; 9- (1-cyclopropylethyl) -8-ethyl-6- (2-trifluoromethyl-4- chlorophenyl) -9H-purine; 9- (1-cyclopropylpentyl) -8-ethyl-6- (2-methyl-4-methoxyphenyl) - 9H-purine; 9- (1-cyclopropylpropyl) -6- (2, 4-dichloro-6-methylphenyl) -8- ethyl-9H-purine; 9- (1-cyclopropylpropyl) -6- (2, 4-dichlorophenyl) -8-ethyl-9H- purine; 9- (1-cyclopropylpropyl) -8-ethyl-6- (2,4, 6-trimethylphenyl) SHpurine; 9- (1-cyclopropylpropyl) -8-ethyl-6- (2-trifluoromethyl-4- chlorophenyl ) -9iϊ-purine; 6- (2, 4-dichloro-5-fluorophenyl) -9- (dicyclopropylmethyl) -8- ethyl-9H-purine; 6- (2,4-dichloro-6-methylphenyl)-8-ethyl-9- (2-penten-3-yl) -9H- purine; 6- (2, 4-dichloro-6-methylphenyl) -9- (dicyclopropylmethyl) -8- ethyl-9H-purine; 6- (2,4-dichlorophenyl) -8-ethyl-9- (l-hexyn-3-yl) -9H-purine; 6- (2 , 4-dichlorophenyl) -8-ethyl-9- (1-methoxycarbonylpropyl) -9H- purine; 6- (2 , 4-dichlorophenyl) -8-ethyl-9- (l-phenyl-2-butynyl) -9H- purine; 6- (2,4-dichlorophenyl) -8-ethyl-9- (2-heptyn-4-yl) -9H-purine; 6- (2,4-dichlorophenyl)-8-ethyl-9- (2-hexyl) SH-purine; 6- (2,4-dichlorophenyl) -8-ethyl-9- (2-hexyn-4-yl) -9H-purine; 6- (2,4-dichlorophenyl)-8-ethyl-9- (2-penten-3-yl) -9H-purine; 6- (2,4-dichlorophenyl) -8-ethyl-9- (2-pentyl) -9H-purine; 6- (2,4-dichlorophenyl) -8-ethyl-9- (3-heptyl) SH-purine; 6- (2,4-dichlorophenyl)-8-ethyl-9- (3-hexyl) -9H-purine; 6- (2,4-dichlorophenyl)-8-ethyl-9- (3-pentyl) -9H-purine; 6- (2,4-dichlorophenyl) -8-ethyl-9- (4-heptyl) -9H-purine; 6- (2 , 4-dichlorophenyl) -8-ethyl-9- [1- (2- methylcyclopropyl) ethyl] -9H-purine; 6- (2 , 4-dichlorophenyl) -9- (dicyclopropylmethyl) -8-ethyl-9ff- purine; 6- (2,4-dichlorophenyl)-9- (dicyclopropylmethyl) -8-ethyl-9H- purine; 6- (2 , 4-dichlorophenyl) -9- (dicyclopropylmethyl) -8-methoxy-9H- purine; 6- (2,4-dichlorophenyl) -9- (diphenylmethyl) -8-ethyl-9H-purine; 9- (dicyclopropylmethyl) -6- (2, 4-dimethylphenyl) -8-ethyl-9H- purine; 9- (dicyclopropylmethyl) -6- (2,4-dimethylphenyl)-8-ethyl-9H- purine; 9- (dicyclopropylmethyl) -6- (2, 6-dimethoxypyridin-3-yl) -8- methoxy-9H-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2,4, 5-trichlorophenyl) -9H- purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-methoxy-4- trifluoromethylphenyl ) - 9H-purine; 9- (dicyclopropylmethyl)-8-ethyl-6- (2-methyl-4,5- dimethoxyphenyl ) -9H-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-methyl-4-chlorophenyl) - 9 H-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-methyl-4- dimethylaminophenyl) -9H-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-methyl-4-methoxy-5- chlorophenyl) -9tf-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-methyl-4-methoxy-5- fluorophenyl) -9H-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-chloro-4-methoxy-5- fluorophenyl) -9H-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-methyl-4-methoxyphenyl) - 9H-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-trifluoromethyl-4- chlorophenyl) -9H-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-trifluoromethyl-4- methoxyphenyl ) - 9H-purine; 9- (dicyclopropylmethyl) -8-ethyl-6- (2-trifluoromethyl-4- propyloxyphenyl) -9H-purine; 6- (2, 6-dimethoxypyridin-3-yl) -8-ethyl-9- (2-pentyl) -9H-purine; 6- (2 , 4-dimethylphenyl) -8-ethyl-9- (2-pentyl) -9tf-purine; 8-ethyl-6- (2-methyl-4, 5-dimethoxyphenyl) -9- (2-pentyl) -9H- purine; 8-ethyl-6- (2-methyl-4, 5-dimethoxyphenyl) -9- (3-pentyl) SH- purine; 8-ethyl-9- (l-hexen-3-yl) -6- (2-methyl-4, 5-dimethoxyphenyl) -9H- purine; 8-ethyl-9- (l-hexen-3-yl) -6- (2-trifluoromethyl-4- methoxyphenyl ) - 9H-purine; 8-ethyl-9- (2-hexyl) -6- (2-trifluoromethyl-4-methoxyphenyl) -9H- purine; 8-ethyl-9- (2-pentyl) -6- (2-trifluoromethyl-4-methoxyphenyl) -9H- purine; 8-ethyl-9- (3-hexyl) -6- (2-methyl-4-methoxyphenyl) -9H-purine; 8-ethyl-9- (3-hexyl)-6- (2-trifluoromethyl-4-methoxyphenyl) -9H- purine; 8-ethyl-9- (3-pentyl) -6- (2-trifluoromethyl-4-chlorophenyl) -9H- purine; 8-ethyl-9- (4-heptyl) -6- (2-methyl-4-chlorophenyl) -9H-purine; 8-ethyl-9- (4-heptyl) -6- (2-methyl-4-methoxyphenyl) -9H-purine; 8-ethyl-9- (4-heptyl) -6- (2-trifluoromethyl-4-chlorophenyl) SH- purine; 8-ethyl-9- (4-heptyl) -6- (2-trifluoromethyl-4 methoxyphenyl ) - 9H-purine; and 9- (dicyclopropylmethyl) -8-ethyl-6- (2-methyl-6-methoxy-3- pyridyl) -9H-purine; or a pharmaceutically acceptable salt form thereof. [4j] In another more preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R 1 is C 3 - 8 cycloalkyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b / -COR 13a , -C0 2 R 13a , -NR 15a COR 13 , -N(COR 13a ) 2 , -NR 15 CONR 13 R 16a , -NR 15a C0 2 R 1 b , -CONR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 4 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group 13a selected from the group -0-, -S(0) n -/ -NR -, -NC0 2 R 14b -, -NC0R 14b - and -NS0 2 R 14b -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , C0R 14b and S0 2 R 14b ; and, R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C 1 - 6 alkyl, C 2 - 3 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -0R 13a , C 1 - 2 alkoxy-Cι- 2 alkyl, and -NR 13a R 16a . [4k] In another even more preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group cyclopropyl, cyclobutyl, and cyclopentyl; R is substituted with 0-1 substituents selected from the group -CN, -S(0)nR 14b , -COR 13a , -C0 2 R 13a , and C _ 8 cycloalkyl, wherein one carbon atom in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 1 b -; 1 R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, Br, Cl, F, CF3, CF 2 CF 3 , -0R 13a , Cι_ 2 alkoxy-Cι- 2 alkyl, and -NR 13a R 16 ; R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R 19 , and -C0NR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 -. 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -NR 17a R 19a , and -C0NR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group C0R 14b and S0 2 R 14b ; R 2 is selected from the group C 1 - 4 alkyl, C 2 _ 4 alkenyl, and C 2 - 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and C 1 - 4 alkoxy; R 9 is independently selected at each occurrence from the group H, C 1 - 4 alkyl and C 3 - 8 cycloalkyl; R 3 is selected from the group H, Br, Cl, F, -CN, Cι_ 4 alkyl, C 3 - 6 cycloalkyl, C 1 - 4 alkoxy, NH 2 , Cι_4 alkylamino, and (C 1 - 4 alkyl ) 2 -amino; R 13 is selected from the group C 1 - 4 alkyl, C 1 - 2 haloalkyl, Cι- 2 alkoxy-Cι_ 2 alkyl, C 3 - 6 cycloalkyl-C _ 2 alkyl, aryl(Ci- 2 alkyl)-, and heteroaryl (C1-2 alkyl)-; R 13 and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 -- 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group Cι_ 4 alkyl, C 1 - 2 haloalkyl, C 1 - 2 alkoxy-Cι- 2 alkyl, C 3 -6 cycloalkyl-Cι_ 2 alkyl, aryl(Cι_ 2 alkyl)-, and heteroaryl (Cι_ 2 alkyl)-; R 14a is selected from the group C 1 - 4 alkyl, Cι_ 2 haloalkyl, Cι_ 2 alkoxy-Cι- 2 alkyl, and C 3 - 6 cycloalkyl-Cι- 2 alkyl; R 14b is selected from the group C 1 -4 alkyl, Cι_ 2 haloalkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι- 2 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C1- 4 haloalkyl, C 1 - 4 alkoxy, C1-4 haloalkoxy, and dimethylamino; R i5 a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C 1 - 4 haloalkyl; 17 19 17 19 alternatively, in an NR R moiety, R and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C3- 1 0 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and C 1 -4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C 1 - 4 haloalkyl, -CN, -S(0) n R 18 / -COR 17 , -C0 2 R 17 , -NR 15 C0R 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C 1 - 4 haloalkyl, -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15, C0 2 R 14a , COR 1 a and S0 2 R 14a . [41] In another still more preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: X is selected from the group 0, S and a bond; R is substituted with 0-1 substituents selected from the group -CN, -C0 2 R 13a , and C 4 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, and R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, CF3, CF 3 , -0R 13a , -OH, -OCH 3 , -OCH 2 CH 3 , -CH 2 OCH 3 , - CH 2 CH 2 OCH 3 , and -NR 13 R 16 ; R la is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH 3 , -N(CH 3 ) 2/ -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; R 3 is selected from the group H, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF3, -CN, SCH 3 , SO2CH3, -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 . [4m] In another further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R is substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CHsCH, -CH≡C(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 OCH 3 , F, and CF 3 ; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) , OCH 2 CH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , CCCH 3 and S0 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH (01 3 ) 2 ; R 3 is selected from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , 0CH 2 CH 3 , 0CH(CH 3 ) 2 , 0CH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF3, -CN, SCH3, SO2CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF3, Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH3, -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0 ) N(CH 3 ) 2 . [4n] In another even further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R is substituted with 0-2 substituents independently selected at each occurrence from the group R la , CH 3 , CH2CH3, CH(CH 3 ) 2 , CH 2 CH2CH3, -(CH 2 ) 3 CH 3 , -CH2OCH3, - CH 2 CH 2 OCH 3 , F, and CF 3 ; and, R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [4o] In another still further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [4p] In another still further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [4q] In another more preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R 1 is selected from the group C 1 -10 alkyl, C 2 - 10 alkenyl, C2-10 alkynyl, C 3 - 8 cycloalkyl, C3-6 cycloalkyl-Cι_6 alkyl and C 1 - 4 alkoxy-Cι_ 4 alkyl; R is substituted with a C 3 - 8 cycloalkyl group, wherein 0-1 carbon atoms in the C4- 8 cycloalkyl group is replaced by a group selected from the group -0-, -S(0) n -/ -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -; R 1 is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -0R 13a , -NR 13a R 16 , Cι_ 2 alkoxy-Cι_ 2 alkyl, and C 3 - 8 cycloalkyl which is substituted with 0- 1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH 2 ) 2 - group; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group Ci-β alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17 R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl , benzothiazolyl , benzoxazolyl , isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 2,3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Ci-e alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a C0NR 17a R 19 , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -C0NR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , C0R 14b and S0 2 R 14b ; and, R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b / -C0R 13a , -0C(0)R 14b , -NR 15a C0R 13a , -N(C0R 13 ) 2 , -NR 15a C0NR 13 R 16a , -NR 15 C0 2 R 14b , -NR 13 R 16a , and -C0NR 13 R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R ,13a C0 2 R 14b , C0R 14b and S0 2 R 14b and wherein any sυ is optionally monooxidized or dioxidized. [4r] In another even more preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: X is selected from the group 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, and C 3 - 8 cycloalkyl; R is substituted with a C 3 - 6 cycloalkyl group, wherein 0-1 carbon atoms in the C 4 -. 6 cycloalkyl group is replaced by a group selected from the group -0-, -S(0) n -, and -NR 13a -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 - 8 alkynyl, Br, Cl, F, CF 3 , CF 2 CF 3 , -0R 13a , -NR 13a R 16a , C 1 - 2 alkoxy-Cι-2 alkyl, and g C 3 _ 6 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; R la is aryl and is selected from the group phenyl and indanyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 -. 6 cycloalkyl, Br, Cl, F, C 1 -4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -NR 17a R a , and -C0NR 17 R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, furanyl, thienyl, imidazolyl, thiazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, CF 3 , -CN, -OR 17 , -S(0) m R 18 , -COR 17 , -NR 17a R 1 , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R --,15a, C ~,0~ 2 R τ> 14b, C-,O_R τ -14b and ■, S-,0._ 2π R14b; R 2 is selected from the group C 1 - 4 alkyl, C - 4 alkenyl, and C _ 4 alkynyl and is substituted with 0-1 substituents selected from the group -CN, OH, Cl, F, and Cι_ 4 alkoxy; R 9 is independently selected at each occurrence from the group H, C 1 - 4 alkyl and C 3 _ 8 cycloalkyl; R 3 is selected from the group H, Br, Cl, F, -CN, C 1 - 4 alkyl, C 3 - 6 cycloalkyl, C 1 - 4 alkoxy, NH 2 , C 1 - 4 alkylamino, and (C 1 - 4 alkyl ) 2 -amino; R 13 is selected from the group C 1 - 4 alkyl, Cι- 2 haloalkyl, C1-2 alkoxy-Cι-2 alkyl, C3-6 cycloalkyl-Cι-2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (Cι_ 2 alkyl)-; R 13 and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, C 3 - 6 cycloalkyl, and C3-6 cycloalkyl- C 1 -6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, Cι- 2 haloalkyl, C1-2 alkoxy-Cι- 2 alkyl, C3-6 cycloalkyl-Cι_ 2 alkyl, aryl(Cι- 2 alkyl)-, and heteroaryl (Cι_ 2 alkyl)-; R 14 is selected from the group C 1 - 4 alkyl, Cι_ 2 haloalkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, and C 3 - 6 cycloalkyl-Cι_ 2 alkyl; R 14b is selected from the group C 1 - 4 alkyl, Cι- 2 haloalkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι_ alkyl; R 15 is independently selected at each occurrence from the group H, Cι- 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- Cι_6 alkyl, phenyl and benzyl, each phenyl or benzyl being, substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, C 1 - 4 haloalkyl, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R i5 a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Ci-6 alkyl; R 17 , R 18 and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, and Cι_ 4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 17 and R 19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0R 14 ; R 17 and R 19a are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C3- 1 0 cycloalkyl, C 3 -6 cycloalkyl-C 1 - 6 alkyl and C1-4 haloalkyl; aryl is phenyl substituted with 1-4 substituents independently selected at each occurrence from the group C 1 - 4 alkyl, C 3 - 6 cycloalkyl, -OR 17 , Br, Cl, F, C1-4 haloalkyl, -CN, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -NR 15 COR 17 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl , isoxazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 1-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, C1- 4 haloalkyl, -CN, -OR 17 , -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15, C0 2 R 14 , COR 14a and S0 2 R 1 a . [4s] In another still more preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: X is selected from the group 0, S and a bond; R 1 is C 1 - 6 alkyl; R is substituted with a C 3 - 6 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 4 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, and -NR -; R is also substituted with 0-2 substituents independently selected at each occurrence from the group R la , R lb , Cι- 6 alkyl, C 2 _ 8 alkenyl, C 2 _ 8 alkynyl, F, CF 3 , -0R 13a , -NR 13a R 16a , -CH 2 OCH 3 , -CH 2 CH 2 0CH 3 , and C 3 - 6 cycloalkyl which is substituted with 0-1 CH 3 and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -0-; provided that R 1 is other than a cyclohexyl- (CH2) 2- group; R l is aryl and is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , and OCF 3 , and 0-3 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, and indazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , -NH 2 , - NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and S0 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; R 3 is selected from the group H, CH 3 , CHCH 3 , CH(CH 3 ) 2 , and CH 2 CH 2 CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is independently selected at each occurence from the group pyridyl, indolyl, benzothienyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, and benzoxazolin-2-on-yl, each heteroaryl being substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3/ Br, Cl, F, CF 3 , -CN, SCH 3 , SO 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , C0 2 CH 3 , COCH 3 and SO 2 CH 3 . [4t] In another further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R 1 is (cyclopropyl)Cι alkyl or (cyclobutyl)Cι alkyl; 1 R is substituted with 1-2 substituents independently selected at each occurrence from the group R l , R lb , CH 3 , CH 2 CH3, CH(CH 3 ) 2 , CH2CH2CH3, -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CH≡C(CH 3 ), -CH 2 OCH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, CH 3 -cyclopropyl, cyclobutyl, CH 3 - cyclobutyl, cyclopentyl, CH 3 -cyclopentyl; R la is phenyl substituted with 0-1 substituents selected from OCH 3 , OCH 2 CH 3 , and OCF 3 , and 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, and tetrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group CH 3 , CO 2 CH 3 , COCH 3 and SO 2 CH 3 ; R 2 is selected from the group CH 3 , CH 2 CH 3 , and CH(CH 3 ) 2 ; R 3 is selected from the group H and CH 3 ; aryl is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C (0)N(CH 3 ) 2 ; and, heteroaryl is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, CF 3 , -CN, SCH 3 , S0 2 CH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -C(0)NH 2 , -C(0)NHCH 3 , and -C(0)N(CH 3 ) 2 . [4u] In another even further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: R 1 is (cyclopropyl)Cι alkyl or (cyclobutyl)Cι alkyl; R 1 is substituted with 1-2 substituents independently selected at each occurrence from the group R la , R lb , CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , -(CH 2 ) 3 CH 3 , -CH=CH 2 , - CH=CH(CH 3 ), -CH≡CH, -CHsC(CH 3 ), -CH 2 0CH 3 , -CH 2 CH 2 OCH 3 , F, CF 3 , cyclopropyl, and CH 3 -cyclopropyl; R la is phenyl substituted with 0-2 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 ; R lb is heteroaryl and is selected from the group furanyl, thienyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, and pyrazolyl, each heteroaryl being substituted on 0-3 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , 0CH 3 , OCH 2 CH 3 , 0CF 3 , Br, Cl, F, CF 3 , -CN, and SCH 3 . [4v] In another further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: D is phenyl substituted with 2-4 substituents independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF3, Br, Cl, F, and CF 3 . [4w] In another further preferred embodiment, the present invention provides a novel compound of formula Ic, wherein: D is pyridyl substituted on 2-4 carbon atoms with a substituent independently selected at each occurrence from the group CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 3 , cyclopropyl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCH 2 CH 2 CH 3 , OCF 3 , Br, Cl, F, and CF 3 . [5] In a third embodiment, the present invention provides a novel pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) : (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; provided that at least one of the groups A and B is N; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 _ιo alkenyl, C _ιo alkynyl, C 3 - 8 cycloalkyl, C3-6 cycloalkyl-Cι- 6 alkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, -S0 2 -Cι_ιo alkyl, -S0 2 -R la , and -S0 2 -R lb ; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 1 b , -C0R 13a , -C0 2 R 13 , -NR 15a C0R 13a , -N(C0R 13a ) 2 , -NR 15a C0NR 13a R 16a , -NR 15a C0 2 R 1 b , -C0NR 13a R 16a , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 -. 8 cycloalkyl is replaced by a group ,13a selected from the group -0-, -S(0) n -/ -NR -NC0 2 R 1 b -, -NCOR 14b - and -NS0 2 R 14b -, and wherein N 4 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 a , C0 2 R 14b , COR 14b and c . τ-,14b S0 R ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , Cι-6 alkyl, C 2 -8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, Cι-4 haloalkyl, -0R 13 , -NR 13a R 16a , and C 3 _ 8 9 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 - 8 cycloalkyl is replaced by -O- ; provided that R 1 is other than: (a) a 3-cyclopropy1-3-methoxypropyl group; (b) an unsubstituted- (alkoxy) methyl group; and, (c) a 1-hydroxyalkyl group; also provided that when R 1 alkyl substituted with OH, then the carbon adjacent to the ring N is other than CH 2 ; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C3-6 cycloalkyl, Br, Cl, F, I, C1-4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 1 a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl , thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl , benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl , 2,3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17 R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 1 b , COR 14b and S0 2 R 14b ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -0R 13 , SH, -S(0) n R 14b , -C0R 13a , -OC(0)R 14b , -NR 15 C0R 13 , -N(C0R 13a ) 2 , -NR 15 C0NR 13 R 16a , -NR 15a C0 2 R 14b , -NR 13a R 16a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R ,13a C0 2 R 14b , C0R 14b and S0 2 R 14b and wherein any si; is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 2 _ 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 Fs; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 _ 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C1-. 4 alkylamino, (C 1 -4 alkyl ) amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C1-7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, Cι_ 4 haloalkoxy, C 1 - 4 alkylthio, C 1 - 4 alkyl sulfinyl, C1- 4 alkylsulfonyl, C 1 - 6 alkylamino and (C 1 - 4 alkyl) 2 amino; provided that when R 1 is unsubstituted Cι- 10 alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 6 cycloalkyl-Cι- 4 alkyl and C 3 _ 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 _6 cycloalkyl-Cι- 6 alkyl, aryl, aryKCι-4 alkyl)-, heteroaryl and heteroaryl (Cι_ 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 -4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 _ 6 cycloalkyl- C1-6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 -. 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 _ 6 cycloalkyl, C 3 -6 cycloalkyl-Cι-6 alkyl, aryl, aryKCι-4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group Cι_4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 14b is selected from the group C 1 - 4 alkyl, Cι_ 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl-C1-6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C1- 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 is selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C3-6 cycloalkyl-Ci-β alkyl, C 1 - 2 alkoxy-Cι_ 2 alkyl, C1-4 haloalkyl, R 14 S (0) n -Cι-4 alkyl, and R 17b R 19b N-C 2 - alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, Ci-β alkyl, C 3 - 10 cycloalkyl, C3-6 cycloalkyl-Cι- 6 alkyl, C 1 - 2 alkoxy-Cι_ 2 alkyl, and C1-4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 17 and R 19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0R 14 , COR 14 and S0 2 R 14 ; aalltteerrnatively, in an NR R moiety, R and R taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19 are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl and C1-4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 C0R 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, Cι- 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 Fs, OCF 3 , S0 2 Me and acetyl; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl , thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl , benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)πιR 18 , -COR 17 , -C0 2 R 17 , -0C(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 14a , COR 14a and S0 2 R 14a . [6] In a second embodiment, the present invention provides a novel method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post- traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related ' diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of formula (I) : (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; provided that at least one of the groups A and B is N; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 _ιo alkenyl, C2-10 alkynyl, C3-8 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, -SO 2 -C 1 - 10 alkyl, -S0 2 -R la , and -S0 2 -R lb ; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b / -COR 13a , -C0 2 R 13a , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a C0NR 13a R 16a , -NR 15a C0 2 R 14b , -C0NR 13 R 16 , 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -# -NR 13a -, -NC0 2 R 14b -, -NC0R 14b - and -NS0 2 R 1 b -, and wherein N in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , C0R 14b and S0 2 R 14b ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C 1 - 6 alkyl, C 2 - 8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C 1 -4 haloalkyl, -0R 13 , -NR 13 R 16 , and C 3 - 8 cycloalkyl which is substituted with 0-1 R and in which 0-1 carbons of C 4 .- 8 cycloalkyl is replaced by -0-; provided that R 1 is other than: (a) a 3-cyclopropyl-3-methoxypropyl group; (b) an unsubstituted- (alkoxy) methyl group; and, (c) a 1-hydroxyalkyl group; also provided that when R 1 alkyl substituted with OH, then the carbon adjacent to the ring N is other than CH ; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_6 alkyl, C3-6 cycloalkyl, Br, Cl, F, I, C1-4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17 R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl , benzothiazolyl , benzoxazolyl , isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl , 2 , 3-dihydrobenzof ranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C1-6 alkyl, C3-6 cycloalkyl, Br, Cl, F, I, C1-4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR 15a C0R 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, Cι_ 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 1 b , -COR 13a , -0C(0)R 14b , -NR 15a C0R 13a , -N(C0R 13a ) 2 , -NR 15a C0NR 13a R 16a , -NR 15 C0 2 R 1 b , -NR 13a R 16a , and -C0NR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R a , C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 2 _ 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and Cι_ 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 Fs; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C1-4 alkoxy, C 1 - 4 alkylthio, C 1 -4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C1- 4 alkylamino, (C 1 - 4 alkyl) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C1-4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, C1- 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, Ci-β alkylamino and (C 1 - 4 alkyl ) 2 amino; provided that when R 1 is unsubstituted Cι-1 0 alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 6 cycloalkyl-Cι- 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, aryl, aryl (C1-4 alkyl)-, heteroaryl and heteroaryl (C1-4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι-4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C1-6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, aryl, aryKCι-4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 -4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 -. 4 haloalkoxy, and dimethylamino; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 _ 6 cycloalkyl-Ci- 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C1- 4 alkyl, Br, Cl, F, I, C 1 -4 haloalkyl, nitro, C 1 - 4 alkoxy, Cι_ 4 haloalkoxy, and dimethylamino; R 14b is selected from the group Cι_4 alkyl, C3 . -.4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 -. 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 - 6 cycloalkyl-C1-6 alkyl; R 17 is selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, Cι_ 2 alkoxy-Cι_ 2 alkyl, C 1 - 4 haloalkyl, R 14 S (0) n -Cι- 4 alkyl, and R 17b R 19b N-C 2 _ 4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, Ci-β alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C1-4 haloalkyl ; alternatively, in an NR 17 R 19 moiety, R 17 and R 19 taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , CO 2 R 14 , COR 14 and SO2R 14 ) alternatively, in an NR 17b R 19b moiety, R 17b and R 19b taken together form 1-pyrrolidinyl, 1-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17 and R 19a are independently selected at each occurrence from the group H, Cι_β alkyl, C 3 - 10 cycloalkyl, C 3 -. 6 cycloalkyl-Cι- 6 alkyl and C1- 4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C3-6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 Fs, OCF 3 , S0 2 Me and acetyl; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl, benzothiazolyl , benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C _e cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 14a , COR 14a and S0 2 R 14a . In another preferred embodiment, R 1 is other than a cyclohexyl- (CH 2 )ι, 2 , 3, 4, 5, 6, 7, 8, 9, or 10- group. In another preferred embodiment, R 1 is other than an aryl- (CH 2 )ι, 2 3, 4, 5, 6, 7, 8, 9, or 10" group, wherein the aryl group is substituted or unsubstituted. In another preferred embodiment, R 1 is other than a heteroaryl- (CH 2 )ι, 2 , 3, 4, 5, 6, 7, 8, 9, or 10- group, wherein the heteroaryl group is substituted or unsubstituted. In another preferred embodiment, R 1 is other than a heterocyclyl- (CH 2 )ι, 2 , 3 , 4/ 5, 6, 7, 8, 9, or 10- group, wherein the heterocyclyl group is substituted or unsubstituted. In another preferred embodiment, when D is imidazole or triazole, R 1 is other than unsubstituted Ci, 2 , 3 , 4 , 5 , 6, 7, 8 , 9 , or 10 linear or branched alkyl or C3, 4, 5, 6, 7, or 8 cycloalkyl. In another preferred embodiment, R la is not substituted with OR 17 . Many compounds of this invention have one or more asymmetric centers or planes. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds, and all such stable isomers are contemplated in the present invention. The compounds may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. All chiral, (enantiomeric and diastereomeric) and racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated. The term "alkyl" includes both branched and straight- chain alkyl having the specified number of carbon atoms. "Alkenyl" includes hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like. "Alkynyl" includes hydrocarbon chains of either a straight or branched configuration and one or more triple carbon- carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl and the like. "Haloalkyl" is intended to include both branched and straight-chain alkyl having the specified number of carbon atoms, substituted with 1 or more halogen; "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "cycloalkyl" is intended to include saturated ring groups, including mono-,bi- or poly- cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and so forth. "Halo" or "halogen" includes fluoro, chloro, bromo, and iodo. The term "substituted", as used herein, means that one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =0), then 2 hydrogens on the atom are replaced. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By "stable compound" or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent . The term "pharmaceutically acceptable salts" includes acid or base salts of the compounds of formulas (I) and (II) . Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaπpnt-.iπal Sciences. 17th ed. , Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference. "Prodrugs" are considered to be any covalently bonded carriers which release the active parent drug of formula (I) or (II) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of formula (I) and (II) are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compounds. Prodrugs include compounds wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formulas (I) and (II); and the like. The term "therapeutically effective amount" of a compound of this invention means an amount effective to antagonize abnormal level of CRF or treat the symptoms of affective disorder, anxiety, depression, immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in a host. Synthesis Compounds of formula (I) can be prepared by the following synthetic routes and schemes. Where a detailed description is not provided, it is assumed that those skilled in the art of organic synthesis will readily understand the meaning. Synthesis of compounds of formula (I) may be prepared by the reaction shown in Scheme 1. Scheme 1 A compound of formula (II) can be alkylated on the imidazole nitrogen atom with an appropriate reagent. Typical conditions for this transformation include treatment of compound (II) with a base, such as sodium hydride, potassium tert-butoxide, sodium hexamethyldisilazide, etc., followed by a reagent J-R 1 , where J represents a halide (chloride, bromide or iodide) or psuedohalide (tosylate, mesylate, triflate, etc.), at an appropriate temperature (0 °C or room temperature, with warming if necessary) in a solvent such as tetrahydrofuran, dimethylformamide or dimethylsulfoxide. Alternatively, this reaction may be performed using the Mitsunobu conditions (Mitsunobu, Synthesis 1981, pp. 1-28) .The compound (II) is treated with an alcohol compound R^H, along with a phosphine (triphenyl, tributyl, etc.) and a phosphine-activating reagent such as diethyl azodicarboxylate. Compounds of Formula (II) may be prepared according to the route shown in Scheme 2. Scheme 2 A compound of Formula (III) may be coupled to an aromatic compound of Formula (IV) , with elimination of the elements of M-K. For compound (III) , K represents a halide, psuedohalide (such as mesylate, tosylate or triflate) , or thiomethyl, and P represents a protecting group (if the conditions of the reaction warrant protection of the imidazole N-H; otherwise, P can be H) . Suitable P groups may include benzyl, 4- methoxybenzyl, methoxymethyl, trimethylsilylethoxymethyl, tert-butoxycarbonyl or benzyloxycarbonyl. For compound (IV), M represents groups such as lithium, bromomagnesium, chlorozinc, (dihydroxy) boron, (dialkoxy) boron, trialkylstannyl and the like. The coupling reaction may be performed in the presence of an appropriate catalyst, such as tetrakis (triphenylphosphine) palladium, bis (triphenylphosphine) palladium dichloride, [1,3- bis (diphenylphosphino) propane] nickel dichloride, etc. Two particularly useful methods involve the coupling of chloroheterocycles with in-si u-prepared arylzinc reagents according to the method of Negishi et al. (J. Org. Chem. 1977, 42, 1821) , and the coupling with arylboronic esters according to the method of Suzuki et al. ( Chem. Letters 1989, 1405) . Appropriate solvents for reactions of this type usually include tetrahydrofuran, diethyl ether, dimethylformamide, or dimethylsulfoxide. Typical temperatures range from ambient up to the boiling point of the solvent. Once coupled, the P group may be removed to afford compound (II) . Conditions for the removal of the protecting groups are well known to those familiar to the art of organic synthesis; e.g. hydrogenation to remove benzyl or benzyloxycarbonyl, a fluoride source (such as tetrabutylammonium fluoride) to remove silylethoxymethyl, an acid source (such as trifluoroacetic acid) to remove tert- butoxycarbonyl or 4-methoxybenzyl, etc. Compounds of formula (III) can be prepared according to the plan shown in Scheme 3. Scheme 3 A diamine compound of formula (V) (in this case, P is a group such as benzyl, which can be introduced already attached to the nitrogen atom; otherwise, P could represent H initially, and another protecting group being introduced in a later step) is used in a cyclocondensation reaction to make the imidazole ring. The conditions used will, of course, depend on the X group chosen, and may include the intermediacy of the compound (VI) . A review of imidazole-forming reactions may be found in Comprehensive Heterocyclic Chemistry (Pergamon Press, 1984) vol. 5, pp. 457-498. Preparation of compounds of formula (V) wherein both A and B are nitrogen atoms may proceed according to the route of Scheme 4. Scheme 4 A compound of formula (VII) may be available from commercial sources, particularly for K = chloride. Compounds bearing psuedohalide K groups may be available from the corresponding dihydroxy compounds by treatment with an appropriate activating reagent, such as an organosulfonic anhydride or sulfonyl chloride. Compound (VII) may be converted to (V) by either (i) monoalkylation with a compound P-NH 2 , followed by reduction of the nitro group; (ii) reduction of the nitro group, to give an amine compound of formula (VTII), followed by monoalkylation with a compound P-NH 2 ; or (iii) use of a source of ammonia (ammonia gas, ammonium hydroxide, etc.) in either route, followed by protection of the amine group with the group P. Pyrimidine chemistry of this type is well represented in the literature, and is reviewed in Comprehensive Heterocyclic Chemistry, vol. 6. Alkylation of chloropyrimidines with amine compounds can be accomplished under either acidic (e.g. HC1 or acetic) or basic (trialkylamines, potassium tert-butoxide, etc.) conditions. Nitro groups in compounds of this type can be reduced to amino groups using one of any number of conditions, including catalytic hydrogenation, tin dichloride, sodium dithionite, zinc metal, iron powder, etc. Preparation of compounds of formula (V) wherein either A or B represent nitrogen atoms is shown in Scheme 5. Scheme 5 (V, B = N) An hydroxypyridone compound of formula (IX) can be nitrated to give compound (X) employing conditions such as concentrated or fuming nitric acid, optionally in the presence of concentrated sulfuric or acetic acid. The hydroxypyridone can be selectively monoactivated with a K group to give a compound of formula (XI); one method to do this involves treatment of the dicyclohexylamine salt of compound (X) with phosphorus oxychloride to give (XI) wherein K = Cl. Alternatively, both the hydroxy and pyridone groups in compound (X) can be activated at the same time, using stronger conditions such as phosphorus oxychloride and heat, or excess toluenesulfonic anhydride, to give compoiαnd (XII) . Compound (XI) may be converted to the protected amine compound (XIII) using the same general route discussed above for the pyrimidines . Selective monoalkylation using compound (XII) is also possible, but will probably give mixtures of regioisomeric products (XIV) and (XV) . The nitro groups in these compounds can then be reduced as discussed above, to give compounds for formula (V) wherein either A or B is nitrogen. An alternative approach to the method involving introduction of the R 1 group at the initial step is shown in Scheme 6. Scheme 6 (xvπ) (XK) (XX) This is particularly useful in the cases where R 1 represents a group where alkylation of compound (II) is impractical (e.g. a very bulky R 1 group), but can also be used in a general manner. Here, compounds of formula (XVT) or (XVII) (either amino- or nitro-pyridines or pyrimidines) are alkylated with an amine reagent under either acidic or basic conditions as described above. Nitro compoiαnd (XVIII) can be converted to amine compoiαnd (XIX) by nitro reduction reactions described earlier. Compound (XIX) can be cyclized to imidazole compound (XX) . As above, this reaction will depend upon the choice of X group. For example, for X = CHR 9 , one can use an orthoester reagent such as R 2 CH(R 9 )C(OR) 3 , with heating in neat solution or high-boiling solvents, and the optional presence of an acid catalyst (such as hydrochloric or sulfuric acid) (see Montgomery and Temple, J. Org. Chem. 1960, 25, 395) . For X = NR 10 , the cyclization is performed using reagents such as an guanidine reagent of the structure R 2 R 10 N-C(=NH)NH 2 or a urea-derived reagent of the structure R 2 R 10 N-C (=NH)D, where D represents a group like OCH 3 , SCH 3 or S0 2 CH 3 . For X = 0, the ring is formed using a reagent of the structure (R0) 4 C (with acetic acid catalysis) , provided one has access to the reagent with the R 2 group of choice (see Brown and Lynn, J. Chem. Soc. Perkin Trans . I 1974, 349) . Alternatively, the diamine (XIX) is treated with phosgene, followed by 0- alkylation to introduce the R 2 group (such as a reagent like R 2 -I or R 2 -Br) . A similar route can be used for X = S, which would use thiophosgene or some similar reagent, followed by S-alkylation with the R 2 group. The sulfur atom in this compound (and sulfide groups throughout the molecule in general) can be oxidized to either the sulfoxide or sulfone if desired by treatment with an appropriate oxidizing agent such as potassium permanganate, potassium peroxomonosulfate or m-chloroperbenzoic acid. Finally, compound (XX) can be used in an aryl coupling reaction as described above to replace the K group with the desired aryl group in compound (I). Methods of synthesis of compounds R^OH, R-J and R 1 -NH 2 are related, in that the alcohol can be used in the synthesis of the other two compounds, as is shown in Scheme 7. Scheme 7 R 1 -OH - R 1 -J R 1 -N 3 - R 1 -NH 2 \ * : (Scheme 1) (Scheme 6) For example, the hydroxy group may be converted to the following J groups, using the indicated reagents (this route is not limited to these J groups) : methanesulfonate, using methanesulfonyl chloride or anhydride and an appropriate base; toluenesulfonate, using toluenesulfonyl chloride or anhydride and an appropriate base; iodide; using iodine / triphenylphosphine; bromide, using phosphorus tribromide or carbon tetrabromide / triphenylphosphine; or trifluoromethanesulfonate, using trifluoromethane-sulfonic anhydride and an appropriate base. Both compounds R : -0H and R 1 - J are used in the methods portrayed in Scheme 1. Conversion of R x -J to R 1 -^ requires the use of an azide source, such as sodium azide, and a solvent such as dimethylsulfoxide or dimethylformamide, or water and a phase-transfer catalyst (such as tetrabutylammonium hydrogen sulfate) . Reduction of the azide compound R x -N 3 to R 1 -NH 2 may be accomplished using reagents such as sodium borohydride or triphenylphosphine, or hydrogen gas and a catalyst (such as palladium on carbon) . The amine R 1 -NH 2 may then be employed in the methods portrayed in Scheme 6. In the cases where the compound R^OH could be represented by a structure of formula (XXI) (Scheme 8), wherein R la and R lb represents substructures which, taken together with the carbinol methine group, comprise the entire group R 1 , this compound may be prepared by addition to a carbonyl compound. Scheme 8 (XXI) (xxπ) This route is particularly useful in the case where R la or R lb represents a cycloalkyl group, such as cyclopropyl. An organometallic reagent (where M' represents a metallic group, such as Li, CuCN, Cul, MgCl, MgBr, Mgl, ZnCl, CrCl, etc.) can be allowed to react with an aldehyde reagent to prepare the alcohol compound of formula (XXI) . Alternatively, a ketone of formula (XXII) may be treated with a reducing agent, such as sodium borohydride, lithium aluminum hydride, etc., which will also generate the alcohol of formula (XXI) . Standard methods of ketone synthesis may be used where appropriate in the preparation of compounds for formula (XXII) , which will be familiar to those skilled in the art of organic synthesis. An homologous approach may also be employed in the synthesis of alcohols R 1 -OH, involving the ring-opening reaction of cyclic ether compounds with organometallic reagents (Scheme 9) . Here, an organometallic reagent R l -M" is used, where M" represents metals such as Mg, Zn or Cu. Especially useful is the method described in Huynh, et al., Tetrahedron Letters 1979, (17), pp. 1503-1506, where organomagnesium reagents are allowed to react with cyclic ethers with catalysis provided by copper (I) iodide. Use of an epoxide compound of formula (XXIII) in this manner would result in synthesis of an alcohol compound of formula (XXIV) , and use of an oxetane compoiαnd of formula (XXV) would generate an alcohol of formula (XXVI) . Both compounds (XXIV) and (XXVI) are variants of R^OH. Synthesis of compound R^ K j with formula (XXVTI) is portrayed in Scheme 10. Scheme 10 A simple reductive amination of ketone (XXII) will produce amine (XXVTI) . This reaction may be performed using anhydrous ammonia in the presence of hydrogen and a catalyst. Alternatively, addition of an organometallic reagent to a nitrile compound gives and imine, which may be treated in situ with a reducing agent (such as sodium cyanoborohydride) to give amine (XXVTI). Finally, a compound of formula (XXVIII), wherein Q is an optionally-substituted oxygen atom (i.e. an oxi e) or nitrogen atom (i.e. a hydrazone) , may be allowed to react with an organometallic reagent R lb -M' ' ' . Here, metallic groups M' ' ' such as MgBr, CuCl or CeCl 2 have been used in additions to oximes or hydrazones. The intermediate addition products of formula (XXIX) may be subjected to reductive cleavage (using conditions such as sodium/liquid ammonia or catalytic hydrogenation) , which will afford amines (XXVII) . Amino acids, either naturally-occurring or synthetic, are potential sources of useful starting materials for the synthesis of the compounds of this invention. Scheme 11 shows some possible applications of this approach. Scheme 11 'V C0 2 H R 1a > .C0 2 H ^ Rla γ- OH NH NH-Prot NH-Prot (XXX) (XXXD (xxxπ) ^V NH" 2 -"' 6 - "'V NH"-Pr"ot'"- j NH-Prot (XXXV) (XXXIV) (XXXm) Protected amino acids of formula (XXXI) are prepared from the parent compounds of formula (XXX) ; useful protecting groups ("Prot") include tert-butoxycarbonyl, benzyloxycarbonyl and triphenyl ethyl . Standard texts in peptide chemistry describe this protection. The carboxylic acid group may be reduced using reagents such as lithium borohydride, which gives alcohol (XXXII) . The hydroxy group may be converted to a leaving group "J" as described before. The compound of formula (XXXIII) may be treated with appropriate reagents to produce a wide variety of functional groups included in the scope of this invention (compound (XXXIV)); displacement of J with cyanide (sodium cyanide in warm dimethylformamide may be used here) gives a nitrile, displacement of J with a mercaptan (in the presence of a base, such as potassium carbonate) gives a disulfide, displacement of J with a secondary amine gives a tertiary amine, etc. The compounds of Formula (I) with unsaturated R 1 groups can be a further source of compounds covered under this invention. Unsaturated (double and triple) bonds can take part in cycloaddition chemistry with appropriate reagents (Scheme 12). Cycloaddition of an alkyne compound of Formula XXXVI with 1,3-dienes to give six-membered ring compounds like that of Formula XXXVTI (commonly known as the Diels-Alder reaction) , and cycloaddition with 3-atom dipolar reagents to give heterocyclic compounds of Formula XXXVTII, are familiar to those skilled in the art of organic synthesis. One specific example of this approach is the synthesis of an isoxazole compounds of Formula XXXIX from the alkyne XXXVI and a nitrile oxide reagent. The synthetic procedure in Scheme 13 shown below may be used to prepare 4 , 5-c imidazopyridines . XXXI XXXXII XXXXV XXXXVI Nitration of 2, 4-dihydroxypyridine (XXXX) with HN0 3 as described earlier (Koagel et al. Reel. Trav. Chim. Pays-Bas. 29, 38, 67, 1948) gave the corresponding 3-nitropyridone (XXXXI) which was treated with an organic amine base, such as cycloheptyl amine to give selectively the corresponding 4- chloropyridone (XXXXIII) . This in turn was reacted with a primary amine RNH 2 , where R is a group described earlier in an aprotic or protic solvent, such as CH 3 CN, DMSO, DMF, or an alkyl alcohol in the presence of an organic or inorganic base, such as a trialkylamine, K 2 C0 3 , Na 2 C0 3 etc, and in temperature range of 20-200 °C to give the 4-amino adduct (XXXXIII) . Pyridone (XXXXIII) was converted to the 2-chloropyridine (XXXXIV) by treatment with P0C1 3 , and (XXXXIV) was coupled with an arylboronic acid ArB(0H) 2 under palladium catalysis to give (XXXXV) . Nitropyridine (XXXXV) was reduced to the corresponding aminopyridine by use of Na 2 S 2 0 4 or a Fe, Sn or SnCl 2 and converted to the imidazo [4, 5-c] pyridine in refluxing propionic acid. The same transformation can be affected by the use of a nitrile, an imidate, thioimidate or trialkylorthopropionate. The synthetic procedure in Scheme 14 shown below may be used to prepare 4, 5-b imidazopyridines . Scheme 14 XXXXII XXXXVII XXXXIX LI Reaction of 4-chloropyridone (XXXXII) with an aryl halide, such as benzyl bromide in benzene and in the presence of Ag 2 C0 3 as described in Scheme 13 (Smith A. M. ; et al. J. Med. Chem..36, 8, 1993) and at temperature ranges of 30-80 °C afforded the corresponding 2-benzyloxypyridine (XXXXVII) . This was coupled with an arylboronic acid, ArB(OH) 2 under palladium-catalyzed conditions to give (XXXXIX) . The benzyloxy group can be removed by treatment with a strong acid, such as trifluoroacetic, triflic, sulfuric, HC1, etc. to give pyridone (L) . This was converted to the 2-halopyridine with the action of POX 3 , PX 5 or the corresponding triflate, tosylate or mesylate, which was displaced with a primary amine RNH 2 to give (LI) . The nitro group was reduced under conditions described in scheme 13 and the aminopyridine was cyclized to the imidazolo [4, 5-b] pyridine (LII) under conditions described in scheme 13. The following examples are provided to describe the invention in further detail. These examples, which set forth the best mode presently contemplated for carrying out the invention, are intended to illustrate and not to limit the invention. The methods discussed below in the preparation of 8- ethyl-9- (1-ethylpentyl) -6- (2,4, 6-trimethylphenyl) purine (Table 1, Example 2, Structure A) and 9-butyl-8-ethyl-6- (2,4, 6-trimethylphenyl) purine (Table 1, Example 27, Structure A) may be used to prepare all of the examples of Structure A contained in Table 1, Table 1A and Table IB, with minor procedural modifications where necessary and use of reagents of the appropriate structure. The methods discussed below in the preparation of 3- (1-cyclopropylpropyl) -7- (2, 4-dichlorophenyl) -2-ethyl-3H- imidazo [4, 5-b] pyridine (Table 1, Example 38, Structure B) and 1- (l-cyclopropylpropyl)-4- (2,4-dichlorophenyl)-2-ethyl- 1H-imidazo [4, 5-c] yridine (Table 1, Example 38, Structure C) may be used to prepare many of the examples of Structures B and C contained in Table 1, Table 1A, Table IB and Table IC, with minor procedural modifications where necessary and use of reagents of the appropriate structure. Example 2 Preparation of 8-Ethyl-9- (1-ethylpentyl) -6- (2,4, 6- trimethylphenyl) urine Part A. A solution of 5-amino-4, 6-dichloropyrimidine (10.0 g, 61.0 mmol) and triethylamine (12.8 mL, 91.5 mmol) in ethanol (100 mL) was treated with benzylamine (7.30 mL, 67.1 mmol), and heated to 50 °C overnight. The resulting mixture was cooled, and the resulting crystalline solid was collected by filtration. The solid was triturated with hexane, refiltered and dried under vacuum. A second crop was collected from the mother liquor and purified like the first crop to afford in total 12.67 g (48.8 mmol, 80%) of 5-amino-6-benzylamino-4- chloropyrimidine. TLC R F 0.10 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : d 7.62 (IH, s) , 7.13-6.97 (5H, m) , 6.61 (IH, br t, J = 5 Hz), 4.43 (2H, d, J = 5.5 Hz), 4.24 (2H, br s). MS (NH j -CI): -7i/e 238 (4), 237 (33), 236 (15), 235 (100). Part B. A solution of the diamine from Part A (10.45 g, 44.5 mmol) and 3 drops concentrated hydrochloric acid in triethyl orthopropionate (70 mL) was heated to 100 °C for 1 hour, then cooled, poured into water (200 mL) and extracted with ethyl acetate (2 x 200 mL) . The extracts were washed in sequence with brine (100 mL) , then combined, dried over anhydrous sodium sulfate, filtered and evaporated. The residue was separated by column chromatography (silica gel, 20:80 ethyl acetate-hexane) to afford the product, N- (6-benzylamino-4- chloropyrimidin-5-yl) -0-ethyl-propionimidate (12.82 g, 40.2 mmol, 90%) as a crystalline solid, m.p. 85-86 °C. TLC R F 0.25 (20:80 ethyl acetate-hexane). : H NMR (300 MHz, CDC1 3 ) : d 8.19 (IH, s), 7.35-7.29 (5H, m) , 5.21 (IH, br t, J = 5 Hz), 4.70 (2H, d, J = 5.9 Hz), 4.29 (2H, br) , 2.15 (2H, br q, J = 7.3 Hz), 1.35 (3H, t, J = 7.0 Hz), 1.06 (3H, t, J = 7.3 Hz). MS (NH 3 -CI): m/e 322 (6), 321 (34), 320 (20), 319 (100). Part C. A solution of the i idate compound prepared in Part B above (10.66 g, 33.4 mmol) and p-toluenesulfonic acid monohydrate (100 mg) in diphenyl ether (10 mL) was heated to 170 °C for 2 hours. The resulting mixture was cooled and poured into 50 mL water. This was extracted with ethyl acetate (2 x 50 mL) , and the extracts were washed in sequence with brine (50 mL) , combined, dried over anhydrous sodium sulfate, filtered and evaporated. The residual material was separated by column chromatography (silica gel, hexane to remove diphenyl ether, then 30:70 ethyl acetate-hexane) to afford the product, 9-benzyl-6-chloro-8-ethylpurine, as an oil (8.16 g, 29.9 mmol, 89%). TLC R F 0.20 (30:70 ethyl acetate-hexane). : H NMR (300 MHz, CDC1 3 ) : d 8.72 (IH, s) , 7.37-7.29 (3H, m) , 7.19- 7.14 (2H, m) , 5.46 (2H, s) , 2.89 (2H, q, J = 7.7 Hz), 1.38 (3H, t, J = 7.7 Hz). MS (NH 3 -CI) : m/e 276 (6), 275 (36), 274 (20), 273 (100). Part D. A solution of zinc chloride (5.32 g, 39.1 mmol) in anhydrous, freshly-distilled tetrahydrofuran (50 mL) was treated at ambient temperature with a solution of mesitylmagnesium bromide (39.1 mL, 1.0 M, 39.1 mmol) in diethyl ether. After 45 minutes, a separate flask containing a solution of bis (triphenylphosphine) -palladium dichloride (0.92 g, 1.3 mmol) in tetrahydrofuran (30 mL) was treated with a solution of diisobutylaluminum hydride (2.6 mL, 1.0 M, 2.6 mmol) in hexane. This mixture was allowed to stir for 15 minutes, then treated with the mesitylzinc chloride solution dropwise by cannula. Then, the chloropurine compound in 10 mL tetrahydrofuran solution was added by syringe, and the mixture was allowed to stir for 12 hours at ambient temperature. It was poured into water (150 mL) , and acidified with dropwise addition of 1 N aqueous hydrochloric acid until the mixture is homogeneous. This is extracted with ethyl acetate (2 x 150 mL) , and the extracts were washed in sequence with saturated brine solution (100 mL) , combined, dried over anhydrous sodium sulfate, filtered and evaporated. The residue was separated by column chromatography (silica gel, 30:70 ethyl acetate-hexane) to afford the product, 9-benzyl-8-ethyl-6- (2,4, 6- trimethylphenyl) purine (6.68 g, 18.7 mmol, 72%), as an off- white waxy solid, m.p. 121-122 °C. l E NMR (300 MHz, CDC1 3 ) : d 9.00 (IH, s), 7.38-7.31 (3H, m) , 7.23-7.21 (2H, m) , 6.96 (2H, s), 5.50 (2H, s), 2.84 (2H, q, J = 7.6 Hz), 2.33 (3H, s) , 2.06 (6H, s), 1.26 (3H, t, J = 7.5 Hz). MS (NH 3 -CI) : m/e 359 (3), 358 (26), 357 (100) . Part E. A solution of the benzyl compound from Part D above (5.33 g, 14.95 mmol) in trifluoroacetic acid (320 mL) partitioned into four Parr bottles, and each was treated with 0.8 g 20% palladium hydroxide on carbon. The bottles were each subjected to hydrogenation (50 psi) in shaker apparati for 18 hours. The atmospheres were purged with nitrogen, and the solutions were combined, filtered through celite and evaporated. The residual material was separated by column chromatography (silica gel, 50:50 ethyl acetate-hexane) to afford the product, 8-ethyl-6- (2,4, 6-trimethylphenyl) purine (3.75 g, 14.1 mmol, 94%), as a white crystalline solid, m.p. 215-217 °C. TLC R F 0.17 (50:50 ethyl acetate-hexane). λ E NMR (300 MHz, CDC1 3 ) : d 12.35 (IH, br s) , 9.03 (IH, s) , 6.96 (2H, s), 3.05 (2H, q, J = 7.7 Hz), 2.32 (3H, s) , 2.05 (6H, s) , 1.50 (3H, t, J = 7.7 Hz). MS (NH 3 -CI) : m/e 269 (2), 268 (19), 267 (100) . Part F. A solution of the purine compound from Part E above (200 mg, 0.75 mmol), 3-heptanol (0.13 mL, 0.90 mmol) and triphenylphosphine (0.24 g, 0.90 mmol) in freshly-distilled tetrahydrofuran (5 mL) was cooled to 0 °C, and treated with diethyl azodicarboxylate (0.14 mL, 0.90 mmol) dropwise by syringe. The mixture was allowed to stir for 12 hours, then evaporated. The residual material was separated by column chromatography (silica gel, 15:85 ethyl acetate-hexane) to afford the title product as a white solid (0.152 g, 0.42 mmol, 56%), m.p. 99-100 °C. TLC R F 0.17 (10:90 ethyl acetate- hexane). λ E NMR (300 MHz, CDC1 3 ) : d 8.91 (IH, s) , 6.95 (2H, s), 4.22 (IH, br), 2.92 (2H, q, J = 7.7 Hz), 2.41 (2H, br) , 2.32 (3H, s), 2.10-1.98 (2H, m) , 2.05 (3H, s) , 2.04 (3H, s) , 1.37 (3H, t, J = 7.5 Hz), 1.34-1.23 (4H, m) , 0.84 (3H, t, J = 7.1 Hz), 0.81 .(3H, t, J = 7.5 Hz). MS (NH 3 -CI): m/e 367 (3), 366 (27) , 365 (100) . Example 27 Preparation of 9-Butyl-8-ethyl-6- (2,4, 6-trimethylphenyl) purine A solution of 8-ethyl-6- (2,4, 6-trimethylphenyl)purine (200 mg, 0.75 mmol) in anhydrous dimethylfomamide (5 mL) was cooled to 0 °C, and treated with sodium hydride dispersion in mineral oil (72 mg 50% w/w, 1.50 mmol). After 1 hour, bromobutane (0.10 mL, 0.90 mmol) was added by syringe, and the mixture was allowed to stir for 12 hours. It was poured into ethyl acetate (120 mL) , and was washed with water (3 x 120 mL) and brine (100 mL) . The aqueous layers were back-extracted in sequence with ethyl acetate (120 mL) , and the extracts were combined, dried over anhydrous sodium sulfate, filtered and evaporated. The residue was separated by column chromatography (silica gel, 20:80 ethyl acetate-hexane) to afford the title product as a viscous oil (64.2 mg, 0.20 mmol, 27%). TLC R j , 0.20 (30:70 ethyl acetate-hexane). H NMR (300 MHz, CDC1 3 ) : d 8.96 (IH, s), 6.95 (2H, s), 4.25 (2H, t, J = 7.5 Hz), 2.93 (2H, q, J = 7.7 Hz), 2.32 (3H, S), 2.04 (6H, s), 1.91-1.86 (2H, m) , 1.50-1.38 (2H, m) , 1.39 (3H, t, J = 7.7 Hz), 1.01 (3H, t, J = 7.5 Hz). MS (NH 3 -CI) : m/e 325 (3), 324 (23), 323 (100). Exaπrole Preparation of 6- (2,4-Dichlorophenyl) -8-ethyl-9- (1- ethylpentyl) purine A solution of 2,4-dichlorobenzeneboronic acid (572 mg, 3.00 mmol) and ethylene glycol (205 mg, 3.30 mmol) in benzene (20 mL) was heated to reflux with azeotropic removal of water for a period of 8 h. The resulting solution was cooled, and ^ treated with 6-chloro-8-ethyl-9- (1-ethylpentyl)purine (see Example 2, Part C above; 562 mg, 2.00 mmol), thallium carbonate (1.03 g, 2.20 mmol) and tetrakis (triphenylphosphine) palladium (116 mg, 0.10 mmol). The resulting mixture was heated to reflux with stirring for 12 h, then cooled, filtered through celite and evaporated. The resulting residue was separated by column chromatography (silica gel, 10:90 ethyl acetate-hexane) to afford the title compound as a viscous oil (530 mg, 1.35 mmol, 68%) . TLC Rp. 0.31 (20:80 ethyl acetate-hexane). X H NMR (300 MHz, CDC1 3 ) : d 8.94 (IH, s), 7.71 (IH, d, J = 8.4 Hz), 7.58 (IH, d, J = 1.8 Hz), 7.41 (IH, dd, J = 8.4, 1.8 Hz), 4.27 (IH, br) , 2.95 (2H, q, J = 7.3 Hz), 2.41 (2H, br) , 2.11-1.98 (2H, br) , 1.42 (3H, t, J = 7.3 Hz), 1.37-1.20 (3H, m) , 1.09-0.99 (IH, m) , 0.84 (3H, t, J = 7.7 Hz), 0.82 (3H, t, J = 7.7 Hz). MS (NH 3 -CI) : m/e calc'd for C 20 H 25 N 4 C1 2 : 391.1456, found 391.1458; 395 (11)., 394 (14), 393 (71), 392 (29), 391 (100). Example 38 Preparation of 3- (1-cyclopropylpropyl) -7- (2,4-dichlorophenyl) - 2-ethyl-3H-imidazo [4, 5-b] yridine Part A. 2,4-Dihydroxypyridine (15.0 g, 135 mmol) was heated in HN0 3 (85 mL) at 80 °C for 15-20 min at which time it went into solution. The temperature was maintained for 5 min and after cooling it was poured into ice/water (-200 mL) . The precipitated solid was collected and dried (19.0 g, 90% yield). X H NMR(300 MHz, dmso d6) : 12.3-12.5 (IH, brs), 11.75- 11.95 (IH, brs), 7.41 (IH, d J = 7.3 Hz), 5.99 (IH, d J = 7.3 Hz) . Part B. 4-Hydroxy-3-nitropyridone (8.0 g, 51.25 mmol) and cycloheptyl amine (6.8 mL, 53.4 mmol) were heated at reflux in methanol (100 mL) for 15 min. The solvent was stripped off and the residual solid was washed with 1:1 EWtOAc/hexanes and dried under vacuum. The cycloheptyl amine salt was stirred in P0C1 3 (60 mL) for 40 h and poured into ice/water (-600 mL) . The precipitated producd was collected and dried under vacuum (7.0 g, 78% yield). X H NMR(300 MHz, dmso d6) : 12.8-13.05 (IH, brs), 7.73 (lh, d J = 7.0 Hz), 6.50 (IH, d J = 7.0 Hz). Part C. 4-Chloro-3-nitro-pyridone (0.5 g, 2.86 mmol) Ag 2 C0 3 (0.83 g, 3 mmol) and benzyl bromide (0.36 mL, 3 mmol) were stirred in dry benzene (20 mL) at 60 °C for 5 h. The reaction mixture was filtered and stripped in vacuo. The residue was chromatographed on silica gel (10% EtOAc/hexanes eluent) to give the product (0.6 g, 79%). H NMR(300 MHz, CDC1 3 ) : 8.15 (1 H, d J = 4.0 Hz), 7.30-7.42 (5 H, m) , 7.04 (IH, d J = 4.0 Hz), 5.50 (2H, s) . Part D. 2-Benzyloxy-4-chloro-3-nitropyridine (0.5 g, 1.9 mmol), 2,4-dichlorophenylboronic acid (0.363 g, 1.9 mmol) Pd(PPh 3 ) 2 Cl 2 (76 mg, 0.11 mmol) and Ba(OH) 2 .8H 2 0 (0.6 g, 1.9 mmol) were heated at reflux in 1,2-dimethoxyethane (6 mL) , and water (6 mL) for 5 h. The mixture was partitioned beteween EtOAc (100 mL) and water (30 mL) and the EtOAc was washed with water, brine, dried and stripped in vacuo. The residue was chromatographed on silica gel (10% EtOAc/hexanes eluent) to give the product (370 mg, 52% yield). X E NMR(300 MHz, CDC1 3 ) : 8.31 (IH, d J = 5.1 Hz), 7.51 (IH, d J = 2.2 Hz), 7.30-7.43 (6 H, ) , 7.20 (IH, d J = 8.0 Hz), 6.91 (IH, d J = 5.1 Hz), 5.56 (2h, s). Part E. 2-Benzyloxy-4- (2,4-dichlorophenyl) -3-nitropyridine (1.65 g, 4.39 mmol) was stirred in CF 3 C0 2 H (5 mL) at 25 °C for 4 h. The CF 3 C0 2 H was stripped in vacuo and the residue was washed with 20% EtOAc/hexanes and used in the next reaction. 1 H NMR(300 MHz, CDC1 3 ) : 7.62 (IH, d J = 7.0 Hz), 7.53 (IH, d J = 2.2 Hz), 7.34 (IH, dd J = 7.0, 2.2 Hz), 7.22 (IH, d J = 8.1 Hz) , 6.33 (IH, d J = 7.0 Hz) . Part F. 4- (2,4-dichlorophenyl) -3-nitropyridone (4.39 mmol) was heated at reflux in POCl 3 (5 mL) for 5 h. After cooling it was poured into ice/water (-60 mL) and extracted with EtOAc (2x100 mL) . The EtOAc was washed with with satNaHC0 3 , brine, dried and stripped in vacuo. Used in the next reaction without further purification. X H NMR(300 MHz, CDC1 3 ):8.60 (IH, d J = 5.2 Hz), 7.54 (IH, d, J = 2.2 Hz), 7.36 (IH, dd J = 8.1, 2.2 Hz) , 7.20 (IH, d J = 8.1 Hz) . Part G. 2-Chloro-4- (2,4-dichlorophenyl) -3-nitropyridine (0.5 g, 1.65 mmol) 1-cyclopropylpropylamine hydrochloride (461 mg, 3.4 mmol) and diisopropyl ethylamine (1.26 mL, 0.72 mmol) were heated at reflux in CH 3 CN (10 mL) for 64 h. The mixture was partitioned between EtOAc (70 mL) and water (40 mL) . The aqueous layer was extracted with EtOAc (50 mL) and the combined EtOAc exctracts washed with brine, dried and stripped in vacuo. The residue was chromatographed on silica gel (10% EtOAc/hexanes eluent) to give the product (310 mg, 51% yield) . X H NMR(300 MHz, CDC1 3 ) : 8.29 (IH, d J = 4.7 Hz), 7.76 (IH, brd J = 8.0 Hz), 7.46 (IH, d J = 2.2 Hz), 7.32 (IH, dd J = 8.5, 2.2 Hz), 7.15 (IH, d J = 8.5 Hz), 3.72-3.85 (IH, m) , 1.70-1.80 (2H, m) , 0.90-1.08 (4H, m) , 0.30-0.66 (4H, m) . Part H. 2- (l-cyclopropyl)propylamino-4- (2,4-dichlorophenyl) -3- nitropyridine (310 mg, 0.85 mmol) was dissolved in dioxane (8 mL) and water (8 mL) containing concNH 4 OH (0.3 mL) was added, followed by Na 2 S 2 0 4 (1.1 g, 6.86 mmol). The reaction was stirred at 25 °C for 4 h and extracted with EtOAc (100 mL) . The EtOAc was washed with brine, dried and stripped in vacuo. The residue was chromatographed on silica gel (25% EtOAc/hexanes and -1% cone NH 4 0H eluent) to give the product (150 mg, 53% yield). H NMR(300 MHz, CDC1 3 ) : 7.73 (IH, d J = 5.5 Hz), 7.53 (IH, d J = 1.8 Hz), 7.35 (IH, dd J = 8.1, 1.8 Hz), 7.24 (IH, d J = 8.1 Hz), 6.35 (IH, d J = 5.5 Hz), 4.3 (IH, brs), 3.5 (IH, brs), 3.42-3.55 (IH, m) , 3.04 (2H, brs), 1.70-1.81 (2H, m) , 0.88-1.08 (4H, m) , 0.3-0.6 (4H, m) . Part I. 3-amino-2- (1-cyclopropyl)propylamino-4- (2,4- dichlorophenyl) -pyridine (140 mg, 0.42 mmol) was heated at reflux in propionic acid (5 mL) for 23 h. Then the mixture was diluted with water (50 mL) neutralized with solid NaHC03 and basified with 50%NaOH. Then it was extracted with EtOAc (80 mL) and the EtOAc was dried and stripped in vacuo. The residue was chromatographed on silica gel (10% and 20%EtOAc/hexanes eluant) to give the product, which was crystallized from hexanes (70 mg, 45% yield) mp 118-119 °C. λ E NMR(300 MHz, CDC1 3 ) : 8.31 (IH, d J = 4.7 Hz), 7.62 (IH, d J = 7.2 Hz), 7.55 (IH, d J = 1.8 Hz), 7.37 (IH, dd J = 7.2, 1.8 Hz), 7.23 (IH, d J = 4.7 Hz), 3.50-3.70 (IH, brs), 2.87-2.96 (2H, q) , 2.36-2.56UH, ) , 2.18-2.35 (IH, m) , 1.90-2.05 (IH, m) , 1.38 (3H, t) , 0.86 (3H, t) , 0.75-0.84 (IH, m) , 0.40-0.54 (IH, m) , 0.15-0.25 (IH, m) . Example 38A Preparation of 1- (1-cyclopropylpropyl) -4- (2, 4-dichlorophenyl) - 2-ethyl-IH-imidazo [4, 5-c] pyridine Part A. A mixture of 4-chloro-3-nitro-2-pyridone (2.0 g, 11.4 mmol), 1-cyclopropylpropyl amine hydrochloride (1.5 g, 11.4 mmol) and N,N-diisopropylethylamine (4.8 ml, 27.4 mmol) in CH 3 CN (50 ml) were stirred at 25 oC for 16 h and at reflux for 4h. After cooling it was stripped in vacuo, and the residue was partitioned between EtOAc (100 mL) and H20 (50 mL) . The insolubles were separated, washed with H 2 0 and EtOAc and vacuum dried 1.51 g. The filtrate layers were separated and the aqueous layer was extracted with EtOAc (2x50 mL) . The Combined extracts were washed with brine, dried over MgS04, filtered and coned, in vacuo. The residue was washed with EtOAc (2x) and vacuum dried, to give 0.69 g, yellow solid. Combined wt. of 4- (l-cyclopropylpropyl)amino-3-nitro-2- pyridone 2.20 g, 81% yield. H NMR(300 MHz, dmso d6): 11.19 (IH, br), 8.94 (IH, d J = 8.8 Hz), 7.33 (IH, t J = 6.9 Hz), 6.03 (IH, d J = 7.7 Hz), 3.18-3.24 (IH, m) , 1.60-1.74 (2H, m) , 1.03-1.1K1H, m), 0.91 (3H, t) , 0.40-0.60 (IH, m) , 0.20-0.39 (IH, m) . Part B. 4- (l-Cyclopropyl)propylamino-3-nitro-2-pyridone (2.20 g, 9.27 mmol) was stirring in P0C1 3 (15 mL) at 25 °C for 16 h. Then it was poured into ice/water (220 mL) and stirred until all the P0C1 3 had reacted. The mixture was neutralized with solid NaHC0 3 , filtered and extracted with EtOAc (3x60 mL) . The combined organic extracts were washed with brine, dried over MgS0 4 , filtered and stripped in vacuo. The crude oil was chromatographed on silica gel (100 g.) and eluted with a gradient from 10-20% EtOAc/hexane to afford 1.91 g 2-chloro- 4- (1-cyclopropylpropyl) amino-3-nitropyridine, 81% yield. X H NMR(300 MHz, CDC1 3 ) : 7.96 (IH, d J = 6.3 Hz), 6.58 (IH, d J = 6.3 Hz), 6.52 (IH, brd J = 5.5 Hz), 2.90-3.00 (IH, m) , 1.61- 1.82 (2H, m) , 1.01 (3H, t J = 7.7 Hz), 0.90-1.02 (IH, m) , 0.51-0.70 (2H, m) , 0.21-0.34 (2H, m) . Part C. In a dried flask, under N 2 , a mixture of 2-chloro-4- (l-cyclopropyl)propylamino-3-nitropyridine (730 mg, 2.85 mmol), 2,4-dichlorophenylboronic acid (544 mg, 2.85 mmol), . dichlorobis (triphenylphosphine) palladium (III) (114 mg, 0.17 mmol) and barium hydroxide octahydrate (899 mg, 2.85 mmol) was heated at reflux in dimethoxyethane (8.6 mL) and H 2 0 (8.6 mL for 1.5 h. After cooling it was partitioned between EtOAc (100 mL) and water (20 mL) and filtered through celite. The aqueous layer was extracted with EtOAc (2x50 mL) . The combined organics were washed with brine, dried over MgS0 4 , filtered and stripped in vacuo. The residue was chromatographed on silica gel (40 gm) , and eluted with 30% EtOAc/hexane to afford a yellow oil, 1.00 g, 90% yield. 2 H NMR(300 MHz, CDC1 3 ) : 8.24 (IH, d J = 6.2 Hz), 7.87 (IH, brd J = 7.3 Hz), 7.43 (IH, s) , 7.34 (2H, s), 6.71 (IH, d J = 6.2 Hz), 3.00-3.10 (IH, m) , 1.70-1.85 (2H, m) , 0.95-1.15 (4H, m) , 0.50-0.71 (2H, ) , 0.25- 0.40 (2H, m) . Part D. The product from Part C (0.94 g, 2.57 mmol), by dissolving in dioxane (26 ml), H 2 0 (26 ml) and cone. NH 4 OH (1.0 ml) while adding Na 2 S 2 0 4 and stirring at room temperature for 2 hrs. Added CH 2 C1 2 and extracted. Extracted the aqueous layer with CH 2 C1 2 (2x) . Combined the organics and washed with brine, dried over MgS04, filtered and coned, in vacuo to give a yellow solid, 1.01 g. It was carried over to the next reaction without purification. Part E. The amine from Part D (1.01 g, 3.00 mmol) was cyclized by refluxing with propionic acid (27 ml, 365.45 mmol) for 8 hrs.. Allowed to cool to RT. then basified with 1M NaOH and 50% NaOH. Extracted with EtOAc (2x60 mL) and CH 2 C1 2 (60 mL) . Combined the organics and washed with H 2 0, brine, dried over MgS0 4 , filtered and coned, in vacuo. The crude oil was chromatographed on silica gel (40 g. ) and eluted with 30% EtOAc/hexane to obtain a pale yellow solid (triturated from hexane), 520 mg, 46% yield. X H NMR(300 MHz, CDC1 3 ) : 8.43 (IH, d J = 5.8 Hz), 7.63 (IH, d J = 8.1 Hz), 7.55 (IH, d J = 1.8 Hz), 7.46 (IH, d J = 5.8 Hz), 7.36 (IH, dd J = 8.1 , 1.8 Hz), 3.40- 3.50 (IH, ) , 2.80-2.90 (2H, q J = 7.7 Hz), 2.10-2.30 (2H, m) , 1.50-1.64 (IH, m) , 1.37 (3H, t J = 7.3 Hz), 0.87 (3H, t J =- 7.3 Hz), 0.81-0.91 (IH, m) , 0.48-0.58 (2H, m) , 0.18-0.26 (IH, m) . Elemental analysis calcd for C 20 H 2 ιN 3 Cl 2 : C, 64.18; H, 5.665; N, 11.23; found: C, 64.37; H, 5.66; N, 11.15. Example 831 Preparation of 6- (2-Chloro-4-methoxyphenyl)-9- dicyclopropylmethyl-8-ethylpurine Part A. A solution of dicyclopropyl ketone (50 g) in absolute methanol (150 mL) in an autoclave vessel was charged with 4 Raney nickel (12 g, washed free of water and in methanol slurry) and then anhydrous ammonia (17 g) . The mixture was subjected to 120 at of hydrogen at 150-160 °C for 5 hours, then cooled and excess gasses purged. The resulting slurry was filtered through celite, and the filtrate was distilled to about one-third the original volume (atmospheric pressure, Vigreaux column) . The pot solution was cooled to 0 °C, diluted with 3 volumes diethyl ether, and treated with 4 N hydrochloric acid solution in anhydrous dioxane until precipitate formation ceased. The solid product (dicyclopropylmethylamine hydrochloride) was collected by filtration, washed with excess diethyl ether, and dried under vacuum (45.22 g, 306 mmol, 67%). H NMR (300 MHz, methanol-d 4 ) : d 1 . 94 ( IH, t , J = 9 . 3 Hz ) , 1 . 11-0 . 99 ( 2H, m) , 0 . 75-0 . 59 (4H, m) , 0 .48-0 .37 (4H, m) . MS (NH 3 -DCI ) : m/e 114 ( 5 ) , 113 ( 100 ) . Part B. A solution of 5-amino-4, 6-dichloropyrimidine (5.00 g, 30.5 mmol) and diisopropylethylamine (12.0 mL, 68.9 mmol) in ethanol (100 mL) was treated with the amine from Part A (3.81 g, 25.8 mmol), and heated to reflux for 72 h. The resulting mixture was cooled and poured into water (300 mL) , which was extracted with ethyl acetate (2 x 300 mL) . The extracts were washed with brine, combined, dried over sodium sulfate, filtered and evaporated. The residual oil was separated by column chromatography (30:70 ethyl acetate-hexane), and the desired product, 5-amino-4-chloro-6- dicyclopropylmethylaminopyrimidine, was triturated with warm ether-hexane, collected by filtration, and dried under vacuum (3.15 g, 13.2 mmol, 43%). m.p. 137-138 °C. TLC R p 0.17 (30:70 ethyl acetate-hexane). *H NMR (300 MHz, CDC1 3 ): d 8.01 (IH, s), 4.95 (IH, br d, J = 7.3 Hz), 3.45 (IH, q, J = 7.0 Hz), 3.37 (2H, br s), 1.06-0.94 (2H, m) , 0.59-0.32 (8H, m) . MS (NH 3 -CI) : m/e 243 (1), 242 (5), 241 (36), 240 (16), 239 (100). Part C. A solution of the diamine from Part B (1.80 g, 7.54 mmol) and 1 drop concentrated hydrochloric acid in triethyl orthopropionate (12 mL) was heated to 100 °C for 6 hours. The excess orthoester was removed by distillation (partial vacuum, short-path) , and the pot residue solidified to give the product, N- (4-chloro-6-dicyclopropylmethylaminopyrimidin-5- yl)-0-ethyl-propionimidate. l E NMR (300 MHz, CDC1 3 ) : d 8.08 (IH, s), 4.84 (IH, br d, J = 8.0 Hz), 4.35 (2H, br) , 3.45 (IH, q, J = 7.7 Hz), 2.14 (2H, q, J = 7.3 Hz), 1.41 (3H, t, J = 7.1 Hz), 1.08 (3H, t, J = 7.7 Hz), 1.03-0.93 (2H, m) , 0.58-0.27 (8H, m) . MS (NH 3 -CI): m/e 327 (1), 326 (7), 325 (36), 324 (21) , 323 (100) . Part D. A solution of the imidate compound prepared in Part C above and p-toluenesulfonic acid monohydrate (50 mg) in diphenyl ether (10 mL) was heated to 170 °C for 2 hours. The resulting mixture was cooled and separated by column chromatography (silica gel, hexane to remove diphenyl ether, then 30:70 ethyl acetate-hexane) to afford the product, 6- chloro-9-dicyclopropylmethyl-8-ethylpurine, as an solid (1.42 g, 5.13 mmol, 68% for both steps C and D) . m.p. 99-100 °C. TLC R F 0.26 (30:70 ethyl acetate-hexane). l E NMR (300 MHz, CDC1 3 ) : d 8.63 (IH, s), 2.99 (2H, br) , 1.92 (IH, br) , 1.50 (3H, t, J = 7.3 Hz), 0.87-0.78 (2H, m) , 0.50-0.39 (4H, m) , 0.20-0.10 (4H, m) . MS (NH 3 -CI): m/e 280 (6), 279 (36), 278 (19), 277 (100). Part E. A solution of 4-amino-3-chlorophenol hydrochloride (18.6 g, 103 mmol) and sodium acetate (18.6 g, 227 mmol) in glacial acetic acid (200 mL) was heated to gentle reflux for 12 hours, then cooled and poured into 4 volumes water. This was neutralized with portionwise addition of sodium bicarbonate, and the resulting mixture was extracted with ethyl acetate (2 x 500 mL) . The extracts were washed with brine, combined, dried over magnesium sulfate, filtered and evaporated. The resulting solid was triturated with warm ether; filtration and vacuum drying gave 4-acetamido-3- chlorophenol (16.1 g, 86.7 mmol, 84%). m.p. 128-129 °C. TLC R j , 0.14 (50:50 ethyl acetate-hexane). : H NMR (300 MHz, 4:1 CDC1 3 «CD 3 0D) : d 7.66 (IH, d, J = 8.8 Hz), 6.88 (IH, d, J = 1.7 Hz), 6.74 (IH, dd, J = 8.8, 1.7 Hz), 2.19 (3H, s) . MS {Kfi- GC/MS) : m/e 186 (100) . Part F. A solution of the phenol of Part E (14.6 g, 78.8 mmol), methyl iodide (10.0 mL, 160 mmol), and sodium carbonate (10.0 g, 94.3 mmol) in acetonitrile (200 mL) was heated to reflux for 48 hours, the cooled and poured into water (800 mL) . This was extracted with ethyl acetate (2 x 800 mL) , and the extracts were washed with brine, combined, dried over magnesium sulfate, filtered and evaporated. The resulting solid was recrystallized from ether-ethyl acetate to afford pure product, 2-chloro-4-methoxyacetanilide (13.2 g, 66.3 mmol, 84%), m. p. 118-119 °C (ether-ethyl acetate). TLC R p 0.30 (50:50 ethyl acetate-hexane). X H NMR (300 MHz, CDC1 3 ) : d 8.15 (IH, d, J = 9.2 Hz), 7.39 (IH, br s) , 6.92 (IH, d, J = 3.0 Hz), 6.82 (IH, dd, J = 9.2, 3.0 Hz), 3.78 (3H, s) , 2.22 (3H, s). MS (NH 3 -CI): m/e 219 (19), 217 (60), 202 (40), 201 (14), 200 (100). Part G. A solution of the amide from Part F (10.1 g, 50.7 mmol) and sodium hydroxide (10 mL, 5 N, 50 mmol) in 95% ethanol (200 mL) was heated to 50 °C for 24 hours. Then, an additional 5 mL sodium hydroxide solution was added, and the mixture was heated to full reflux for an additional 48 hours. The solution was cooled and evaporated, and the residual material was partitioned between ether and water. The aqueous phase was extracted a second time with ether, and the extracts were washed with brine, combined, dried over sodium sulfate, filtered and evaporated. The resulting product, 2-chloro-4- methoxyaniline, was purified by elution through a short column of silica gel with 30:70 ethyl acetate-hexane, and the eluant was evaporated (7.98 g, 100%). Part H. A solution of the aniline from Part G (7.98 g, 50 mmol) in cone. HC1 (25 mL) was cooled to -5 °C, and treated dropwise with a concentrated aqueous solution of sodium nitrite (3.80 g, 55.1 mmol). After 30 minutes, the mixture was charged with 15 mL cyclohexane and 15 L dichloromethane, then treated dropwise with a concentrated aqueous solution of potassium iodide (16.6 g, 100 mmol). This mixture was allowed to stir for 4 hours, then was extracted with dichloromethane (2 x 100 mL) . The extracts were washed in sequence with 1 N aqueous sodium bisulfite (100 mL) and brine (60 mL) , then combined, dried over magnesium sulfate, filtered and evaporated to afford sufficiently pure product, 3-chloro-4- iodoanisole (7.00 g, 26.1 mmol, 52%). TLC Rp 0.39 (5:95 ethyl acetate-hexane). H NMR (300 MHz, CDC1 3 ) : d 7.69 (IH, d, J = 8.8 Hz), 7.03 (IH, d, J = 3.0 Hz), 6.57 (IH, dd, J = 8.8, 3.0 Hz), 3.78 (3H, s). MS (H 2 0-GC/MS) : m/e 269 (100). Part I. A solution of the iodide compound from Part H (7.00 g, 26.1 mmol) in anhydrous tetrahydrofuran (50 mL) was cooled to * -90 °C, and treated with a hexane solution of n-butyllithium (16.5 mL, 1.6 M, 26.4 mmol). After 15 minutes, the solution was treated with triisopropylborate (6.10 mL, 26.4 mmol) and was allowed to warm to ambient temperature over 6 hours. The resulting mixture was treated with 6 N aqueous HC1 (5 mL) and water (5 mL) , which was stirred for 1 hour, then poured into water (100 mL) and extracted with ethyl acetate (2 x 100 mL) . The extracts were washed in sequence with 1 N aqueous sodium bisulfite and brine (80 mL each) , combined, dried over sodium sulfate, filtered and evaporated. The residual solid was triturated with 1:1 ether-hexane, collected by filtration and dried under vacuum to afford pure product, 2-chloro-4- methoxybenzeneboronic acid (3.05 g, 16.4 mmol, 63%). m.p. 191- 195 °C. Part J. A solution of the chloride from Part D (770 g, 2.78 mmol), the boronic acid from Part I (770 mg, 4.13 mmol), 2 N aqueous sodium carbonate solution (4 mL, 8 mmol) and triphenylphosphine (164 mg, 0.625 mmol) in DME (20 mL) was degassed by repeated cycles of brief vacuum pumping followed by nitrogen purging. To this was added palladium (II) acetate (35 mg, 0.156 mmol), and the mixture was degassed again and then heated to reflux for 14 hours. It was cooled, and poured into water (100 mL) . This mixture was extracted with ethyl acetate (2 x 100 mL) , and the extracts were washed in sequence with brine (60 mL) , combined, dried over sodium sulfate, filtered and evaporated. The residual material was separated by column chromatography (silica gel, 15:85 ethyl acetate- hexane) to afford the title product as a solid. This was recrystallized to purity from hexane (791 mg, 2.07 mmol, 74%). m.p. 139-140 °C (hexane). TLC R F 0.18 (30:70 ethyl acetate- hexane). X H NMR (300 MHz, CDC1 3 ) : d 8.93 (IH, s) , 7.74 (IH, d, J = 8.4, Hz), 7.10 (IH, d, J = 2.6 Hz), 6.96 (IH, dd, J = 8.4, 2.6 Hz), 4.20 (IH, v br) , 3.87 (3H, s) , 2.97 (2H, v br) , 2.00 (2H, vbr), 1.44 (3H, br t, J = 7 Hz), 0.89-0.79 (2H, m) , 0.62-0.52 (2H, m) , 0.51-0.40 (2H, m) , 0.26-0.16 (2H, m) . MS (NH 3 -CI): m/e 387 (1), 386 (9), 385 (41), 384 (30), 383 (100). Analysis calc'd for C 21 H 23 C1N 4 0: C, 65.87; H, 6.05; N, 14.63; found: C, 65.77; H, 6.03; N, 14.57. In Table 1, Table 1A and Table IB, melting point data correspond to compounds of Structure A unless otherwise indicated. TABLE 1 (A) (B) (C) Ex. πp, R J X R 3 R 4 R 5 R 11 R 6 R 1 * R lb No. °C * 1 CH, CH, H CH j CH j H CH, Λ CΛ 128-129 2 CH, CH j H CH 3 CH, H CH j Λ CΛ 99-100 3 CH 3 CH j H CH 3 CH, H CH, CΛ CH j OCH j oil 4 CH 3 CH j H CH 3 CH 3 H CH, C - 5 CH, CH j H CH 3 CH, H CH 3 Λ c-C,H 5 143-145 6 CH 3 CHJ H CH, CH j H CH, CΛ 6 H i3 - 7 CH, CHJ H CH, CHJ H CH, CΛ C,H, 68-71 8 CH, CHJ H CH, CHJ H CH J CΛ (CH j ) j θCH, oil 9 CH, CH, H CH, CHJ H CH, CΛ (CHJ)JOH 196-197 10 CH, • CHJ H CH, CH, H CH, CjHs (CH j ) j -(Ql) b oil 11 CH, CHJ H CH, CH, H CH, CΛ (CHj) j -(Q2) b oil 12 CH 3 CHJ H CH, CH, H CH, C j Hs CH j N(CH,) j - 13 CH, CHJ H CH j CH, H CH, C-C J H J C 120-121 14 CH, CHJ H CH, CH j H CH,' C-C J H J (CH j ) j OH 209-210 15 CH 3 CHJ H CH, CH, H CH, c-C,H 5 H 140-150 16 CH 3 CHJ H CH, CH, H CH, C-C,Hs C-CJHJ 186-187 17 CH, CHJ H CH, CH, H CH 3 H CΛ 121-122 CHJ CH j H CH 3 CH, H CH, H 3-(CH,0)-C 6 H 4 oil CH 3 CH j H CH, CH j H CH, H 2-Br-CΛ 84-85 CH, CHJ H CH j CHJ H CH, H 4-CH,-CΛ 48-50 CH, CHJ H CH j CH j H CH, H 4-C -CΛ - CH 3 CHJ H CH, CH, H CH 3 H 2-(C 4 H 9 )-C 4 H 8 - CH 3 CHJ H CH j CH, H • CH 3 H 3-(C 4 H s )-C 5 H 10 - CH, CHJ H CH 3 CH, H CH, H (CHJ)JOCH, - CH, CHJ H CH 3 CH, H CHJ H CH j OCH, - CH, CHJ H CH, CH, H CHJ H CΛ 120-123 CH, CHJ H CH, CH, H CH 3 H C oil . CH, CHJ H CH, CH, H CH 3 H C 4 H, oil CH, CHJ H CH j CH, H CH, CH j OCH, CH j OCH j - CH, CHJ H CH, CH, H CH, C j Hs OC 2 H 5 91-93 CH, CHJ H CH, CH, H CH, H (CH j ) j CH 120-121 CH, CHJ H CH, CH, H CH, H 0(CHJ)J-OCHJ CH, CHJ H CH j CH, H CH, CH j OCH, C - CH, CHJ H Cl Cl H H C j H, CΛ oil CH 3 CHJ H Cl Cl H H CΛ oil CH, CHJ H Cl Cl H H CΛ CHJOCHJ - CH, CHJ H Cl Cl H H CΛ C-C 3 H 5 oil (A) 118-119 (B) 125-126 (C) CH, CHJ H Cl Cl H H CΛ C.H, oil CH, CH, H Cl Cl H H CΛ (CH j ) j C H, - CH, CH, H Cl Cl H H CΛ CH j CN - CH, CH, H Cl Cl H H CΛ (CH j ) j -(Ql) b - CH, CHJ H ci Cl H H CΛ (CH j ),-(Q2) c - CH, CHJ H ci Cl H H jH, CH j N(CH j ) j - CH, CHJ H Cl Cl H H c-C j Hs C - CH, CHJ H ci Cl H H c-C,H 5 CH j OCH, - CH, CHJ H ci Cl H H C-CJHJ CΛ oil CH, CHJ H Cl Cl H H c-C,Hs C-CΛ 156-157 CH, CHJ H Cl Cl H H H 3-(CH,0)-CΛ oil CH, CHJ H Cl Cl H H H 2-Br-CΛ - CH j CH j H Cl Cl H H H 4-CH,-C,H 4 114-115 CHJ CH, H Cl Cl H H H 4-C.H j -CA oil CHJ CH j H Cl Cl H H H 2-(C 4 H 9 )-C 4 H 8 CH, CHJ H Cl Cl H H H 3-(C 4 H,)-CΛo CH, CH, H Cl Cl H H H (CH j ) j θCH, CH, CH, H Cl Cl H H H CH j OCH j CH, CH, H Cl Cl H H H CΛ CH j CH, H Cl Cl H H H C j H, CH j CH j H Cl Cl H H H C CHJ CH, H Cl Cl H H CH j OCH, CH j OCH j CH, CH, H Cl Cl H H H 0{CH j ) j -OCH j CH, CH, H Cl Cl H H CH j OCH, CH, CH, H CH, OCH, H CH, CΛ Λ CH, CH, H CH, OCH j H CH, CΛ C 4 H, oil CH, CH, H CH, OCH j H CH, CΛ CH j OCH j CH, CH, H CH, OCH, H CH, CΛ C CH, CH j H CH, OCH, H CH, CΛ c-C j Hs CH j CHJ H CH, OCH j H CH, CΛ δ Hn CHJ CHJ H CH, OCHJ H CH, Λ C j H, CHJ CHJ H CH, OCHJ H CH j ' Λ (CH j ) j OCH, CHJ CH, H CH, OCH, H CHJ CΛ CH j CN CHJ CH, H CH, OCH, H CHJ CΛ (CH j ) j -(Ql) b CHJ CH, H CH, OCH j H CHJ C j H, (CH j ) j -(Q2) c CHJ CH, H CH, OCH, H CH, CΛ CHJN(CH,) J CHJ CH j H CH, OCH, H CH, c-C,H, C CHJ CH, H CH, OCH, H CH j c-C,H 5 CH J OCH, CH, CH, H CH, OCH, H CHJ c-C,H, CΛ CH, CH, H CH, OCH, H CH j c-CΛ c-C,H 5 167-169 CH, CH, H CH j OCH, H CHJ H CjHs 134-135 CH, CH, H CH, OCH, H CH, H S-tCH j OJ-C.H, CHJ CH, H CH, OCH, H CH, H 2-Br-CΛ CH, CH, H CH, OCH, H CH, H 4-CH,-C β H 4 CH j CH, H CH, OCH, H CH, H 4-C.H5-CΛ CHJ CH, H CH, OCH, H CH, H 2-(C 4 H 9 )-C 4 H e CHJ CH, H CH, OCH, H CH, H 3-(CΛ)-CΛo CHJ CH, H CH, OCH j H CH, H (CH j ) j θCH, - CH, CHJ H CH, OCH j H CH, H CH j OCH j CH, CHJ H CH j OCH j H CH, H Λ 93 CH 3 CH j H CH, OCH j H CH, H C 94 CH 3 CH j H CH, H CH j H 95 CH, CH, H CH, H CH, CH j OCH, CH j OCH, 96 CH, CH j H CH, OCH j H CH, OC,H 5 97 CH, H CH, OCH j H H OC,H 5 98 CH, CH j H CH j H H 0(CH,) j -OCH, 99 CH, H CH, OCH, H CH j OCH j 100 CH, H CH, CH, H H CH, 138-140 101 H CH, H CH, CH, H C j Hs C J H J 198-199 102 H CH, H CH, CH j H CH, CΛ C 4 H, 147-148 103 H CH, H CH, H CH, CΛ CH j OCH, 140-142 104 H CH, H CH, H CH j CΛ CΛ 105 H H CH, CH, H CΛ c-CΛ 106 H CH, H CH j CH, H CH, CΛ c Aι 107 H H CH j H CH, C,H, 108 H CH, H CH j H C (CH j ) j θCH j 109 H CH, H CH, H CH, CΛ CH j CN 110 H H CH j CH, H CH, C j R, (CH j ) j -(Ql) b 111 H H CH j H CH j CΛ (CH j ),-(Q2) c 112 H CH j H H CΛ CH,N(CH,), 113 H H CH, H c-C,H 5 C 114 H CH, H CH, CH, H c-C j Hs CH J OCH J 115 H CH, H CH, H CH, CΛ 116 H CH, H CH, H CH, c-C j Hs C-C J H J 117 H H CH, H CH, H CΛ 118 H H CH, CH, H CH j H 3-(CH,0)-CΛ 119 H H CH, CH, H CH, H 2-Br-CΛ 120 H H CH, CH j H CH, H 4-CH,-CΛ 121 H H CH, H CH, H -C -C 122 H H CH, H CH, H 3-CΛs oil 123 H CH j H CH j CH, H CH, H 2-(CjH 5 )-CΛa oil 124 H CH, H CH, H CH, H (CH J ) J OCH J 125 H H CH, CH, H CH, H CH J OCH J 126 H H CH, CH j H H CΛ 127 H H CH j CH, H H CΛ 128 H H CH, H H C 129 H CH, H CH, H CH j OCH, 130 H CH, H H CH, CΛ OC j H 5 - 131 H CH, H CH, H CH, H OC j Hs 132 H CH, H CH, CH, H CH, H 0(CH J ) J -OCH J 133 H CH, H CH, CH J H CH 3 CH j OCH, C 134 H CH j H Cl Cl H H Λ CΛ 135 H CH, H Cl Cl H H C 136 H CHJ H Cl Cl H H C CH j OCH, 137 H CH, H Cl Cl H H CΛ C 138 H CHj H Cl Cl H H C j H, C-CΛ 140 H CH, H Cl Cl H H CΛ CΛ 141 H CH, H Cl Cl H H CΛ (CH j J j CCH, 142 H CH, H Cl Cl H H CΛ CH j CN 143 H CH, H Cl Cl H H CΛ (CH j ),-(Ql) " 144 H CH, H Cl Cl H H CΛ (CH j ) j -(Q2) c 145 H CH j H Cl Cl H H CΛ CH j N(CH,) j 146 H CH j H Cl Cl H H c-C,H 5 C 147 H CHJ H Cl Cl H H c-C j Hs CH j OCH, 148 H CH, H Cl Cl H H c-C j Hs C 149 H CH, H Cl Cl H H C-CJHJ C-C j Hs 150 H CH, H Cl Cl H H H C 151 H CH, H Cl Cl H H H 3-(CH,0)-C 5 H 4 152 H CH, H Cl Cl H H H 2-Br-C 6 H 4 153 H CH, H Cl Cl H H H 4-CH,-C 6 H 4 154 H CH, H Cl Cl H H H 4-C.H 5 -C.H, 155 H CH, H Cl Cl H H H 2-(CΛ)-C 4 H, 156 H CHJ H Cl Cl H H H 3-{CΑ)-C 3 U 10 157 H CH, H Cl Cl H H H (CHJ)JOCH, 158 H CH, H Cl Cl H H H CH j OCH, 159 H CH, H Cl Cl H H H CΛ 160 H CH, H Cl Cl H H H C j H, 161 H CH, H Cl Cl H H H CΛ 162 H CH J H Cl Cl H ri CH j OCH j CH J OCH J 163 H CH, H Cl Cl H H CΛ OC j H j 164 H CH, H Cl Cl H H H OC J H J 165 H CH, H Cl Cl H H H 0(CH J ) J -OCH J 166 H CH, H Cl Cl H H CH j OCH j 167 H CH, H CH, OCH, H CH, Λ CΛ 168 H CHj H CH, OCH, H CH, CΛ CΛ 169 H CH J H CH, OCH, H CH, CΛ CH j OCH, 170 H CH J H CH j OCH, H CH, CΛ 171 H CH J H CH J OCH, H CH, CΛ c-C j H; 172 H CH, H CH J OCH, H CH, Λ C ΛJ 173 H CH, H CH, OCH, H CH, CΛ C,H- 174 H CH, H CH, OCH, H CH, CΛ (CH,),OCH j 175 H CH j H CH j OCH, H CH, jHs CH j CN 176 H CH, H CH, OCH, H CH j Λ (CH j ) j -(Ql) b 177 H CH, H CH, OCH, H CHJ Λ (CH J ) J -(Q2) c 178 H CH, H CH, OCH, H CHJ CΛ CH J N(CH J ) , 179 H CH, H CH, OCH, H CHJ C-CJHJ CΛ 180 H CH, H CH, OCH, H CHJ C-CΛ CH j OCH, 181 H CH, H CH, OCH, H CH, c-C,H 5 CΛ 182 H CH, H CH, OCH, H CH, c-C j H, c-C j Hs 183 H CH, H CH j OCH, H CH, H CΛ 184 H CH, H CH, OCH 3 H CH, H 3-(CH,0)-C 6 H 4 185 H CH, H CH, OCH 3 H CH, H 2-Br-C 6 H 4 186 H CH, H CH, OCH 3 H CH j H 4-CH j -C 6 H 4 187 H CH, H CH, OCH j H CHJ H 4- Λ-C.H, 188 H CH, H CH, OCHJ H CHJ H 2-(C 4 H,)-C 4 H 8 189 H CH, H CH, OCHJ H CH, H 3-(C 4 H,)-C 5 H 10 190 H CH, H CH, OCH, H CH, H (CH j ) j θCH j 191 H CH, H CH, OCH, H CH, H CH j OCH j 192 H CH j H CHJ OCH, H CH, H CΛ 193 H CH, H CHJ OCH, H CH, H C j H, 194 H CH, H CHJ OCH j H CH, H C 195 H CH, H CHJ OCH j H CH, CH j OCH, CH j OCH, 196 H CH, H CH, OCH, H CH, CΛ OC j H 5 197 H CH, H CH, OCH, H CH, H OC j Hs 198 H CH, H CH, OCH, H CH, H θ(CH j ),-OCH, 199 H CH, H CH j OCH, H CH, CH j OCH, C 200 CH, CH, H CHJ CH, H CH, ' CH, CΛ 98-100 201 CH, 0 H CHJ CH, H CH, CΛ CΛ 202 CH, 0 H CH, CH, H CH, CΛ CΛ oil 203 CH, 0 H CH, CH, H CH, CΛ CH j OCH, 204 CH, 0 H CH, CH, H CH, CΛ CΛ 205 CH, 0 H CH, CH, H CH, CΛ C-C j Hs 206 CH, O H CH j CH, H CH, Λ c Λι 207 CH, O H CH, CH, H CH, CΛ C 208 CH, O H CH, CH j H CH, CΛ (CH j ) j θCH, 209 CH, 0 H CH, CH, H CH, Λ CH j CN 210 CH, O H CH, CH, H CH, Λ (CH j ) j -(Ql) b 211 CH, O H CH, CH j H CH, CΛ (CH j ) j -(Q2) ' 212 CH j O H CH, CH, H CH, CΛ CH j N(CH,) j 213 CH j 0 H CH, CH, H CH, C-C j H ; CΛ 214 CH, 0 H CH, CHj H CH, c-C j Hs CH j OCH j 215 CH, 0 H CH j CH, H CH, c-C j Hs 216 CH, 0 H CH, CH, H CH, C-CJHJ c-C j H, 217 CH, ' 0 H CH, CH, H CHJ H CΛ 218 CH, 0 H CH, CH, H CH j H 3-(CH 3 0)-C 6 H 4 219 CH, 0 H CH, CH j H CH, H 2-Br-C 6 H 4 220 CH, 0 H CH, CH, H CH, H 4-CHj-C.H, 221 CH, 0 H CH, CH, H CH, H 4-CΛ-C.H 4 222 CH, 0 H CH, CHJ H CH, H 2-(C 4 H,)-C 4 H, 223 CH, 0 H CH, CH, H CH, H 3-(C 4 H,) -C 5 H 10 224 CH, 0 H CH, CHJ H CH, H (CH,),OCH j 225 CH j 0 H CH, CHJ H CH, H CH j OCH j 226 CH, 0 H CH j CHJ H CH, H CΛ 227 CH, 0 H CH, CHJ H CH,' H CΛ 228 CH j 0 H CH j CHJ H CH, H CΛ 229 CHJ 0 H CHJ CH, H CH, CH j OCH j CHJOCHJ 230 CH, 0 H CH, CH, H CH, CΛ OCJH 5 231 CH, 0 H CH, CH, H CH, C j H, OC j H 5 232 CH, 0 H CH, CH, H CH, H 0(CH,),-OCH j 233 CH, 0 H CH, CH, H CH, CH j OCH, CΛ 234 CH, 0 H Cl Cl H H C j H, CΛ 235 CH, 0 H Cl Cl H H CΛ 236 CH, 0 H Cl Cl H H CΛ CH j OCH j 237 CH, 0 H Cl Cl H H CΛ CΛ 238 CH, 0 H Cl Cl H H CΛ C-CJHJ 240 CH, 0 H Cl Cl H H j Hs C 241 CH j 0 H Cl Cl H H CΛ (CH j J j OCH, 242 CHJ 0 H Cl Cl H H CΛ CH j CN 243 CH, 0 H Cl Cl H H ' CΛ (CH j ) j -(Ql) b 244 CH j 0 H Cl Cl H H CΛ (CH,) j -(Q2) c 245 CHJ 0 H Cl Cl H H CΛ CH j NtCH,), 246 CHJ 0 H Cl Cl H H C-C j Hs C 247 CHJ 0 H Cl Cl H H c-C j Hs CH j OCH, 248 CHJ 0 H Cl Cl H H C-CJHJ CΛ 249 CHJ 0 H Cl Cl H H c-C j Hs C-CJHJ 132-134 250 CH, 0 H Cl Cl H H H CΛ - * 251 CH, 0 H Cl Cl H H H 3-(CH,0)-CΛ 252 CH, 0 H Cl Cl H H H 2-Br-CΛ 253 CH j 0 H Cl Cl H H H 4-CH,-C 6 H 4 254 CHJ 0 H Cl Cl H H H 4-C 6 H 5 -C 6 H 4 255 CHJ 0 H Cl Cl H H H 2-{C 4 H 9 )-C 4 H 8 256 CH j 0 H Cl Cl H H H MCftKA 257 CHJ " 0 H Cl Cl H H H (CH j ),OCH, 258 CH, 0 H Cl Cl H H H CH j OCH, 259 CH, 0 H Cl Cl H H H CΛ 260 CH, 0 H Cl Cl H H H C 261 CH j 0 H Cl Cl H H H CΛ 262 CH, 0 H Cl Cl H H CH j OCH, CH j OCH, 263 CH, 0 H Cl Cl H H CΛ OC,H 5 264 CH, 0 H Cl Cl H H H oc,H 5 265 CH, 0 H Cl Cl H H H O (CH,) j -OCH, 266 CH, 0 H Cl Cl H H CH j OCH, CΛ 267 CH j 0 H CH j OCH j H CH j CΛ C.H, 268 CH, 0 H CHJ OCH j H CHJ CΛ C 269 CH, 0 H CH, OCH, H CHJ CΛ CH j OCH, 270 CH, 0 H CH j OCH, H CH j CΛ CΛ 271 CH, 0 H CHJ OCH, H CHJ Λ C-CJHJ 272 CH, 0 H CHJ OCH, H CHJ Λ C 3 273 CH, 0 H CHJ OCH, H CHJ CΛ C 274 CH j 0 H CHJ OCH j H CHJ CΛ (CH j J j OCH j 275 CHJ 0 H CH, OCH j H CHJ CΛ CH j CN 276 CHJ 0 H CH, OCH j H CHJ CΛ (CH j ) j -(Ql) b 277 CHJ 0 H CH, OCH, H CHJ C j H, (CHJ)J- (Q2) * 278 CH, 0 H CH, OCH, H CHJ CΛ CHJN(CHJ)J 279 CH j 0 H CH 3 OCH, H CHJ C-CΛ CΛ 280 CHJ 0 H CH j OCH j H CH, c-cΛ CH j OCH, 281 CH, 0 H CHJ OCH, H CH, C-CΛ CΛ 282 CH, 0 H CHJ OCH, H CH, C-CΛ C-C 3 H 5 283 CH, 0 H CHJ OCH, H CH, H CΛ 284 CH, 0 H CHJ OCH, H CH, H S-fCH j OJ-C.H, 285 CH, 0 H CHJ OCH, H CH, H 2-Br-CΛ 286 CH, 0 H CHJ OCH, H CH, H 4-CH j -C 6 H 4 287 CH, 0 H CHJ OCH, H CH, H 4-C -C 288 CH, 0 H CHJ OCH, H CH, H 2-(C 4 H 9 )-C 4 H β 289 CH, 0 H CHJ OCH, H CH, H 3-(C 4 H,)-CΛo 290 CH, 0 H CHJ OCH, H CH, H (CH j ) j θCH, 291 CH j 0 H CHJ OCH, H CH, H CHJOCHJ 292 CH, 0 H CHJ OCH, H CH, H CΛ 293 CHJ 0 H CH, OCH, H CH 3 H C j H, - 294 CH, 0 H CH, OCH, H CH j H C - 295 CH, 0 H CH, OCH, H CH j CH j OCH, CH j OCH, - 296 CH j 0 H CH, OCH, H CH, CΛ OCJHJ - 297 CH, 0 H CH, OCH, H CH, H OC,H 5 - 298 CH, 0 H CH, OCH, H CH, H O (CH j ), -OCH, - 299 CH, o H CH, OCH, H CH, CH j OCH, C - 300 CH, CH, CH, H Cl H H c-C j H j c-C j H j 106-109 301 CHJ S H CH, CH, H CH, CΛ CΛ - 302 CHJ S H CH, CH, H CH, CΛ - 303 CHJ S H CH j CH, H CH, CΛ CH j OCH, - 304 CHJ S H CH, CH j H CH, CΛ CΛ - 305 CHJ S H CH, CHJ H CH j Λ c-C,H 5 - 306 CH 3 S H CH, CHJ H CH, CΛ C 3 - 307 CH j S H CH, CH, H CH j C j H, C j H, 308 CHJ S H CH, CHJ H CHJ CΛ (CH j ),OCH, - 309 CHJ S H CH, CH, H CH j CΛ CH j CN - 310 CH j S H CH, CH, H CH j Λ (CH,),-(Q1) b - 311 CHJ S H CH, CH, H CHJ CΛ (CH j ) j -(Q2) ' - 312 CH, S H CH, CH, H CHJ CΛ CHJN(CHJ), - 313 CH, S H CH, CH, H CH j c-C j H, C - 314 CH, S H CH, CH, H CHJ c-C,H, CH j CCH j - 315 CH, S H CH, CHJ H CHJ C-CJHJ CΛ - 316 CH, S H CH, CH, H CHJ C-CJHJ C-CJHJ - 317 CH, s H CH, CH, H CHJ H CΛ - 318 CH, s H CH, CH j H CHJ H 3-(CHJO) -CΛ - 319 CH, s H CH, CHJ H CH, H 2-Br-C 6 H 4 - 320 CH j s H CH, CHJ H CH, H 4-CH,-C β H 4 - 321 CHJ s H CH, CH, H CH j H 4-CΛ-C.H, - 322 CH, s H CH, CH, H CHJ H 2-(C 4 H,)-CΛ - 323 CH, s H CH, CH, H CHJ H 3-(C 4 H,)-CΛo - 324 CH, s H CH, CH, H CH, H (CH j J j OCH, - 325 CH, s H CH, CH j H CH, H CH j OCH, - 326 CH, s H CH, CH, H CH j H CΛ - 327 CH, s H CH, CH j H CH, H C - 328 CH, s H CH, CH, H CH, H CΛ - 329 CH, s H CH, CH, H CH, CH j OCH, CH j OCH, - 330 CH, s H CH, CH, H CH, CΛ OC j H j s 331 CH j s H CH, CH, H CH, H OC j H j - 332 CH, s H CH, CH j H CH, H 0(CH j ) j -OCH, - 333 CH, S H CH j CH j H CH, CH j OCH, CΛ 334 CH, S H Cl Cl H H CΛ C 335 CH, S H Cl Cl H H Λ C 336 CH, S H Cl Cl H H CΛ CH j OCH, 337 CH j ' S H Cl Cl H H CΛ C 338 CHJ S H Cl Cl H H CΛ C-C j H j 339 CH j S H Cl Cl H H C j H, CΛ3 341 CH, S H Cl Cl H H CΛ (CH j ) j θCH, 342 CH, S H Cl Cl H H CΛ CH j CN 343 CH, S H Cl Cl H H CΛ (CH j ) j -(Ql) b 344 CH, S H Cl Cl H H Λ (CH j ) j -(Q2) e 345 CH, S H Cl Cl H H CΛ CHJN(CH,)J 346 CH, S H Cl Cl H H c-C j H, CΛ 347 CH, S H Cl Cl H H C-C j H, CH j OCH, 348 CH, S H Cl Cl H H C-C j Hs CΛ 349 CH, S H Cl Cl H H C-C j Hs C-C j Hs 350 CH, S H Cl Cl H H H CΛ 351 CH, S H Cl Cl H H H 3-(CH,0)-CΛ 352 CH, s H Cl Cl H H H 2-Br-CΛ 353 CH, s H Cl Cl H H H 4-CH,-C 6 H 4 354 CHJ s H Cl Cl H H H 4-CΛ-CΛ 355 CHJ s H Cl Cl H H H 2-(c 4 H,)-CΛ 356 CHJ s H Cl Cl H H H 3-(C 4 H,)-GΛ 0 357 CHJ s H Cl Cl H H H (CHJ)JOCHJ 358 CHJ s H Cl Cl H H H CH j OCH, 359 CH, s H Cl Cl H H H CΛ 360 CH j s H Cl Cl H H H Λ 361 CH, s H Cl Cl H H H C 362 CH, s H Cl Cl H H CH j OCH, CH j OCH, 363 CH j s H Cl Cl H H CΛ OC j Hs 365 CH, s H Cl Cl H H H 0(CH,),-OCHJ 366 CH, s H Cl Cl H H CH j OCH, 367 CH, s H CH j OCH j H CH, CΛ CΛ 368 CH, s H CHJ OCH, H CH, CΛ C 369 CH, s H CH, OCH j H CH, CΛ CHJOCHJ 370 CH, s H CH, OCH j H CH, CΛ CΛ 371 CH, s H CH, OCH j H CH, Λ c-C j H, 372 CH, s H CH, OCH, H CH j CΛ c Aι 373 CH, S H CH, OCH, H CH j CΛ C 374 CH, Ξ H CH, OCH, H CH, CΛ (CH,), OCH, 375 CH, S H CH, OCH, H CH, Λ CH j CN 376 CHJ S H CH j OCH, H CH, CΛ (CH j ) j -(Ql) b 377 CH, ' S H CHJ OCH, H CH, CΛ (CH,),-(Q2) c 378 CH, s H CH, OCH, H CH j CΛ CHJN(CHJ) J 379 CH, s H CH, OCH, H CHJ c-C,H 5 C 380 CH, s H CH, OCH j H CH, c-C j Hs CH j OCH, 381 CH, s H CH, OCH, H CH, C-CΛ CΛ 382 CH, s H CH, OCH j H CH, c-C,Hs C-C j Hs 383 CH, s H CH, OCH j H CH, H 384 CH, s H CH, OCH j H CH, H 3-(CH,0)-C 6 H 4 385 CH, s H CH, OCHJ H CH, H 2-Br-C 6 H 4 386 CH, s H CH j OCHJ H CH, H 4-CH j -C 6 H 4 387 CH, s H CHJ OCHJ H CH, H -CΛ-C.H, 388 CH, s H CH, OCH, H CH, H 2-(C 4 H 9 )-C 4 H 8 389 CH j s H CH j OCH, H CH, H 3-ICΛ1-CΛ 390 CHJ s H CH, OCH, H CH, H (CH j ),OCH, 391 CH j s H CH j OCH, H CH, H CH j OCH j 392 CH, s H CHJ OCH, H CH, H CΛ 393 CH, s H CHJ OCH, H CH, H C-H, 394 CH j s H CH j OCH, H CH, H C 395 CH j s H CHJ OCH, H CHJ CH j OCH, CH j OCH, 396 CH j s H CHJ OCH, H CH, CΛ OC j H 5 397 CH j s H CH, OCH, H CH j H OC j H 5 398 CHJ s H CH, OCHJ H CH, H 0(CH j ) j -OCH, 399 CHJ s H CH, OCH, H CH, CH j OCH, 400 CH, CH j H Cl Cl H CH, C c-C j H, 153-156 401 CH j CH, CH, CH, CH, H CH, CΛ CΛ 402 CH, CH, CH, CH, CH, H CH, C-CΛ C 4 H, 107-108 403 CH, CH j CH, CH, CH, H CH, c-C j H, c-CΛ 187-188 404 CH, HJ CH, CH, CH, H CH, H C 4 H, oil 405 CH, CH, CH, CH, CH, H CH, CΛ C 4 H, 98-99 406 CH, CH j CH, CH, CH, H CH, H C 149-150 407 CH, CH, CH, CH j CH, H CHJ CΛ (CH j ) j CCH, 408 CH j CH, CH, CH j CH, H CHJ H (CH j ),OCH, 409 CHJ CH j CH, CH, CH, H CH, CH j OCH, CH j OCH, 410 CHJ CH, CH, CH, CH j H CH, CΛ CH j OCH, - s 411 CHJ CH j H CH, Cl H H CΛ CΛ 412 CH, CHJ H CH, Cl H H C-CΛ CΛ 413 CH j CH, H CH, Cl H H C-C 3 H 5 C-C 3 H 5 139-140 414 CH, CH, H CH, Cl H H CH j C j H, oil (A,C) 415 CH, CH, H CH, Cl H H CΛ oil 416 CH, H CH, Cl H H H CΛ - 417 H CH, Cl H H CΛ (CH j ),OCH, - 418 CH, H CH j Cl H H H (CH j ) j θCH, - 419 CH, H Cl H H CH j OCH j CH j OCH, - 420 CH, H Cl H H Λ CH j OCH, - 421 CH, H Cl CH, H H C Λ - 422 CH, CH j H Cl CH, H H C-C j H; C - 423 CH, H Cl CH, H H C-C j Hs c-CΛ 177-178 424 CH, H Cl CH, H H CH, C oil 425 CH, H Cl • CH j H H C j Hs CΛ - 426 CH, CH j H Cl H H H CΛ 427 CH, CH, H Cl H H j Hs (CH,),OCH, - 428 CH, CH j H Cl CH, H H H (CH,),OCH, - 429 CH, CH j H Cl CH, H H CH j OCH, CH j OCH, - 430 CH, CH, H Cl CH, H H CΛ - 431 CH, CH, H Cl Cl H OCH j CΛ C-C j H, 141-144 432 CH, CH, H CH, CH, H CΛ CΛ 108-110 433 CH j CH, H Cl Cl H c-C j H j c-CΛ 194-195 434 H CH, CH, H CΛ C- — C j f gt-.fi j oil 435 CH j H CH, CH, H Λ CH j OH 155-157 436 H CH, OCH, H H CΛ C — C^H^C i j oil 437 H CH, OCH, H H CH, C oil 438 H CH, OCH, H H H 4-(CH,0)-C 6 H 4 oil 439 CH, CH, H CH j OCH, H H C-CΛ oil 440 CH j CH, H CH, OCH j H H CH j C 5 H 11 . oil 441 CH, H Cl NMe, H H CΛ CΛ - 442 CH, H Cl NMe, H H C-C j H j CΛ - 443 CH, CH, H Cl NMe, H H C-C j H, C-CΛ - 444 CH, CH, H Cl NMe, H H H C - 445 CH, CH, H Cl NMe, H H CΛ CΛ - 446 CH, H Cl NMe, H H H CΛ - 447 CH, H Cl NMe, H H C j Hs (CH j ) j θCH, - 448 CH, H Cl NMe, H H H (CH j J j OCH, - 449 CH, H Cl NMe, H H CH j OCH, CH j OCH j - ' 450 CH, CH, H Cl NMe, H H CΛ - 451 CH, CH j H CH, NMe, H H C Λ CΛ - ro so σs σs ro 00 OS H U tf af af ft. x tf af tf af af s af af X af tf af af af CJ CJ CJ CJ CJ J CJ CJ CJ CJ CJ o CJ CJ X X X X X X of cf αJ * ςf α5" oj" X X X X X X X X X X X X X X X X X X X X X X X X X X X X X X af af u CJ υ CJ CJ CJ CJ CJ CJ CJ J CJ υ CJ CJ CJ CJ u J CJ CJ CJ CJ CJ o o CJ CJ CJ CJ CJ u αr αr αr aT iir αr r αf αf αr x x x x af af af af af υ a CJf yX yX yX yX yX yX Xy yX Xc yX tCJf Tf x" tf tf tf x" tf af 3f 3f af af x" x" tf af a x" af tf af af af 3f af af af af af Tf af af af af af af af tf af af af af o cj * cj" OS Os C m "tf ιn iiJ t^ co σs θ rH c n sι , ιn ^ ι r*. co σs θ ιH N m "tf in ID r- m O ιn ιn ιn ιn ιn ιn ιn -n ιo so ιo vo i-> sD vD iD i-3 iD r-- r- r- r- r- r- r- r-- •<* sr 492 CH 3 CH, H CH j CH, H H c-C j Hs CΛ - 493 CH, CHJ H CHJ CH, H H c-C j Hs C-C j H; 149-150 494 CH, CHJ H CH, CH, H H H C j H, 99-100 495 CH, CHJ H CH j CH j H H Λ C - 496 CH, CH, H CH j CHj H H H C - 497 CH j CH, H CHJ CH j H H CΛ ( CH j ) j θCH j - 498 CHJ CH, H CH j CHJ H H H ( CH j ) ,OCH, - 499 CH, CH, H CHJ CHJ H H CH j OCH j CH j OCH, - 500 CH j CH j H CHJ CH j H H CΛ CH j OCH, - 501 CHJ CH, H CH, CHJ H CH, CH, CΛ - 502 CH j CH, H CH j CHJ H CH, CH, C oil 503 CH, CH, H CHJ CHJ H CH, CH, C 5 H 11 oil 504 CH, CHJ H CH j CHJ H CH, CΛ 2 -CΛ 109-110 505 CH j CHJ H CH j CHJ H CH, CΛ C.i j ϋ j f j - 506 CH j CHJ H Cl Cl H H CH, CΛ oil (A, B,C) 507 CH, CHJ H Cl Cl H H CH, CΛ oil 508 CH, CHJ H Cl Cl H H CH j CjHn - 509 CH, CHJ H Cl Cl H H CΛ 2-C 4 H, - 510 CH j CHJ H Cl Cl H H CΛ C ri j C ^.tis - 511 CHJ CHJ H Cl CF j H H Λ c-C,^ oil (A) 78-80 (B) 116-117 (C) 512 CHJ CH, H Cl CF j H H C-C j H, c-C j H j 145-146 513 CH, CH, H Cl CF, H H CΛ C oil 514 CH, CH, H Cl CF, H H CΛ CΛ oil 515 CHJ CH, H Cl CF, H H CΛ CH j OC j H j - 516 CHJ CH, H OCH, Cl H Cl CΛ C-CΛ - 517 CHJ CH, H OCH, Cl H Cl C-CJKJ C-CJHJ 183-184 518 CH, CHJ H OCH, Cl H Cl CΛ C 109-110 519 CH, CH, H OCH, Cl H Cl CΛ ( CH,) ,OCH j - 520 CHJ CH, H OCH, Cl H Cl Λ C l j uC jf j - 521 CHJ CH j H CH j CH, H CH, C C 115-120 522 CHJ 0 H CH j CH, H CH, C j H, C j H, - 523 CHJ CH, H Cl Cl H H C j H, CΛ 99-lOls 524 CH, CH, H CH j OCH, H H C j H, C j H, oil 525 CH, CH, H OCH, CH, H CH, C j H, C Λ 109-111 526 CH, CHJ H CH 3 Cl H H CJH, C oil 527 CH j CHJ H CH 3 CH, CH, H C - 528 CH, CHJ H Cl CF, H H C j H, C oil 529 CH, CHJ H Cl CF, H Cl CjH, C - 530 CHJ CHJ H OCH 3 Cl H Cl CΛ CΛ 129-131 531 CH j CHJ H CH 3 CH, H CH, CH, (CH,) j CHCH j 77-85 532 CH j 0 H CH j CH, H CH, CH, (CH,)JCHCHJ - 533 CH, CHJ H Cl Cl H H CH, (CH,)JCHCHJ - 534 CH, CHJ H CH j OCH, H H CHJ (CHJ)JCHCHJ - 535 CHJ CHJ H OCH, CHJ H CH, CH, (CHJ)JCHCHJ - 536 CH, CHJ H CH, Cl H H CH, (CHJ)JCHCHJ - 537 CH, CH, H CH, CH, CH, H CH, (CHJ)JCHCH, - 538 CH, CH, H Cl CF, H H CΛ (CHJ)JCH oil 539 CH, CH, H Cl CF, H Cl CH, (CHJ)JCHCHJ - 540 CH, CH, H OCH, Cl H Cl CH, (CHJ)JCHCHJ 541 CH, CH, H CH, CH, H CH, CH, C-CJH, 118-127 542 CH, 0 H CH, CH, H CH, CH, C-C j Hs - 543 CH, CH, H Cl Cl H H CH, C-C 3 H 5 oil 544 CH, CH j H CH, OCH, H H CH, c-C,H 5 oil 545 CH, CHJ H OCH, CH, H CH, CH, c-C j Hs - 546 CH, CHJ H CH j Cl H H CH j c-C j H, - 547 CH, CHJ H CHJ CH j CH, H CH, C-C j H, - 548 CH, CHJ H Cl CF, H H CH, c-C j Hs oil 549 CH, CHJ H Cl CF, H Cl CH, C-C 3 H 5 - 550 CH, CH, H OCH j Cl H Cl CH, c-C j Hs - 551 CH, CH, H CH, CH, H CH, CH j CH 3 oil 552 CH, 0 H CH, CH, H CH, CH, CH j - 553 CH, CH j H Cl Cl H H CH, CH, - 554 CH, CHJ H CH, OCH, H H CH, CH 3 - 555 CH, CH, H OCH, CH, H CH j CH, CH j - 556 CH, CH, H CH, Cl H H CH, CHJ - 557 CH, CHJ H CH, CH, CH, H CH, CHJ - 558 CH, CHJ H Cl CF, H H CH, C oil 559 CH, CHJ H Cl CF, H Cl CH, CH j - 560 CHJ CH, H OCH, Cl H Cl CH j CHJ - 561 CHJ CH, H CH, CH, H CH j CΛ C 5 Hn 102-103 562 CH j 0 H CH, CH, H CHJ CΛ C j Hn - 563 CHJ CH, H Cl Cl H H Λ 5 H 11 V 564 CHJ CHJ H CH, OCH, H H Λ C 4 H, oil 565 CHJ CHJ H OCHJ CH, H CH j CΛ C 5 Hu - 566 CH j CH, H CH, Cl H H CΛ c Λι 567 CH J CH, H CH, CH, CH, H CΛ c Λι 568 CH, CH, H Cl CF, H H CΛ CsHu 569 CH J CH, H Cl CF, H l CΛ C 5 H 11 570 CH J CH, H OCH, Cl H Cl CΛ CsHu 571 CH J CH, H CH, CH, H CH 3 CΛ oil 572 CH J 0 H CH, CH, H CH 3 CΛ C j HsOtCH j l j 573 CH J CH, H Cl Cl H H CΛ C j HsOtCH j J j 574 CH J CH, H CH, OCH, H H CΛ C j H j OtCH j J j 575 CH J CH, H OCH, CH, H CH 3 Λ C j HsOtCH j l j 576 CH, CH, H CH j Cl H H CΛ C j ^OfCH j ), 577 CH, CH, H CH J CH, CH, H CΛ C j HsOfCH,), 578 CH, CH, H Cl CF, H H j Hs C j HsOfCH,), 579 CH, CH, H Cl CF j H Cl CΛ C j HsOJCH,), 580 CH, CH, H OCH j Cl H Cl CΛ C^OfCH,), 581 CH J CH, H CH j CH, H CH, CΛ CjHjOCHj oil 582 CH, 0 H CH, CH, H CH 3 CΛ C 2 H j C-Xr riς 583 CH, CH, H Cl Cl H H CΛ C J H J OCH J 584 CH, CH, H CH j OCH, H H CΛ C 2 H 5 OCH 2 585 CH, CH, H OCH J CH j H CH 3 CΛ C J H J CXH J 586 CH, CH, H CH j Cl H H Λ --,H« .H 2 587 CH J CH, H CH J CH j CH, H CΛ C J IΓ OCH J 588 CH J CH, H Cl CF, H H CΛ v—^H j ^ ri j 589 CH J CH, H Cl CF, H Cl CΛ C^H j OCH j 590 CH J CH j H OCH j Cl H Cl Λ (-.^H^OC !^ 591 CH J CH J H CH j CH, H CH, H c-C j HsCHtOMe) oil (CH j ), 592 CH J 0 H CH, CH, H CH, H c-C^CHfOMe) (CH J ) J 593 CH, CH j H Cl Cl H H H c-CjHsCHfOMe) (CH j ), 594 CH, CH J H CH, OCH, H H H c-CΛCH(θMe) (CH,), 595 CH, CH, H OCH, CH, H CH j H c-CΛCH(θMe) (CH,), 596 CH, CH, H CH, Cl H H H c-C j H j CHiOMe) (CH,), 597 CH, CH J H CH, CH, CH 3 H H c-CΛCH(θMe) (CH,), 598 CH, CH, H Cl CF, H H H c-C^CHfOMe) ro I I I I I I I I I I I I I I I I I I I I I I I I I I I I Os ro 00 Os CΛ X X af af CJ U J af tf 3f af af ~ af T? aT af af ,? ,r . a ~ af af cj * C X af af af af af X r. X n T" afo af« af«ι ,U- ,CJ r „ X a"7f. X_ aTr. -33c aTf cj" n "7. M CJ CJ X "7f. X , a*Tf» a*Tfι ,Ur CJr CJ CJ j CJ CJ I O CJ u CJ U I I CJ CJ CJ c cj CJ i i CJ J u CJ CJ x χ χ χ χ χ x χ x χ 3 ^ ^ ^ tf tf af a χ χ χ χ χ χ χ χ χ χ χ χ χ χ χ X PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC Λ Λ PC PC PC PC P PC PC PC S PC tf rH rH af af af af af af af CJ CJ CJ x" x" af af af af af af af af af af tf o 8 B 8 8 8 B 8 B 8 8 u af tf af af af af af af af af x" X af 8 CJ 8 B 8 8 8 8 8 B 8 8 u X X af af af x ^ af af tf x" x ^ af af af x" af af af af tf af af af af af af af af tf af af af tf af af o u O o u af af af af af tf af tf af af af af af af x ^ af af af af af af af af af af af af af af af 3f tf af af af af u u o CJ Tf •Λ af af x" af af af af af af tf af x ^ af x" x" af af x ^ af af tf af af af af af af 3f af af tf af af af tf af Tf J CJ J CJ υ u CJ J CJ CJ J CJ J u U CJ J CJ CJ CJ Os Os σs o n sr in r- σs o en sr vo σs o m in vo o ro sr in o en o σs o o o o o o o n m in to vo co vo co vo vo vo vo o 636 CH, CH, CH, CH, Cl H H H 637 CH, CH, CH, CH, Cl H H Λ ( CH j ) j OCH, 638 CH, CH, CH, CH, Cl H H CH, C 639 CH, CH, CH 3 Cl H H C C j H, 640 CH j CH, CH, CH 3 Cl H H C j Hs C j H, 641 CH, CH, Cl CF j H H CΛ Λ 643 CH, CH, Cl F j H H C-C j H, C-C j Hs 644 CH j CH, Cl H H H C 645 CH, Cl H H CΛ 646 CH, CH, Cl CF, H H H CΛ 647 CH, CH, Cl CF, H H CΛ (CH j J j OCH j 648 CH, CH, Cl CF, H H CH j Λ 649 CH, CH, CH, Cl CF, H H C j H, C j H, 650 CH, CH, CH, Cl CF, H H CΛ C 651 CH, CH, Cl CF, H Cl Λ CΛ 652 CH, CH j CH, Cl H Cl C-C j H, C 653 CH, Cl H Cl C-CjHs C-C j Hs 654 CH, Cl H Cl H C 655 CH, CH j Cl CF, H Cl CΛ CΛ 656 CH, CH, CH, Cl CF, H Cl H Λ 657 CH, CH, CH, Cl CF, H Cl C j H, (CH j ) j θCH, 658 CH, CH, CH, Cl CF, H Cl CH, CΛ 659 CH, CH, CH, Cl CF, H Cl C j H- CΛ 660 CH, CH, CH, Cl CF, H Cl Λ C 661 CH, CH, CH, OCH 3 Cl H Cl CΛ CΛ 662 CH, CH j CH, OCH, Cl H Cl C-C j Hs C 663 CH, CH, OCH, Cl H Cl C-C j H, C-CΛ 664 CH, CH, CH, OCH, Cl H Cl H CΛ 665 CH j CH, CH, OCH, Cl H Cl Λ C 666 CH, CH, OCH, Cl H Cl H Λ 667 CH j OCH, Cl H Cl CΛ (CH,) ,OCH, 668 CH, CH, OCH j Cl H Cl CH j 669 CH, CH, OCH, Cl H Cl CJH, CΛ 670 CH, CH, CH, OCH, Cl H Cl CΛ CΛ 671 CH, CH, CH, H H CΛ CΛ 672 CH, CH, CH, CH j H H c-C j H; CΛ 673 CH, CH, CH, CH, H H c-C j H, C-C 3 H 5 674 CH, CH, CH, CH, CH, H H H C 675 CH, CH, CH, CH, H H CΛ C 676 CH j CH, CH j CH j CH, H H H CΛ 677 CH 3 CH, CHJ CH j CH j H H CΛ (CH,) jOCH, 678 CH, CH j CHJ CH j CHJ H H CH j CΛ 679 CH j CH, CHJ CH, CHJ H H C CΛ 680 CH, CH, CHJ CH j CH, H H CΛ CΛ 681 CH j CH j H CH 3 OCH, H H C j H, C 682 CH j CH, H OCH, CH, H CH, C j Hs CΛ 107-109 683 CHJ CHJ H Cl CF, H Cl C j H, CΛ 684 CHJ CHJ H CH j CH, CH, H C j Hs C 685 CHJ CHJ H CHJ OCH, H H C-C j Hs c-C,H 5 101-103 686 CH 3 CHJ H OCH j CH, H CH, C-C j Hs C-C 3 H 5 187-188 687 CH 3 CH j H Cl CF, H Cl C-C j Hs c-CΛ 688 CH 3 CHJ H CH j CH, CH, H C-C j Hs c-C j Hs 119-121 689 CH 3 CH, H CHJ OCH, H H H CΛ 108-109 690 CH, CH j H OCH j CH, H CH, H C - i 1 691 CH, CHJ H Cl CF, H Cl H CΛ 692 CH 3 CHJ H CH j CH, CH, H H CΛ oil 693 CH, CHJ H CHJ OCH, H H C-CjHs C 4 H, oil 694 CH, CHJ H OCH 3 CH, H CH, c-C j H, CΛ 695 CH 3 CHJ H Cl CF j H Cl c-CΛ CΛ 696 CH j CHJ H CH, CH, CH, H c-CΛ CΛ 697 CHJ CHJ H CH, OCH, H H CH, c 4 H, oil 698 CHJ CHJ H OCH, CH j H CH, CH, Λ 699 CH j CHJ H Cl CF j H Cl CH, CΛ 700 CHJ CHJ H CH, CH, CH, H CH, CΛ 701 CH j 0 H CH, OCH, H H CΛ C 702 CHJ 0 H OCH, CH, H CH, CΛ CΛ 703 CH, 0 H Cl C j H Cl CjHs C 704 CH, 0 H CH j CH, CH, H CΛ CΛ 705 CH, 0 H CH, OCH j H H c-C j Hs c-CjHc 706 CH, 0 H OCH, CH, H CH, c-C j H, C-C j H, 707 CH 3 0 H Cl CF, H Cl c-CΛ C-C J H J 708 CH 3 0 H CH 3 CHJ CH, H C-CΛ c-C j H, 710 CHJ 0 H OCH 3 CH j H CH, H CΛ 712 CHJ 0 H CH j CH, CH, H H CΛ 713 CHJ 0 H CHJ OCH j H H c-CΛ CΛ - v 714 CHJ 0 H OCHJ CH, H CH, C-CΛ CΛ 715 CHJ 0 H Cl CF, H Cl C-CΛ C o , — , , o ro r- * < — σs — c_> r^ <) () Os ro 00 Os H af af af af af af af af af af af tf af af af af tf af af af af af af af af af af af af af CJ' U' J' CJ' J' u υ af tf υ u ft. o cj" CJ" X J υ o o o υ u af CJ" X X t X X X X X X X X X X X X X X X X X X X X X X X X X X X X X af af af af CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ U CJ CJ CJ CJ CJ CJ U CJ CJ CJ CJ CJ CJ U CJ CJ CJ CJ CJ CJ CJ cj" cj" CJ" CJ" af X X X X X X X X X X X X X X X ft. X X X X ft, r-j ft. rH Of υ B CJ J υ CJ CJ CJ B 8 CJ CJ " 8 8 X X rH ft, X ft. X _r *_~ *τ. X X X rH rH X rH 8 u υ CJ CJ u CJ CJ u CJ CJ CJ υ CJ CJ CJ o J X PC PC X X X X o o o o o af af af af af af af tf af af af af af af af af af af af af af af af af af af af af a CJf a CJf a uf a uf Tf IΛ PC PC PC PC PC C PC PC PC PC PC PC PC PC PC PC PC PC PC tJ-ι *J-ι t^-i af af af af Tf CJ O U U CJ CJ U CJ CJ U O CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ U CD - r ^ co cn θ rH C N rn sr ιn vD t^ oo σs θ rH CN rn sr ιn cD r ^ oo σs θ rH CN rn sr ιn co t^- 00 OS O rH CN rH r H r H r H j c N C N CN CN C CN CN CN CN ro rn rn rn rn ro rn rn rn rn sr sr s|. sr sr sr sr sr sr sr in in in t- c- r- r- 753 CH, CH, H CF 3 Cl H H C,H, C-C,H, oil (A) 95-97 (C) 754 CH, CH, H CH, Cl H H C C-C J H S 87-88 755 CH 3 CH, H CF, CF, H H C C-C J H S 756 CH 3 CH, H Cl CN H H C C-C J H S 757 CH 3 CH, H Cl Cl F H C j H- c-C j Hs 758 CH, CH j H Cl Cl Cl H CjH, c-C 759 CH, CHJ H CH j OCH, F H C j H, c-C j Hs 760 CH, CHJ H CHJ OCH, Cl H C j H, c-CΛ 761 CH, CH, H Cl CH, F H C j H, C-C 3 H 5 762 CH, CH, H Cl CF, Cl H CΛ c-C,^ 763 CH, CH, H Cl CF, F H C 3 H, c-C,^ 764 CH j CH, H Cl OCH, Cl H CΛ C-C J H J 765 CH, CH, H Cl OCH, F H C c-C 3 H 5 766 CH, CH, H Cl OCHJ CH, H C,H, c-C j Hs 767 CH 3 CH j H CH j OCH, CH, H CjH, c-C j Hs oil 768 CH, CHJ H Cl H Cl H C,H, c-C j H j 769 CH 3 CHJ H Cl Cl OCH, H CΛ c-CΛ 770 CH, CH, H Cl CH, OCH, H Λ c-C j Hs 771 CH, CH, H CH j Cl OCH, H CΛ c-C 3 H 5 772 CH j CHJ H CHJ CH, OCH, H C C-C 3 H 5 773 CH j CHJ H CHJ CH, H CH, CH, CH j Cl 109-110 774 CH, CH j H Cl Cl H H CjH, CΛ 775 CH, CHJ H Cl CH, H H CΛ C,H- 776 CH, CHJ H Cl OCH, H H C j Hs C j H, oil 777 CH, CHJ H CH, OCH j H H CΛ C j H, oil 778 CHJ CHJ H Cl CF j H H Λ C j H, oil 779 CHJ CHJ H CFj Cl H H CΛ C,H, oil 780 CHJ CH, H CHJ Cl H H CΛ C,H, 781 CH, CH, H CFJ CF j H H CΛ C-H, 782 CH, CH, H Cl CN H H CΛ C 783 CH, CH, H Cl Cl F H Λ C,H, 784 CH, CH, H Cl Cl Cl H Λ CΛ 785 CH, CH, H CH j OCH, F H CΛ C,H- 786 CH, CH, H CHJ OCH, Cl H CΛ C,H, 787 CH j CH j H Cl CH, F H CΛ C,H, - v 788 CH, CHJ H Cl CF, Cl H CΛ C,H, 789 CH, CHJ H Cl CF, F H CΛ C,H, 790 CH, CH, H Cl OCH, Cl H Λ C,H, - 791 CH j CH, H Cl OCHJ F H CΛ C 3 H 7 - 792 CH, CH, H Cl OCH, CH, H Λ CjH, - 793 CH, CH, H CH, OCH, CH, H CΛ C oil 794 CH, CH j H Cl H Cl H CΛ C j H, - 795 CH, CHJ H Cl Cl OCH, H CΛ C j H, - 796 CH, CH j H Cl CH, OCH, H CΛ C j H, - 797 CH, CHJ H CH, Cl OCH, H CΛ C,H, - 798 CH, CHJ H CH j CH, OCH, H CΛ CΛ - 799 CH, CHJ H CHJ CH, CH j H CΛ C j H, oil 800 CH, CHJ H CF, Cl H H H 4-CH 3 0-C 6 H 4 138-139 801 CH, CHJ H CFJ Cl H H c-C j H; c-C j Hs 138-139 802 CH, CHJ H CFJ Cl H H CΛ c-C j Hs oil (A) 125-125 (C) 803 CH, CH, H CFJ Cl H H CH j c-C j Hs oil 804 CH, CH, H CFJ Cl H H CHJ CΛ oil 805 CH, CHJ H CF, Cl H H CHJ CΛ oil 806 CH, CHJ H CF, Cl H H CHJ C s Hu - 807 CH, CHJ H CF, Cl H H CJHS oil 808 CH j CHJ H CF j Cl H H CJH, C oil 809 CH, CHJ H CFJ Cl H H CJHS CΛ oil 810 CH, CH, H Cl CN H H H 4 -CH,0-C 6 H 4 - 811 CH, CH, H Cl CN H H C-CJHJ c-CΛ 180-182 812 CH, CH, H Cl CN H H CΛ C-CΛ - 813 CH, CH, H Cl CN H H CH, C-CΛ - 814 CH, CH, H Cl CN H H CH, CΛ - 815 CH, CH, H Cl CN H H CH, CΛ - 816 CH, CH, H Cl CN H H CH, C 5 Hu - 817 CH, CH, H Cl CN H H CΛ C - 818 CH, CH, H Cl CN H H CΛ C,H, - 819 CH, CH, H Cl CN H H CΛ CΛ - 820 CH, CH, H CFj CF, H H H 4-CH j θ-C 6 H 4 - 821 CH, CH, H CFJ CF, H H C-CΛ C-C 3 H 5 149-150 822 CH, CH, H CFJ CF, H H CΛ C-C j Hs - 823 CH, CH, H CFJ CF, H H CH, C-C 3 H 5 - 824 CH, CH, H CF, CF, H H CH, C 3 H, oil 825 CH, CH, H CF, CF, H H CH j CΛ - 826 CH, CH, H CF 3 CF, H H CH, C 5 H 11 - 827 CH 3 CH, H CFj CFJ H H CΛ C - 828 CH j CH, H CF J CFJ H H CΛ CJH- - 829 CH, CH, H CFJ CFJ H H JH S CJH S - 830 CHJ CH j H Cl OCH, H H H 4-CH j O-C 6 H 4 58-60 831 CHJ CHJ H Cl OCHJ H H C-CJHJ C-C j Hs 139- 140 832 CH 3 CHJ H Cl OCHJ H H CΛ C-C 3 H 5 oil 833 CH 3 CH j H Cl OCHJ H H H c-C,Hs oil 834 CH 3 CHJ H Cl OCHJ H H CH j C oil 835 CH, CHJ H Cl OCH, H H CH 3 CΛ oil 836 CH, CHJ H Cl OCH j H H CH 3 5 Hn oil 837 CH, CHJ H Cl OCH j H H CΛ CΛ oil 838 CH, CHJ H Cl OCH 3 H H C,H- C oil 839 CH, CHJ H Cl OCH 3 H H CjHs CjHs oil 840 CH, CHJ H Cl Cl F H H 4-CH,0-C 6 H 4 - 841 CH, CH, H Cl Cl F H C-C 3 H 5 c-C j H, 148-149 842 CH, CH, H Cl Cl F H Λ c-CΛ - 843 CH, CH, H Cl Cl F H CH j C -CΛ - 844 CH, CH, H Cl Cl F H CH, C - 845 CH, CH, H Cl Cl F H CH, C - 846 CH 3 CH j H Cl Cl F H CH, C 5 Hu - 847 CH, CHJ H Cl Cl F H CΛ C - 848 CH, CHJ H Cl Cl F H CΛ C j H, - 849 CH, CH, H Cl Cl F H CΛ C j Hs - 850 CH, CH j H Cl Cl Cl H H 4-CH,0-C 6 H 4 - 851 CH, CHJ H Cl Cl Cl H c-C j H, c-CΛ - 852 CH, CHJ H Cl Cl Cl H CΛ c-CΛ - 853 CH, CHJ H Cl Cl Cl H CH j C-CΛ - 854 CH, CHJ H Cl Cl Cl H CHJ c,H, - 855 CH, CHJ H Cl Cl Cl H CHJ CΛ - 856 CH, CHJ H Cl Cl Cl H CH, C 5 H 11 - 857 CH j CHJ H Cl Cl Cl H CΛ CΛ - 858 CH, CHJ H Cl Cl Cl H c,H, C - 859 CH, CHJ H Cl Cl Cl H CΛ CΛ - 860 CH, CHJ H CH j OCH j F H H 4-CH,0-CΛ - 861 CH, CHJ H CH, OCH j F H C-C,Hs C-CΛ 128-129 862 CH, CH, H CH, OCH 3 F H CΛ C-C j Hs - 863 CH, CH j H CH, OCH, F H CH, C-C j H, - 864 CH, CH, H CH, OCH j F H CH, C j H, - 865 CH, CH, H CH, OCH, F H CH j C - 866 CHJ CH, H CH j OCH j F H CHJ C 5 H 11 - 867 CH, CH, H CH, OCH, F H CΛ C - 868 CH, CH, H CH, OCH, F H CΛ C j H, - 869 CH, CH, H CH, OCH j F H C j Hs CΛ - 870 CH, CH j H CH, OCH, Cl H H 4 -CH j θ-C (S H 4 oil 871 CH j CHJ H CH, OCH, Cl H C-C j H j C-C j Hs 179-181 872 CH j CHJ H CH, OCH, Cl H CΛ C-C j Hs - 873 CH j CHJ H CH, OCH, Cl H CH j c-CΛ - 874 CHJ CHJ H CH, OCH, Cl H CHJ C j H, - 875 CHJ CHJ H CH, OCH, Cl H CH, CΛ - 876 CHJ CHJ H CH, OCH, Cl H CH, C 5 Hn - 877 CHJ CHJ H CH, OCH, Cl H CΛ CΛ - 878 CH, CHJ H CH, OCH, Cl H CΛ C 3 H, - 879 CH, CHJ H CH j OCH, Cl H CΛ CΛ - 880 CH, CHJ H Cl CH, F H H 4 -CH 3 0-C«H 4 - 881 CHJ CHJ H Cl CH, F H C-C,H j C-C j H, 13-0-131 882 CHJ CHJ H Cl CH, F H C j Hs C-C 3 H 5 - 883 CHJ CHJ H Cl CH, F H CH, C-C j Hs - 884 CHJ CH, H Cl CH, F H CH, C j H, - 885 CHJ CHj H Cl CH, F H CH, C - 886 CHJ CHJ H Cl CH, F H CH, c sHu - 887 CHJ CH j H Cl CH, F H CΛ C - 888 CHJ CHJ H Cl CH, F H C.H. C,H, - 889 CHJ CH j H Cl CH, F H CΛ CΛ - 890 CHJ CHJ H Cl CF, Cl H H 4-CH j θ-C j H, - 891 CH, CHJ H Cl CF, Cl H c-CΛ C-CJHJ - 892 CH j CH j H Cl CF, Cl H CΛ c-C j H. - 893 CHJ CHJ H Cl CF, Cl H CH j C-C 3 H 5 - 894 CHJ CHJ H Cl CF, Cl H CH, C j H, - 895 CHJ CH, H Cl CF, Cl H CH j CΛ - 896 CH, CHj H Cl CF, Cl H CHJ c Λι - 897 CH j CHJ H Cl CF, Cl H C j H, C - 898 CHJ CH, H Cl CF, Cl H CJH, C j H, - 899 CH 3 CH, H Cl CF, Cl H CJH, CΛ - 900 CH, CH, H CH, OCH, H H H CΛ oil 901 CH, CHj H CH, OCH, H H CΛ CΛ 69-73 902 CH, CHJ H Cl CH, H H CjH, C,H, oil 903 CH, CHJ H Cl CF, F H H 4-CH j θ-C j H. - 904 CH, CHJ H Cl CF, F H c-C 3 Hs C-C 3 H 5 - « 905 CH, CH, H Cl CFJ F H CΛ C-C 3 H 5 - 906 CH j CHJ H Cl CFJ F H CH, c-C j H, - 907 CH, CH, H Cl CF, F H CH, C j H, - 908 CH, CH, H Cl CF, F H CH, CΛ - 909 CH, CHJ H Cl CFJ F H CH, CjHu - 910 CH, CH, H Cl CF, F H CjHs - 911 CHJ CH j H Cl CF, F H C C j H, - 912 CH j CHJ H Cl CF, F H CΛ Λ - 913 CHJ CH, H Cl OCH, Cl H H 4-CH j θ-C 6 H 4 - 914 CH, CH, H Cl OCH, Cl H c-CΛ C-C j Hs oil 915 CH, CH, H Cl OCH, Cl H CΛ C-C 3 H 5 - 916 CH, CH, H Cl OCH, Cl H CH, C-C 3 H 5 - 917 CH, CH, H Cl OCH, Cl H CH j C,H, - 918 CH, CH, H Cl OCH, Cl H CH, CΛ - 919 CH, CH, H Cl OCH, Cl H CH, C 5 H 11 - 920 CH, CH, H Cl OCH, Cl H CΛ C - 921 CH, CH, H Cl OCH j Cl H CΛ c 3 H, 922 CH, CH, H Cl OCH j Cl H CjHs C Λ - 923 CH, CH, H Cl OCH, F H H 4-CH,0-C,H 4 - 924 CH, CH, H Cl OCH j F H C-C,Hs C-C j Hs - 925 CH, CH, H Cl OCHj F H CjH, C-C 3 H 5 - 926 CH, CH, H Cl OCHj F H CH, C-C 3 H 5 - 927 CH, CH, H Cl OCH, F H CH, C,H, - 928 CH, CH, H Cl OCH, F H CH, Λ - 929 CH, CH j H Cl OCH, F H CHJ 5 Hu - 930 CH, CHJ H Cl OCH, F H CΛ C - 931 CH, CHJ H Cl OCH, F H C j H, C 3 H, - 932 CH, CHJ H Cl OCH, F H CΛ C j Hs - 933 CH, CHJ H Cl OCH, CH, H H 4-CH,0-C 6 H 4 - 934 CHJ CH, H Cl OCH, CHJ H C-C j Hs C-C 3 H 5 150-151 935 CH, CH, H Cl OCH, CH, H CΛ C-C j Hs - 936 CH, CH, H Cl OCH, CH, H CH j C-C 3 Hs - 937 CH, CH j H Cl OCH, CH, H CHJ C j H, - 938 CH, CH j H Cl OCH, CH, H CHJ Λ - 939 CH, CH, H Cl OCH, CH, H CHJ C j. - 940 CH, CH, H Cl OCH, CH, H CΛ C Λ - 941 CH, CH, H Cl OCH, CH, H C j H, C j H, - 942 CH, CH, H Cl OCH, CH, H CΛ CΛ - 943 CH, CH, H CH 3 OCH, CH j H H 4-CH j θ-C j H, - 944 CH, CH, H CH, OCHj CHJ H C-C 3 H 5 c-C j H, 148-151 s. 945 CH, CH, H CH, OCH, CHJ H C C-C j Hs oil 946 CH 3 CH, H CH j OCH, CH, H CH, C-CΛ - 947 CH, CH j H CH, OCH, CH, H CH, c,H, oil 948 CH j CH, H CH, OCH j CH, H CH, CΛ - 949 CH, H CH, OCH, CH j H CH, Αl - 950 CH j CH, H CH j OCH 3 CH, H C j Hs C - 951 CH 3 CH j H CH, OCH 3 CH, H C j H, CΛ oil 952 CH 3 H CH, OCH j CH, H CΛ j Hs oil 953 CH j CH j H Cl H Cl H H 4-CH,0-C 6 H 4 - 954 CH j CH j H Cl H Cl H C-C 3 H 5 C-C j Hs 151-153 955 CH j H Cl H Cl H CΛ C-C j Hs - 956 H Cl H Cl H CH, c-C 3 Hs - 957 H Cl H Cl H CH 3 C 3 H, - 958 H Cl H Cl H CH 3 CΛ - 959 H Cl H Cl H CH 3 C s Hu - 960 H Cl H Cl H CΛ CΛ - 961 CH, H Cl H Cl H CΛ CΛ 962 CH j H Cl H Cl H CΛ Λ - 963 CH, H Cl Cl OCH, H H 4-CH,0-C 6 H 4 - 964 CH, H Cl Cl OCH, H C-C j H, c-C,Hs - 965 CH, CH, H Cl Cl OCH, H CΛ C-C - 966 CH, CH, H Cl Cl OCH, H CH j c-CjHs - 967 CH, H Cl Cl OCH, H CH J C j H, - 968 CH, H Cl Cl OCH, H CH, C - 969 CH, H Cl Cl OCH, H CH J CsHu - 970 CH, CH, H Cl Cl OCH, H C J H S C 4 H, - 971 CH, CH, H Cl Cl OCH, H C.H- C j H- - 972 CH, CH, H Cl Cl OCH, H C j Hs CΛ - 973 CH, CH j H Cl CH j OCH, H H 4-CHjθ-CΛ - 974 CH, CH, H Cl CH j OCH, H C-C,Hs C-C 3 H 5 - 975 CH, CH, H Cl CH j OCH, H CΛ C-C 3 H 5 - 976 CH, CH, H Cl CH, OCH, H CH, C-C 3 H 5 - 977 CH, CH, H Cl CH j OCH, H CH, C,H, - 978 CH, CH, H Cl CH, OCH, H CH, CΛ - 979 CH j CH j H Cl CH, OCH, H CH, CsHu - 980 H Cl CH, OCH, H CΛ CΛ - 981 CH, H Cl CH j OCH, H C,H, CΛ - 982 CH, H Cl CH, OCH, H CΛ C j Hs - 983 CH, H CH, Cl OCH, H H 4-CH,0-C„H 4 - 984 CH, H CH, Cl OCH, H C-C 3 H 5 C-C j H, - 985 CH, H CH, Cl OCH, H C j Hs C-C J H J - 986 CH, CH, H CH, Cl OCH, H CH, c-C j H, - 987 CH 3 CHJ H CH j Cl OCH, H CH, C,H 7 - 988 CH, CHJ H CH j Cl OCH j H CH j CΛ - 989 CH, CHJ H CH j Cl OCHJ H CH j CsH - 990 CH j CHJ H CH j Cl OCH j H CJHS C - 991 CHJ CHJ H CHJ Cl OCH j H C 3 H, C j H, - 992 CHJ CH, H CHJ Cl OCH j H C j Hs CΛ - 993 CHJ CH j H CHJ CH J OCH, H H 4-CH,0-C,H 4 - 994 CHJ CHJ H CHJ CH J OCH, H c-C 3 Hs c-C,Hs - 995 CHJ CHJ H CHJ CH, OCH, H C j Hs C-C 3 H 5 - 996 CH, CH, H CHJ CH j OCH, H CH j C-C 3 H 5 - 997 CH 3 CH j H CHJ CHJ OCH, H CHJ CΛ - 998 CH j CHJ H CHJ CHJ OCH j H CHJ CΛ - 999 CHJ CH, H CHJ CHJ OCH, H CHJ C 5 Hu - 1000 CHJ CH, H CHJ CHJ OCH j H CJH S CΛ - 1001 CHJ CH, H CHJ CHJ OCH j H CΛ CΛ 1002 CHJ CH j H CHJ CHJ OCHJ H CΛ C j Hs - 1003 CHJ CHJ H CHJ OCHJ OCHJ H H 4-CH,0-C 6 H 4 oil 1004 CHJ CHJ H CHJ OCH j OCHJ H C-C 3 H 5 c-C,Hs 138-140 1005 CH 3 CHJ H CHJ OCHJ OCH j H CΛ C-C 3 H 5 - 1006 CHJ CHJ H CHJ OCHJ OCH j H CH 3 C-C j Hs - 1007 CHJ CHJ H CHJ OCH, OCHJ H CH j C j H, - 1008 CHJ CHJ H CHJ OCH 3 OCH, H CHJ C - 1009 CHJ CHJ H CHJ OCHJ OCH, H CH, C 5 Hu - 1010 CHJ CHJ H CHJ OCHJ OCH, H CΛ CΛ - 1011 CHJ CH, H CHJ OCH j OCH, H CΛ C j H, - 1012 CH 3 CH, H CHJ OCH j OCH, H CΛ CΛ oil 1013 CH 3 CHJ H Cl OCHJ OCH j H H 4-CH,0-C e H 4 - 1014 CH, CHJ H Cl OCH, OCHJ H c-CΛ C-C 3 H 5 - 1015 CH 3 CHJ H Cl OCH 3 OCHJ H Λ c-C j H j - 1016 CH j CHJ H Cl OCH 3 OCHJ H CH 3 c-C j Hs - 1017 CHJ CHJ H Cl OCH 3 OCHJ H CH j C j H, - 1018 CHJ CHJ H Cl OCH 3 OCH, H CH, C 4 H, - 1019 CHJ CHJ H Cl OCH, OCH 3 H CH, C s Hu - 1020 CHJ CHJ H Cl OCH, OCH, H CΛ C - 1021 CHJ CHJ H Cl OCH j OCH 3 H CΛ C j H- - 1022 CHJ CHJ H Cl OCH, OCH 3 H CΛ C j Hs - 1023 CHJ CHJ H Cl OCF j H H H 4-CHjθ-C,Hι oil 1024 CHJ CHJ H Cl OCF j H H c-CΛ C-C 3 H 5 119-120v 1025 CHJ CHJ H Cl OCF j H H CΛ C-C 3 H 5 103-104 1026 CHJ CHJ H Cl OCF 3 H H CH, C-C 3 H 5 - O 99/01454 FCT/US9α :/ijyu 1027 CH j CH, H Cl OCF, H H CH, C 3 H- oil 1028 CH j CH, H Cl OCF j H H CH, C oil 1029 CHJ CH, H Cl OCF, H H CH, C 5 Hu - 1030 CH, CH, H Cl OCF, H H CJHS C - 1031 CHJ CH, H Cl OCF j H H C,H, C,H, - 1032 CHJ CH, H Cl OCFJ H H CJHS CΛ oil 1033 CHJ CH, H Cl SCFJ H H H 4-CH30-CΛ - 1034 CH 3 CH, H Cl SCF j H H c-CΛ C-CΛ - 1035 CH 3 CH, H Cl SCF j H H CΛ C-C 3 H 5 - 1036 CH, CH, H Cl SCF j H H CH j C-C j Hs - 1037 CH j CH j H Cl SCF, H H CH 3 CΛ - 1038 CHJ CH, H Cl SCF j H H CH, CΛ - 1039 CHJ CH, H Cl SCFJ H H CH 3 C 5 Hu - 1040 CHJ CH, H Cl SCFJ H H CjHs - 1041 CHJ CH, H Cl SCFJ H H C j H, CΛ 1042 CHJ CH, H Cl SCFJ H H C j Hs Λ - 1044 CHJ CH j H Cl CFJ H H H 4 -CHjθ-CΛ 105-107 1045 CH j CH j H CF, Q3 H H c-CΛ C-C 3 H 5 168-169 1046 CHJ CHJ H Cl Q3 H H C-CΛ C-C j H j 130-132 1047 CHJ CHJ H CF, SCH j H H C-CΛ C-C j Hs - 1048 CHJ CH, H Cl SCH j H H C-CΛ C-C j Hs - 1049 CH, CH, H CF, COCK, H H C-CΛ C-C j Hs - 1050 CH, CH, H Cl COCH j H H c-C j H, C-C j H, - 1051 CH j CH, H CF, CHCH, H H c-CΛ C-C 3 H 5 - 1052 CHJ CH, H Cl CHCH, H H c-CΛ C-C j H, - 1053 CH, CH j H Cl CH, H H H 4-CH,0-CΛ 113-115 1054 CHJ CH, H OCH j OCH, H H H 4-CHjθ-CΛ, - 1055 CHJ CH, H OCH, OCH j H H c-C 3 Hs -CΛ 128-130 1056 CHJ CH j H OCH, OCHJ H H C j Hs "C,Hs - 1057 CH, CHJ H OCH, OCH j H H CH, C-C 3 H 5 - 1058 CH, CHJ H OCH, OCH, H H CH, CΛ - 1059 CH, CHJ H OCH, OCH j H H CH, Λ - 1060 CH, CHJ H OCH, OCH, H H CH, sH - 1061 CH, CHJ H OCH, OCH j H H CΛ CΛ - 1062 CH, CHJ H OCH, OCH, H H C,H, C - 1063 CH, CHJ H OCH, OCH, H H CΛ Λ - 1064 CH 3 CHJ H OCH, CF j H H H 4-CH,0-CΛ - 1065 CH, CHJ H OCH, CFJ H H C-CΛ c-C,H j 158-159 *- 1066 CH, CHJ H OCH, CF, H H CΛ c-C 3 Hs - 1067 CH, CHJ H OCH, CF, H H CH, C-C,Hs - 1068 CH, CH, H OCH, CF, H H CH, CΛ - 1069 CH 3 CH, H OCH j CF, H H CH, CΛ - 1070 CH, CH j H OCH, CF, H H CH, 5 Hu - 1071 CH 3 CHJ H OCH, CF, H H CΛ CΛ - 1072 CH 3 CHJ H OCH, CF j H H CΛ CΛ - 1073 CH j CHJ H OCH, CFJ H H CΛ CΛ - 1074 CH 3 CHJ H CF, OCH 3 H H H 4-CH3O-CΛ oil 1075 CH 3 CHJ H CF, OCH j H H C-C 3 H 5 c-C 3 H 5 129-130 1076 CH, CHJ H CF, OCH 3 H H C j Hs C-C 3 H 5 119-122 1077 CH 3 CHJ H CF, OCH j H H CH, c-C,Hs - 1078 CH 3 CHJ H CF, OCH j H H CH, CΛ oil 1079 CH 3 CHJ H CF, OCH 3 H H CH, C oil 1080 CH 3 CHJ H CF, OCH 3 H H CH, c sHu - 1081 CH j CHJ H CFJ OCH j H H CjH, C - 1082 CH, CHJ H CFJ OCHJ H H CΛ CΛ oil 1083 CH j CHJ H CF, OCH, H H CΛ CΛ 77-78 1084 CH, CHJ H OCH, Cl OCH j H H 4 -CH,0-C 6 H 4 - 1085 CH, CHJ H OCH, Cl OCH, H c-C j H j C-C 3 H - 1086 CH, CHJ H OCH, Cl OCH, H C j H, c-C j Hs - 1087 CH, CH, H OCH j Cl OCH j H CH, C-C 3 H 5 - 1088 CH, CH, H OCH, Cl OCH, H CH, C 3 H, - 1089 CH, CHJ H OCH, Cl OCH, H CH, - 1090 CH, CHJ H OCH, Cl OCH, H CH, C j Hu - 1091 CH, CHJ H OCH, Cl OCH, H CjH, CΛ - 1092 CH j CHJ H OCH, Cl OCH j H C j H, c,H, - 1093 CHJ CHJ H OCH, Cl OCHj H CΛ CjH, - 1094 CH, CH, H OCH, CHJ OCH j H H 4-CH3O-CΛ - 1095 CHCH j H OCH, CHJ OCH, H C-C j H, C-C 3 H 5 - 1096 CH, CHJ H OCH, CHJ OCH, H CΛ C-C 3 H 5 - 1097 CH, CHJ H OCH, CHJ OCH, H CH, C-C j Hs - 1098 CH, CHJ H OCH, CHJ OCH, H CH 3 C j H, - 1099 CH, CHJ H OCH, CHJ OCH j H CH j CΛ - 1100 CH, CH, H OCH, CH 3 OCH, H CH, C 5 H ll - 1101 CH j CH, H OCH, CH 3 OCH, H CΛ C - 1102 CHJ CHJ H OCH, CH j OCH, H C j H, CΛ - 1103 CHJ CHJ H OCH j CHJ OCH, H CjHs CjHs - 1104 CH, CHJ H OCH, CFJ OCH, H H 4-CH,0-C 6 H 4 - 1105 CH, CHJ H OCH, CFJ OCH j H c-C j Hs c-CΛ - 1106 CH, CHJ H OCH, CFJ OCH, H CΛ C-CΛ - 1107 CH, CHJ H OCH, CFJ OCH, H CH j C-C 3 H 5 - Os o sr o N ro H ro sr sr 00 Os CΛ af af af af af H J af af V f af tf υ, af CJ. af CJ, PC PC A j" d 1 d * J z y. tf z CJ ft. O cj" u" 3C PC π PC PC PC w CJ CJ o J CJ CJ O t do * w J g af d * CJ X CJ o c c CJ af i i i o CJ tf CO f af O O υ U f, υ υ υ u o af af a CJ CJ o af af af CJ o af CJ CJ o af af CJ af CJ o af CJ CJ J 3f CJ CJ CJ af af af af tf af af X υ af af af af af af af " af af tf af af af af af af af af af af af af af af af af af af af u CJ J d * cj" d * d * u υ J CJ tf X j d * u" d * d" u υ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ U CJ CJ CJ CJ CJ CJ CJ CJ 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 * tf ft? ft", ft," ft? tf Z z z f af af CJ CJ U CJ U Cj CJ tJ CJ B β § i I 8 8 8 8 8 8 8 * b * * * * <J a o * * u- tf 8 g 8 8 8 8 B 8 B B 8 B 8 B 8 B B 8 B B 8 8 B 8 B 8 8 8 S S S S CJ U O CJ U O U U U O x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x O S Os ro sr in r~ σs o rH CN ro sr vo r- co CΛ o VD ro ro ro ro ro ro ro ro ro ro sr sr sr sr sr rH rH rH 1148 CH j CH, H Cl OCH, H H C j H, CH,C1 1149 CH, CH, H Cl OCH j H H CH j CN 1150 CH, CH, H CFj OCHJ H H C-C j H; oil 1151 CH j CHJ H Cl CFJ H H CH, C 3 H, 97-98 1152 CH, CHJ H CH j OCH, CH j H C c-CΛ 1153 CH, CHJ H Cl CF j H H C C-C 3 H 5 oil 1154 CH j CHJ H Cl OCH j H H CΛ c-CΛ 1155 CHJ CHJ H Cl OCF, H H CΛ c-CΛ oϋ 1156 CHJ CHJ H Cl CH, H H C c-C j H, 119-120 1157 CHJ CHJ H CFj OCH, H H CΛ c-C j H j oil 1158 CHJ CH, H Cl Cl H CH, CΛ C-C 3 H 5 oil 1159 CHJ CH j H CH j OCH, Cl H C c-C,Hs 1160 CHJ CH, H CHJ OCH, F H CΛ c-CΛ 1161 CHJ CH, H Cl Cl H H 4-F-CΛ. c-CΛ °il 1162 CHJ CHJ H CH j OCH, CH j H 4-F-C.H, c-CΛ 1163 CHJ CH, H Cl CF, H H 4-F-C 6 H 4 c-CΛ °il 1164 CHJ CH, H Cl OCH, H H 4-F-C.H. c-C 3 Hs 1165 CHJ CHJ H Cl OCF, H H 4-F-C.H. c-C j Hs 1166 CHJ CHJ H Cl CH, H H 4-F-CΛ c-C 3 Hs 1167 CHJ CH, H CF, OCH, H H 4-F-C β H 4 c-C j H, 1168 CH, CH, H Cl Cl H CH, 4-F-CΛ c-C 3 Hs 1169 CHJ CH, H CH, OCH, Cl H 4-F-C 6 H 4 C-C 3 H 5 1170 CHJ CHJ H CH, OCH, F H 4-F-CΛ c-C j H, 1171 CHJ CHJ H Cl Cl H H CH, c-C 4 H, 109-110 1172 CHJ CHJ H CH, OCH, CH 3 H CH, -CΛ 1173 CH 3 CHJ H Cl CF, H H CH, c-CΛ 136-137 1174 CH j CHJ H Cl OCH, H H CH, c-C 1175 CHJ CHJ H Cl OCF, H H CH, C -CΛ 1176 CHJ CH, H Cl CH, H H CH, c-C 4 H, 1177 CHJ CH, H CF, OCH, H H CHj c-C 4 H, 1178 CHJ CH j H Cl Cl H CH, CH, c-CΛ 1179 CH 3 CHJ H CH, OCH, Cl H CH j c-CΛ 1180 CH j CHJ H CH, OCH, F H CH, C-CΛ 1181 CHJ CHJ H Cl Cl H H C C-CΛ 1182 CHJ CHJ H CH, OCH, CH 3 H C j Hs C — C 4H7 — 1183 CHJ CHJ H Cl CF, H H CΛ C-CΛ 1184 CHJ CHJ H Cl OCH j H H C j Hs C-CΛ 1185 CHJ CHJ H Cl OCF j H H CΛ C-CΛ 1186 CHJ CHJ H Cl CH 3 H H CΛ C -CΛ 1187 CHJ CHJ H CF, OCH, H H C c-C 4 H- 1188 CH j CHH Cl Cl H CH, C j Hs c-CΛ - 1189 CHJ CH, H CH, OCH, Cl H C j Hs c-C.H, - 1190 CHJ CH, H CH, OCH, F H C j Hs c-C 4 H, - 1191 CHJ CH j H Cl Cl H H C j H, -C - 1192 CHJ CHJ H CH, OCH 3 CH, H C j H, c-C 4 H, - 1193 CHJ CHJ H Cl CF, H H c-C 4 H, - 1194 CHJ CHJ H Cl OCH, H H C,H- c-CΛ - 1195 CHJ CHJ H Cl OCF, H H C,H, C-CΛ - 1196 CH 3 CHJ H Cl CH, H H C.H. C -CΛ - 1197 CH, CHJ H CF, OCH, H H CΛ C -CΛ - 1198 CH, CHJ H Cl Cl H CH, CΛ c-CΛ - 1199 CH 3 CHJ H CH, OCH, Cl H C 3 H, C -CΛ - 1200 CH j CHJ H CH j OCH, F H C 3 H- C-CΛ - 1201 CH j CHJ H Cl Cl H H c-C 4 H- C -CΛ - 1202 CH j CHJ H CH j OCH, CH, H c-CΛ -C 1203 CH j CHJ H Cl CF, H H c-CΛ -C - 1204 CH, CHJ H Cl OCH, H H C-C 4 H- c-C 4 H, - 1205 CH j CHJ H Cl OCF, H H C-C.H- C -CΛ - 1206 CHJ CHJ H Cl CH, H H c-CΛ C -CΛ - 1207 CH 3 CHJ H CFj OCH, H H c-CΛ c-C 4 H, - 1208 CH j CHJ H Cl Cl H CH, C-C 4 H- C -CΛ - 1209 CHJ CHJ H CH j OCH, Cl H c-C 4 H- C-CΛ - 1210 CHJ CHJ H CH j OCH, F H C-C 4 H, C -CΛ - 1211 CHJ s H SCHJ Cl H Cl CΛ C,H, 63-65 1212 CHJ CH j H OCHJ Cl H H c-CΛ C-C 3 H 5 152-154 1213 CHJ CHJ H OCHJ Cl H H Λ c-C 3 Hs - 1214 CHJ CHJ H OCH, Cl H H C,H, C-C 3 H 5 - 1215 CHJ CH j H OCH, Cl H H CH, C -CΛ - 1216 CHJ CHJ H OCH, Cl H H CH, C j H, - 1217 CH j CH, H OCH, Cl H H CΛ C j H, - 1218 CH, CH j H OCH, Cl H H CΛ CΛ - 1219 CH j CHJ H OCH, Cl H H C j H, CΛ - 1220 CHJ CHJ H OCH, Cl H H CH, C - 1221 CHJ CH, H OCH, Cl H H H 4-CH j θ-C 6 H 4 - 1222 CHJ CH, H OCH, CH, H H C-C,Hs c-C j H, oil 1223 CH 3 CH j H OCH, CH, H H C j Hs c-C j Hs - 1224 CH 3 CHJ H OCH, CH, H H C j H, c-CΛ - 1225 CH j CH j H OCH, CH, H H CH j C-CΛ - 1226 CH, CH j H OCH, CH, H H CHJ C j H, - 1227 CH, CHJ H OCH, CH, H H CJHS C j H, - 1228 CH, CH, H OCH j CH, H H CΛ C j H, - 1229 CH j CH, H OCH j CH, H H C j H, C 3 H- - 1230 CHJ CHJ H OCH j CH, H H CH, CΛ - 1231 CH, CHJ H OCH, CH, H H H 4-CH j O-C j H, - 1232 CH j CHJ H OCH j OCH j H F C -CΛ C-C 3 H 5 176-178 1233 CHJ CHJ H OCH j OCH j H F CΛ C-C 3 H 5 - 1234 CHJ CHJ H OCH j OCH, H F C j H, C-C j Hs - 1235 CH 3 CHJ H OCH, OCH, H F CH j c-CΛ - 1236 CH, CHJ H OCH j OCH, H F CH J CΛ - 1237 CH, CHJ H OCH j OCH, H F C J H S CΛ - 1238 CH j CH, H OCH, OCH, H F CΛ CΛ - 1239 CH j CH, H OCH, OCH, H F C j H, CΛ - 1240 CH, CH, H OCH, OCH, H F CH 3 CΛ - 1241 CH, CH, H OCH, OCH, H F H 4-CH30-CΛ - 1242 CH, CH, H CF, F H H C-C j Hs C-C j Hs 1243 CH, CH, H CF, F H H c-C,Hs - 1244 CH, CH, H CF, F H H C j H, C-C 3 H 5 115-118 1245 CH, CH, H CF, F H H CH j c-C 4 H, - 1246 CH, CH, H CF, F H H CH 3 CΛ - 1247 CH, CH, H CF, F H H CjH, CΛ - 1248 CH, CH, H CF, F H H CΛ CΛ - 1249 CH j CH, H CF, F H H C 3 H, CΛ - 1250 CHJ CH, H CF, F H H CH j C - 1251 CHJ CH, H CF, F H H H 4-CH,0-CΛ 57-70 1252 CHJ CH, H CF, F H H BnOCH j BnOCH j oil 1253 CHJ CH, H CF, F H H CH j CΛ 119-120 1254 CHJ CH, H CF, F H H CΛ 135-139 1255 CH, CH, H Cl OCF, H H C j H, c-C,Hs oil 1256 CH j CH, H Cl OCF, H H CΛ C,H, oil 1257 CH, CH, H Cl CF, H H H CH j =CH-CH=CH 83-85 1258 CH, CH, H CF, OBn H H C-C 3 H 5 c-CΛ 163-165 1259 CH, CH, H CF, OH H H C-C 3 H 5 C-C,Hs 245-246 1260 CH, CH, H CF, OC,H- H H C-C 3 H 5 c-CΛ 127-128 1261 CH, CH, H CF, OC,H- H H C C-C 3 H 5 - 1262 CHJ CHJ H CF, OC,H, H H C j H, c-CΛ - 1263 CHJ CHJ H CF, OC,H, H H CH j C -CΛ - 1264 CHJ CHJ H CF, OC,H, H H CH j c,H, - 1265 CHJ CHJ H CF j OC,H, H H C J H S CΛ - 1266 CHJ CHJ H CF J OC,H- H H C J H S CΛ - 1267 CHJ CHJ H CF J OC,H, H H C J H, C 3 H, - Os ro 00 Os CΛ j j 1 I X X fc t L . ft, ft. ft. t ι . t u ift. ft. t u c j j aC X X X X K χ χ χ χ χ χ J rχ, X χ χ χ χ χ χ c r ι< χ χ χ § • § ■ § § § s s s s s § § § § ^ CJ d c g 1 &- g 1 g " tf $ * $ $ $ $ § $ $ * % $ * * * o υf tof xu" xυ" xu" xu" xu" xcj" xc" xcj" xcj" xcj" xcj" xu" Hcj rcHj rcHj ruH ruH cj cj→ ccji. cj tuf ccj-j acjf xcj" xcj" fcjH rcjH cj! rcj! oft? cc-ji xcj" 3of rcjH υ! vo, PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC PC 3-ι tf tf af af af af af af af af af af af af af af af af af o o o o o o o o o o o o o o o o o o af af af Tf <Λ X" af af af af 3f af 3f af af x" 3f af af tf af af x" af af af af " x" x" x" tf tf tf 3f 3f " af tf " af af 3f af af Tf U U U O U U U U U U O U CJ CJ U U CJ CJ U CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ U CJ CJ CJ CJ U CJ CJ OS OS cc cΛ "tf ιn vD ^ co cΛ θ rH CN rθ "tf ιjJ vo t^ co σs θ rH cN ro stf in vo r-- oo σs θ CN ro sr in vo r- co cΛ O rH vD vo co co oo co σo co σs cΛ CΛ cΛ CΛ σs σs cΛ σs σs o o o o o o o o o o rH CN CN o cN CN CN CN CN CN CN CN CN CN CN CN CN CN C CN CN CN ro ro ro ro ro ro co ro ro ro ro ro ro m ro ro ro ro ro ro ro ro rH ro o • H o υ υ υ υ ro af 5 X af af x x' x' af X X X X o af X υ υ u af af tf. 8 af af $ * af af af o X X X X PC x x X X X υ o § o CJ' CJ' U' O" CJ' CJ' CJ' CJ' CJ' O' a. o af z z o CJ" af x" 8 x o o o X υ CJ υ υ m af x o a o 8 z I o X ro - u t af af af af af af af af af af af af af af x tf x x 3j, af af u" u * d° u" x u X X x x x x x x x g x x υ x x x X J x x x CJ rH a ϋf a t a t af 8 8 8 8 8 8 8 CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ u H υ u u u 8 8f & Bf B S yf ruH a 8 f 8 rH rH X rH rH rH rH ftj rH X X J CJ CJ CJ J CJ J CJ O CJ J CJ O CJ O CJ CJ CJ CJ CJ J x X X X X X X X ro Os ro af a^ a^ af af a^ a^ a^ af ai af af x" af af af tf tf af af af af af af tf af f I CJ CJ CJ CJ CJ CJ CJ CJ ^ CT CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ J CJ u a of af tf af a CJ CJ a CfJ x CJ" af J CJ J u CJ υ X X X X X X X X X X X X X X ft. X X af a 8f a8f a8f x8 8 8 a8f a8f 8 af u 8 3 a 8 f ft? gaf tf rc J H a 8 f .o-i .cH j a 8 f fc c j "' a 8 f tcf S ac 8 f c j af x ft, X 8 u 8 rH ft, CJ J CJ CJ x J CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ O U CJ CJ CJ CJ CJ J x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x PC PC PC PC PC PC PC PC tJ-ι 3-ι PC PC PC PC af af X^ CJ CJ CJ CJ . CJ CJ CJ CJ CJ CJ CJ CJ CJ CJ a CJf aCJf aCJf aCJf aCJf aCJf o aCJf aCJf aCJf aUf aCJf aCJf aCJf aCJf aCJf o sCJf CJ X X X X X X X X X 3M X X X X t f af af af u u c u u u υ u u u u u u υ CJf aCJf CJ" xCJ" aCJf aCJf 3CJf CaJf aCJf aCJf 3CJf aU aCJf aCJf aCJf aCJf aCJf 3CJf CJ CJ Os θ rH q rn *<ϊt , ιn , κθ ' αo ^ θ rH C rn sr in vo r^ co σs O rH CN ro sr tn vD o co σs O rH ro sr Os r^ c-- r^ r^ ι ι oo co oo co co co oo co co co σs σs σs σs o rn rn rn ro cn ro ( ro (*o ro ro ro rn rn ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro ro 1395 CH, CH, H Cl OCF 3 H H CH, 2-(2- pyridyl) - c-C j H 4 1396 CH j CH j H Cl CH j H H CH j 2-(2- pyridyl) - 1397 CH, CH, H CF, OCH, H H CH, 2-(2- pyridyl) - c-C,H 4 1398 CH, CH j H Cl Cl H CH, C CHH,, 2-(2- pyridyl) - c-C 3 H 4 1399 CH, CH j CH J OCH, Cl CH j 2-(2- pyridyl) - c-C,H 4 1400 CH j 0 H Cl Cl H H CH J 2-(2- pyridyl) - c-C,H 4 Key: (a) Where the compound is indicated as an "oil", data is provided below: Example 3 spectral data: TLC R, 0.27 (30:70 ethyl acetate-hexane) . "Ή NMR (300 MHz, CDCI 3 ) : 5 8.90 (IH, s) , 6.95 (2H, s) , 4.45 (IH, br) , 4.27-4.17 (2H, m) , 3.85 (IH, dd, J = 9.5, 4.8 Hz), 3.27 (3H, s) , 2.94 (2H, q, J = 7.5 Hz) , 2.56-2.46 (IH, m) , 2.32 (3H, s), 2.06 (3H, s) , 2.03 (3H, s) , 1.37 (3H, t, J = 7.5 Hz), 0.85 (3H, t, J = 7.5 Hz) . MS (NH j -CI) : m/e 355 (3) , 354 (25), 353 (100) . Analysis calc'd for C 21 H-,N 4 θ»1.5H j θ: C, 66.46; H, 8.23; N, 14.76; found: C, 67.00; H, 8.10; N, 14.38. Example 8 spectral data: TLC R F 0.34 (50:50 ethyl acetate-hexane) . H NMR (300 MHz, CDCI 3 ) : 58.89 (IH, s) , 6.95 (2H, s) , 4.46 (IH, br) , 3.41-3.33 (IH, m) , 3.22 (3H, s) , 2.94 (2H, q, J = 7.3 Hz), 2.93-2.85 (IH, m) , 2.84-2.69 (2H, m) , 2.51 (IH, br) , 2.32 (3H, s) , 2.30-2.20 (IH, m) , 2.04 (6H, s) , 1.37 (3H, t, J = 7.7 Hz), 0.84 (3H, t, J = 7.3 Hz) . MS (NH j -CI) : /e calc'd for C JJ H J0 N 4 O: 366.2420, found 366.2400; 369 (3) , 368 (27), 367 (100) . Example 10 spectral data: TLC R F 0.13 (ethyl acetate). * Η NMR (300 MHz, CDC1,) : 58.93 (IH, s), 8.10 (IH, s) , 7.96 (IH, s) , 6.96 (2H, s) , 4.39 (IH, br) , 4.24-4.14 (IH, m) , 4.12-4.00 (IH, m) , 3.20 (IH, br) , 2.80 (2H, q, J = 7.0 Hz), 2.78-2.68 (IH, m) , 2.42 (IH, br), 2.33 (3H, s) , 2.13-2.04 (IH, m) , 2.06 (3H, s) , 2.03 (3H, s) , 1.33 (3H, t, J = 7.5 Hz), 0.80 (3H, t, J = 7.3 Hz). MS (NH j -CI) : m/e calc'd for C JJ H^N,: 404.2563, found 404.2556; 406 (4), 405 (28), 404 (100). Example 11 spectral data: TLC R- 0.60 (ethyl acetate) . "Ή NMR (300 MHz, CDC1 3 ) : δ 8.92 (IH, s), 8.51 (IH, s) , 6.96 (2H, s) , 4.78-4.68 (IH, m) , 4.57-4.47 (IH, m) , 4.32-4.22 (IH, m) , 3.43 (IH, br) , 2.81 (2H, q, J = 6.9 Hz), 2.78 (IH, br) , 2.43 (IH, br) , 2.33 (3H, s), 2.10-2.00 (IH, m) , 2.07 (3H, s) , 2.03 (3H, s) , 1.32 (3H, t, J = 7.0 Hz), 0.78 (3H, t, J = 7.5 Hz). MS (NH j -CI) : m/e calc'd for C jj H^N,: 405.2515, found 405.2509; 407 (4), 406 (27), 405 (100) . Example 18 spectral data: TLC R F 0.20 (30:70 ethyl acetate-hexane). *H NMR (300 MHz, CDCl,) : 59.00 (IH, s) , 7.26 (IH, obscurred) , 6.96 (2H, s) , 6.86-6.76 (3H, m) , 5.46 (2H, s), 3.76 (3H, s) , 2.85 (2H, q, J = 7.7 Hz), 2.33 (3H, s) , 2.06 (6H, s) , 1.28 (3H, t, J = 7.7 Hz). MS (NH j -CI) : /e 389 (4), 388 (28), 387 (100). Analysis calc'd for C j4 H j6 N 4 θ: C, 74.58; H, 6.78; N, 14.50; found: C, 74.36; H, 6.73; N, 13.83. Example 27 spectral data: TLC R- 0.20 (30:70 ethyl acetate-hexane). X H NMR (300 MHz, CDCl,) : δ 8.96 (IH, s) , 6.95 (2H, s) , 4.25 (2H, t, J = 7.5 Hz) , 2.93 (2H, q, J = 7.7 Hz), 2.32 (3H, s), 2.04 (6H, s) , 1.91-1.86 (2H, m) , 1.50-1.38 (2H, m) , 1.39 (3H, t, J = 7.7 Hz) , 1.01 (3H, t, J = 7.5 Hz) . MS (NH,-CI) : m/e 325 (3) , 324 (23) , 323 (100) . Example 28 spectral data: TLC R F 0.28 (30:70 ethyl acetate-hexane). X H NMR (300 MHz, CDCl,): 58.96 (IH, s) , 6.95 (2H, S ) , 4.24 (2H, t, J = 7.9 Hz), 2.93 (2H, q, J = 7.6 Hz), 2.32 (3H, s), 2.04 (6H, s) , 1.90 (2H, m) , 1.44-1.36 (7H, m) , 0.93 (3H, t, J = 7.1 Hz). MS (NHj-CI) : m/e 339 (3), 338 (25), 337 (100). Analysis calc'd for C JJ H- J N,: C, 74.96; H, 8.40; N, 16.65; found: C, 74.24; H, 8.22; N, 16.25. Example 34 spectral data: MS (ESI): m/e 365 (M+2) , 363 (M+H * , 100%). Example 35 spectral data: TLC R F 0.31 (20:80 ethyl acetate-hexane). * Η NMR (300 MHz, CDCl,) : δ 8.94 (IH, s) , 7.71 (IH, d, J = 8.4 Hz) , 7.58 (IH, d, J = 1.8 Hz) , 7.41 (IH, dd, J = 8.4, 1.8 Hz), 4.27 (IH, br) , 2.95 (2H, q, J = 7.3 Hz), 2.41 (2H, br) , 2.11-1.98 (2H, br), 1.42 (3H, t, J = 7.3 Hz), 1.37-1.20 (3H, m) , 1.09-0.99 (IH, m) , 0.84 (3H, t, J = 7.7 Hz), 0.82 (3H, t, J = 7.7 Hz). MS (NH j -CI) : m/e calc'd for C M H, 5 N 4 C1,: 391.1456, found 391.1458; 395 (11), 394 (14), 393 (71), 392 (29), 391 (100) . Example 38 spectral data: MS (NH j -CI) : m/e 375 (M+H * , 100%) . Example 40 spectral data: MS (NH,-CI) : m/e 377 (M+H * , 100%) . Example 48 spectral data: MS (NH j -CI) : m/e 423 (M+H * , 100%) . Example 50 spectral data: TLC R F 0.27 (30:70 ethyl acetate-hexane). "Ή NMR (300 MHz, CDCl,) : δ 9.03 (IH, s) , 7.70 (IH, d, J = 8.0 Hz) , 7.59 (IH, d, J = 1.8 Hz) , 7.41 (IH, dd, J = 8.0, 1.8 Hz), 7.36-7.30 (2H, m) , 7.24-7.19 (3H, m) , 5.50 (2H, s) , 2.87 (2H, q, J = 7.5 Hz), 1.31 (3H, t, J = 7.5 Hz). MS (NH,-CI) : m/e calc'd for C J Λ,N 4 C1,: 382.0752, found 382.0746; 388 (3), 387 (12), 386 (16), 385 (66), 384 (26), 383 (100) . Example 51 spectral data: MS (NH,-CI) : m/e 413 (M+H * , 100%) . Example 54 spectral data: MS (NH,-CI) : m/e 459 (M+H * , 100%) . Example 68 spectral data: TLC R.0.28 (30:70 ethyl acetate-hexane). 1 H NMR (300 MHz, CDCl,): δ 8.91 (IH, s) , 6.69 (2H, s) , 4.30-4.19 (IH, m) , 3.82 (3H, s) , 2.92 (2H, q, J = 7.6 Hz), 2.41 (IH, br) , 2.08 (3H, s) , 2.07 (3H, s) , 2.06 (IH, br) , 1.38 (3H, t, J = 7.6 Hz), 1.36-1.22 (4H, m) , 1.10-0.98 (IH, m) , 0.96-0.87 (IH, m) , 0.84 (3H, t, J = 7.0 Hz) , 0.81 (3H, t, J = 6.7 Hz) . MS (NH,-CI) : m/e 383 (4) , 382 (27) , 381 (100) . Example 122 spectral data: TLC R.0.10 (20:80 ethyl acetate-hexane). 4 H NMR (300 MHz, CDClj) : δ 8.97 (IH, s) , 6.94 (2H, s) , 4.14 (2H, d, J = 7.7 Hz), 3.48 (IH, q, J = 7.0 Hz), 2.63 (3H, s) , 2.31 (3H, s) , 2.01 (6H, s) , 1.43-1.19 (8H, m) , 0.94 (3H, t, J = 7.3 Hz) , 0.84 (3H, t, J = 7.0 Hz) . MS (NH,-CI) : m/e 367 (3) , 366 (25) , 365 (100). Example 123 spectral data: TLC R, 0.24 (30:70 ethyl acetate-hexane). * Η NMR (300 MHz, CDCl,): δ 8.97 (IH, s) , 6.94 (2H, s) , 4.25 (2H, t, J = 8.1 Hz), 3.48 (IH, q, J = 7.1 Hz), 2.63 (3H, s) , 2.31 (3H, s) , 2.01 (6H, s) , 1.81 (2H, m) , 1.47-1.19 (8H, m) , 0.91 (6H, m) . MS (NHj-CI) : m/e 381 (4), 380 (27), 379 (100). Analysis calc'd for C J Λ 4 N 4 : C, 76.15; H, 9.05; N, 14.80; found: C, 76.29; H, 9.09; N, 14.75. Example 202 spectral data: TLC RF 0.20 (10:90 ethyl acetate-hexane). IH NMR (300 MHz, CDC13): d 8.82 (IH, s) , 6.96 (2H, s) , 4.46-4.38 (IH, m) , 4.13 (3H, s) , 2.34 (3H, s) , 2.28-2.11 (2H, m) , 2.07 (6H, s) , 1.95-1.81 (2H, m) , 1.38-1.17 (3H, m) , 1.14-0.99 (IH, m) , 0.83 (3H, t, J = 7.7 Hz), 0.80 (3H, t, J = 7.7 Hz). MS (NH3-CI) : m/e calc'd for C j3 Hj 0 N 4 O: 366.2420, found 366.2408; 369 (4), 368 (26), 367 (100). Example 404 spectral data: TLC R- 0.20 (20:80 ethyl acetate-hexane) . * Η NMR (300 MHz, CDCl j ): δ 6.93 (2H, s) , 4.20 (2H, t, J = 7.7 Hz), 2.90 (2H, q, J = 7.6 Hz), 2.83 (3H, s), 2.30 (3H, s) , 2.03 (6H, s) , 1.88 (2H, m) , 1.42-1.34 (7H, m) , 0.93 (3H, t, J = 6 Hz) . MS (NH j -CI) : m/e 353 (3) , 352 (27) , 351 (100) . Example 414 spectral data: TLC R.0.36 (20:80 ethyl acetate-hexane) . X H NMR (300 MHz, CDCl,): δ 8.92 (IH, s) , 7.66 (IH, d, J = 8.1 Hz), 7.32-7.26 (2H, m) , 4.54 (IH, m) , 2.95 (2H, q, J = 7.4 Hz), 2.43 (3H, s) , 2.39 (IH, m) , 2.03 (IH, m) , 1.74 (3H, d, J = 7.0 Hz) , 1.41 (3H, t, J = 7.5 Hz) , 1.31 (IH, m) , 1.16 (IH, m) , 0.92 (3H, t, J = 7.3 Hz) . MS (NH,-CI) : m/e calc'd for C 19 Hj 4 N 4 Cl: 343.1690, found 343.1704; 346 (7), 345 (34), 344 (23) , 343 (100) . Example 415 spectral data: TLC R.0.25 (10:90 ethyl acetate-hexane). X H NMR (300 MHz, CDCl j ) : δ 8.91 (IH, s) , 7.71 (IH, d, J = 8.1 Hz), 7.34-7.30 (2H, m) , 4.30-4.20 (IH, m) , 2.94 (2H, q, J = 7.5 Hz), 2.50-2.35 (2H, m) , 2.44 (3H, s) , 2.08-1.95 (2H, m) , 1.43 (3H, t, J = 7.5 Hz), 1.29 (3H, m) , 1.08-0.98 (IH, m) , 0.84 (3H, t, J = 7.0 Hz), 0.81 (3H, t, J = 7.3 Hz). MS (NH j -CI) : m/e 374 (7), 373 (33), 372 (25), 371 (100). Analysis calc'd for CjiHj-CIN,: C, 68.00; H, 7.35; N, 15.10; found: C, 68.25; H, 7.30; N, 14.85. Example 424 spectral data: TLC R.0.28 (5:95 ethyl acetate-dichloromethane) . 'H NMR (300 MHz, CDCl,) : δ 8.95 (IH, s) , 7.60 (IH, d, J = 7.7 Hz) , 7.37 (IH, d, J = 0.8 Hz) , 7.21 (IH, dd, J = 7.7, 0.8 Hz), 4.58-4.50 (IH, m) , 2.96 (2H, dq, J = 7.5, 2.0 Hz), 2.46-2.33 (IH, in), 2.40 (3H, s) , 2.08-1.96 (IH, m) , 1.74 (3H, d, J = 6.6 Hz), 1.40 (3H, t, J = 7.5 Hz), 1.39-1.22 (IH, m) , 1.20-1.08 (IH, m) , 0.92 (3H, t, J = 7.3 Hz). MS (NH 3 -CI) : m/e calc'd for C 19 Hj 4 ClN 4 : 343.1690, found 343.1697; 346 (8), 345 (38), 344 (25), 343 (100) . Example 434 spectral data: TLC R, 0.78 (50:50 ethyl acetate-hexane). * Η NMR (300 MHz, CDCL,) : δ 8.90 (IH, s) , 6.95 (2H, s) , 2.97 (2H, J = 7.3 Hz), 2.60-2.50 (IH, m) , 2.41- 2.33 (IH, m) , 2.32 (3H, s) , 2.20-2.10 (IH, m) , 2.05 (3H, s) , 2.02 (3H, s) , 1.85-1.80 (IH, m) , 1.39 (3H, t, J = 7.5 Hz), 0.85 (3H, t, J = 7.5 Hz), 0.50-0.35 (2H, m) , 0.25- 0.15 (IH, m) , 0.10-0.00 (IH, m) . MS (NH.-CI) : m/e calc'd for C j ,^^: 362.2470, found 362.2458; 365 (4), 364 (27), 363 (100). Example 436 spectral data: TLC R- 0.31 (30:70 ethyl acetate-hexane) . * H NMR (300 MHz, CDCl,): δ 8.88 (IH, s) , 7.77 (IH, d, J = 9.2 Hz), 6.87 (2H, m) , 4.40-4.25 (IH, m) , 3.86 (3H, s), 2.99 (2H, q, J = 7.5 Hz), 2.60-2.35 (2H, m) , 2.47 (3H, s) , 2.15-2.00 (IH, m) , 1.80-1.70 (IH, ) , 1.45 (3H, t, J = 7.5 Hz), 0.84 (3H, t, J = 7.5 Hz), 0.50-0.35 (2H, m), 0.30-0.20 (IH, m) , 0.10-0.00 (IH, m) , -0.85 - -0.95 (IH, m) . Example 437 spectral data: TLC R F 0.25 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDCL,) : δ 8.90 (IH, s) , 7.73 (IH, d, J = 9.2 Hz), 6.89-6.86 (2H, m) , 4.58-4.51 (IH, ' m) , 3.86 (3H, s) , 2.95 (2H, dq, J = 7.6, 1.8 Hz), 2.47 (3H, s) , 2.45-2.34 (IH, m) , 2.07- 1.97 (IH, m) , 1.73 (3H, d, J = 7.0 Hz), 1.42 (3H, t, J = 7.6 Hz), 1.40-1.27 (IH, m) , 1.20-1.07 (IH, m) , 0.92 (3H, t, J = 7.4 Hz). MS (NH 3 -CI) : m/e calc'd for C JO H J -N^: 339.2185, found 339.2187; 341 (3), 340 (22), 339 (100). Analysis calc'd for C J0 H J6 N 4 O: C, 70.98; H, 7.74; N, 16.55; found: C, 69.97; H, 7.48; N, 15.84. Example 438 spectral data: TLC R F 0.42 (40:60 ethyl acetate-hexane). *H NMR (300 MHz, CDCl,) : 58.98 (IH, s) , 7.77 (IH, d, J = 9.1 Hz), 7.17 (2H, d, J = 8.8 Hz), 6.90-6.83 (4H, m), 5.42 (2H, s) , 3.86 (3H, s) , 3.78 (3H, s) , 2.86 (2H, q, J = 7.5 Hz), 2.49 (3H, s) , 1.33 (3H, t, J = 7.5 Hz). MS (NH,-CI) : m/e 391 (4), 390 (26), 389 (100). Analysis calc'd for C j3 H, 4 N 4 0,: C, 71.11; H, 6.24; N, 14.42; found: C, 71.14; H, 5.97; N, 14.03. Example 439 spectral data: TLC R F 0.41 (30:70 ethyl acetate-hexane) . l H NMR (300 MHz, CDCl,) : δ 8.89 (IH, s) , 7.77 (IH, d, J - 3.1 Hz), 6.89 (2H, m) , 3.86 (3H, s) , 3.53 (IH, m), 2.91 (2H, q, J = 7.5 Hz), 2.49 (3H, s) , 2.28 (IH, m) , 2.21 (IH, m) , 1.43 (3H, t, J = 7.3 Hz), 0.86 (3H, t, J = 7.3 Hz), 0.78 (2H, m) , 0.46 (2H, m) , 0.20 (IH, m) . Example 440 spectral data: TLC R, 0.28 (30:70 ethyl acetate-hexane). ''H NMR (300 MHz, CDCl,): δ 8.89 (IH, s) , 7.73 (IH, d, J = 9.1 Hz), 6.90-6.86 (2H, m) , 4.60-4.40 (IH, ) , 3.86 (3H, s), 2.95 (2H, dq, J = 7.7, 2.2 Hz), 2.47 (3H, s) , 2.44-2.36 (IH, m) , 2.05- 1.98 (IH, m), 1.74 (3H, d, J = 7.0 Hz), 1.42 (3H, t, J = 7.5 Hz), 1.40-1.20 (5H, m) , 1.13-1.05 (IH, m), 0.830 (3H, t, J = 6.6 Hz). Example 502 spectral data: TLC R, 0.63 (50:50 ethyl acetate-hexane). * H NMR (300 MHz, CDCl,) : 58.92 (IH, s) , 6.95 (2H, s) , 4.60-4.47 (IH, ) , 2.93 (2H, q, J = 7.7 Hz), 2.43-2.33 (IH, m) , 2.32 (3H, s) , 2.16-2.06 (IH, m) , 2.05 (3H, s) , 2.03 (3H, s) , 1.76 (3H, d, J = 7.0 Hz), 1.36 (3H, t, J = 7.7 Hz), 1.36-1.20 (4H, m) , 0.86 (3H, t, J = 7.2 Hz). MS (NH 3 -CI) : m/e calc'd for C 2 jH, 0 N 4 : 350.2470, found 350.2480; 353 (3), 352 (28), 351 (100) . Example 503 spectral data: * H NMR (300 MHz, CDC1 3 ) : 58.92 (IH, s) , 6.94 (2H, s) , 4.58- 4.48 (IH, m) , 2.93 (2H, q, J = 7.3 Hz), 2.32 (3H, s) , 2.05 (3H, s) , 2.02 (3H, s) , 1.76 (3H, d, J = 6.6 Hz), 1.36 (3H, t, J = 7.3 Hz), 1.34-1.05 (8H, m) , 0.88 (3H, t, J = 7 Hz). MS (NHj-CI): m/e calc'd for C JJ H, J N 4 : 365.2705, found 365.2685; 367 (3), 366 (27), 365 (100) . Example 506 spectral data: TLC R, 0.28 (20:80 ethyl acetate-hexane) . X H NMR (300 MHz, CDClj) : δ 8.95 (IH, s) , 7.67 (IH, d, J = 8.4 Hz) , 7.57 (IH, d, J = 1.8 Hz) , 7.42-7.37 (IH, m) , 4.56 (IH, hextet, J = 7.1 Hz), 2.99 (2H, q,. J = 7.5 Hz), 2.43-2.33 (IH, m) , 2.09-1.97 (IH, m) , 1.74 (3H, d, J = 7.0 Hz), 1.41 (3H, t, J = 7.5 Hz), 1.35-1.07 (2H, m) , 0.92 (3H, t, J = 7.3 Hz) . MS (NH,~CI) : m/e 367 (12) , 366 (14) , 365 (67) , 364 (24) , 363 (100) . Example 507 spectral data: MS (NH,-CI) : m/e 377 (M+H * , 100%) . Example 511 spectral data: TLC R, 0.51 (30:70 ethyl acetate-hexane) . 1 H NMR (300 MHz " , CDCl,) : δ 8.97 (IH, s) , 7.87 (IH, d, J = 8.1 Hz) , 7.83 (IH, d, J = 1.1 Hz) , 7.68 (IH, dd, J = 8.1, 1.1 Hz), 3.60-3.51 (IH, m) , 2.94 (2H, q, J = 7.5 Hz), 2.53-2.39 (IH, m) , 2.36-2.20 (IH, m) , 1.96 (IH, br) , 1.42 (3H, t, J = 7.5 Hz), 0.88 (3H, t, J = 7.3 Hz), 0.88-0.78 (IH, m) , 0.52-0.44 (2H, m) , 0.24-0.16 (IH, m) . MS (NH,-CI) : m/e 412 (7), 411 (33), 410 (23), 409 (100) . Example 513 spectral data: TLC R F 0.62 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDCI 3 ) : δ 8.97 (IH, s) , 7.87 (IH, d, J = 8.0 Hz), 7.83 (IH, d, J = 0.7 Hz), 7.68 (IH, dd, J = 8.0, 0.7 Hz), 4.21 (IH, br) , 2.96 (2H, q, J = 7.5 Hz), 2.42 (2H, br) , 2.12-1.97 (2H, m), 1.43 (3H, t, J = 7.5 Hz), 1.40-1.20 (4H, m) , 0.85 (3H, t, J = 7.3 Hz), 0.83 (3H, t, J = 7.6 Hz). MS (NH j -CI) : m/e 428 (8), 427 (38), 426 (29), 425 (100). Example 514 spectral data: TLC R F 0.51 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDCl,) : 58.96 (IH, s) , 7.86 (IH, d, J = 8.1 Hz), 7.83 (IH, d, J = 0.8 Hz) , 7.68 (IH, dd, J = 8.1, 0.8 Hz), 4.20 (IH, br) , 2.97 (2H, q, J = 7.7 Hz), 2.54-2.39 (2H, m) , 2.15- 2.01 (2H, ) , 1.43 (3H, t, J = 7.7 Hz), 0.84 (6H, t, J = 7.5 Hz). MS (NH 3 -CI) : m/e 400 (7), 399 (37), 398 (26), 397 (100). Example 524 spectral data: TLC R, 0.50 (30:70 ethyl acetate-hexane) . * Η NMR (300 MHz, CDCI 3 ) : 58.89 (IH, s) , 7.76 (IH, d, J = 9.1 Hz), 6.90-6.87 (2H, m) , 4.35 (IH, v br) , 3.86 (3H, s), 2.93 (2H. q, J = 7.6 Hz), 2.48 (3H, s) , 2.39 (2H, br) , 2.00-1.90 (2H, m) , 1.43 (3H, t, J = 7.6 Hz), 1.38-1.22 (2H, m) , 1.18-1.02 (2H, m) , 0.90 (6H, t, J = 7.3 Hz) . MS (NHj-CI) : m/e calc'd for C JJ H^N.O: 367.2498, found 367.2506; 369 (3), 368 (25), 367 (100) . Example 526 spectral data: TLC R, 0.28 (10:90 ethyl acetate-hexane) . H NMR (300 MHz, CDCl,): 58.91 (IH, s) , 7.69 (IH, d, J = 8.1 Hz), 7.34-7.30 (2H, m) , 4.40-4.35 (IH, m) , 2.93 (2H, q, J = 7.4 Hz), 2.44 (3H, s) , 2.38 (2H, m) , 1.96 (2H, m) , 1.43 (3H, t, J = 7.5 Hz), 1.35-1.22 (2H, ) , 1.15-1.05 (2H, m) , 0.90 (6H, t, J = 7.1 Hz) . MS (NH,-CI) : m/e 374 (8), 373 (35), 372 (25), 371 (100) . Analysis calc'd for C 21 H j7 N 4 Cl: C, 68.00; H, 7.35; N, 15.10; found: C, 67.89; H, 7.38; N, 14.94. Example 528 spectral data: TLC R p 0.65 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDCl,) : 58.97 (IH, s) , 7.86 (IH, d, J = 8.0 Hz) , 7.82 (IH, d, J = 1.1 Hz) , 7.67 (IH, dd, J = 8.0, 1.1 Hz), 4.38 (IH, br) , 2.95 (2H, q, J = 7.5 Hz), 2.39 (2H, br) , 2.04-1.92 (2H, br), 1.42 (3H, t, J = 7.5 Hz), 1.40-1.21 (3H, m) , 1.19-1.03 (IH, m) , 0.91 (6H, t, J = 7.3 Hz). MS (NH j -CI) : m/e 428 (8), 427 (37), 426 (27), 425 (100). Example 538 spectral data: TLC R F 0.56 (30:70 ethyl acetate-hexane) . *H NMR (300 MHz, CDCl,) : δ 8.96 (IH, s) , 7.88 (IH, d, J = 8.0 Hz) , 7.83 (IH, d, J = 0.8 Hz), 7.68 (IH, dd, J = 8.0, 0.8 Hz), 3.77 (IH, br) , 2.95 (2H, q, J = 7.5 Hz), 2.61 (IH, br) , 2.08 (IH, br) , 1.45 (3H, t, J = 7.5 Hz), 1.36-1.25 (IH, m) , 1.17 (3H, d, J = 6.6 Hz), 0.71 (3H, t, J = 7.3 Hz), 0.69 (3H, d, J = 7.0 Hz). MS (NH j -CI) : m/e 414 (7), 413 (33), 412 (24), 411 (100) . Example 534 spectral data: MS (ESI): m/e 363 (M+2) , 361 (M * , 100 %) . Example 544 spectral data: TLC R.0.63 (50:50 ethyl acetate-hexane). X H NMR (300 MHz, CDCl,): δ 8.90 (IH, s) , 7.74 (IH, d, J = 9.1 Hz), 6.89-6.86 (2H, m) , 3.86 (3H, s) , 3.79-3.73 (IH, m) , 2.93 (3H, dq, J = 7.7, 2.6 Hz), 2.49 (3H, s) , 2.03-1.99 (IH, m) , 1.81 (3H, d, J = 6.9 Hz), 1.41 (3H, t, J = 7.3 Hz), 0.84-0.74 (2H, m) , 0.53-0.41 (2H, m), 0.28-0.21 (IH, m) . Example 548 spectral data: TLC R F 0.42 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDCl,) : δ 8.99 (IH, s) , 7.84 (IH, d, J = 7.7 Hz) , 7.82 (IH, d, J = 0.9 Hz) , 7.68 (IH, dd, J = 7.7, 0.9 Hz), 3.83-3.70 (IH, m) , 3.00- .90 _(2H, m) , 2.09-1.98 (IH, m) , 1.83 (3H, d, J = 7.0 Hz), 1.40 (3H, t, J = 7.3 Hz), 0.88-0.78 (IH, ) , 0.57-0.41 (2H, m) , 0.30-0.20 (IH, m) . MS (NH,-CI) : m/e 398 (6), 397 (31), 396 (22), 395 (100). Example 551 spectral data: TLC R F 0.56 (50:50 ethyl acetate-hexane) . *H NMR (300 MHz, CDCl,): δ 8.93 (IH, s) , 6.94 (2H, s) , 4.75 (IH, heptet, J = 7.0 Hz), 2.95 (2H, q, J = 7.7 Hz), 2.32 (3H, s) , 2.04 (6H, s) , 1.80 (6H, d, J = 7.0 Hz), 1.36 (3H, t, J = 7.7 Hz). MS (NH3-CI) : m/e 311 (4), 310 (34), 309 (100); Analysis calc'd for C ω H, 4 N 4 «0.5H j θ: C, 71.89; H, 7.94; N, 17.65; found: C, 71.59; H, 7.83; N, 17.41. Example 558 spectral data: TLC R, 0.53 (30:70 ethyl acetate-hexane) . l H NMR (300 MHz, CDC1 3 ) : δ 8.98 (IH, s) , 7.86-7.81 (2H, m) , 7.67 (IH, dd, J = 8.4, 1.1 Hz) , 4.60-4.48 (IH, m) , 3.01-2.93 (2H, m) , 2.49-2.35 (IH, m) , 2.13-2.00 (IH, m) , 1.76 (3H, d, J = 7.0 Hz), 1.41 (3H, t, J = 7.5 Hz), 1.40-1.20 (4H, m) , 0.87 (3H, t, J = 7.3 Hz). MS (NH,- CI) : m/e 414 (8), 413 (38), 412 (27), 411 (100). Example 564 spectral data: TLC R, 0.34 (30:70 ethyl acetate-hexane) . "H NMR (300 MHz, CDCl,): δ 8.89 (IH, s) , 7.77 (IH, d, J = 9.2 Hz), 6.89 (2H, m) , 4.30-4.20 (IH, m) , 3.86 ' (3H, s), 2.93 (2H, q, J = 7.5 Hz), 2.48 (3H, s) , 2.45-2.35 (2H, m) , 2.10-1.95 (2H, m) , 1.44 (3H, t, J = 7.5 Hz), 1.40-1.20 (3H, m) , 1.10-0.95 (IH, m) , 0.84 (3H, t, J = 7.3 Hz) , 0.81 (3H, t, J = 7.3 Hz) . Example 571 spectral data: TLC R_ 0.40 (50:50 ethyl acetate-hexane). H NMR (300 MHz, CDCl,): 58.89 (IH, s) , 6.95 (2H, s) , 4.51 (IH, br) , 3.44-3.24 (4H, m) , 2.96 (2H, q, J = 7.3 Hz), 2.95-2.87 (IH, ) , 2.85-2.75 (IH, m) , 2.59-2.49 (IH, m) , 2.32 (3H, s) , 2.27- 2.18 (IH, m) , 2.04 (3H, s) , 2.04 (3H, s) , 1.38 (3H, t, J = 7.7 Hz), 1.12 (3H, t, J = 7.0 Hz), 0.84 (3H, t, J = 7.3 Hz). MS (NH,-CI) : m/e calc'd for C j ,H, 2 N 4 0: 380.2576, found 380.2554; 383 (4), 382 (28), 381 (100). Example 581 spectral data: TLC R F 0.33 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDCI 3 ) : 58.89 (IH, s) , 6.95 (2H, s) , 4.49-4.39 (IH, ) , 4.23-4.13 (IH, m) , 3.91 (IH, dd, J = 9.9, 4.8 Hz), 3.48 (IH, dq, J = 9.1, 7.0 Hz), 3.30 (IH, dq, J = 9.1, 7.0 Hz), 2.95 (2H, q, J = 7.7 Hz), 2.60-2.47 (IH, m) , 2.32 (3H, s) , 2.15-2.01 (IH, m) , 2.04 (3H, s), 2.03 (3H, s) , 1.37 (3H, t, J = 7.5 Hz), 1.00 (3H, t, J = 7.0 Hz), 0.86 (3H, t, J = 7.3 Hz). MS (NH 3 -CI) : m/e calc'd for C jj H 31 N 4 0: 367.2498, found 367.2497; 369 (4), 368 (27) , 367 (100) . Example 591 spectral data: TLC R 0.42 (50:50 ethyl acetate-hexane) . 1 R NMR (300 MHz, CDCl,) : 58.91 (IH, s), 6.95 (2H, s) , 3.76 (IH, br) , 3.47-3.40 (IH, m) , 3.21 (3H, s) , 2.99-2.90 (IH, m) , 2.88 (2H, q, J = 7.3 Hz), 2.76 (IH, br) , 2.51-2.41 (IH, m) , 2.32 (3H, s), 2.09 (IH, br) , 2.08 (3H, s) , 2.04 (3H, s) , 1.35 (3H, t, J = 7.3 Hz), 0.84-0.76 (IH, m) , 0.56-0.44 (2H, m) , 0.30-0.21 (IH, m) . MS (NH 3 -CI) : m/e calc'd for C j3 H 31 N 4 0: 379.2498, found 379.2514; 381 (4), 380 (27), 379 (100). Example 690 spectral data: TLC R, 0.12 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDCl,) : d 9.01 (IH, s) , 7.38-7.22 (5H, m) , 6.75 (IH, s) , 6.69 (IH, s) , 5.48 (2H, s) , 3.70 (3H, s), 2.84 (2H, q, J = 7.7 Hz), 2.37 (3H, s) , 2.05 (3H, s) , 1.26 (3H, t, J = 7.7 Hz). MS (NH j -CI) : m/e 375 (4), 374 (28), 373 (100). Example 692 spectral data: TLC R F 0.32 (30:70 ethyl acetate-hexane) . *H NMR (300 MHz, CDCl j ): δ 8.98 (IH, s) , 7.48 (IH, s) , 7.37-7.18 (5H, m) , 7.11 (IH, s) , 5.49 (2H, s) , 2.84 (2H, q, J = 7.3 Hz), 2.38 (3H, s) , 2.29 (6H, s) , 1.31 (3H, t, J = 7.3 Hz). MS (NHj-CI) : m/e calc'd for C 2 ,H j .N 4 : 356.2001, found 356.1978; 359 (4), 358 (28), 357 (100) . Example 693 spectral data: TLC R, 0.22 (20:80 ethyl acetate-hexane). * H NMR (300 MHz, CDClj) : δ 8.90 (IH, s) , 7.78 (IH, d, J = 9.5 Hz), 6.90-6.87 (2H, m) , 3.86 (3H, s) , 3.62 (IH, br), 2.91 (2H, q, J = 7.5 Hz), 2.50 (3H, s) , 2.40 (IH, br) , 2.26-2.13 (IH, m) , 1.92 (IH, br), 1.58 (IH, br) , 1.43 (3H, t, J = 7.5 Hz), 1.35-1.25 (IH, m) , 1.13-1.03 (IH, m), 0.95-0.75 (2H, m) , 0.85 (3H, t, J = 7.1 Hz), 0.54-0.42 (2H, m) , 0.22-0.17 (IH, m) . MS (NH 3 -CI) : m/e 381 (4), 380 (25), 379 (100). Example 697 spectral data: TLC R- 0.28 (30:70 ethyl acetate-hexane). X H NMR (300 MHz, CDCI 3 ) : δ 8.89 (IH, s) , 7.74 (IH, d, J = 9.5 Hz), 6.90-6.86 (2H, m) , 4.58-4.45 (IH, m) , 2.95 (2H, dq, J = 7.7, 2.2 Hz), 2.48 (3H, s) , 2.45-2.35 (IH, m) , 2.09-1.99 (IH, m) , 1.74 ( 3H, d, J = 7 .0 Hz ) , 1.42 ( 3H, t , J = 7 .5 Hz ) , 1.37 -1.23 ( 3H, ra) , 1.11-1.03 ( IH, m) , 0 .86 (3H, t , J = 7 .0 Hz ) . Example 724 spectral data: TLC Rp 0.45 (30:70 ethyl acetate-hexane). * Η NMR (300 MHz, CDC1 3 ) : δ 8.92 (IH, s) , 7.75 (IH, d, J = 8.4 Hz), 7.09 (IH, d, J = 2.6 Hz), 6.96 (IH, dd, J = 8.4, 2.6 Hz), 3.87 (3H, s) , 3.76 (IH, br) , 2.94 (2H, q, J = 7.3 Hz), 2.61 (IH, br) , 2.09 (IH, br) , 1.45 (3H, t, J = 7.3 Hz), 1.36-1.26 (IH, m) , 1.15 (3H, d, J = 6.6 Hz), 0.71 (3H, t, J = 7.3 Hz) , 0.68 (3H, d, J = 6.6 Hz) . MS (NH.-CI) : m/e 111 (1), 376 (8), 375 (38), 374 (25), 373 (100). Example 725 spectral data: TLC R F 0.31 (30:70 ethyl acetate-hexane) . * H NMR (300 MHz, CDClj): 58.88 (IH, s) , 7.80 (IH, d, J = 9.2 Hz), 6.89 (2H, m) , 3.86 (3H, s) , 3.75 (IH, m) , 2.92 (2H, q, J = 7.4 Hz), 2.60 (IH, m) , 2.48 (3H, s) , 2.05 (IH, m) , 1.46 (3H, t, J = 7.4 Hz), 1.16 (3H, d, J = 7.0 Hz), 0.70 (3H, t, J = 7.3 Hz), 0.67 (3H, d, J = 6.6 Hz) .. Example 727 spectral data: TLC R, 0.44 (30:70 ethyl acetate-hexane). l H NMR (300 MHz, CDCl j ) : δ 8.90 (IH, s), 7.84 (IH, d, J = 2.2 Hz), 7.74 (IH, d, J = 8.4 Hz), 7.65 {IH, dd, J = 8.4, 2.2 Hz), 3.76 (IH, br) , 2.93 (IH, q, J = 7.3 Hz), 2.60 (IH, br) , 2.08 (IH, br) , 1.42 (3H, t, J = 7.3 Hz), 1.37-1.27 (IH, ) , 1.16 (3H, d, J = 7.0 Hz), 0.69 (3H, t, J = 7.3 Hz) , 0.67 (3H, d, J = 7.0 Hz) . MS (NH,-CI) : m/e 414 (7) , 413 (33) , 412 (27), 411 (100) . Example 750 spectral data: TLC R F 0.42 (30:70 ethyl acetate-hexane) . * Η NMR (300 MHz, CDCl,) : δ 8.94 (IH, s) , 7.73 (IH, d, J = 8.4 Hz) , 7.10 (IH, d, J = 2.6 Hz), 6.96 (IH, dd, J = 8.4, 2.6 Hz) , 3.87 (3H, s) , 3.63 (IH, v br) , 2.92 (2H, q, J = 7.3 Hz) , 2.38 (IH, br), 2.22-2.10 (IH, m) , 1.94 (IH, br) , 1.42 (3H, t, J = 7.3 Hz), 1.41-1.29 (IH, m), 1.23-1.08 (IH, m) , 0.91 (3H, t, J = 7.3 Hz), 0.89-0.79 (IH, m) , 0.51-0.41 (2H, m) , 0.25-0.15 (IH, m) . MS (NH,-CI) : m/e 388 (8), 387 (34), 386 (25), 385 (100). Example 751 spectral data: TLC R F 0.36 (40:60 ethyl acetate-hexane) . X H NMR (300 MHz, CDCl j ): δ 8.89 (IH, s) , 7.77 (IH, d, J = 9.1 Hz), 6.90 (2H, m) , 3.86 (3H, s) , 3.62 (IH, m), 2.84 (2H, q, J = 7.5 Hz), 2.49 (3H, s) , 2.40 (IH, m) , 2.19 (IH, m) , 1.90 (IH, m) , 1.43 (3H, t, J = 7.5 Hz), 1.38 (IH, m) , 1.19 (IH, m) , 0.91 (3H, t, J = 7.3 Hz), 0.80 (IH, m), 0.49 (2H, m) , 0.21 (IH, m) . Example 753 spectral data: TLC R, 0.44 (30:70 ethyl acetate-hexane) . * Η NMR (300 MHz, CDCl j ): δ 8.92 (IH, s) , 7.84 (IH, d, J = 1.8 Hz), 7.73 (IH, d, J = 8.5 Hz), 7.65 (IH, dd, J = 8.5, 1.8 Hz), 3.65 (IH, br) , 2.92 (IH, q, J = 7.5 Hz), 2.38 (IH, br) , 2.25-2.14 (IH, m) , 1.94 (IH, br) , 1.43-1.26 (IH, m) , 1.40 (3H, t, J = 7.5 Hz), 1.21-1.06 (IH, m) , 0.92 (3H, t, J = 7.3 Hz), 0.91-0.79 (IH, m) , 0.52-0.44 (2H, m) , 0.22-0.16 (IH, m) . MS (NHj-CI) : m e 426 (9), 425 (42), 424 (31), 423 (100). Example 767 spectral data: MS (NH,-CI) : m/e 379 (M+H * , 100%) . Example 776 spectral data: TLC R F 0.41 (30:70 ethyl acetate-hexane) . * Η NMR (300 MHz, CDCl,) : δ 8.93 (IH, s) , 7.73 (IH, d, J = 8.4 Hz) , 7.09 (IH, d, J = 2.6 Hz) , 6.96 (IH, dd, J = 8.4, 2.6 Hz), 4.28 (IH, br) , 3.87 (3H, s) , 2.95 (2H, q, J = 7.3 Hz), 2.41 (2H, br) , 2.10-1.93 (2H, m) , 1.43 (3H, t, J = 7.3 Hz), 1.40-1.23 (IH, m) , 1.18-1.03 (IH, m) , 0.91 (3H, t, J = 7.3 Hz), 0.82 (3H, t, J = 7.5 Hz). MS (NH,-CI) : m/e calc'd for C, 0 H,,C1N 4 0 : 373.1795, found 373.1815; 376 (8), 375 (35), 374 (24), 373 (100). Example 777 spectral data: TLC R F 0.46 (30:70 ethyl acetate-hexane). l H NMR (300 MHz, CDCl j ): δ 8.89 (IH, s) , 7.76 (IH, d, J = 9.0 Hz), 6.90-6.87 (2H, m) , 4.29 (IH, br) , 3.86 {3H, s), 2.94 (2H, q, J = 7.4 Hz), 2.48 (3H, s) , 2.40 (2H, br) , 2.10-1.92 (2H, m) , 1.44 (3H, t, J = 7.4 Hz), 1.37-1.22 (IH, m) , 1.18-1.02 (IH, m) , 0.90 (3H, t, J = 7.3 Hz), 0.81 (3H, t, J = 7.3 Hz). MS (NH,-CI) : m/e calc'd for C J ΛO: 353.2341, found 353.2328; 355 (3), 354 (23), 353 (100) . Example 778 spectral data: TLC R F 0.58 (30:70 ethyl acetate-hexane) . * H NMR (300 MHz, CDCl,) : δ 8.97 (IH, s) , 7.86 (IH, d, J = 8.0 Hz) , 7.83 (IH, d, J = 0.8 Hz), 7.68 (IH, dd, J = 8.0, 0.8 Hz), 4.30 (IH, br) , 2.96 (2H, q, J = 7.5 Hz), 2.41 (2H, br) , 2.11-1.95 (2H, m) , 1.43 (3H, t, J = 7.5 Hz), 1.42-1.22 (2H, m) , 0.92 (3H, t, J = 7.3 Hz), 0.83 (3H, t, J = 7.3 Hz) . MS (NH j -CI) : m/e 414 (8), 413 (39), 412 (28), 411 (100). Example 779 spectral data: TLC R, 0.44 (30:70 ethyl acetate-hexane) . *H NMR (300 MHz, CDCl,) : δ 8.91 (IH, s) , 7.84 (IH, d, J = 1.8 Hz) , 7.72 (IH, d, J = 8.0 Hz), 7.65 (IH, dd, J = 8.0, 1.8 Hz), 4.31 (IH, br) , 2.94 (IH, q, J = 7.5 Hz), 2.40 (2H, br) , 2.10-1.93 (2H, ) , 1.40 (3H, t, J = 7.5 Hz), 1.37-1.21 (IH, m) , 1.19-1.02 (IH, m) , 0.91 (3H, t, J = 7.3 Hz), 0.81 (3H, t, J = 7.3 Hz). MS (NH,-CI) : m/e 414 (9), 413 (43), 412 (31), 411 (100). Example 793 spectral data: MS (NH,-CI) : m/e 367 (M+H * , 100%) . Example 799 spectral data: TLC R F 0.61 (30:70 ethyl acetate-hexane) . * H NMR (300 MHz, CDCl j ): δ 8.90 (IH, s) , 7.47 (IH, s) , 7.10 (IH, s) , 4.28 (IH, br) , 2.93 (2H, q, J = 7.3 Hz), 2.41 (IH, br) , 2.36 (3H, s) , 2.28 (6H, s) , 2.07-1.91 (3H, m) , 1.42 (3H, t, J = 7.3 Hz), 1.35-1.21 (IH, m) , 1.19-1.03 (IH, ) , 0.90 (3H, t, J = 7.2 Hz), 0.81 (3H, t, J = 7.3 Hz). MS (NH j -CI) : /e calc'd for C 2J H J0 N 4 = 350.2470, found 350.2476; 353 (3), 352 (24), 351 (100) . Example 802 spectral data: TLC R- 0.38 (30:70 ethyl acetate-hexane) . α H NMR (300 MHz, CDClj): δ 8.92 (IH, s) , 7.84 (IH, d, J = 1.8 Hz), 7.73 (IH, d, J = 8.4 Hz), 7.65 (IH, dd, J = 8.4, 1.8 Hz), 3.53 (IH, br) , 2.91 (IH, q, J = 7.4 Hz), 2.52-2.35 (IH, m) , 2.34- 2.20 (IH, m) , 1.95 {IH, br) , 1.40 (3H, t, J = 7.4 Hz), 0.89-0.79 (IH, m) , 0.87 (3H, t, J = 7.3 Hz), 0.55-0.42 (2H, m) , 0.25-0.15 (IH, m) . MS (NH,-CI) : m/e 412 (8), 411 (41), 410 (29), 409 (100) . Example 803 spectral data: TLC R.0.33 (30:70 ethyl acetate-hexane). l H NMR (300 MHz, CDCl,) : δ 8.93 (IH, s) , 7.85 (IH, d, J = 2.2 Hz), 7.71 (IH, d, J = 8.4 Hz), 7.64 (IH, dd, J = 8.4, 2.2 Hz), 3.77 (IH, dq, J = 9.9, 7.0 Hz), 2.93 (IH, dq, J = 7.5, 2.0 Hz), 2.09-1.98 (IH, m) , 1.82 (3H, d, J = 7.0 Hz), 1.39 (3H, t, J = 7.5 Hz), 0.86-0.78 (IH, m) , 0.59-0.50 (IH, m) , 0.49-0.40 (IH, rn) , 0.29-0.20 (IH, m) . MS (NH 3 -CI) : m/e 399 (2), 398 (8), 397 (39), 396 (24), 395 (100). Example 804 spectral data: TLC R_.0.31 (20:80 ethyl acetate-hexane). X H NMR (300 MHz, CDCl j ): δ 8.92 {IH, s) , 7.84 (IH, d, J = 1.8 Hz), 7.71-7.62 (2H, m) , 4.55 (IH, ) , 2.95 (2H, q, J = 7.5 Hz), 2.43-2.32 (IH, m) , 2.10-1.98 (IH, ) , 1.75 (3H, d, J = 7.0 Hz), 1.39 (3H, t, J = 7.5 Hz), 1.38-1.27 (IH, m) , 1.19-1.09 (IH, m) , 0.93 (3H, t, J = 7.1 Hz). MS (NH j -CI) : m/e 400 (7), 399 (32), 398 (22), 397 (100). Analysis calc'd for C u Hj 0 ClF,N 4 : C, 57.51; H, 5.08; N, 14.12; found: C, 57.55; H, 5.06; N, 13.95. Example 805 spectral data: TLC Rp 0.41 (30:70 ethyl acetate-hexane) . 1 H NMR (300 MHz, CDCl,): δ 8.92 (IH, s) , 7.84 (IH, d, J = 1.8 Hz), 7.70 (IH, d, J = 8.0 Hz), 7.64 (IH, dd, J = 8.0, 1.8 Hz), 4.58-4.49 (IH, ) , 2.95 (IH, q, J = 7.5 Hz), 2.45-2.33 (IH, ) , 2.11-2.00 (IH, m) , 1.75 (3H, d, J = 6.6 Hz), 1.39 (3H, t, J = 7.5 Hz), 1.38-1.21 (4H, m) , 0.86 (3H, t, J = 7.0 Hz) . MS (NH,-CI) : m/e 414 (8) , 413 (40) , 412 (29) , 411 (100) . Example 807 spectral data: TLC R F 0.49 (30:70 ethyl acetate-hexane) . * Η NMR (300 MHz, CDCl,) : δ 8.91 (IH, s) , 7.84 (IH, d, J = 1.8 Hz), 7.73 (IH, d, J = 8.4 Hz), 7.65 (IH, dd, J = 8.4, 1.8 Hz), 4.38-4.19 (IH, m) , 2.94 (IH, q, J = 7.5 Hz), 2.40 (2H, br) , 2.10- 1.98 (2H, m) , 1.41 (3H, t, J = 7.5 Hz), 1.38-1.20 (3H, m) , 1.09-0.99 (IH, m) , 0.84 (3H, t, J = 7.0 Hz), 0.81 (3H, t, J = 7.5 Hz). MS (NH,-CI) : m/e 428 (7), 427 (32), 426 (25), 425 (100) . Example 808 spectral data: TLC R F 0.51 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDCl,) : δ 8.91 (IH, s) , 7.84 (IH, d, J = 1.8 Hz) , 7.72 (IH, d, J = 8.4 Hz), 7.64 (IH, dd, J = 8.4, 1.8 Hz), 4.37 (IH, br) , 2.93 (IH, q, J = 7.5 Hz), 2.38 (2H, br) , 2.02-1.90 (2H, m) , 1.40 (3H, t, J = 7.5 Hz), 1.38-1.20 (2H, m) , 1.18-1.01 (2H, m) , 0.90 (6H, t, J = 7.3 Hz). MS (NH,-CI): m/e 428 (8), 427 (39), 426 (30), 425 (100). Example 809 spectral data: TLC Rp 0.40 (30:70 ethyl acetate-hexane) . ' H NMR (300 MHz, CDCl,): δ 8.90 (IH, s) , 7.84 (IH, d, J = 2.2 Hz), 7.72 (IH, d, J = 8.1 Hz), 7.65 (IH, dd, J = 8.1, 2.2 Hz), 4.20 (IH, br) , 2.94 (IH, q, J = 7.5 Hz), 2.51-2.38 (2H, m) , 2.13- 2.00 (2H, m) , 1.41 (3H, t, J = 7.5 Hz), 0.82 (6H, t, J = 7.5 Hz). MS (NH,-CI) : m/e 400 (7), 399 (36), 398 (25), 397 (100). Example 824 spectral data: TLC R, 0.27 (20:80 ethyl acetate-hexane). ' H NMR (300 MHz, CDCl,) : δ 8.94 (IH, s) , 8.10 (IH, s) , 7.94 (IH, d, J = 8.8 Hz), 7.87 (IH, d, J = 8.1 Hz), 4.56 (IH, m) , 2.96 (2H, q, J = 7.5 Hz), 2.40 (IH, m) , 2.10-2.00 (IH, m) , 1.76 (3H, d, J = 7.0 Hz), 1.39 (3H, t, J = 7.5 Hz), 1.33-1.10 (2H, m) , 0.93 (3H, t, J = 7.1 Hz). U F NMR (300 MHz, CDCl,): δ -58.2, -63.4. MS (NH,-CI) : m/e 433 (3), 432 (24), 431 (100). Example 832 spectral data: TLC Rp 0.34 (30:70 ethyl acetate-hexane). 1 H NMR (300 MHz, CDClj) : δ 8.94 (IH, s) , 7.73 (IH, d, J = 8.5 Hz), 7.10 (IH, d, J = 2.6 Hz), 6.96 (IH, dd, J = 8.5, 2.6 Hz), 3.87 (3H, s) , 3.55 (IH, br) , 2.92 (2H, q, J = 7.3 Hz), 2.53-2.35 (IH, m), 2.31-2.18 (IH, m) , 1.96 (IH, br) , 1.42 (3H, t, J = 7.3 Hz), 0.87 (3H, t, J = 7.5 Hz), 0.87-0.79 (IH, m) , 0.53-0.43 (2H, m) , 0.25-0.15 (IH, ) . MS (NH,-CI) : /e 374 (8), 373 (34), 372 (24), 371 (100). Example 833 spectral data: TLC R p 0.20 (30:70 ethyl acetate-hexane). X H NMR (300 MHz, CDCl,) : δ 8.96 (IH, s) , 7.70 (IH, d, J = 8.4 Hz) , 7.10 (IH, d, J = 2.5 Hz) , 6.96 (IH, dd, J = 8.4, 2.5 Hz), 4.16 (2H, d, J = 7.0 Hz), 3.87 (3H, s) , 3.01 (2H, q, J = 7.3 Hz), 1.46 (3H, t, J = 7.3 Hz), 1.37-1.27 (IH, m) , 0.66-0.52 (4H, m) . MS (NH,-CI) : m/e 346 (6), 345 (32), 344 (23), 343 (100). Example 834 spectral data: TLC R F 0.18 (30:70 ethyl acetate-hexane) . 1 H NMR (300 MHz, CDCl,): δ 8.94 (IH, s) , 7.69 (IH, d, J = 8.4 Hz), 7.09 (IH, d, J = 1 Hz) , 6.96 (IH, dd, J = 8.4, 1 Hz), 4.60-4.50 (IH, m) , 3.87 (3H, s) , 2.97 (2H, q, J = 7.3 Hz), 2.49-2.33 (IH, m) , 2.09-1.97 (IH, m) , 1.74 (3H, d, J = 7.0 Hz), 1.41 (3H, t, J = 7.5 Hz), 1.40- 1.22 (IH, m) , 1.21-1.09 (IH, m) , 0.92 (3H, t, J = 7.1 Hz). MS (NH,-CI) : m/e calc'd for 359.1639, found 359.1623; 362 (7), 361 (33), 360 (23), 359 (100). Analysis calc'd for H,0: C, 62.20; H, 6.32; N, 15.27; found: C, 62.33; H, 6.36; N, 14.86. Example 835 spectral data: TLC R p O.39 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDCl,) : 58.94 (IH, s) , 7.69 (IH, d, J = 8.4 Hz) , 7.09 (IH, d, J = 2.5 Hz) , 6.95 (IH, dd, J = 8.4, 2.5 Hz), 4.53-4.47 (IH, m) , 3.87 (3H, s) , 3.01-2.92 (2H, m) , 2.48-2.35 (IH, m) , 2.11-1.99 (IH, m) , 1.74 (3H, d, J = 6.9 Hz), 1.41 (3H, t, J = 7.5 Hz), 1.38- 1.22 (3H, m) , 1.14-1.00 (IH, m) , 0.86 (3H, t, J = 7.1 Hz). MS (NH,-CI) : m/e 376 (7), 375 (33), 374 (23) , 373 (100) . Example 836 spectral data: TLC R F 0.42 (30:70 ethyl acetate-hexane) . * H NMR (300 MHz, CDCl,) : 58.94 (IH, s) , 7.79 (IH, d, J = 8.8 Hz) , 7.09 (IH, d, J = 2.5 Hz) , 6.95 (IH, dd, J = 8.8, 2.5 Hz), 4.55-4.47 (IH, m) , 3.87 (3H, s) , 3.01-2.92 (2H, m) , 2.48-2.35 (IH, m), 2.10-1.97 (IH, m) , 1.74 (3H, d, J = 7.0 Hz), 1.41 (3H, t, J = 7.5 Hz), 1.35- 1.20 (5H, ) , 1.18-1.02 {IH, m) , 0.84 (3H, t, J = 7.0 Hz). MS (NH,-CI) : /e calc'd for C ji H jj ClNO: 387.1952, found 387.1944; 391 (1), 390 (8), 389 (35), 388 (25), 387 (100). Example 837 spectral data: TLC R, 0.45 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDC1 3 ) : 58.93 (IH, s) , 7.73 (IH, d, J = 8.8 Hz), 7.09 (IH, d, J = 2.6 Hz), 6.96 (IH, dd, J = 8.8, 2.6 Hz), 4.25 (IH, br) , 3.87 (3H, s) , 2.95 (2H, q, J = 7.3 Hz), 2.41 (2H, br), 2.10-2.00 (2H, m) , 1.43 (3H, t, J = 7.3 Hz), 1.37-1.20 (3H, m) , 1.12-0.98 (IH, m) , 0.84 (3H, t, J = 7.3 Hz) , 0.82 (3H, t, J = 7.4 Hz) . MS (NHj-CI) : m/e 390 (8), 389 (34) , 388 (25), 387 (100) . Example 838 spectral data: TLC R, 0.48 (30:70 ethyl acetate-hexane) . ** H NMR (300 MHz, CDClj): 58.94 (IH, s) , 7.72 (IH, d, J = 8.5 Hz), 7.09 (IH, d, J = 2.2 Hz), 6.96 (IH, dd, J = 8.5, 2.2 Hz) , 4.36 (IH, v br) , 3.87 (3H, s), 2.94 (2H, q, J = 7.3 Hz) , 2.39 (2H, br), 2.02-1.90 (2H, m) , 1.42 (3H, t, J = 7.3 Hz), 1.39-1.21 (2H, m) , 1.18-1.03 (2H, m) , 0.90 (6H, t, J = 7.3 Hz). MS (NHj-CI) : m/e calc'd for C-Λ,C1N 4 0: 387.1952, found 387.1958; 391 (1), 390 (8), 389 (34), 388 (26), 387 (100). Example 839 spectral data: TLC R F 0.36 (30:70 ethyl acetate-hexane) . l H NMR (300 MHz, CDC1 3 ) : δ 8.93 (IH, s) , 7.73 (IH, d, J = 8.5 Hz), 7.09 (IH, d, J = 2.6 Hz), 6.96 (IH, dd, J = 8.5, 2.6 Hz), 4.19 (IH, br s) , 3.87 (3H, s) , 2.96 (2H, q, J = 7.5 Hz), 2.52- 2.38 (2H, m) , 2.13-1.99 (2H, m) , 1.43 (3H, t, J = 7.5 Hz), 0.83 (6H, t, J = 7.3 Hz). MS (NHj-CI) : m e calc'd for C 19 H 24 C1N 4 0: 359.1639, found 359.1632; 362 (7), 361 (34), 360 (23) , 359 (100) . Example 870 spectral data: MS (NH,-CI) : m/e 423 (M+H * , 100%) . Example 900 spectral data: TLC R F 0.38 {50:50 ethyl acetate-hexane) . l H NMR (300 MHz, CDCl,) : δ 8.93 (IH, s) , 7.75 (IH, d, J = 9.2 Hz), 6.90-6.86 (2H, m) , 4.23 (2H, t, J = 7.7 Hz), 3.86 (3H, s) , 2.95 (2H, q, J = 7.7 Hz), 2.48 (3H, s) , 1.93-1.83 (2H, m) , 1.45 (3H, t, J = 7.6 Hz), 1.43-1.36 (4H, m) , 0.92 (3H, t, J = 7.0 Hz) . Example 902 spectral data: TLC R F 0.28 (5:95 ethyl acetate-dichloromethane) . λ H NMR (300 MHz, CDCI 3 ) : δ 8.94 (IH, s) , 7.63 (IH, d, J = 8.1 Hz) , 7.37 (IH, d, J = 1.0 Hz) , 7.21 (IH, dd, J = 8.1, 1.0 Hz), 4.38 (IH, br) , 2.94 (2H, q, J = 7.5 Hz), 2.41 (3H, s) , 2.40 (2H, br) , 2.00-1.90 (2H, m) , 1.42 (3H, t, J = 7.5 Hz), 1.35-1.22 (2H, m) , 1.17-1.03 (2H, m) , 0.90 (6H, t, J = 7.3 Hz). MS (NH j -CI) : m/e calc'd for C JJ H JJ CIN,: 371.2002, found 371.1993; 374 (8), 373 (34), 372 (25), 371 (100). Example 944 spectral data: MS (NH j -CI) : m/e 377 (M+H * , 100%) . Example 945 spectral data: MS (NH 3 -CI) : m/e 365 (M+H * , 100%) . Example 947 spectral data: MS (NH,-CI) : m/e 353 (M+H * , 100%) . Example 951 spectral data: MS (NHj-CI) : m/e 381 (M+H * , 100%) . Example 952 spectral data: MS (NH,-CI) : m/e 353 (M+H * , 100%) . Example 1003 spectral data: TLC R F 0.10 (30:70 ethyl acetate-hexane) . l H NMR (300 MHz, CDCl,) : δ 8.99 (IH, s) , 7.43 (IH, s) , 7.19 (2H, d, J = 8.8 Hz) , 6.86 (2H, d, J = 8.8 Hz), 6.84 (IH, s), 5.42 (2H, s) , 3.94 (3H, s) , 3.91 (3H, s) , 3.78 (3H, s) , 2.86 (2H, q, J = 7.7 Hz) , 2.45 (3H, s) , 1.35 (3H, t, J = 7.7 Hz) . MS (NHj-CI) : m/e 421 (4) , 420 (27), 419 (100). Analysis calculated for C j4 H j6 N 4 0,: C, 68.88; H, 6.26; N, 13.39; found: C, 68.53; H, 6.30; N, 12.96. Example 1012 spectral data: m.p. 147-148 °C. TLC R F 0.18 (30:70 ethyl acetate-hexane). 'H NMR (300 MHz, CDCl,): δ 8.88 (IH, s) , 7.60 (IH, s) , 6.77 (IH, s) , 4.61 (2H, t, J = 8.6 Hz), 3.44 (IH, v br) , 3.24 (2H, t, J = 8.6 Hz), 2.94 (2H, br) , 2.44 (3H, s) , 2.03 (2H, vbr), 1.45 (3H, br t, J = 6 Hz) , 0.89-0.79 (2H, m) , 0.58 (2H, br) , 0.50-0.40 (2H, m) , 0.27-0.17 (2H, m) . MS (NH,-CI) : m/e 377 (4), 376 (27), 375 (100). Analysis calc'd for C 23 Hj 6 N 4 0: C, 73.77; H, 7.01; N, 14.96; found: C, 73.69; H, 7.08; N, 14.40. Example 1023 spectral data: TLC R F 0.22 (30:70 ethyl acetate-hexane) . l H NMR (300 MHz, CDCI 3 ) : δ 9.04 (IH, s) , 7.78 (IH, d, J = 8.4 Hz) , 7.44 (IH, d, J = 1.1 Hz), 7.30 (IH, dd, J = 8.4, 1.1 Hz), 7.20 (2H, d, J = 8.5 Hz), 6.87 (2H, d, J = 8.5 Hz), 5.44 (2H, s) , v 3.79 (3H, s), 2.90 (2H, q, J = 7.5 Hz), 1.32 (3H, t, J = 7.5 Hz). MS (NH,-CI) : m/e 467 (1), 466 (8), 465 (35), 464 (27), 463 (100). Example 1027 spectral data: TLC R F 0.41 (25:75 ethyl acetate-hexane). X H NMR (300 MHz, CDClj) : δ 8.96 (IH, s) , 7.76 (IH, d, J = 8.4 Hz), 7.45-7.44 (IH, m) , 7.27 (IH, dm, J = 8 Hz), 4.61-4.51 (IH, m) , 2.98 (2H, dq, J = 7.5, 1.6 Hz), 2.48-2.35 (IH, m) , 2.10-1.98 (IH, m) , 1.75 (3H, d, J = 7.0 Hz), 1.41 (3H, t, J = 7.5 Hz), 1.35-1.22 (2H, m) , 0.93 {3H, t, J = 7.2 Hz). MS (NH,-CI) : m/e calculated for 413.1349, found 413.1344; 416 (8), 415 (35), 414 (24), 413 (100). Example 1028 spectral data: TLC R F 0.45 (25:75 ethyl acetate-hexane). ' H NMR (300 MHz, CDC1 3 ) : δ 8.96 (IH, s) , 7.77 (IH, d, J = 8.4 Hz), 7.44 (IH, m) , 7.27 (IH, dm, J = 8 Hz), 4.57-4.49 (IH, m) , 2.97 (2H, dq, J = 7.7, 1.7 Hz), 2.47-2.36 (IH, m) , 2.12-2.02 (IH, m) , 1.75 (3H, d, J = 7.0 Hz), 1.41 (3H, t, J = 7.7 Hz), 1.33-1.21 (4H, m) , 0.86 (3H, t, J = 7.3 Hz). MS (NH 3 -CI) : m/e calculated for C j ^C^N.O: 427.1509, found 427.1507; 430 (8), 429 (35), 428 (25), 427 (100). Example 1032 spectral data: TLC R F 0.44 (25:75 ethyl acetate-hexane) . "Ή NMR (300 MHz, CDCl,) : δ 8.95 (IH, s) , 7.80 (IH, d, J = 8.4 Hz), 7.45-7.44 (IH, m) , 7.30 (IH, dm, J = 8 Hz), 4.23-4.17 (IH, m) , 2.97 (2H, q, J = 7.6 Hz), 2.54-2.39 (2H, m) , 2.14-2.00 (2H, m) , 1.43 (3H, t, J = 7.6 Hz), 0.84 (6H, t, J = 7.3 Hz) . MS (NH 3 -CI) : m/e calculated for C U H J1 C1F 3 N 4 0: 413.1368, found 413.1373 ; 416 (8), 415 (34), 414 (24), 413 (100). Example 1150 spectral data: TLC R F 0.23 (30:70 ethyl acetate-hexane). H NMR (300 MHz, CDCl,) : δ 8.90 (IH, s) , 7.73 (IH, d, J = 8.8 Hz), 7.36 (IH, d, J = 2.6 Hz), 7.17 (IH, dd, J = 8.8, 2.6 Hz), 3.92 (3H, s) , 3.70-3.55 (IH, m) , 2.91 (2H, q, J = 7.4 Hz), 2.45- 2.35 (IH, m) , 2.25-2.15 (IH, m) , 2.00-1.90 (IH, ) , 1.40 (3H, t, J = 7.4 Hz), 1.40-1.30 (IH, m) , 1.20-1.10 (IH, ) , 0.91 (3H, t, J = 7.2 Hz), 0.87-0.77 (IH, m) , 0.54-0.44 (2H, m) , 0.25-0.15 (IH, m) . MS (NH 3 -CI) : m/e calc'd for C, j Hj 6 F 3 N 4 0: 419.2057, found 419.2058; 421 (3), 420 (25) , 419 (100) . Example 1153 spectral data: TLC R F 0.48 (30:70 ethyl acetate-hexane) . * Η NMR (300 MHz, CDCl,) : δ 9.00 (IH, s) , 7.89 (IH, d, J = 8.0 Hz) , 7.84 (IH, s) , 7.69 (IH, d, J = 8.0 Hz), 7.40-7.30 (5H, m) , 5.14 (IH, d, J = 10.2 Hz), 2.82 (IH, dq, J = 15.5, 7.7 Hz), 2.68 (IH, dq, J = 15.5, 7.7 Hz), 2.15 (IH, br) , 1.23 (3H, t, J = 7.7 Hz), 1.13-1.03 (IH, ra), 0.78-0.62 (2H, m) , 0.53-0.43 (IH, m) . MS (NH,-CI) : m/e calculated for C J Λ J CIF J N,: 457.1407, found 457.1389; 460 (9), 459 (35), 458 (29), 457 (100). Example 1155 spectral data: TLC R F 0.46 (25:75 ethyl acetate-hexane). 'H NMR (300 MHz, CDCl,): 58.98 (IH, s) , 7.83 (IH, d, J = 8.4 Hz), 7.46-7.27 (7H, m) , 5.13 (IH, d, J = 10.7 Hz), 2.88-2.62 (2H, m) , 2.15 (IH, br) , 1.26 (3H, t, J = 7.5 Hz), 1.12-1.02 {IH, m) , 0.78-0.62 (2H, m) , 0.54-0.44 (IH, m) . MS (NH j -CI) : m/e calculated for C j4 H jl ClF 3 N 4 0: 473.1361, found 473.1365; 476 (9), 475 (36), 474 (29), 473 (100). Example 1157 spectral data: TLC R F 0.19 (30:70 ethyl acetate-hexane). * H NMR (300 MHz, CDCI 3 ) : 58.93 (IH, s) , 7.77 (IH, d, J = 8.8 Hz), 7.40-7.30 (6H, m) , 7.19 (IH, dd, J = ' 8.8, 2.2 Hz), 5.13 (IH, d, J = 10.6 Hz), 3.92 (3H, s) , 2.79 (IH, dq, J = 15, 7.7 Hz), 2.64 (IH, dq, J = 15, 7.7 Hz), 2.12 (IH, br) , 1.21 (3H, t, J = 7.7 Hz), 1.10-1.00 (IH, m) , 0.77-0.62 (2H, m) , 0.55-0.45 (IH, m) . MS (NH 3 -CI) : m/e calc'd for C, 5 H, 4 F 3 N 4 0: 453.1902, found 453.1903; 455 (4), 454 (28), 453 (100). Example 1158 spectral data: TLC R F 0.16 (20:80 ethyl acetate-hexane) . * H NMR (300 MHz, CDCI 3 ) : 58.98 (IH, s) , 7.46-7.25 (7H, m) , 5.12 (IH, br d, J = 9 Hz), 2.85-2.62 (2H, m), 2.14 (IH, br) , 2.13 (3H, d, J = 0.7 Hz), 1.18 (3H, dq, J = 7.7, 4.1 Hz), 0.75-0.35 (4H, m) . MS (NH,-CI) : m/e calc'd for C j4 H,,Cl,N 4 : 437.1300, found 437.1294; 440 (19), 439 (67) , 438 (32), 437 (100) . Example 1161 spectral data: MS (NH j -CI) : m/e 441 (M+H * , 100%) . Example 1163 spectral data: TLC R F 0.44 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDClj) : 59.00 (IH, s) , 7.89 (IH, d, J = 8.4 Hz) , 7.84 (IH, s) , 7.69 (IH, d, J = 8.4 Hz), 7.38 (2H, d, J = 9 Hz) , 7.05 (2H, d, J = 9 Hz) , 5.08 (IH, d, J = 10.2 Hz), 2.82 (IH, dq, J = 15.5, 7.7 Hz), 2.68 (IH, dq, J = 15.5, 7.7 Hz), 2.14 (IH, m) , 1.25 (3H, t, J = 7.7 Hz), 1.10-1.01 (IH, m) , 0.74-0.62 (2H, m) , 0.51-0.41 (IH, ) . MS (NH,-CI) : m/e calculated for C, 4 H, 0 C1F 4 N 4 : 475.1313, found 475.1307; 479 (1), 478 (9), 477 (35), 476 (30), 475 (100) . Example 1222 spectral data: MS (NH,-CI) : m/e 363 {M+H * , 100%) . Example 1252 spectral data: TLC R F 0.24 (20:80 ethyl acetate-hexane) . H NMR (300 MHz, CDCI 3 ) : δ 8.72 (IH, s) , 7.87 (IH, dd, J = 8.8, 5.5 Hz) , 7.46 (IH, dd, J = 8.8, 2.5 Hz) , 7.35-7.26 (IH, m) , 7.24-7.18 (6H, m) , 7.08-7.01 (4H, m) , 4.89-4.79 (IH, m) , 4.49 (2H, d, J = 12.1 Hz), 4.37 (2H, d, J = 12.1 Hz), 4.27 (2H, t, J = 9.3 Hz), 4.01 (2H, dd, J = 9.9, 5.2 Hz), 2.98 (2H, q, J = 7.7 Hz), 1.39 (3H, t, J = 7.7 Hz). MS (NH,-CI) : m/e calc'd for C 31 H j ,F 4 N 4 0 j : 565.2227, found 565.2226; 567 (7), 566 (36), 565 (100). Example 1255 spectral data: TLC R F 0.50 (25:75 ethyl acetate-hexane) . H NMR (300 MHz, CDCI 3 ) : δ 8.96 (IH, s) , 7.80 (IH, d, J = 8.4 Hz), 7.45-7.43 (IH, m) , 7.31-7.27 (IH, dm, J = 8 Hz), 3.80-3.73 (IH, m) , 2.93 (2H, q, J = 7.3 Hz), 2.40 (IH, br) , 2.25-2.14 (IH, m), 1.95 (IH, br) , 1.42 (3H, t, J = 7.5 Hz), 1.35-1.10 (2H, ) , 0.92 (3H, t, J = 7.3 Hz), 0.91-0.80 (IH, m) , 0.53-0.44 (2H, m) , 0.24-0.14 (IH, m) . MS (NH j -CI) : m/e calculated for C J Λ J C1F,N 4 0: 439.1519, found 439.1524; 442 (8), 441 (34), 440 (26), 439 (100) . Exarcple 1256 spectral data: TLC R F 0.48 (25:75 ethyl acetate-hexane) . 'H NMR (300 MHz, CDCl,) : δ 8.95 (IH, s) , 7.79 (IH, d, J = 8.4 Hz), 7.45-7.43 (IH, m) , 7.27 (IH, dm, J = 8 Hz), 4.35-4.25 (IH, m) , 2.96 (2H, q, J = 7.4 Hz), 2.42 (2H, br) , 2.12-1.93 (2H, m) , 1.43 (3H, t, J = 7.4 Hz), 1.37-1.22 (2H, m) , 0.91 (3H, t, J = 7.2 Hz), 0.83 (3H, t, J = 7.5 Hz). MS (NH 3 -CI) : m/e calculated for C M H JJ C1F,N 4 0 :• 427.1514, found 427.1515; 430 (8), 429 (34), 428 (25), 427 (100). Example 1295 spectral data: TLC R r 0.37 (50:50 ethyl acetate-hexane) . 'H NMR (300 MHz, CDClj) : δ 8.91 (IH, s) , 7.38 (IH, s) , 6.83 (IH, s) , 4.46 (IH, , J = 7.3 Hz), 3.94 (3H, v s), 3.91 (3H, s), 2.96 (2H, q, J = 7.6 Hz), 2.49-2.39 (IH, m) , 2.43 (3H, s), 2.12-2.02 (IH, ) , 1.75 (3H, d, J = 6.5 Hz), 1.44 (3H, t, J = 7.5 Hz), 0.86 (3H, t, J = 7.5 Hz). MS ( NHj-CI) : m/e calc ' d for C, 0 H j ,N 4 O 2 : 355 .2134 , found 355.2139 ; 357 ( 3 ) , 356 ( 23 ) , 355 (100) . Example 1296 spectral data: TLC R F 0.37 (30:70 ethyl acetate-hexane). * H NMR (300 MHz, CDCl,) : δ 9.00 (IH, s) , 7.68 (IH, d, J = 8.4 Hz) , 7.57 (IH, d, J = 2.2 Hz) , 7.39 (IH, dd, J = 8.4, 2.2 Hz), 7.27 (2H, d, J = 8.4 Hz), 6.89 (2H, d, J = 8.4 Hz), 5.56 (IH, dd, J = 9.7, 7.4 Hz), 3.79 (3H, s) , 2.92-2.75 (3H, m) , 2.65-2.55 (IH, m) , 1.31 (3H, t, J = 7.5 Hz), 0.92 (3H, t, J = 6.6 Hz). MS (NH j -CI) : m/e calc'd for C 2j H,,Cl,N 4 0: 441.1249, found 441.1247; 445 (12), 444 (18), 443 (67), 442 (30), 441 (100). Example 1319 spectral data: MS (NH,-CI) : m/e 459 (M+H * , 100%) . Example 1320 spectral data: l H NMR (300 MHz, CDCL,) : δ 8.99 (s, IH) , 7.68 (d, IH, J = 8.4 Hz), 7.58 (d, IH, J = 1.9 Hz), 7.42-7.3 (m, 6H) , 6.04 (q, IH) , 2.82, (m, 2H) , 2.16 (d, 3H, J = 7.4 Hz), 1.27 (t, 3H, J = 7.3, 7.7 Hz). Example 1321 7906-5 spectral data: *H NMR (300 MHz, CDC1 3 ) : δ 9.02 (s, IH) , 7.98 (d, IH), 7.71 (d, IH), 7.57 (d, IH) , 7.42-7.26 (m, 3H) , 7.15 (m, IH) , 5.38 (d, IH) , 2.65 (m, IH) , 2.4 (m, IH) , 1.85 (m, IH) , 1.82 (s, 3H) , 0.97 (t, 3H) , 0.8 (m, 2H) , 0.6 (m, 2H) . Example 1322 spectral data: MS (NH j -CI : m/e 437 (M+H * , 100%) . Example 1323 spectral data: MS (NH,-CI : m/e 455 (M+H * , 100%) . Example 1324 spectral data: MS (ESI) : m/e 425 (M+H * ) , 381 (M +H * -C0 2 , 100%) . Example 1325 spectral data: MS (NH,-CI m/e 413 (M+H * , 100%) . Example 1326 spectral data: MS (NH j -CI m/e 427 (M+H * , 100%) . Example 1327 spectral data: MS (NH,-CI m/e 427 (M+H * , 100%) . Example 1328 spectral data: MS (NH j -CI m/e 427 (M+H * , 100%) . Example 1329 spectral data: MS (NH,-CI m/e 423 (M+H * , 100%) . Example 1330 spectral data: MS (NH j -CI m/e 418 (M+H * , 100%) . Example 1331 spectral data: MS (NH j -CI m/e 418 (M+H * , 100%) . Example 1332 spectral data: MS (NH,-CI m/e 499 (M+H * , 100%) . Example 1333 spectral data: MS (NH,-CI m/e 453 (M+H * , 100%) . Example 1334 spectral data: MS (NH,-CI m/e 423 (M+H * , 100%) . Example 1335 spectral data: MS (NH,-CI m/e 372 (M+H * , 100%) . Example 1337 spectral data: MS (NH,-CI m/e 443 (M+H * , 100%) . Example 1338 spectral data: MS (NH j -CI m/e 427 (M+H * , 100%) . Example 1339 spectral data: MS (NH,-CI m/e 379 (M+H * , 100%) . Example 1341 spectral data: MS (NH,-CI m/e 393 (M+H * , 100%) . Example 1342 spectral data: MS (NH,-CI m/e 378 (M+H * , 100%) . Example 1343 spectral data: MS (NH,-CI m/e 346 (M+H * , 100%) . Example 1344 spectral data: MS (NH,-CI m/e 363 (M+H * , 100%) . Example 1346 spectral data: MS (NH,-CI m/e 416 (M+H * , 100%) . Example 1370 spectral data: TLC R F 0.23 (30:70 ethyl acetate-hexane) . 1 H NMR (300 MHz, CDCl,) : δ 8.89 (IH, s) , 7.72 (IH, d, J = 8.4 Hz) , 7.35 (IH, d, J = 2.5 Hz), 7.17 (IH, dd, J = 8.4, 2.5 Hz), 4.27 (IH, br) , 3.91 (3H, s) , 2.93 (2H, q, J = 7.7 Hz), 2.40 (2H, br), 2.10-1.95 (2H, m) , 1.41 (3H, t, J = 7.7 Hz), 1.39-1.27 (IH, m) , 1.20-1.07 (IH, m) , 0.91 (3H, t, J = 7.3 Hz), 0.81 (3H, t, J = 7.5 Hz). MS (NH,-CI) : m/e calc'd for 407.2058, found 407.2052; 409 (3), 408 (24), 407 (100) . Example 1371 spectral data: MS (ESI): m/e 377 (M+2), 375 (M * , 100 %) . (b) Ql = 2-tetrazolyl (c) Q2 = l,2,4-triazol-2-yl TABLE 1A (A) (B) (C) Ex. R 2 X R 3 R 4 R 12 R 11 R 6 R l. R lb mp, No. °C a 1043 CH 3 CH 2 H CH 3 CH 3 CH 3 H CH 3 C 3 H 7 oil Key: (a) Where the compound is indicated as an "oil", data is provided below: Example 1043 spectral data: TLC R F 0.40 (30:70 ethyl acetate-hexane) J H NMR (300 MHz, CDC1 3 ) : d 8.91 (IH, s) , 7.43 (IH, s) , 7.10 (IH, s) , 4.60- 4.50 (IH, m) , 2.94 (2H, dq, J = 7.5, 2.0 Hz) , 2.45-2.35 (IH, m) , 2.35 (3H, s) , 2.28 (6H, s) , 2.07-1.97 (IH, m) , 1.73 (3H, d, J = 6.9 Hz) , 1.41 (3H, t, J = 7.5 Hz) , 1.40-1.27 (IH, m) , 1.20-1.07 (IH, m) , 0.92 (3H, t, J = 7.3 Hz) . MS (NH 3 -CI) : m/e calc'd for C 21 H 29 N 4 : 337.2392, found 337.2396; 339 (3), 338 (23), 337 (100) . Analysis calc'd for C 21 H 28 N 4 : C, 74.96; H, 8.40; N, 16.65; found: C, 74.28; H, 8.02; N, 16.37. TABLE IB (A) (B) (C) Ex. R 2 X R 4 R 5 R la R lb mp, No. °C a 1270 CH 3 CH 2 CF 3 0(CH 2 ) 2 - c-C 3 H 5 c-C 3 H 5 - OH 1271 CH 3 CH 2 CF 3 OCH 2 C0 2 - c-C 3 H 5 c-C 3 H 5 - C 2 H 5 1272 CH 3 CH 2 CF 3 OCH 2 CO- c-C 3 H 5 c-C 3 H 5 - N(CH 3 ) 2 1273 CH 3 CH 2 CF 3 0(CH 2 ) 2 - C-C 3 H 5 c-C 3 H 5 - NMe 3 + Cl " 1274 CH 3 CH 2 CF 3 OCH 2 CH- c-C 3 H 5 c-C 3 H 5 - (OH)C 2 H 5 1275 CH 3 CH 2 OCH 2 OCH 3 CH 3 CH 3 C 3 H 7 77-79 1276 CH 3 CH 2 OH CH 3 CH 3 C 3 H 7 - 1277 CH 3 CH 2 OC 2 H 5 CH 3 CH 3 C 3 H 7 - 1278 CH 3 CH 2 OC 3 H 7 CH 3 CH 3 C 3 H 7 - 1279 CH 3 CH 2 0(CH 2 ) 2 - CH 3 CH 3 C 3 H 7 - OH 1280 CH 3 CH 2 OCH 2 C0 2 - CH 3 CH 3 C 3 H 7 - C 2 H 5 1281 CH 3 CH 2 OCH 2 CO- CH 3 CH 3 C 3 H 7 - N(CH 3 ) 2 1282 CH 3 CH 2 0(CH 2 ) 2 - CH 3 CH 3 C 3 H 7 - NMe 3 * Cl " 1283 CH 3 CH 2 OCH 2 CH- CH, CH, C,H 7 ( OH ) C 2 H 5 TABLE IC Ex. mp, X R 4 R 5 R 11 R l a R lb ° C No . 1501 CH 2 Cl CF 3 H C 3 H 7 OCH 3 76-78 1502 CH 2 Cl CF 3 H C 2 H 5 C 2 H 4 OCH 3 oil 1503 CH 2 Cl Cl H C 2 H 5 C 2 H 4 OCH 3 - 1504 CH 2 Cl OCH 3 H C 2 H 5 C 2 H 4 OCH 3 - 1505 CH 2 CF 3 OCH 3 H C 2 H 5 C 2 H 4 OCH 3 - 1506 CH 2 Cl S0 2 CH 3 H C 2 H 5 C 2 H 4 OCH 3 - 1507 CH 2 Cl COCH 3 H C 2 H 5 C 2 H 4 OCH 3 - 1508 CH 2 CH 3 OCH 3 CH 3 C 2 H 5 C 2 H 4 OCH 3 - 1509 CH 2 Cl CH 3 F C 2 H 5 C 2 H 4 OCH 3 - 1510 CH 2 CH 3 OCH 3 F C 2 H 5 C 2 H 4 OCH 3 - 1511 CHJ CH 3 CH 3 CH 3 C 2 H 5 C 2 H 4 OCH 3 - 1512 CH 2 Cl CF 3 H c -C 3 H 5 C 2 H 4 OCH 3 - 1513 CH 2 Cl Cl H c-C 3 H 5 C 2 H 4 OCH 3 - 1514 CH 2 Cl OCH 3 H c-C 3 H 5 C 2 H 4 OCH 3 - 1515 CH 2 CF 3 OCH 3 H c-C 3 H 5 C 2 H 4 OCH 3 - 1516 CH 2 Cl S0 2 CH 3 H c-C 3 H 5 C 2 H 4 OCH 3 - 1517 CHj Cl COCH 3 H c-C 3 H 5 C 2 H 4 OCH 3 - 1518 CH 2 CH 3 OCH 3 CH 3 c-C 3 H 5 C 2 H 4 OCH 3 - 1519 CH 2 Cl CH 3 F c-C 3 H 5 C 2 H 4 OCH 3 - <Λ CΛ CΛ CΛ CΛ •Λ <Λ CΛ <Λ t — O VO * -J 5 <Λ £ l - — έ ) > t» > U> > > W U> SO 00 •-J OS CΛ J-. C*> K> -- * n π o o n n n n n o o x x X X x x x x x n « n J-! G X G X ° I-, G X o n o n o n x o n x π n π π o n n x X ^ "4 X X X X o X s * x ° X o n n n n n n n n n n o o o n O o n o n n o n X X x x x x x x x o o o o o o o P o o o o o o o o o o o o o o o o o o π n o o o o o n n π n π n n n n n n n n n π o X x x X X X X X x x x x x x x x x x x x x x x X o 1557 0 Cl COCH 3 H c -C 3 H 5 C 2 H 4 OCH 3 1558 0 CH 3 OCH 3 CH 3 c-C 3 H 5 C 2 H 4 OCH 3 1559 0 Cl CH 3 F c -C 3 H 5 C 2 H 4 OCH 3 1560 0 CH 3 OCH 3 F c-C 3 H 5 C 2 H 4 OCH 3 1561 0 CH 3 CH 3 CH 3 c-C 3 H 5 C 2 H 4 OCH 3 1562 0 Cl CF 3 H C 2 H 5 CH 2 OCH 3 oil 1563 0 Cl OCH 3 H C 2 H 5 CH 2 OCH 3 1564 0 CF 3 0CH 3 H C 2 H 5 CH 2 OCH 3 1565 0 Cl S0 2 CH 3 H C 2 H 5 CH 2 OCH 3 1566 0 Cl COCH 3 H C 2 H 5 CH 2 OCH 3 1567 0 CH 3 OCH 3 CH 3 C 2 H 5 CH 2 OCH 3 1568 0 Cl CH 3 F C 2 H 5 CH 2 OCH 3 1569 0 CH 3 OCH 3 F C 2 H 5 CH 2 OCH 3 1570 0 CH 3 CH 3 CH 3 C 2 H 5 CH 2 OCH 3 1571 0 Cl CF 3 H c -C 3 H 5 CH 2 OCH 3 1572 0 Cl Cl H c -C 3 H 5 CH 2 OCH 3 1573 0 Cl OCH 3 H c-C 3 H 5 CH 2 OCH 3 1574 0 CF 3 0CH 3 H c -C 3 H 5 CH 2 OCH 3 1575 0 Cl SOjCH 3 H c -C 3 H 5 CH 2 OCH 3 1576 0 Cl COCH 3 H c-C 3 H 5 CH 2 OCH 3 1577 0 CH 3 0CH 3 CH 3 c-C 3 H 5 CH 2 OCH 3 1578 0 Cl CH 3 F c -C 3 H 5 CH 2 OCH 3 1579 CH, OCH, c -C 3 H 5 CH 2 OCH 3 1580 O CH, CH, CH, c-C 3 H 5 CH 2 OCH 3 TABLE ID R ib R la ^/ Ex . mp , No . X R 4 R 5 R 11 R l a R lb ° C 1601 CH 2 ' CH 3 Cl H C 2 H 5 c -C 3 H 5 109 -111 1602 CH 2 Cl Cl H C 2 H 5 C 2 H 4 OCH 3 - 1603 CHj Cl OCH 3 H C 2 H 5 C 2 H 4 OCH 3 - 1604 CH 2 CF 3 OCH 3 H C 2 H 5 C 2 H 4 OCH 3 - 1605 CH 2 Cl S0 2 CH 3 H C 2 H 5 C 2 H 4 OCH 3 - 1606 CH 2 Cl COCH 3 H C 2 H 5 C 2 H 4 OCH 3 - 1607 CH 2 CH 3 OCH 3 CH 3 C 2 H 5 C 2 H 4 OCH 3 - 1608 CH 2 Cl CH 3 F C 2 H 5 C 2 H 4 OCH 3 - 1609 CH 2 CH 3 OCH 3 F C 2 H 5 C 2 H 4 OCH 3 - 1610 CH 2 CH 3 CH 3 CH 3 C 2 H 5 C 2 H 4 OCH 3 - 1611 CH 2 Cl CF 3 H c -C 3 H 5 C 2 H 4 OCH 3 - 1612 CH 2 Cl Cl H c -C 3 H 5 C 2 H 4 OCH 3 - 1613 CH 2 Cl OCH 3 H c -C 3 H 5 C 2 H 4 OCH 3 - 1614 CHj CF 3 OCH 3 H c -C 3 H 5 C 2 H 4 OCH 3 - 1615 CH 2 Cl S0 2 CH 3 H c -C 3 H 5 C 2 H 4 OCH 3 - 1616 CH 2 Cl COCH 3 H c -C 3 H 5 C 2 H 4 OCH 3 - 1617 CH 2 CH 3 OCH 3 CH 3 c -C 3 H 5 C 2 H 4 OCH 3 - 1618 CH 2 Cl CH 3 F c -C 3 H 5 C 2 H 4 OCH 3 - 1619 CH 2 CH 3 OCH 3 F c -G 3 H 5 C 2 H 4 OCH 3 - 1620 CH 2 CH 3 CH 3 CH 3 c -C 3 H 5 C 2 H 4 OCH 3 - 1621 CH 2 Cl CF 3 H C 2 H 5 CH 2 OCH 3 oil 1622 CH 2 Cl Cl H C 2 H 5 CH 2 OCH 3 - 1623 CH 2 Cl OCH 3 H C 2 H 5 CH 2 OCH 3 - 1624 CH 2 CF 3 OCH 3 H C 2 H 5 CH 2 OCH 3 - 1625 CHj Cl S0 2 CH 3 H C 2 H 5 CH 2 OCH 3 - 1626 CHJ Cl COCH 3 H C 2 H 5 CH 2 OCH 3 - 1627 CH 2 CH 3 OCH 3 CH 3 C 2 H 5 CH 2 OCH 3 - 1628 CH 2 Cl CH 3 F C 2 H 5 CH 2 OCH 3 - 1629 CH 2 CH 3 OCH 3 F C 2 H 5 CH 2 OCH 3 - 1630 CH 2 CH 3 CH 3 CH 3 C 2 H 5 CH 2 OCH 3 - 1631 CH 2 Cl CF 3 H c -C 3 H 5 CH 2 OCH 3 - 1632 CH 2 Cl Cl H c -C 3 H 5 CH 2 OCH 3 - 1633 CH 2 Cl OCH 3 H c-C 3 H 5 CH 2 OCH 3 - 1634 CH 2 CF 3 OCH 3 H c-C 3 H 5 CH 2 OCH 3 - •H 5 o H υ α, a a a a a a a X υ u X J U CJ J a a a a a a X a J u J CJ| CJ| J CJ u J J U u J CJ J I I I I I υ J CJ υ u J CJ a CJ CJ| J ui Ol J I CJ CJ| u| SH X rH H υ u S 71 X C u CJ CJ CJ CJ fa < J a r X u u a u J U U J δ CJ υ s υ s s J s m SO C~ 00 Os C § CN O i so f^ oo σ — CN CO ml so M oo Os CO CO CO co • <t j- ^ ^ t 't ' in in i ml ml ml ml ml ml o O SO SO SO VO 5 SO O θ so o © o © o s so so sol SO sol so o a s s s 1671 0 Cl Cl H c -C,H 5 CH 2 OCH 3 - 1672 0 Cl OCH 3 H C -C 3 H 5 CH 2 OCH 3 __ 1673 0 CF 3 0CH 3 H c -C 3 H 5 CH 2 OCH 3 _ 1674 0 Cl S0 2 CH 3 H c -C 3 H 5 CH 2 OCH 3 _ 1675 0 Cl COCH 3 H c -C 3 H 5 CH 2 OCH 3 _ 1676 0 CH 3 OCH 3 CH 3 c -C 3 H 5 CH 2 OCH 3 _ 1677 0 Cl CH 3 F c -C 3 H 5 CH 2 OCH 3 _ 1678 0 CH 3 OCH 3 F c -C 3 H 5 CH 2 OCH 3 _ 1679 0 CH 3 CH, CH 3 c -C 3 H 5 CH 2 OCH 3 _ The methods discussed below in the preparation of 1- benzyl-6-methyl-4- (2,4, 6-trimethylphenyl) imidazo[4, 5- c] pyridine (Example 2001, Table 2, Structure A) may be used to prepare all of the examples of Structure A contained in Table 2, with minor procedural modifications where necessary and use of reagents of the appropriate structure. The methods of Schemes 13 and 14 may be used to prepare many of the examples of Structure B and Structure C contained in Table 2, with minor procedural modifications where necessary and use of reagents of the appropriate structure. Examnle 2001 Preparation of l-benzyl-6-methyl-4- (2,4, 6- trimethylphenyl ) imidazo [4 , 5-c] yridine Part A. A solution of 4-chloro-6-methyl-3-nitropyridone (5.0 g, 26.5 mmol) in acetonitrile (93 mL) was treated with benzylamine (2.89 mL, 26.5 mmol) and diisopropylethylamine (5.54 mL, 31.8 mmol). The mixture was heated to reflux for 4 hrs., then cooled to ambient temperature and allowed to stir for 12 hrs. The mixture was partitioned between dichloromethane and water (200 mL each) , and the aqueous layer was extracted with dichloromethane (200 mL) . The extracts were washed in sequence with water (200 mL) and combined, and the resulting precipitate was collected by filtration. The filtrate was dried over sodium sulfate, refiltered and evaporated to afford a second crop of crystalline product, 4-benzylamino-6-methyl-3-nitropyridone (6.74 g total, 26.0 mmol, 98%). m.p. 246-247 °C. TLC R F 0.35 (10:90 isopropanol-ethyl acetate). H NMR (300 MHz, CDC1 3 ) : d 10.48 (IH, br s) , 9.69 (IH, br s) , 7.41-7.26 (5H, m) , 5.66 (IH, s), 4.57 (2H, d, J = 5.5 Hz), 2.26 (3H, s) . MS (NH 3 -CI): m/e 261 (10), 260 (70), 226 (100). Part B. A solution of the pyridone from Part A (6.72 g, 25.9 mmol) in phosphorus oxychloride (52 mL, 25.5 mmol) was stirred at ambient temperature for 3 d. The reaction mixture was poured into a mixture of ice (150 g) and dichloromethane (200 mL) . After the ice had melted, 100 mL more dichloromethane was added, and the pH of the mixture was adjusted to 7 with solid NaHC0 3 . The mixture was separated, and the aqueous phase was extracted with dichloromethane. The extracts were combined, dried over sodium sulfate, filtered and evaporated to afford the product (4-benzylamino-2-chloro-6-methyl-3-nitropyridine) as a bright yellow crystalline solid (6.45 g, 23.2 mmol, 90%). TLC R p 0.76 (ethyl acetate). *H NMR (300 MHz, CDC1 3 ) : d 7.43-7.26 (5H, m) , 7.04 (IH, br) , 6.47 (IH, s) , 4.48 (2H, d, J = 5.5 Hz), 2.40 (3H, s) . MS (NH 3 -CI) : m/e 281 (5), 280 (35), 279 (17), 278 (100) . Part C. A solution of the nitro compound from Part B above (6.42 g, 23.1 mmol) in methanol (162 mL) was treated with iron powder (13.61 g) and glacial acetic acid (13.6 mL) . The resulting mixture was heated to reflux for 2 h, then cooled, filtered through celite (with methanol washing) and evaporated. The residual material was taken up in dichloromethane (231 mL) and 1 N aq. HC1 (162 mL) , and adjusted to neutral pH by addition of solid NaHC0 3 . This mixture was filtered through celite and separated, and the aqueous phase was extracted with dichloromethane. The extracts were combined, dried over Na 2 S0 4 , filtered and evaporated to afford the product, 3-amino-4-benzylamino-2- chloro-6-methylpyridine, as a solid (5.59 g, 22.6 mmol, 98%). m.p. 177-178 °C. TLC R F 0.60 (ethyl acetate). X H NMR (300 MHz, CDC1 3 ): d 7.41-7.32 (5H, m) , 6.33 (IH, s) , 4.54 (IH, br) , 4.36 (2H, d, J = 5.1 Hz), 3.30 (2H, br s) , 2.35 (3H, s). MS (NH 3 -CI): m/e 251 (6), 250 (37), 249 (19), 248 (100) . Part D. A suspension of the diamine from Part C above (2.15 g, 8.68 mmol) in triethyl orthopropionate (5 mL) was treated with cone. HC1 (3 drops), and heated to reflux for 1 h, then cooled and the excess orthoester removed by vacuum distillation. The pot residue was taken up in ethyl acetate (120 mL) , which was washed with water and brine (100 mL each) . The aqueous phases were back-extracted in sequence with ethyl acetate, and the extracts were combined, dried over Na 2 S0 4 , filtered and evaporated to afford N- (4-benzylamino-2-chloro-6-methylpyridin-3- yDpropionamide O-ethyl imidate (2.62 g, 91%). TLC R F 0.40 (30:70 ethyl acetate-hexane). l E NMR (300 MHz, CDC1 3 ) : d 7.39-7.29 (5H, m) , 6.29 (IH, s) , 4.64 (IH, br t, J = 5.8 Hz), 4.37 (2H, d, J = 5.8 Hz), 4.25 (2H, br) , 2.35 (3H, s) , 2.18-2.11 (2H, m) , 1.36 (3H, t, J = 7.0 Hz), 1.06 (3H, t, J = 7.7 Hz). MS (NH- . -CI): m/e 335 (7), 334 (34), 333 (22), 332 (100) . Part E. A solution of the compound from Part D (2.62 g, 7.90 mmol) in phenyl ether (10 mL) was heated to 170 °C for 6 h, then cooled and poured into ethyl acetate (150 mL) . This was washed with water and brine (100 mL each) , then dried over Na 2 S0 4 , filtered and evaporated. The residual liquid was separated by column chromatography (hexane, then ethyl acetate) to afford the product, l-benzyl-4-chloro-2- ethyl-6-methylimidazo [4, 5-c] pyridine, as an oil (2.16 g, 96 %) . m.p. 140-141 °C. TLC R p 0.06 (30:70 ethyl acetate- hexane). X H NMR (300 MHz, CDC1 3 ) : d 7.36-7.32 (3H, m) , 7.02- 6.98 (2H, ) , 6.93 (IH, s) , 5.31 (2H, s) , 2.89 (2H, q, J = 7.3 Hz), 2.58 (3H, s) , 1.39 (3H, t, J = 7.3 Hz). MS (NH 3 - CI): m/e 289 (6), 288 (35), 287 (20), 286 (100). Part F. A solution of zinc chloride (538 mg) in tetrahydrofuran (7 mL) was treated with a tetrahydrofuran solution of 2-mesitylmagnesium bromide (3.95 mL, 1.0 M) , and stirred for 1 h. In another flask, a solution of bis (triphenylphosphine) palladium chloride (93 mg, 0.132 mmol) in tetrahydrofuran (5 mL) was treated with a hexane solution of diisobutylaluminum hydride (0.263 mL, 1.0 M) , and this solution was stirred for 20 min. The arylzinc solution was then delivered by cannula to the flask containing the palladium catalyst, which was followed by the chloride prepared in Part E. The mixture was heated to reflux for 12 h, then cooled, and poured into water (100 mL) . This was extracted with ethyl acetate (2 x 150 mL) , and the extracts were washed with brine, combined, dried over Na 2 S0 4 , filtered and evaporated. The residual material was separated by column chromatography (1:1 ethyl acetate-hexane) to afford the title product as a solid, recrystallized to purity from ether (187 mg, 29%). m.p. 177-180 °C (ether). TLC R F 0.27 (50:50 ethyl acetate-hexane). H NMR (300 MHz, CDC1 3 ) : d 7.38-7.32 (3H, m) , 7.10-7.05 (2H, m) , 6.96 (IH, s), 6.93 (2H, s) , 5.32 (2H, s) , 2.84 (2H, q, J = 7.3 Hz), 2.64 (3H, s) , 2.30 (3H, s) , 2.02 (6H, s), 1.26 (3H, t, J = 7.3 Hz). MS (NH 3 -CI) : m/e 372 (4), 371 (29), 370 (100). Analysis calc'd for C^IL^N.,: C, 81.26; H, 7.38; N, 11.37; found: C, 80.70; H, 7.26; N, 11.20. TABLE 2 Ex. No. mp, X R 4 R 5 R 11 R 6 R 1 °C • 2001 CH j Cl Cl H H c-C 4 H 7 - 2002 CH 2 Cl Cl H H C — C j Hg 111-112 2003 CH 2 Cl Cl H H c-C 6 H n oil 2004 CH j Cl Cl H H "" ~ * *-*7**13 128-130 2005 CH J Cl Cl H H c-C 8 H 15 - 2006 CH 2 Cl Cl H H 2 "CH3 ~C — CgHg oil 2007 CH 2 Cl Cl H H 3- ■ "Cri j — C~ .5HQ - 2008 CH 2 Cl Cl H H 2- OCH 3 -c-C 5 H 8 - 2009 CH j Cl Cl H H 2,5- (CH 3 )j-c-C 5 H 7 - 2010 CH 2 Cl Cl H H 2-(CH 3 ) 2 CH-5-CH 3 -c-C 6 H, - 2011 CH 2 Cl Cl H H 9- -fluorenyl oil 2012 CH 2 Cl Cl H H 1 -tetrahydronaphthyl oil 2013 CH 2 Cl Cl H H : L-indanyl oil 2014 CH j Cl Cl H H 4 -chromanyl oil 2015 CH j Cl Cl H H 2- -oxo-c-C 5 H 7 166-168 2016 CH J Cl Cl H H 5-dibenzosuberyl - 2017 CH, Cl Cl H H 5-dibenzosuberenyl - 2018 CH 2 Cl CF 3 H H c-C 4 H 7 - 2019 CH 2 Cl CF 3 H H c-C 5 H 9 146-147 2020 CH 2 Cl CF 3 H H c-C 6 H n oil 2021 CH 2 Cl CF 3 H H c-C 7 H 13 129-130 2022 CH 2 Cl CF 3 H H c-C„H 15 - 2023 CH j Cl CF 3 H H 2 — H 3 _ C- gHg 98-99 2024 CH 2 Cl CF 3 H H J -" -.H3 — C — C-gHg - 2025 CH 2 Cl CF 3 H H 2-OCH 3 -c-C 5 H 8 - 2026 CH 2 Cl CF 3 H H 2,5-(CH 3 ) 2 -c-C 5 H 7 - 2027 CH 2 Cl CF 3 H H 2-(CH 3 ) 2 CH-5-CH 3 -c-C 6 H, - 2028 CH 2 Cl CF 3 H H 9-fluorenyl - 2029 CH 2 Cl CF 3 H H 1-tetrahydronaphthyl - 2030 CH 2 Cl CF 3 H H 1-indanyl - 2031 CH 2 Cl CF 3 H H 4-chromanyl - 2032 CH 2 Cl CF 3 H H 2-0X0-C-C 5 H- - 2033 CHj Cl CF 3 H H 5-dibenzosuberyl - 2034 CH 2 Cl CF 3 H H 5-dibenzosuberenyl - 2035 CHj Cl OCH 3 H H c-C 4 H 7 - 2036 CH 2 Cl OCH 3 H H C — C-gHg - 2037 CH 2 Cl OCH 3 H H c-C 6 H n - 2038 CH 2 Cl OCH 3 H H c-C 7 H 13 - 2039 CH 2 Cl OCH 3 H H c-C 8 H 15 - 2040 CH 2 Cl OCH 3 H H t " * -ji3"~C — C-.gH.g - 2041 CH 2 Cl OCH 3 H H -J — C.H3 ~~ C * ~L.gHg - 2042 CH 2 Cl OCH 3 H H 2-OCH 3 -c-C 5 H 8 - 2043 CH 2 Cl OCH 3 H H 2,5-(CH 3 ) 2 -c-C 5 H 7 - 2044 CH 2 Cl OCH 3 H H 2-(CH 3 ) 2 CH-5-CH 3 -c-C 6 H 9 - 2045 CH 2 Cl OCH 3 H H 9-fluorenyl - 2046 CH 2 Cl OCH 3 H H 1-tetrahydronaphthyl - 2047 CH 2 Cl OCH 3 H H 1-indanyl - 2048 CH 2 Cl OCH 3 H H 4-chromanyl - 2049 CH 2 Cl OCH 3 H H 2-oxo-c-C 5 H 7 - 2050 CH 2 Cl OCH 3 H H 5 -dibenzosuberyl - 2051 CH 2 Cl OCH 3 H H 5-dibejιzosuberenyl - 2052 CHj Cl OCF 3 H H c-C 4 H 7 - 2053 CH J Cl OCF 3 H H C — 5H9 oil 2055 CH J Cl OCF 3 H H c-C 7 H 13 - 2056 CH 2 Cl OCF 3 H H c-C 8 Hi 5 - 2057 CHj Cl OCF 3 H H 2-CH 3 -c-C 5 H 8 - 2058 CH J Cl OCF 3 H H J — -H *- C — C- j flg - 2059 CH 2 Cl OCF 3 H H 2-OCH 3 -c-C 5 H 8 - 2060 CH 2 Cl OCF 3 H H 2,5-(CH 3 ) 2 -c-C 5 H 7 - 2061 CHj Cl OCF 3 H H 2-(CH 3 ) 2 CH-5-CH 3 -c-C 6 H, - 2062 CHj Cl OCF 3 H H 9-fluorenyl 2063 CHj Cl OCF 3 H H 1-tetrahydronaphthyl 2064 CH 2 Cl OCF 3 H H 1-indanyl 2065 CHj Cl OCF 3 H H 4-chromanyl 2066 CH 2 Cl OCF 3 H H 2-oxo-c-C 5 H 7 2067 CH 2 Cl OCF 3 H H 5-dibenzosuberyl 2068 CH 2 Cl OCF 3 H H 5-dibenzosuberenyl 2069 CH 2 Cl CH 3 H H c-C 4 H 7 2070 CH 2 Cl CH 3 H H C — ~gHg 2072 CH 2 Cl CH 3 H H c-C 7 H 13 2073 CH 2 Cl CH 3 H H c-C 8 H 15 2074 CH 2 Cl CH 3 H H 2-CH 3 -c-C 5 H 8 2075 CH 2 Cl CH 3 H H J -" -.H.3 — C — C-grig 2076 CH 2 Cl CH 3 H H 2-OCH 3 -c-C 5 H 8 2077 CH 2 Cl CH 3 H H 2,5-(CH 3 ) 2 -c-C 5 H 7 2078 CH 2 Cl CH 3 H H 2- (CH 3 ) 2 CH-5-CH 3 -c-C 6 H 9 2079 CHj Cl CH 3 H H 9-fluorenyl 2080 CH 2 Cl CH 3 H H 1-tetrahydronaphthyl 2081 CH 2 Cl CH 3 H H 1 - indanyl 2082 CH 2 Cl CH 3 H H 4-chromanyl 2083 CH 2 Cl CH 3 H H 2-oxo-c-C 5 H 7 2084 CH 2 Cl CH 3 H H 5-dibenzosuberyl 2085 CH 2 Cl CH 3 H H 5 -dibenzosuberenyl 2086 CH 2 CF 3 Cl H H C— C 4 H 7 2087 CH 2 CF 3 Cl H H C— C 5 H9 143-145 2088 CH 2 CF 3 Cl H H c-CgH j ! 2089 CHj CF 3 Cl H H c-C 7 H 13 2090 CH 2 CF 3 Cl H H c-C 8 H 15 2091 CH 2 CF 3 Cl H H A —_H 3 — C — ^ j H 8 2092 CH 2 CF 3 Cl H H S — C-H — C— -gH 2093 CH 2 CF 3 Cl H H 2-OCH 3 -c-C 5 H 8 2094 CH 2 CF 3 Cl H H 2,5-(CH 3 )j-c-C 5 H 7 2095 CH j CF 3 Cl H H 2- (CH 3 ) 2 CH-5-CH 3 -c-C 6 H, 2096 CH 2 CF 3 Cl H H 9-fluorenyl 2097 CH 2 CF 3 Cl H H 1-tetrahydronap thyl 2098 CH 2 CF 3 Cl H H 1 -indanyl 2099 CHj CF 3 Cl H H 4-chromanyl 2100 CH 2 CF 3 Cl H H 2-oxo-c-C 5 H 7 - 2101 CH j CF 3 Cl H H 5 -dibenzosuberyl - 2102 CH 2 CF 3 Cl H H 5 -dibenzosuberenyl - 2103 CHj CF 3 OCH 3 H H c-C 4 H 7 - 2104 CH J CF 3 OCH 3 H H c-C 5 H 9 103-106 2105 CHj CF 3 OCH 3 H H c-C 6 H u - 2106 CH J CF 3 OCH 3 H H c-C 7 H 13 - 2107 CH 2 CF 3 OCH 3 H H C-CgH 15 - 2108 CH 2 CF 3 OCH 3 H H 2. ~CH 3 "~C — C-^H - 2109 CH 2 CF 3 OCH 3 H H 3 — Cri 3 '~C — CgHg - 2110 CH 2 CF 3 OCH 3 H H 2-OCH 3 -c-C 5 H 8 - 2111 CH 2 CF 3 OCH 3 H H 2,5-(CH 3 ) 2 -c-C 5 H 7 - 2112 CH 2 CF 3 OCH 3 H H 2- (CH 3 ) 2 CH-5-CH 3 -c-C 6 H, - 2113 CHj CF 3 OCH 3 H H 9-fluorenyl - 2114 CH 2 CF 3 OCH 3 H H 1 -tetrahydronaphthyl - 2115 CH 2 CF 3 OCH 3 H H 1- indanyl - 2116 CH 2 CF 3 OCH 3 H H 4-chromanyl - 2117 CH 2 CF 3 OCH 3 H H 2-oxo-c-C 5 H 7 - 2118 CH 2 CF 3 OCH 3 H H 5 -dibenzosuberyl - 2119 CH 2 CF 3 OCH 3 H H 5 -dibenzosuberenyl - 2120 CH 2 CF 3 F H H c-C 4 H 7 - 2123 CH 2 CF 3 F H H c-C 7 H 13 119-122 2124 CH 2 CF 3 F H H c-C 8 H 15 - 2125 CH 2 CF 3 F H H 2 ~ C^'C — CgHg - 2126 CHj CF 3 F H H 3 — CH3"*"C~C 5 Hg - 2127 CH J CF 3 F H H 2-OCH 3 -c-C 5 H β - 2128 CHJ CF 3 F H H 2,5-(CH 3 ) 2 -c-C 5 H 7 - 2129 CH J CF 3 F H H 2- (CH 3 ) jCH-5-CH 3 -c-C 6 H 9 155-156 2130 CHJ CF 3 F H H 9-fluorenyl 184-185 2131 CH J CF 3 F H H 1 -tetrahydronaphthyl - 2132 CH J CF 3 F H H 1- indanyl - 2133 CH J CF 3 F H H 4-chromanyl - 2134 CH J CF 3 F H H 2-oxo-c-C 5 H 7 - 2135 CH J CF 3 F H H 5 -dibenzosuberyl - 2136 CH J CF 3 F H H 5 -dibenzosuberenyl - 2137 CH J CH 3 OCH 3 CH 3 H c-C 4 H 7 - 2138 CH 2 CH 3 OCH 3 CH 3 H c-C 5 H 9 - 2139 CH 2 CH 3 OCH 3 CH 3 H C ~C 6 H U - 2140 CH 2 CH 3 OCH 3 CH 3 H c-C 7 H 13 - 2141 CHj CH 3 OCH 3 CH 3 H c-C 8 H 15 - 2142 CH J CH 3 OCH 3 CH 3 H 2. — CH ~ c— C5H3 - 2143 CH 2 CH 3 OCH 3 CH 3 H j —— H 3 — C — ^ gHg - 2144 CH 2 CH 3 OCH 3 CH 3 H 2-OCH 3 -c-C 5 H„ - 2145 CH 2 CH 3 OCH 3 CH 3 H 2,5-(CH 3 ) 2 -c-C 5 H 7 - 2146 CH 2 CH 3 OCH 3 CH 3 H 2- (CH 3 ) 2 CH-5-CH 3 -c-C 6 H 9 - 2147 CH 2 CH 3 OCH 3 CH 3 H 9-fluorenyl - 2148 CH 2 CH 3 OCH 3 CH 3 H 1 -tetrahydronaphthyl - 2149 CHj CH 3 OCH 3 CH 3 H 1- indanyl - 2150 CH 2 CH 3 OCH 3 CH 3 H 4-chromanyl - 2151 CH 2 CH 3 OCH 3 CH 3 H 2-oxo-c-C 5 H 7 - 2152 CH 2 CH 3 OCH 3 CH 3 H 5 -dibenzosuberyl - 2153 CH 2 CH 3 OCH 3 CH 3 H 5 -dibenzosuberenyl - 2154 CHj CH 3 OCH 3 Cl H c-C 4 H 7 - 2155 CHj CH 3 OCH 3 Cl H C^-CgHo 115-116 2156 CH 2 CH 3 OCH 3 Cl H c-CgH-iπ - 2157 CH 2 CH 3 OCH 3 Cl H C-C 7 H 13 - 2158 CH 2 CH 3 OCH 3 Cl H C~CgH 15 - 2159 CH 2 CH 3 OCH 3 Cl H ~ Lπ3~ G """C ig - 2160 CH 2 CH 3 OCH 3 Cl H 3 — -.H3 — C — v_gHg - 2161 CH 2 CH 3 OCH 3 Cl H 2-OCH 3 -c-C 5 H 8 - 2162 CH 2 CH 3 OCH 3 Cl H 2,5-(CH 3 ) 2 -c-C 5 H 7 - 2163 CH 2 CH 3 OCH 3 Cl H 2- (CH 3 ) 2 CH-5-CH 3 -c-C 6 H 9 - 2164 CH 2 CH 3 OCH 3 Cl H 9-fluorenyl - 2165 CH 2 CH 3 OCH 3 Cl H 1 -tetrahydronaphthyl - 2166 CH 2 CH 3 OCH 3 Cl H 1- indanyl - 2167 CHj CH 3 OCH 3 Cl H 4-chromanyl - 2168 CH 2 CH 3 OCH 3 Cl H 2-oxo-c-C 5 H 7 - 2169 CHj CH 3 OCH 3 Cl H 5 -dibenzosuberyl - 2170 CHJ CH 3 OCH 3 Cl H 5 -dibenzosuberenyl - 2171 CH 2 CH 3 OCH 3 F H c-C 4 H 7 - 2172 CH 2 CH, OCH 3 F H C ""CgHe,) - 2173 CH 2 CH 3 OCH 3 F H c-C 6 H n - 2174 CH 2 CH 3 OCH 3 F H C — -. 7 rl j - 2175 CH 2 CH 3 OCH 3 F H C-CgH 15 - 99/01454 2176 CH j CH 3 OCH 3 F H 2 — CH 3 _ C "CgHg 2177 CH j CH 3 OCH 3 F H 3 — CH 3 ~C~ CgHg 2178 CH 2 CH 3 OCH 3 F H 2-OCH 3 -c-C 5 H 8 2179 CH 2 CH 3 OCH 3 F H 2,5-(CH 3 ) 2 -c-C 5 H 7 2180 CH 2 CH 3 OCH 3 F H 2-(CH 3 ) 2 CH-5-CH 3 -c-C 6 H 9 2181 CH 2 CH 3 OCH 3 F H 9-fluorenyl 2182 CH 2 CH 3 OCH 3 F H 1 -tetrahydronaphthyl 2183 CH 2 CH 3 OCH 3 F H 1- indanyl 2184 CH 2 CH 3 OCH 3 F H 4-chromanyl 2185 CH 2 CH 3 OCH 3 F H 2-oxo-c-C 5 H 7 2186 CH 2 CH 3 OCH 3 F H 5 -dibenzosuberyl 2187 CH 2 CH 3 OCH 3 F H 5 -dibenzosuberenyl 2188 CH 2 CH 3 CH 3 H CH 3 c-C 4 H 7 2189 CH 2 CH 3 CH 3 H CH 3 c-C 5 H 9 2190 CH 2 CH 3 CH 3 H CH 3 c-CjHn 2191 CH 2 CH 3 CH 3 H CH 3 c-C 7 H 13 2192 CH 2 CH 3 CH 3 H CH 3 c-C 8 H 15 2193 CH 2 CH 3 CH 3 H CH 3 2-CH 3 -c-C 5 H 8 2194 CH 2 CH 3 CH 3 H CH 3 3 -"C.H3 — C — L5H9 2195 CH 2 CH 3 CH 3 H CH 3 2-OCH 3 -c-C 5 H 8 2196 CH 2 CH 3 CH 3 H CH 3 2,5-(CH 3 ) 2 -c-C 5 H 7 2197 CH 2 CH 3 CH 3 H CH 3 2- (CH 3 ) 2 CH-5-CH 3 -c-C 6 H 9 2198 CH 2 CH 3 CH 3 H CH 3 9-fluorenyl 2199 CH 2 CH 3 CH 3 H CH 3 1- tetrahydronaphthyl 2200 CH 2 CH 3 CH 3 H CH 3 1- indanyl 2201 CHj CH 3 CH 3 H CH 3 4-chromanyl 2202 CHj CH 3 CH 3 H CH 3 2-oxo-c-C 5 H 7 2203 CHj CH 3 CH 3 H CH 3 5 -dibenzosuberyl 2204 CHJ CH 3 CH 3 H CH 3 5 -dibenzosuberenyl 2205 CH j Cl Cl H CH 3 c-C 4 H 7 2206 CHj Cl Cl H CH 3 C — C Hg 2207 CHj Cl Cl H CH 3 c-C 6 H xl 2208 CH j Cl Cl H CH 3 c-C 7 H 13 2209 CHj Cl Cl H CH 3 c-C 8 H 15 2210 CH j Cl Cl H CH 3 2-CH 3 -c-C 5 H 8 2211 CHj Cl Cl H CH 3 3-CH 3 -c-C 5 H 8 2212 CH 2 Cl Cl H CH 3 2-OCH 3 -c-C 5 H 8 2213 CH 2 Cl Cl H CH 3 2,5-(CH 3 ) 2 -c-C 5 H 7 2214 CH 2 Cl Cl H CH 3 2- (CH 3 ) 2 CH-5-CH 3 -c-C 6 H 9 - 2215 CH 2 Cl Cl H CH 3 9-fluorenyl - 2216 CH 2 Cl Cl H CH 3 1 -tetrahydronaphthyl oil 2217 CH, Cl Cl H CH 3 1 -indanyl - 2218 CH 2 Cl Cl H CH 3 4-chroιtιanyl - 2219 CH 2 Cl Cl H CH 3 2-oxo-c-C 5 H 7 - 2220 CHj Cl Cl H CH 3 5 -dibenzosuberyl - 2221 CH 2 Cl Cl H CH 3 5 -dibenzosuberenyl - 2222 CH 2 CH 3 OCH 3 OCH 3 H c-C 4 H 7 - 2223 CH 2 CH 3 OCH 3 OCH 3 H C —_gH 9 oil 2224 CH 2 CH 3 OCH 3 OCH 3 H c-CgH j ! - 2225 CH 2 CH 3 OCH 3 OCH 3 H c-C 7 H 13 - 2226 CH 2 CH 3 OCH 3 OCH 3 H c-C 8 H 15 - 2227 CH 2 CH 3 OCH 3 OCH 3 H 2-CH 3 -c-C 5 H 8 oil. 2228 CH 2 CH 3 OCH 3 OCH 3 H 3-CH 3 -c-C 5 H 8 - 2229 CH 2 CH 3 OCH 3 OCH 3 H 2-OCH 3 -c-C 5 H 8 - 2230 CH 2 CH 3 OCH 3 OCH 3 H 2,5-(CH 3 ) 2 -c-C 5 H 7 - 2231 CH 2 CH 3 OCH 3 OCH 3 H 2- (CH 3 ) 2 CH-5-CH 3 -c-C 6 H 9 - 2232 CH 2 CH 3 OCH 3 OCH 3 H 9-fluorenyl - 2233 CH 2 CH 3 OCH 3 OCH 3 H 1- tetrahydronaphthyl - 2234 CHj CH 3 OCH 3 OCH 3 H 1- indanyl - 2235 CH J CH 3 OCH 3 OCH 3 H 4-chromanyl - 2236 CH J CH 3 OCH 3 OCH 3 H 2-oxo-c-C 5 H 7 - 2237 CH 2 CH 3 OCHj OCH 3 H 5 -dibenzosuberyl - 2238 CH 2 CH 3 OCH 3 OCH 3 H 5 -dibenzosuberenyl - 2239 0 Cl Cl H H C —— gH 9 - 2240 0 Cl CF 3 H H C — -gHg - 2241 0 Cl OCH 3 H H C— C^H 9 - 2242 0 Cl OCF 3 H H C — ^ ςH 9 - 2243 0 Cl CH 3 H H C — C^H - 2244 0 CF 3 Cl H H C — CgH 9 - 2245 0 CF 3 OCH 3 H H C — CgH 9 - 2246 0 CH 3 OCH 3 CH 3 H C — -gH 9 - 2247 0 CH 3 OCH 3 Cl H C— ςH 9 - 2248 0 CH 3 OCH 3 F H C — «gH - 2249 0 CH 3 CH 3 H CH 3 C— ^H 9 - 2250 0 Cl Cl H CH 3 C-C 5 H 9 - Key: a) Where the compound is listed as an Oil", spectral data is as follows: Example 2003 spectral data: MS (NH 3 -CI) : m/e 374 (M+H * , 100%) . Example 2006 spectral data: TLC R F 0.20 (20:80 ethyl acetate-hexane). : H NMR (300 MHz, CDC1 3 ) : δ 8.94 (IH, s), 7.67 (IH, d, J = 8.1 Hz), 7.57 (IH, d, J = 1.8 Hz), 7.40 (IH, dd, J = 8.1, 1.8 Hz), 4.83 (IH, q, J = 8.0 Hz), 3.20-3.04 (IH, m) , 2.98 (2H, q, J = 7.3 Hz), 2.50-2.38 (IH, m) , 2.30-2.15 (2H, m) , 2.03-1.93 (2H, m) , 1.75-1.60 (IH, m) , 1.42 (3H, t, J = 7.3 Hz), 0.68 (3H, d, J = 6.9 Hz). MS (NH 3 -CI) : m/e calc'd for C 19 H 21 C1 2 N 4 : 375.1143, found 375.1149; 380 (2), 379 (12), 378 (15), 377 (66) , 376 (27) , 375 (100) . Example 2011 spectral data: MS (NH 3 -CI) : m/e 457 (M+H\ 100%). Example 2012 spectral data: TLC R F 0.38 (30:70 ethyl acetate-hexane) . X H NMR (300 MHz, CDC1 3 ) : δ 8.94 (IH, s), 7.72 (IH, d, J = 8.5 Hz), 7.58 (IH, d, J = 1.8 Hz), 7.47-7.40 (2H, m) , 7.24-7.18 (IH, m) , 6.56 (IH, d, J = 7.7 Hz), 6.18-6.10 (IH, m) , 4.82-4.76 (IH, m) , 3.15-2.30 (5H, m) , 2.10- 1.77 (3H, m) , 1.27 (3H, t, J = 7.5 Hz). MS (NH 3 -CI): m/e calc'd for C 23 H 21 C1 2 N 4 : 423.1143, found 423.1142; 427 (13), 426 (18), 425 (67), 424 (31) , 423 (100) . Example 2013 spectral data: TLC R r 0.28 (30:70 ethyl acetate-hexane). J H NMR (300 MHz, CDC1 3 ) : δ 8.91 (IH, s) , 7.68 (IH, d, J = 8.5 Hz), 7.58 (IH, d, J = 1.8 Hz), 7.46-7.38 (2H, m) , 7.22-7.15 (IH, m) , 6.91 (IH, d, J = 7.7 Hz), 6.42 (IH, br t , J = 7 Hz), 5.30-5.22 (IH, m) , 3.43-3.33 (IH, m) , 3.20-3.03 (IH, m) , 2.89-2.76 (2H, m) , 2.56-2.43 (IH, m) , 2.01-1.90 (IH, m) , 1.31 (3H, t, J = 7.5 Hz) . MS (NH 3 -CI) : m/e calc'd for C 22 H 19 C1 2 N 4 : 409.0987, found 409.0987; 413 (12), 412 (17), 411 (67), 410 (29), 409 (100) . Example 2014 spectral data: TLC R P 0.38 (30:70 ethyl acetate-hexane) . 1 H NMR (300 MHz, CDC1 3 ) : δ 8.95 (IH, s) , 7.71 (IH, d, J = 8.4 Hz), 7.59 (IH, d, J = 2.2 Hz), 7.42 (IH, dd, J = 8.4, 2.2 Hz), 7.26-7.19 (IH, m) , 6.98- 6.90 (IH, m) , 6.58 (IH, d, J = 7.7 Hz), 6.30-6.22 (IH, m) , 4.60-4.53 (IH, m) , 4.43-4.33 (IH, m) , 4.20 (IH, br) , 2.82-2.72 (IH, m) , 2.69-2.58 (IH, m) , 2.46-2.36 (IH, m) , 2.18-2.08 (IH, m) , 1.29 (3H, t, J = 7.5 Hz). MS (NH 3 -CI) : m/e calc'd for C 22 H 19 C1 2 N 4 0: 425.0936, found 425.0926; 429 (12), 428 (17), 427 (67), 426 (30), 425 (100). Example 2020 spectral data: TLC R F 0.43 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 8.98 (IH, s) , 7.81 (2H, d, J = 8.4 Hz), 7.67 (IH, dd, J = 8.0, 0.7 Hz), 4.26 (1H, m) , 3.00 (2H, q, J = 7.6 Hz), 2.75-2.66 (2H, m) , 2.06-1.90 (4H, m) , 1.50-1.36 (4H, m) , 1.40 (3H, t, J = 7.5 Hz). MS (NH 3 -CI): m/e 412 (7), 411 (34), 410 (25), 409 (100). Example 2053 spectral data: TLC R P 0.36 (25:75 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 8.96 (IH, s), 7.73 (IH, d, J = 8.4 Hz) , 7.44 (IH, d, J = 1.1 Hz), 7.28 (IH, dd, J = 8.4, 1.1 hz) , 4.79 (IH, pentet, J = 8.4 Hz), 3.01 (2H, q, J = 7.7 Hz), 2.62-2.50 (2H, m) , 2.23-2.07 (2H, m) , 1.89-1.77 (2H, m) , 1.66-1.49 (2H, m) , 1.41 (3H, t, J = 7.7 Hz). MS (NH 3 - CI): m/e calculated for C 19 H 19 C1F 3 N 4 0: 411.1205, found 411.1208; 414 (7), 413 (34), 412 (24), 411 (100). Example 2216 spectral data: TLC R P 0.13 (20:80 ethyl acetate-hexane) . * Η NMR (300 MHz, CDC1 3 ) : δ 8.94 (IH, s), 7.48-7.02 (5H, m) , 6.53 (IH, dd, J = 7.7, 1.5 Hz), 6.18-6.10 (IH, m) , 3.16-2.20 (5H, m) , 2.13 (3H, d, J = 4.8 Hz), 2.06-1.70 (3H, m) , 1.23 (3H, dt, J = 7.4, 4.4 Hz). MS (NH 3 -CI) : m/e calc'd for C 24 H 23 C1 2 N 4 : 437.1300, found 437.1299; 439 (67), 437 (100) . Example 2223 spectral data: TLC R F 0.36 (50:50 ethyl acetate-hexane). H NMR (300 MHz, CDC1 3 ) : δ 8.91 (IH, s) , 7.33 (IH, s) , 6.83 (IH, s) , 4.78 (IH, pentet, J = 8.5 Hz), 3.94 (3H, s) , 3.90 (3H, s) , 2.98 (2H, q, J = 7.6 Hz), 2.58-2.48 (2H, m) , 2.42 (3H, s) , 2.19-2.07 (2H, m) , 1.84-1.56 (4H, m) , 1.43 (3H, t, J = 7.5 Hz). MS (NH 3 -CI): m/e calc'd for C 21 H 27 N 4 0 2 : 367.2134, found 367.2120; 369 (3), 368 (24), 367 (100). Example 2227 spectral data: TLC R F 0.45 (50:50 ethyl acetate-hexane). 1 H NMR (300 MHz, CDC1 3 ) : δ 8.90 (IH, s), 7.37 (IH, s) , 6.83 (IH, s), 4.85 (IH, q, J = 8.4 Hz), 3.94 (3H, s) , 3.91 (3H, s) , 3.19-3.11 (IH, m) , 2.96 (2H, dq, J = 7.9, 1.5 Hz), 2.41 (3H, s) , 2.24-2.16 (2H, m) , 2.04-1.94 (2H, m) , 1.71-1.62 (2H, m) , 1.44 (3H, t, J = 7.4 Hz), 0.69 (3H, d, J = 6.9 Hz). MS (NH 3 -CI) : m/e calc'd for C 22 H 29 N 4 0 2 : 381.2290, found 381.2294; 383 (4) , 382 (25) , 381 (100) . The methods discussed below in the preparation of 3- benzyl-5-methyl-7- (2, 4, 6-trimethylphenyl) -imidazo [4,5- b] yridine (Example 3001, Table 3) may be used to prepare all of the examples of Structure A contained in Table 3, with minor procedural modifications where necessary and use of reagents of the appropriate structure. The methods of Schemes 13 and 14 may be used to prepare many of the examples of Structure B and Structure C contained in Table 3, with minor procedural modifications where necessary and use of reagents of the appropriate structure. Example 3QQ1 Preparation of 3-benzyl-5-methyl-7- (2,4, 6- trimethylphenyl ) imidazo [4 , 5-b] pyridine Part A. A solution of 2, 4, 6-trimethylbenzeneboronic acid in benzene (0.5 M) is treated with excess n-butanol, and the solution is heated to reflux under a Dean-Stark still head to azeotropically remove water. Solvent is removed by evaporation, and the resulting dibutyl 2,4,6- trimethylbenzeneboronate is used directly in Part B. Part B. The method of Snieckus et al. (Fu, J. M. ; Zhao, B. P.; Sharp, M. J.; Snieckus, V. Can . J. Chem. 1994, 72, 227- 236) may be employed here. Thus, a solution of 4-chloro-6- methyl-3-nitro-2-pyridone in dimethylformamide (0.1 M) is treated with the boronate from Part A (1.2 eq) , tribasic potassium phosphate (2.4 eq) , and [1,1'- bis (diphenylphosphino) -ferrocene] dichloropalladium (0.1 eq) . The mixture is stirred at ambient temperature for 30 hrs . , then poured into 4 volumes ethyl acetate . This is washed with 3 equal volumes of water, then brine. The extract is dried over Na 2 S0 4 , filtered and evaporated. Chromatographic separation affords pure 6-methyl-3-nitro-4- (2,4, 6-trimethylphenyl) -2-pyridone. Part C. The pyridone from Part B is suspended in 6 eq phosphorus oxychloride, and stirred with mild heating until the compound dissolves. The mixture is cooled, and poured over ice. After melting, the mixture is extracted twice with dichloromethane, and the extracts are combined, dried over Na 2 S0 4 , filtered and evaporated. The product, 2-chloro- 6-methyl-3-nitro-4- (2,4, 6-trimethylphenyl) yridine, is purified by either chromatography or recrystallization. Part D. The chloride from Part C is dissolved in ethanol, and treated with benzylamine (1.2 eq.). The mixture is heated to reflux until the starting material is consumed as determined by thin-layer chromatography. The mixture is evaporated, and the residual material is partitioned between water and ethyl acetate. The organic layer is separated, washed with brine, dried over Na 2 S0 4 , filtered and evaporated. The product, 2-benzylamino-6-methyl-3- nitro-4- (2, 4, 6-trimethylphenyl) yridine, is purified by either chromatography or recrystallization. Part E. The nitro compound from Part D is dissolved in 1:1 aqueous dioxane, and treated with cone. aq. ammonium hydroxide solution. To this is added solid sodium dithionite in several portions over 2 h. The mixture is allowed to stir for an additional 4 h, then partitioned between water and ethyl acetate. The organic layer is separated, washed with brine, dried over Na^O^, filtered and evaporated. The product, 3-amino-2-benzylamino-6- methyl-4- (2,4, 6-trimethylphenyl) yridine, is purified by either chromatography or recrystallization. Part F. A suspension of the diamine from Part E above in triethyl orthopropionate is treated with cone. HC1, and heated to reflux for 1 h, then cooled and the excess orthoester removed by vacuum distillation. The pot residue contains sufficiently pure N- [2-benzylamino-4- (2,4, 6- trimethylphenyl) -6-methylpyridin-3-yl] propionamide O-ethyl imidate. Part G. A solution of the compound from Part F in phenyl ether is treated with a catalytic amount of p- toluenesulfonic acid and heated to 170 °C for 6 h, then cooled. The residual liquid is separated by column chromatography (hexane, then ethyl acetate) to afford the title product. TABLE 3 (A) (B) (C) Ex. No. mp, X R 4 R 5 R 11 R 6 R 1 °c ' 3001 CH 2 Cl Cl H H C(=0)OC 2 H 5 - 3002 CH 2 Cl Cl H H C(=0)OC 3 H 7 90-91 3003 CH 2 Cl Cl H H C(=0)OC 4 H 9 57-59 3004 CH 2 Cl Cl H H C(=0)OCH(CH 3 ) 2 80-81 3005 CH 2 Cl Cl H H C(=0)OCH 2 CH(CH 3 ) 2 60-62 3006 CH 2 Cl Cl H H C(=0)N(CH 3 ) 2 - 3007 CH 2 Cl Cl H H C(=0)N(C 2 H 5 ) j 120-123 3008 CH 2 Cl Cl H H C(=0)N[CH(CH 3 ) j ] 2 147-149 3009 CH 2 Cl Cl H H C(=0) (l-morpholinyl) 158-159 3010 CHj Cl Cl H H S0 2 C 6 H 5 132-133 3011 CH J Cl Cl H H SOj(4-CH 3 -C 6 H 4 ) 154-155 3012 CH 2 Cl Cl H H S0 2 (4-OCH 3 -C 6 H 4 ) 156-158 3013 CHj Cl Cl H H S0 2 -( 2 -thienyl) 176-178 3014 CH J Cl Cl H H S0 2 CH 2 C 6 H 5 127-129 3015 CH J Cl Cl H H SO 2 C3H 100-101 3016 CHj Cl Cl H H O2C4H9 79-80 3017 CH J Cl Cl H H C(-=0)-(2-Cl-C 6 H 4 ) 110-113 3018 CH J Cl CF 3 H H C(=0)OC 2 H 5 - 3019 CH J Cl CF 3 H H C(=0)OC 3 H 7 - 3021 CH 2 Cl CF 3 H H C(=0)OCH(CH 3 ) 2 3022 CH 2 Cl CF 3 H H C(=0)OCH 2 CH(CH 3 ) 2 3023 CH 2 Cl CF 3 H H C(=0)N(CH 3 ) 2 3026 CHj Cl CF 3 H H C(=0) (l-morpholinyl) 3027 CH J Cl CF 3 H H S0 2 C 6 H 5 3028 CH J Cl CF 3 H H S0 2 (4-CH 3 -C 6 H 4 ) 3029 CH J Cl CF 3 H H S0 2 (4-OCH 3 -C 6 H 4 ) 3030 CH 2 Cl CF 3 H H S0 2 - (2 -thienyl) 3031 CH 2 Cl CF 3 H H S0 2 CH 2 C 6 H 5 3032 CH 2 Cl CF 3 H H S0 2 C 3 H 7 3033 CH 2 Cl CF 3 H H SO2C4H9 3034 CH 2 Cl CF 3 H H C(=0)-(2-Cl-C 6 H 4 ) 3035 CH 2 Cl OCH 3 H H C(=0)OC 2 H 5 3036 CH 2 Cl OCH 3 H H C(=0)OC 3 H 7 3038 CH J Cl OCH 3 H H C(=0)OCH(CH 3 ) 2 3039 CH 2 Cl OCH 3 H H C(=0)OCH 2 CH(CH 3 ) 2 3040 CH 2 Cl OCH 3 H H C(=0)N(CH 3 ) 2 3043 CH 2 Cl OCH 3 H H C(=0) (l-morpholinyl) 3044 CH 2 Cl OCH 3 H H S0 2 C 6 H 5 3045 CH 2 Cl OCH 3 H H S0 2 (4-CH 3 -C 6 H 4 ) 3046 CHj Cl OCH 3 H H S0 2 (4-OCH 3 -C 6 H 4 ) 3047 CH J Cl OCH 3 H H S0 2 -( 2 -thienyl) 3048 CH J Cl OCH 3 H H Sθ2Cri2CgH 3049 CHj Cl OCH 3 H H S0 2 C 3 H 7 3050 CH J Cl OCH 3 H H SO -4H9 3051 CH J Cl OCH 3 H H C(=0)-(2-Cl-C 6 H 4 ) 3052 CH J Cl OCF 3 H H C(=0)OC 2 H 5 3053 CH J Cl OCF 3 H H C(=0)OC 3 H 7 3054 CH J Cl OCF 3 H H C(=0)OC 4 H 9 3055 CH 2 Cl OCF 3 H H C(=0)OCH(CH 3 ) 2 3056 CH 2 Cl OCF 3 H H C(=0)OCH 2 CH(CH 3 ) 2 3057 CH 2 Cl OCF 3 H H C(=0)N(CH 3 ) 2 3058 CH 2 Cl OCF 3 H H C(=0)N(C 2 H 5 ) 2 3059 CH 2 Cl OCF 3 H H C(=0)N[CH(CH 3 ) 2 ] 2 3060 CH 2 Cl OCF 3 H H C(=0) (l-morpholinyl) 3061 CHj Cl OCF 3 H H S0 2 C 6 H 5 3062 CH 2 Cl OCF 3 H H S0 2 (4-CH 3 -C 6 H 4 ) 3063 CH 2 Cl OCF 3 H H S0 2 (4-OCH 3 -C 6 H 4 ) 3064 CH 2 Cl OCF 3 H H S0 2 -( 2 -thienyl) 3065 CH 2 Cl OCF 3 H H SOjCH 2 CjH 5 3066 CH 2 Cl OCF 3 H H S0 2 C 3 H 7 3067 CHj Cl OCF 3 H H S0 2 C 4 H 9 3068 CH J Cl OCF 3 H H C(=0)-(2-Cl-C 6 H 4 ) 3069 CHj Cl CH 3 H H C(=0)OCjH 5 3070 CH J Cl CH 3 H H C(=0)OC 3 H 7 3072 CH J Cl CH 3 H H C(=0)OCH(CH 3 ) 2 3073 CH 2 Cl CH 3 H H C(=0)OCH 2 CH(CH 3 ) 2 3074 CH 2 Cl CH 3 H H C(=0)N(CH 3 ) 2 3075 CH 2 Cl CH 3 H H C(=0)N(C 2 H 5 ) 2 3076 CH 2 Cl CH 3 H H C(=0)N[CH(CH 3 ) 2 ] 2 3077 CH 2 Cl CH 3 H H C(=0) (l-morpholinyl) 3078 CH 2 Cl CH 3 H H S0 2 C 6 H 5 3079 CH 2 Cl CH 3 H H S0 2 (4-CH 3 -C 6 H 4 ) 3080 CH 2 Cl CH 3 H H S0 2 (4-OCH 3 -C 6 H 4 ) 3081 CH 2 Cl CH 3 H H S0 2 -(2-thienyl) 3082 CH 2 Cl CH 3 H H S0 2 CH 2 C 6 H 5 3083 CHj Cl CH 3 H H O2C3H 3084 CH 2 Cl CH 3 H H S0 2 C 4 H 9 3087 CHJ CF 3 Cl H H C(=0)OC 3 H 7 3088 CH J CF 3 Cl H H C(=0)OC 4 H 9 3090 CH J CF 3 Cl H H C(=0)OCH 2 CH(CH 3 ) 2 3091 CH 2 CF 3 Cl H H C(=0)N(CH 3 ) 2 3092 CH J CF 3 Cl H H C(=0)N(C 2 H 5 ) 2 3093 CH J CF 3 Cl H H C(=0)N[CH(CH 3 ) 2 ] 2 3094 CHj CF 3 Cl H H C(=0) (l-morpholinyl) 3095 CHJ CF 3 Cl H H S0 2 C 6 H 5 3096 CH 2 CF 3 Cl H H S0 2 (4-CH 3 -C 6 H 4 ) 3097 CH J CF 3 Cl H H S0 2 (4-OCH 3 -C 6 H 4 ) 3098 CH J CF 3 Cl H H S0 2 - (2 -thienyl) 3099 CH J CF 3 Cl H H S0 2 CH 2 C 6 H 5 3100 CH 2 CF 3 Cl H H S0 2 C 3 H 7 3101 CHj CF 3 Cl H H S0 2 C 4 H 9 3102 CH J CF 3 Cl H H C(=0)-(2-Cl-C 6 H 4 ) 3103 CH J CF 3 OCH 3 H H C(=0)OC 2 H 5 3104 CH J CF 3 OCH 3 H H C(=0)OC 3 H 7 3105 CH 2 CF 3 OCH 3 H H C(=0)OC 4 H 9 3107 CH, CF 3 OCH 3 H H C(=0)OCH 2 CH(CH 3 ) 2 3108 CH 2 CF 3 OCH 3 H H C(=0)N(CH 3 ) 2 3109 CH 2 CF 3 OCH 3 H H C(=0)N(C 2 H 5 ) 2 3111 CH 2 CF 3 OCH 3 H H C(=0) (l-morpholinyl) 3112 CH 2 CF 3 OCH 3 H H S0 2 C 6 H 5 3113 CH 2 CF 3 OCH 3 H H S0 2 (4-CH 3 -C 6 H 4 ) 3114 CH 2 CF 3 OCH 3 H H S0 2 (4-OCH 3 -C 6 H 4 ) 3115 CH 2 CF 3 OCH 3 H H S0 2 -(2-thienyl) 3116 CH 2 CF 3 OCH 3 H H S0 2 CH 2 C 6 H 5 3117 CH 2 CF 3 OCH 3 H H S0 2 C 3 H 7 3118 CH 2 CF 3 OCH 3 H H vJ2 * * rf ** 3120 CH J CF 3 F H H C(=0)OC 2 H 5 3123 CH J CF 3 F H H C(=0)OCH(CH 3 ) 2 3124 CH J CF 3 F H H C(=0)OCH 2 CH(CH 3 ) 2 3125 CHJ CF 3 F H H C(=0)N(CH 3 ) 2 3128 CHj CF 3 F H H C(=0) (l-morpholinyl) 3129 CH J CF 3 F H H S0 2 C 6 H 5 3130 CH J CF 3 F H H SOj(4-CH 3 -C«H 4 ) 3131 CH J CF 3 F H H S0 2 (4-OCH 3 -C 6 H 4 ) 3132 CH 2 CF 3 F H H S0 2 -(2-thienyl) 3133 CH 2 CF 3 F H H S0 2 CH 2 C 6 H 5 3134 CH 2 CF 3 F H H S0 2 C 3 H 7 3135 CH 2 CF 3 F H H SO 2 C 4 H 3136 CH 2 CF 3 F H H C(=0)-(2-Cl-C 6 H 4 ) 3137 CH 2 CH 3 OCH 3 CH 3 H C(=0)OC 2 H 5 3138 CH 2 CH 3 OCH 3 CH 3 H C(=0)OC 3 H 7 3139 CH 2 CH 3 OCH 3 CH 3 H C(=0)OC 4 H 9 3140 CH 2 CH 3 OCH 3 CH 3 H C(=0)OCH(CH 3 ) 2 3142 CH 2 CH 3 OCH 3 CH 3 H C(=0)N(CH 3 ) j 3143 CH j CH 3 OCH 3 CH 3 H C(=0)N(C 2 H 5 ) 2 3144 CH, CH 3 OCH 3 CH 3 H C(=0)N[CH(CH 3 ) 2 ] 2 3145 CH j CH 3 OCH 3 CH 3 H C(=0) (l-morpholinyl) 3146 CHJ CH 3 OCH 3 CH 3 H S0 2 C 6 H 5 3147 CH j CH 3 OCH 3 CH 3 H S0 2 (4-CH 3 -C 6 H 4 ) 3148 CH 2 CH 3 OCH 3 CH 3 H S0 2 (4-OCH 3 -C 6 H 4 ) 3149 CH, CH 3 OCH 3 CH 3 H S0 2 - (2 -thienyl) 3150 CH j CH 3 OCH 3 CH 3 H S0 2 CH 2 C 6 H 5 3151 CHJ CH 3 OCH 3 CH 3 H O2"*— 3"7 3152 CH 2 CH 3 OCH 3 CH 3 H U2 -4H9 3153 CH 2 CH 3 OCH 3 CH 3 H C(=0)-(2-Cl-C 6 H 4 ) 3154 CH j CH 3 OCH 3 Cl H C(=0)OC 2 H 5 3155 CH j CH 3 OCH 3 Cl H C(=0)OC 3 H 7 3156 CHJ CH 3 OCH 3 Cl H C(-=0)OC 4 H 9 3157 CH 2 CH 3 OCH 3 Cl H C(=0)OCH(CH 3 ) 2 3158 CH 2 CH 3 OCH 3 Cl H C(=0)OCH 2 CH(CH 3 ) 2 3159 CH 2 CH 3 OCH 3 Cl H C(=0)N(CH 3 ) 2 3160 CH 2 CH 3 OCH 3 Cl H C(=0)N(C 2 H 5 ) 2 3162 CH 2 CH 3 OCH 3 Cl H C(=0) (l-morpholinyl) 3163 CH 2 CH 3 OCH 3 Cl H S0 2 C 6 H 5 3164 CH 2 CH 3 OCH 3 Cl H S0 2 (4-CH 3 -C 6 H 4 ) 3165 CH 2 CH 3 OCH 3 Cl H S0 2 (4-OCH 3 -C 6 H 4 ) 3166 CH 2 CH 3 OCH 3 Cl H S0 2 -( 2 -thienyl) 3167 CH 2 CH 3 OCH 3 Cl H S0 2 CHCjH 5 3168 CH 2 CH 3 OCH 3 Cl H SOjC 3 H 7 3169 CH 2 CH 3 OCH 3 Cl H OjC 4 H 9 3170 CH 2 CH 3 OCH 3 Cl H C(=0)-(2-Cl-C 6 H 4 ) 3171 CH 2 CH 3 OCH 3 F H C(=0)OC 2 H 5 3172 CH 2 CH 3 OCH 3 F H C(=0)OC 3 H 7 3174 CH 2 CH 3 OCH 3 F H C(=-0)OCH(CH 3 ) 2 3175 CH j CH 3 OCH 3 F H C(=0)OCH 2 CH(CH 3 ) 2 3176 CH 2 CH 3 OCH 3 F H C(=0)N(CH 3 ) 2 3177 CH 2 CH 3 OCH 3 F H C(=0)N(C 2 H 5 ) 2 3179 CH J CH 3 OCH 3 F H C(=0) (l-morpholinyl) 3180 CH J CH 3 OCH 3 F H S0 2 C 6 H 5 3181 CH 2 CH 3 OCH 3 F H S0 2 (4-CH 3 -C 6 H 4 ) 3182 CH 2 CH 3 OCH 3 F H S0 2 (4-OCH 3 -C 6 H 4 ) 3183 CH 2 CH 3 OCH 3 F H S0 2 -(2-thienyl) 3184 CH 2 CH 3 OCH 3 F H S0 2 CHjC 6 H 5 3185 CH 2 CH 3 OCH 3 F H S0 2 C 3 H 7 3186 CH 2 CH 3 OCH 3 F H Sθ *-- 4 H 3188 CH J CH 3 CH 3 H CH 3 C(=0)OC 2 H 5 3189 CH 2 CH 3 CH 3 H CH 3 C(=0)OC 3 H 7 3190 CH 2 CH 3 CH 3 H CH 3 C(=0)OC 4 H 9 3191 CH 2 CH 3 CH 3 H CH 3 C(=0)OCH(CH 3 ) 2 3193 CH 2 CH 3 CH 3 H CH 3 C(=0)N(CH 3 ) 2 3194 CH 2 CH 3 CH 3 H CH 3 C(=0)N(C 2 H 5 ) 2 3195 CH 2 CH 3 CH 3 H CH 3 C(:-0)N[CH(CH 3 ) 2 ] 2 3196 CH 2 CH 3 CH 3 H CH 3 C(=0) (l-morpholinyl) 3197 CHj CH 3 CH 3 H CH 3 S0 2 C 6 H 5 3198 CHJ CH 3 CH 3 H CH 3 S0 2 (4-CH 3 -C 6 H 4 ) 3199 CH J CH 3 CH 3 H CH 3 S0 2 (4-OCH 3 -C 6 H 4 ) 3200 CHJ CH 3 CH 3 H CH 3 S0 2 -(2-thienyl) 3201 CH J CH 3 CH 3 H CH 3 S0 2 CHjC 6 H 5 3202 CHJ CH 3 CH 3 H CH 3 S0 2 C 3 H 7 3203 CH J CH 3 CH 3 H CH 3 SO 2 - H 9 3204 CH J CH 3 CH 3 H CH 3 C(=0)-(2-Cl-C 6 H 4 ) 3205 CH J Cl Cl H CH 3 C(=0)OC 2 H 5 3206 CH J Cl Cl H CH 3 C(=0)OC 3 H 7 3207 CH J Cl Cl H CH 3 C(=0)OC 4 H 9 3208 CH 2 Cl Cl H CH 3 C(=0)OCH(CH 3 ) 2 3210 CH 2 Cl Cl H CH 3 C(=0)N(CH 3 ) 2 3211 CH 2 Cl Cl H CH 3 C(=0)N(C 2 H 5 ) 2 3212 CH 2 Cl Cl H CH 3 C(=0)N[CH(CH 3 ) 2 ] 2 3213 CH 2 Cl Cl H CH 3 C(=0) (l-morpholinyl) 3214 CH 2 Cl Cl H CH 3 S0 2 C 6 H 5 3215 CH 2 Cl Cl H CH 3 S0 2 (4-CH 3 -C 6 H 4 ) 3216 CH 2 Cl Cl H CH 3 S0 2 (4-OCH 3 -C 6 H 4 ) 3217 CH 2 Cl Cl H CH 3 S0 2 -( 2 -thienyl) 3218 CH 2 Cl Cl H CH 3 S0 2 CH 2 C 6 H 5 3219 CH 2 Cl Cl H CH 3 SO 2 C H 7 3220 CH 2 Cl Cl H CH 3 S0 2 C 4 H 9 3221 CH 2 Cl Cl H CH 3 C(=0)-(2-Cl-C 6 H 4 ) 3222 CH 2 CH 3 OCH 3 OCH 3 H C(=0)OC 2 H 5 3223 CH 2 CH 3 OCH 3 OCH 3 H C(=0)OC 3 H 7 3224 CH 2 CH 3 OCH 3 OCH 3 H C(=0)OC 4 H 9 3225 CH 2 CH 3 OCH 3 OCH 3 H C(=0)OCH(CH 3 ) 2 3226 CH 2 CH 3 OCH 3 OCH 3 H C(=0)OCH 2 CH(CH 3 ) 2 3227 CH 2 CH 3 OCH 3 OCH 3 H C(=0)N(CH 3 ) 2 3228 CH 2 CH 3 ' OCH 3 OCH 3 H C(=0)N(C 2 H 5 ) 2 3229 CH 2 CH 3 OCH 3 OCH 3 H C(=0)N[CH(CH 3 ) 2 ] 2 3230 CH 2 CH 3 OCH 3 OCH 3 H C(=0) (l-morpholinyl) 3231 CH 2 CH 3 OCH 3 OCH 3 H S0 2 C 6 H 5 3232 CH 2 CH 3 OCH 3 OCH 3 H S0 2 (4-CH 3 -C 6 H 4 ) 3233 CH 2 CH 3 OCH 3 OCH 3 H S0 2 (4-OCH 3 -C 6 H 4 ) 3234 CH 2 CH 3 OCH 3 OCH 3 H S0 2 -( 2 -thienyl) 3235 CH 2 CH 3 OCH 3 OCH 3 H S0 2 CH 2 C 6 H 5 3236 CH 2 CH 3 OCH 3 OCH 3 H S0 2 C 3 H 7 3237 CHj CH 3 OCH 3 OCH 3 H S0 2 C 4 H 9 3238 CHJ CH 3 OCH 3 OCH 3 H C(=0)-(2-Cl-C 6 H 4 ) 3239 0 Cl Cl H H SO 2 C 3 H 3240 0 Cl CF 3 H H S0 2 C 3 H 7 3241 0 Cl OCH 3 H H SO C H 3242 0 Cl OCF 3 H H S0 2 C 3 H 7 3243 0 Cl CH 3 H H S0 2 C 3 H 7 3244 0 CF 3 Cl H H S0 2 C 3 H 7 3245 0 CF 3 OCH 3 H H S0 2 C 3 H 7 3246 0 CH 3 OCH 3 CH 3 H SOjC 3 H 7 3247 0 CH 3 OCH 3 Cl H S0 2 C 3 H 7 3248 0 CH 3 OCH 3 F H S0 2 C 3 H 7 - 3249 0 CH 3 CH 3 H CH 3 S0 2 C 3 H 7 - 3250 0 Cl Cl H CH 3 S0 2 C 3 H 7 - 3251 CH 2 Cl Cl H H C ( = =0) - ( 3 -Cl -C 6 H 4 ) 115-118 The methods used in the preparation of the compounds of Structure A of Table 1 may be used for the compounds of Structure A of Table 4. For example, replacing variously- substituted pyridine- and pyrimidineboronic acids for benzeneboronic acids in the palladium-catalyzed aryl cross- coupling method (see Examples 35 or 831) will afford the desired 6-pyridyl- or 6-pyrimidylpurine compounds. The methods of Schemes 13 and 14 may be used to prepare many of the examples of Structure B and Structure C contained in Table 4, with minor procedural modifications where necessary and use of reagents of the appropriate structure. TABLE 4 (A) ;B) (c; . No . X R 4 Z R 5 Y R 6 R l. p.ib m.p. , °C a 4001 CH 2 CH 3 CH N(CH 3 ) 2 N H c-C 3 H 5 c-C 3 H 5 4002 CH 2 CH 3 CH N(CH 3 ) 2 N H CH 3 c-C 3 H 5 4003 CH 2 CH 3 CH N(CH 3 ) 2 N H C 2 H 5 c-C 3 H 5 4004 CH 2 CH 3 CH N(CH 3 ) 2 N H C 3 H 7 c-C 3 H 5 4005 CH 2 CH 3 CH N(CH 3 ) 2 N H C 4 H 9 c-C 3 H 5 4006 CH 2 CH 3 CH N(CH 3 ) 2 N H CH 3 C 3 H 7 4007 CH 2 CH 3 CH N(CH 3 ) 2 N H C 2 H 5 C 3 H 7 4008 CH 2 CH 3 CH N(CH 3 ) 2 N H C 3 H 7 C 3 H 7 4009 CH 2 CH 3 CH N(CH 3 ) 2 N H C 2 H 5 C 4 H 9 4010 CHj CH 3 CH N(CH 3 ) 2 N H H 4-CH 3 0-C 6 H 4 4011 0 CH 3 CH N(CH 3 ) 2 N H c-C 3 H 5 C-C 3 H 5 4012 0 CH 3 CH N(CH 3 ) 2 N H CH 3 c-C 3 H 5 4013 0 CH 3 CH N(CH 3 ) 2 N H C 2 H 5 c-C 3 H 5 4014 0 CH 3 CH N(CH 3 ) 2 N H C 3 H 7 c-C 3 H 5 4015 0 CH 3 CH N(CH 3 ) 2 N H C 4 H 9 C-C 3 H 5 4016 0 CH 3 CH N(CH 3 ) 2 N H CH 3 C 3 H 7 4017 0 CH 3 CH N(CH 3 ) 2 N H C 2 H 5 C 3 H 7 4018 0 CH 3 CH N(CH 3 ) 2 N H C 3 H 7 C 3 H 7 4019 0 CH 3 CH N(CH 3 ) 2 N H C 2 H 5 C 4 H 9 4020 0 CH 3 CH N(CH 3 ) 2 N H H 4-CH 3 0-C 6 H 4 - 4021 CHj CH 3 CH CH 3 N CH 3 c-C 3 H 5 c-C 3 H 5 4022 CH 2 CH 3 CH CH 3 N CH 3 CH 3 c-C 3 H 5 4023 CHj CH 3 CH CH 3 N CH 3 C 2 H 5 c-C 3 H 5 4024 CH J CH 3 CH CH 3 N CH 3 C 3 H 7 c-C 3 H 5 4025 CH 2 CH 3 CH CH 3 N CH 3 C 4 H 9 c -C 3 H 5 4026 CH 2 CH 3 CH CH 3 N CH 3 CH 3 C 3 H 7 4027 CH 2 CH 3 CH CH 3 N CH 3 C 2 H 5 C 3 H 7 4028 CH 2 CH 3 CH CH 3 N CH 3 C 3 H 7 C 3 H 7 4029 CHj CH 3 CH CH 3 N CH 3 C 2 H 5 C 4 H 9 4030 CH J CH 3 CH CH 3 N CH 3 H 4 -CH 3 0-C 6 H 4 4031 0 CH 3 CH CH 3 N CH 3 c-C 3 H 5 c-C 3 H 5 4032 0 CH 3 CH CH 3 N CH 3 CH 3 c-C 3 H 5 4033 0 CH 3 CH CH 3 N CH 3 C 2 H 5 c-C 3 H 5 4034 0 CH 3 CH CH 3 N CH 3 C 3 H 7 c-C 3 H 5 4035 0 CH 3 CH CH 3 N CH 3 C 4 H 9 c-C 3 H 5 4036 0 CH 3 CH CH 3 N CH 3 CH 3 C 3 H 7 4037 0 CH 3 CH CH 3 N CH 3 C 2 H 5 C 3 H 7 4038 0 CH 3 CH CH 3 N CH 3 C 3 H 7 C 3 H 7 4039 0 CH 3 CH CH 3 N CH 3 C 2 H 5 C 4 H 9 4040 0 CH 3 CH CH 3 N CH 3 H 4 -CH 3 0-C 6 H 4 4041 CHj CH 3 CH SCH 3 N H c -C 3 H 5 c-C 3 H 5 4042 CH J CH 3 CH SCH 3 N H CH 3 c-C 3 H 5 4043 CH J CH 3 CH SCH 3 N H C 2 H 5 c-C 3 H 5 4044 CH J CH 3 CH SCH 3 N H C 3 H 7 c-C 3 H 5 4045 CH 2 CH 3 CH SCH 3 N H C 4 H 9 c-C 3 H 5 4046 CH 2 CH 3 CH SCH 3 N H CH 3 C 3 H 7 4047 CH 2 CH 3 CH SCH 3 N H C 2 H 5 C 3 H 7 4048 CHj CH 3 CH SCH 3 N H C 3 H 7 C 3 H 7 4049 CH J CH 3 CH SCH 3 N H C 2 H 5 C H 9 4050 CH J CH 3 CH SCH 3 N H H 4 -CH 3 0-C 6 H 4 4051 0 CH 3 CH SCH 3 N H c-C 3 H 5 c-C 3 H 5 4052 0 CH 3 CH SCH 3 N H CH 3 c-C 3 H 5 4053 0 CH 3 CH SCH 3 N H C 2 H 5 c-C 3 H 5 4054 0 CH 3 CH SCH 3 N H C 3 H 7 c-C 3 H 5 4055 0 CH 3 CH SCH 3 N H C H 9 c-C 3 H 5 4056 0 CH 3 CH SCH 3 N H CH 3 C 3 H 7 4057 0 CH 3 CH SCH 3 N H C 2 H 5 C 3 H 7 4058 0 CH 3 CH SCH 3 N H C 3 H 7 C 3 H 7 4059 0 CH 3 CH SCH 3 N H C 2 H 5 C H 9 4060 0 CH 3 CH SCH 3 N H H 4 -CH 3 0-C 6 H 4 u> ιb -> -. n o o o o o o o o o o o o o o o o o o co co co co oo co -J σs LΠ t o σs *- t o σi Ω Ω Ω Ω Ω Ω Ω Ω O O O O O O O O X X X X X X X X X X o o O o O o O O Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω cn co cn X X X X X X X X X X X X X X X X X X Ω n Ω Ω Ω Ω Ω n X X X X X X X X 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω X X X X X X X X X X X X X X X X X X X X u X* X a X X 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 cn c a Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω c cn cn cn X X X X X X X X X X X X X X X X X Ω Ω Ω Ω Ω Ω X X X X X a Ω Ω X X p n. o n Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω p Ω Ω Ω Ω Ω Ω p Ω Ω X X X X X X <P X X X X X X x X p X X X " X a X X X X X X X I I I I 4099 0 CH 3 N CH 3 N CH 3 C 2 H 5 C 4 H 9 4100 0 CH 3 N CH 3 N CH 3 H 4-CH 3 0-C 6 H 4 4101 CH 2 CH 3 CH CH 3 N H c-C 3 H 5 c-C 3 H 5 4102 CHj CH 3 CH CH 3 N H CH 3 c-C 3 H 5 4103 CHj CH 3 CH CH 3 N H C 2 H 5 c-C 3 H 5 4104 CH 2 CH 3 CH CH 3 N H C 3 H 7 c-C 3 H 5 4105 CH 2 CH 3 CH CH 3 N H C 4 H 9 c-CjHj 4106 CH 2 CH 3 CH CH 3 N H CH 3 C 3 H 7 4107 CH 2 CH 3 CH CH 3 N H C 2 H 5 C 3 H 7 4108 CH 2 CH 3 CH CH 3 N H C 3 H 7 C 3 H 7 4109 CH 2 CH 3 CH CH 3 N H C 2 H 5 C4H5 4110 CH 2 CH 3 CH CH 3 N H H 4-CH 3 0-C 6 H 4 4111 0 CH 3 CH CH 3 N H c-C 3 H 5 c-C 3 H 5 4112 0 CH 3 CH CH 3 N H CH 3 c-C 3 H 5 4113 0 CH 3 CH CH 3 N H C 2 H 5 c-C 3 H 5 4114 0 CH 3 CH CH 3 N H C 3 H 7 c-C 3 H 5 4115 0 CH 3 CH CH 3 N H C 4 H 9 c-C 3 H 5 4116 0 CH 3 CH CH 3 N H CH 3 C 3 H 7 4117 0 CH 3 CH CH 3 N H C 2 H 5 C 3 H 7 4118 0 CH 3 CH CH 3 N H C 3 H 7 C 3 H 7 4119 0 CH 3 CH CH 3 N H C 2 H 5 C 4 H 9 4120 0 CH 3 CH CH 3 N H H 4-CH 3 0-C 6 H 4 4121 CH 2 CH 3 N N(CH 3 ) 2 CH H c-C 3 H 5 c-C 3 H 5 4122 CH 2 CH 3 N N(CH 3 ) 2 CH H CH 3 c-C 3 H 5 4123 CH 2 CH 3 N N(CH 3 ) j CH H C 2 H 5 c-C 3 H 5 4124 CH 2 CH 3 N N(CH 3 ) 2 CH H C 3 H 7 c-C 3 H 5 4125 CHj CH 3 N N(CH 3 ) 2 CH H C 4 H 9 c-C 3 H 5 4126 CH J CH 3 N N(CH 3 ) 2 CH H CH 3 C 3 H 7 4127 CHJ CH 3 N N(CH 3 ) 2 CH H C 2 H 5 C 3 H 7 4128 CH J CH 3 N N(CH 3 ) 2 CH H C 3 H 7 C 3 H 7 4129 CHJ CH 3 N N(CH 3 ) 2 CH H C 2 H 5 C 4 H 9 4130 CH J CH 3 N N(CH 3 ) 2 CH H H 4-CH 3 0-C 6 H 4 4131 0 CH 3 N N(CH 3 ) 2 CH H c-C 3 H 5 c-C 3 H 5 4132 0 CH 3 N N(CH 3 ) 2 CH H CH 3 c-C 3 H 5 4133 0 CH 3 N N(CH 3 ) 2 CH H CjH 5 c-C 3 H 5 4134 0 CH 3 N N(CH 3 ) 2 CH H C 3 H 7 c-C 3 H 5 4135 0 CH 3 N N(CH 3 ) 2 CH H C H 9 c-C 3 H 5 4136 0 CH 3 N N(CH 3 ) 2 CH H CH 3 C 3 H 7 Os o f 00 OS CΛ X X a a a x a a a a a X X a a a a a X X X a a a a X X X X X X X X X X X X X X J υ u u CJ CJ CJ J CJ CJ o υ CJ u CJ u J CJ CJ CJ CJ u CJ u CJ CJ CJ J a a a a a X X X X X X a a a a a a a u a X X X X X X X X a u υ u u u u u CJ CJ υ CJ u u u J CJ CJ CJ J J CJ υ CJ J CJ CJ CJ o o o o 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 a a a a a a a a a a a a a a a a a a a a a a a a a X X X u u υ υ J CJ u CJ u υ u u υ CJ J CJ CJ CJ CJ υ CJ J CJ υ CJ J J J C o o υ o o o o o a a a a a a a a a a u CJ CJ J CJ CJ J CJ CJ CJ o O o o O o o o o o © σs o ro σs o ro r- o ro σs ro ro ro σs O σs so σs X X a a X X X X X X X X X X X X X X J X X X X X X X a a J a a a a a a a a a a u υ CJ u CJ u u J u υ CJ CJ u CJ cj J J CJ CJ J CJ CJ u CJ CJ CJ V CJ CJ u υ a a a x x x X a a a a a a a a a a a a a a a a a a a a a a a a a a a a a X X X u CJ o CJ CJ CJ CJ J CJ CJ CJ CJ u CJ CJ u CJ CJ o CJ CJ CJ u u o CJ o CJ o CJ CJ u CJ CJ J u CJ u X a a a a a a a a a a a a a a a a a a a a a X X X x X X X X CJ J u CJ u J a a a a a X a a CJ CJ CJ CJ CJ J CJ CJ J CJ CJ CJ CJ J CJ CJ CJ CJ CJ CJ CJ u u CJ CJ o o o O O O u u u CJ CJ CJ CJ o o o o o o o o o o o o 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 X X X X a a a X X X X X X X X X X X X X X X X a a a X X X X X X X X X X X X CJ J CJ CJ CJ CJ CJ J CJ CJ CJ J CJ J J J J o o o o o o o o o o o o o o o o o o o υ o o o o o o u CJ u u CJ υ CJ CJ u υ CJ CJ in σs r~ r- σs "tf O 4213 0 N(CH 3 ) 2 N OCH 3 CH H C 2 H 5 c-C 3 H 5 - 4214 0 N(CH 3 ) 2 N OCH 3 CH H C 3 H 7 c-C 3 H 5 - 4215 0 N(CH 3 ) 2 N OCH 3 CH H C 4 H 9 c-C 3 H 5 - 4216 0 N(CH 3 ) 2 N OCH 3 CH H CH 3 C 3 H 7 - 4217 0 N(CH 3 ) 2 N OCH 3 CH H C 2 H 5 C 3 H 7 - 4218 0 N(CH 3 ) 2 N OCH 3 CH H C 3 H 7 C 3 H 7 - 4219 0 N(CH 3 ) 2 N OCH 3 CH H C 2 H 5 C 4 H 9 - 4220 0 N(CH 3 ) 2 N OCH 3 CH H H 4-CH 3 0-C 6 H 4 - 4221 CH j OCH 3 N OCH 3 CH H C j H 5 2 - furanyl - 4222 CHj OCH 3 N OCH 3 CH H C 3 H 7 2 -furanyl - 4223 CH 2 OCH 3 N OCH 3 CH H C 2 H 5 b - 4224 CH j OCH 3 N OCH 3 CH H C 3 H 7 b - 4225 CH 2 OCH 3 N OCH 3 CH H C 6 H 5 b - 4226 CH 2 OCH 3 N OCH 3 CH H c-C 3 H 5 b - 4227 CH 2 OCH 3 N OCH 3 CH H CH 3 CH=CHCH 3 - 4228 CH 2 OCH 3 N OCH 3 CH H C 3 H 7 CH=CH 2 - 4229 CH 2 OCH 3 N OCH 3 CH H CH 3 C 6 H 5 - 4230 CH 2 OCH 3 N OCH 3 CH H CH 3 c-C 4 H 7 - Key: a) Where the compound is indicated as an 'oil*, spectral data is provided below: Example 4166 elemental analysis: calc. for C α9 H 25 N 5 0 2 C 64.20, H 7.10, N 19.70; observed C 64.13, H 6.67, N 19.30. Example 4171 elemental analysis: calc. for C 20 H 23 N 5 O 3 C 62.98, H 6.09, N 18.36; observed C 62.80, H 6.10, N 18.19. b) C-C-CH 3 The methods used in the preparation of the compounds of Table 1 may be employed in the synthesis of those compounds of Structure A in Table 5 and Table 5A. The methods employed to make the analogues bearing a benzofuran group are illustrated in the following examples. The methods of Schemes 13 and 14 may be used to prepare many of the examples of Structure B and Structure C contained in Table 5 and Table 5A, with minor procedural modifications where necessary and use of reagents of the appropriate structure. Example 5001 Preparation of 9-Dicyclopropylmethyl-8-ethyl-6- (6-methyl-2, 3- dihydrobenzofuran-5-yl ) purine Part A. Sodium hydride dispersion in mineral oil (5.05 g, 50% w/w, 105 mmol) was washed with hexane and dried under vacuum. DMF (100 mL) was added, the slurry was cooled to 0 °C, and treated with a solution of zn-cresol (10 mL, 95.6 mmol) in DMF (20 mL) . The resulting mixture was allowed to stir for 1 h, _ then was treated with chloromethyl methyl ether (8.00 mL, 105 mmol) by syringe. The mixture was stirred overnight, then poured into ethyl acetate (200 mL) . This was washed with water (3 x 200 mL) and brine (100 mL) , and the aqueous phases were back-extracted in sequence with ethyl acetate. The extracts were combined, dried over magnesium sulfate, filtered and evaporated. The oily product was purified by elution through a plug of silica gel with 10:90 ethyl acetate-hexane. Evaporation then afforded the pure product, 3- (methoxymethoxy) toluene, as an oil (13.93 g, 91.5 mmol, 96%). TLC R F 0.46 (10:90 ethyl acetate-hexane). : H NMR (300 MHz, CDC1 3 ): d 7.17 (IH, t, J = 7.7 Hz), 6.86-6.81 (3H, m) , 5.17 (2H, s), 3.48 (3H, s) , 2.33 (3H, s) . MS (H 2 0-GC/MS) : m/e 153 (60), 121 (100) . Part B. A solution of 3- (methoxymethoxy) toluene (5.00 g, 32.9 mmol) and TMEDA (5.30 mL, 35.1 mmol) in THF (50 mL) was cooled to 0 °C, and treated with a hexane solution of n-butyllithium (22.0 mL, 1.6 M, 35.2 mmol). After 4 hours, the solution was cooled to -78 °C, and treated dropwise with ethylene oxide (2.00 mL, 40 mmol, condensed from a lecture bottle through a cold-finger into a graduated dropping funnel) . The mixture was allowed to stir and warm to ambient temperature overnight, then was poured into satd. aq. ammonium chloride solution (120 mL) . This was extracted with ethyl acetate (2 x 120 mL) , and the extracts were washed in sequence with brine, combined, dried over magnesium sulfate, filtered and evaporated. The residual oil was separated by column chromatography (10:90 ethyl acetate-hexane) to afford the desired product, 2- [2- (methoxymethoxy) -4-methylphenyl]ethanol, as a viscous liquid (2.25 g, 11.5 mmol, 35%), along with 2.50 g recovered starting material. The l E NMR spectrum showed regioselectivity in excess of 10:1. TLC R F 0.09 (10:90 ethyl acetate-hexane). X H NMR (300 MHz, CDC1 3 ) : d 7.06 (IH, d, J = 7.7 Hz), 6.92 (IH, br s), 6.78 (IH, br d, J = 7.7 Hz), 5.20 (2H, s) , 3.83 (2H, q, J = 6.4 Hz), 3.49 (3H, s) , 2.89 (2H, t, J = 6.6 Hz), 2.32 (3H, S), 1.61 (IH, t, J = 5.9 Hz). MS (NH 3 -DCI) : m/e 214 (76), 212 (100), 197 (9), 182 (30), 165 (38). Part C. A solution of the MOM compound from Part B (1.84 g, 9.38 mmol) was dissolved in 1:1 THF-isopropanol (20 mL) , and treated with HC1 in dioxane (2.5 mL, 4 N, 10.0 mmol). The reaction was stirred at ambient temperature overnight. Aqueous workup gave sufficiently pure product, 2- (2-hydroxy-4- methylphenyl ) ethanol . Part D. A solution of the diol from Part C (ca. 9 mmol) and triphenylphosphine (2.83 g, 10.8 mmol) in THF (20 mL) was cooled to 0 °C, and treated with diethyl azodicarboxylate (1.70 mL, 10.8 mmol) by syringe. The solution was stirred overnight, then evaporated, and the residue separated by a flash column to afford the product, 6-methyl-2,3- dihydrobenzofuran (780 mg, 5.81 mmol, 65%). TLC R j . 0.29 (2:98 ethyl acetate-hexane). : H NMR (300 MHz, CDC1 3 ) : d 7.07 (IH, d, J = 7.4 Hz), 6.66 (IH, d, J = 7.4 Hz), 6.62 (IH, s) , 4.54 (2H, t, J = 8.6 Hz), 3.16 (2H, t, J = 8.6 Hz), 2.30 (3H, s) . MS (D 2 0-GC/MS) : m/e 135 (100) . Part E. A solution of the above compound (780 mg) and N- bromosuccinimide (1.24 g, 6.97 mmol) in dichloroethane (10 mL) was heated to reflux overnight, then cooled, filtered and evaporated. Column chromatography (hexane, then 2:98 ethyl acetate-hexane) gave first 5-bromo-6-methylbenzofuran (270 mg, 1.27 mmol, 22%), then 5-bromo-6-methyl-2, 3-dihydrobenzofuran (923 mg, 4.33 mol, 75%), both as solids. For the dihydro product: TLC Rp 0.35 (2:98 ethyl acetate-hexane). H NMR (300 MHz, CDC1 3 ): d 7.31 (IH, s) , 6.68 (IH, s) , 4.56 (2H, t, J = 8.8 Hz), 3.17 (2H, t, J = 8.8 Hz), 2.33 (3H, s) . MS (H j O- GC/MS) : m/e 215 (76), 213 (100). Part F. A solution of the bromide from Part E (923 mg, 4.33 mmol) in tetrahydrofuran (20 mL) was cooled to -78 °C, and treated with a hexane solution of n-butyllithium (3.0 mL, 1.6 M, 4.8 mmol). After 1 hour, the reaction mixture was treated with triisopropylborate (1.00 mL, 4.33 mmol) and allowed to. come to ambient temperature over 6 hrs. Then, 1 mL of 6 N aq. HC1 and 3 mL water were added, and the resulting mixture was allowed to stir for 1 hr. It was poured into water (100 mL) , and extracted with ethyl acetate (2 x 100 mL) . The extracts were washed with brine (60 mL) , combined, dried over sodium sulfate, filtered and evaporated to afford a solid, which was purified by trituration with hexane to give 6-methyl-2, 3- dihydrobenzofuran-5-boronic acid (718 mg, 4.03 mmol, 93%). Part G. A mixture of the boronic acid from Part F (298 mg, 1.67 mmol), 6-chloro-9-dicyclopropylmethyl-8-ethylpurine (309 mg, 1.12 mmol), 2 N aqueous sodium carbonate solution (1.7 mL, 3.4 mmol) and triphenylphosphine (61 mg, 0.233 mmol) in DME (20 mL) was degassed by repeated cycles of brief vacuum pumping followed by nitrogen purging. To this was added palladium (II) acetate (13 mg, 0.058 mmol), and the mixture was degassed again and then heated to reflux for 14 hours. It was cooled, and poured into water (100 mL) . This mixture was extracted with ethyl acetate (2 x 100 mL) , and the extracts were washed in sequence with brine (60 mL) , combined, dried over sodium sulfate, filtered and evaporated. The residual material was separated by column chromatography (silica gel, 20:80 ethyl acetate-hexane) to afford the title product as a solid. This was recrystallized to purity from ether (253 mg, 0.77 mmol, 69%) . m.p. 147-148 °C . TLC R F 0.18 (30:70 ethyl acetate-hexane) . : H NMR (300 MHz, CDC1 3 ) : d 8.88 (IH, s), 7.60 (IH, s), 6.77 (IH, s), 4.61 (2H, t, J = 8.6 Hz), 3.44 (IH, v br) , 3.24 (2H, t, J = 8.6 Hz), 2.94 (2H, br) , 2.44 (3H, s) , 2.03 (2H, v br) , 1.45 (3H, br t, J = δ Hz), 0.89-0.79 (2H, m) , 0.58 (2H, br) , 0.50-0.40 (2H, m) , 0.27-0.17 (2H, m) . MS (NH 3 - CI): m/e 377 (4), 376 (27), 375 (100). Analysis calc'd for C 23 H 26 N 4 0: C, 73.77; H, 7.01; N, 14.96; found: C, 73.69; H, 7.08; N, 14.40. Examples 5201. 5231 and 5232 Preparation of 9-dicyclopropylmethyl-8-ethyl-6- (6- methylbenzofuran-5-yl) purine, 6- (2-bromo-6-methylbenzofuran-5- yl) -9-dicyclopropylmethyl-8-ethylpurine and 6- (7-bromo-6-. methyl-2 , 3-dihydrobenzofuran-5-yl) -9-dicyclopropylmethyl-8- ethylpurine A solution of the compound of Example 5001 (250 mg, 0.668 mmol) and N-bromosuccinimide (119 mg, 0.669 mmol) in 1,2- dichloroethane (10 mL) was heated to reflux for 12 hours, then cooled and evaporated. The resulting mixture was taken up in ether, filtered and evaporated, and the residual material was separated by flash chromatography (silica gel, 20:80 ethyl acetate-hexane) to afford, in order, the following three products : 6- (2-Bromo-6-methylbenzofuran-5-yl) -9-dicyclopropylmethyl-8- ethylpurine: m.p. 177-178 °C. TLC Rp 0.23 (20:80 ethyl acetate-hexane). l E NMR (300 MHz, CDC1 3 ) : d 8.92 (IH, s), 7.85 (IH, s), 7.42 (IH, s), 6.74 (IH, s) , 4.15 (IH, v br) , 2.97 (2H, v br) , 2.54 (3H, s), 2.00 (2H, v br) , 1.44 (3H, br t, J = 7 Hz), 0.90-0.80 (2H, m) , 0.63-0.53 (2H, m) , 0.50-0.40 (2H, m) , 0.26-0.16 (2H, m) . MS (NH 3 -CI) : m/e calc'd for C 23 H 24 BrN 4 0: 451.1133, found 451.1132; 455 (3), 454 (25), 453 (99), 452 (31), 451 (100). 9-Dicyclopropylmethyl-8-ethyl-6- (6-methylbenzofuran-5- yl) purine: m.p. 139-141 °C. TLC R F 0.16 (20:80 ethyl acetate- hexane). l E NMR (300 MHz, CDC1 3 ) : d 8.92 (IH, s) , 7.95 (IH, s), 7.60 (IH, d, J = 2.2 Hz), 7.48 (IH, d, J = 0.7 Hz), 6.78 (IH, dd, J = 2.2, 0.7 Hz), 4.40 (IH, v br) , 2.97 (2H, v br) , 2.56 (3H, s), 2.04 (2H, v br) , 1.44 (3H, br t, J = 7 Hz), 0.90-0.80 (2H, m) , 0.62-0.52 (2H, ) , 0.51-0.41 (2H, m) , 0.29-0.18 (2H, m) . MS (NH 3 -CI): m/e calc'd for C 23 H 25 N 4 0: 373.2028, found 373.2033; 375 (3), 374 (26), 373 (100). 6- (7-Bromo-6-methyl-2,3-dihydrobenzofuran-5-yl) -9- dicyclopropylmethyl-8-ethylpurine: m.p. 179-180 °C. TLC R F 0.04 (20:80 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : d 8.89 (IH, s), 7.47 (IH, s) , 4.73 (2H, t, J = 8.6 Hz), 3.80 (IH, v br) , 3.37 (2H, t, J = 8.6 Hz) , 2.95 (2H, v br) , 2.44 (3H, s), 1.44 (3H, br t, J = 7 Hz), 0.89-0.79 (2H, m) , 0.61- 0.52 (2H, ) , 0.51-0.41 (2H, m) , 0.28-0.18 (2H, m) . MS (NH 3 - CI) : m/e calc'd for C 23 H 26 BrN 4 0: 453.1290, found 453.1285; 455 (98), 453 (100). TABLE 5 Ex. R 1 m.p. No. °C 5001 CH 2 H CH 3 CH 2 CH 2 0 c-C 3 H 5 c-C 3 H 5 147-148 5002 CH 2 H CH 3 CH 2 CH 2 0 H 4-(CH 3 0)-C 6 H 4 - 5003 CH 2 H CH 3 CH 2 CHj 0 CH 3 c-C 3 H 5 - 5004 CHj H CH 3 CH 2 CH 2 0 C 2 H 5 c-C 3 H 5 - 5005 CH 2 H CH 3 CHj CH 2 0 C 3 H 7 c-C 3 H 5 - 5006 CH 2 H CH 3 CH j CHJ 0 C 4 H 9 c-C 3 H 5 - 5007 CH 2 H CH 3 CH 2 CHJ 0 C 2 H 5 C 3 H 7 - 5008 CH j H CH 3 CH 2 CHJ 0 C 2 H 5 C 4 H 9 - 5009 CH 2 H CH 3 CH j CHJ 0 C 3 H 7 C 3 H 7 - 5010 CH 2 H CH 3 CHJ CHJ 0 CH 3 C 3 H 7 - 5011 CH 2 H CH 3 0 CHJ 0 c-C 3 H 5 c-C 3 H 5 168-169 5012 CH 2 H CH 3 0 CHJ 0 H 4-(CH 3 0)-C 6 H 4 - 5013 CH 2 H CH 3 0 CHJ 0 CH 3 c-C 3 H 5 - 5014 CH 2 H CH 3 0 CHJ 0 C 2 H 5 c-C 3 H 5 - 5015 CH 2 H CH 3 0 CHJ 0 C 3 H 7 c-C 3 H 5 - 5016 CH 2 H CH 3 0 CHJ 0 C 4 H 9 c-C 3 H 5 - 5017 CH j H CH 3 0 CH 2 0 C 2 H 5 C 3 H 7 - 5018 CH 2 H CH 3 0 CH 2 0 C 2 H 5 C 4 H 9 - 5019 CH 2 H CH 3 0 CH 2 0 C 3 H 7 C 3 H 7 - 5020 CH j H CH 3 0 CH 2 0 CH 3 C 3 H 7 - 5021 CH j H CH 3 0 CH j CH 2 c-C 3 H 5 c-C 3 H 5 - 5022 CH 2 H CH 3 0 CH j CH 2 H 4-(CH 3 0)-C 6 H 4 - 5023 CH 2 H CH 3 0 CHJ CH 2 CH 3 c-C 3 H 5 - 5024 CH 2 H CH 3 0 CHJ CH 2 C H 5 c-C 3 H 5 - 5025 CH 2 H CH 3 0 CH 2 CH 2 C 3 H 7 c-C 3 H 5 - 5026 CH j H CH 3 0 CH 2 CH 2 C 4 H 9 c-C 3 H 5 - 5027 CHJ H CH 3 0 CH 2 CH 2 C 2 H 5 C 3 H 7 - 5028 CH 2 H CH 3 0 CH 2 CH 2 C 2 H 5 C 4 H 9 - 5029 CH 2 H CH 3 0 CH 2 CH 2 C 3 H 7 C 3 H 7 - 5030 CH 2 H CH 3 0 CH 2 CH 2 CH 3 C 3 H 7 - 5031 CH 2 H CH 3 CH j 0 CH j c-C 3 H 5 c-C 3 H 5 - 5032 CH j H CH 3 CH 2 0 CH 2 H 4-(CH 3 0)-C 6 H 4 - 5033 CHJ H CH 3 CH j 0 CH 2 CH 3 c-C 3 H 5 - 5034 CH 2 H CH 3 CH 2 0 CH 2 C 2 H 5 c-C 3 H 5 - 5035 CH 2 H CH 3 CH 2 0 CH 2 C 3 H 7 c-C 3 H 5 - 5036 CH 2 H CH 3 CH 2 0 CH 2 C 4 H 9 c-C 3 H 5 - 5037 CH 2 H CH 3 CH 2 0 CH 2 C 2 H 5 C 3 H 7 - 5038 CH 2 H CH 3 CH 2 0 CH 2 C 2 H 5 C 4 H 9 - 5039 CH 2 H CH 3 CH 2 0 CH j C 3 H 7 C 3 H 7 - 5040 CH 2 H CH 3 CH 2 0 CHJ CH 3 C 3 H 7 - 5041 CH 2 H Cl CH j CH 2 0 c-C 3 H 5 c-C 3 H 5 - 5042 CH 2 H Cl CHJ CH 2 0 H 4-(CH 3 0)-C 6 H 4 - 5043 CH 2 H Cl CHJ CH 2 0 CH 3 c-C 3 H 5 - 5044 CH 2 H Cl CH 2 CH 2 o C 2 H 5 5045 CH 2 H Cl CH 2 CH 2 0 C 3 H 7 5046 CHj H Cl CH 2 CH 2 0 C 4 H 9 c-C 3 H 5 5047 CH 2 H Cl CH 2 CH 2 0 C 2 H 5 C 3 H 7 5048 CHj H Cl CH 2 CH 2 0 C 2 H 5 C 4 H 9 5049 CHj H Cl CH 2 CH 2 O C 3 H 7 C 3 H 7 5050 CH J H Cl CH 2 CH 2 O CH 3 C 3 H 7 5051 CH J H Cl 0 CH 2 O c-C 3 H 5 c-C 3 H 5 5052 CH 2 H Cl 0 CH 2 O H 4-(CH 3 0)-C 6 H 4 5053 CH 2 H Cl 0 CH 2 O CH 3 c-C 3 H 5 5054 CH 2 H Cl 0 CH 2 O C 2 H 5 c-C 3 H 5 5055 CH 2 H Cl 0 CH 2 O C 3 H 7 c-C 3 H 5 5056 CH 2 H Cl 0 CH 2 O C 4 H 9 c-C 3 H 5 5057 CH 2 H Cl 0 CH 2 O C 2 H 5 C 3 H 7 5058 CH 2 H Cl 0 CH 2 O C 2 H 5 C 4 H 9 5059 CH 2 H Cl 0 CH 2 O C 3 H 7 C 3 H 7 5060 CH 2 H Cl 0 CH 2 O CH 3 C 3 H 7 5061 0 H CH 3 CH 2 CH 2 O c-C 3 H 5 c-C 3 H 5 5062 0 H CH 3 CH 2 CH 2 O H 4-(CH 3 0)-C 6 H 4 5063 0 H CH 3 CH 2 CH 2 O CH 3 c-C 3 H 5 5064 0 H CH 3 CH 2 CH 2 O C 2 H 5 c-C 3 H 5 5065 0 H CH 3 CH 2 CH 2 O C 3 H 7 c-C 3 H 5 5066 0 H CH 3 CH 2 CH 2 O C H 9 c-C 3 H 5 5067 0 H CH 3 CH 2 CH 2 O CjH 5 C 3 H 7 5068 0 H CH 3 CH 2 CH 2 O C 2 H 5 C 4 H 9 5069 0 H CH 3 CH 2 CH 2 O C 3 H 7 C 3 H 7 5070 0 H CH 3 CH 2 CHj O CH 3 C 3 H 7 5071 0 H CH 3 0 CHJ O c-C 3 H 5 c-C 3 H 5 5072 0 H CH 3 0 CH J o H 4-(CH 3 0)-C 6 H 4 5073 0 H CH 3 0 CH J o CH 3 c-C 3 H 5 5074 0 H CH 3 0 CH J 0 C 2 H 5 c-C 3 H 5 5075 0 H CH 3 0 CH J 0 C 3 H 7 c-C 3 H 5 5076 0 H CH 3 0 CH J o C 4 H 9 c-C 3 H 5 5077 0 H CH 3 0 CH 2 o C 2 H 5 C 3 H 7 5078 0 H CH 3 0 CHj 0 C 2 H 5 C 4 H 9 5079 0 H CH 3 0 CH J o C 3 H 7 C 3 H 7 5080 0 H CH 3 0 CH J o CH 3 C 3 H 7 5081 0 H Cl CH 2 CH, o c-C 3 H 5 c-C 3 H 5 5082 0 H Cl CHj CH j 0 H 4-(CH 3 0) 5084 0 H Cl CH 2 CH j O 5085 0 H Cl CH 2 CH 2 O C 3 H 7 c-C 3 H 5 5086 0 H Cl CH 2 CH 2 O C 4 H 9 c-C 3 H 5 5087 0 H Cl CH 2 CH 2 o C 2 H 5 C 3 H 7 5088 0 H Cl CH 2 CH 2 o C 2 H 5 C 4 H 9 5089 0 H Cl CH 2 CH 2 0 C 3 H 7 C 3 H 7 5090 0 H Cl CH 2 CH 2 o CH 3 C 3 H 7 5091 0 H Cl 0 CH 2 o c-C 3 H 5 c-C 3 H 5 5092 0 H Cl 0 CH 2 o H 4-(CH 3 0)-C 6 H 4 5093 0 H Cl 0 CH 2 o CH 3 c-C 3 H 5 5094 0 H Cl 0 CH 2 o C 2 H 5 c-C 3 H 5 5095 0 H Cl 0 CH 2 o C 3 H 7 c-C 3 H 5 5096 0 H Cl 0 CH j o C 4 H 9 c-C 3 H 5 5097 0 H Cl 0 CH j o C 2 H 5 C 3 H 7 5098 0 H Cl 0 CH 2 o C 2 H 5 CH 9 5099 0 H Cl 0 CH 2 o C 3 H 7 C 3 H 7 5100 0 H Cl 0 CH 2 0 CH 3 C 3 H 7 5101 CHj CH 3 CH 3 CH 2 CH 2 o c-C 3 H 5 c-C 3 H 5 5102 CH J CH 3 CH 3 CH 2 CH j 0 H 4-(CH 3 0)-C 6 H 4 5103 CH J CH 3 CH 3 CH 2 CHJ o CH 3 c-C 3 H 5 5104 CH j CH 3 CH 3 CHj CH 2 o C 2 H 5 c-C 3 H 5 5105 CH 2 CH 3 CH 3 CH J CH j o C 3 H 7 c-C 3 H 5 5106 CH 2 CH 3 CH 3 CH 2 CH 2 o CH 9 c-C 3 H 5 5107 CH 2 CH 3 CH 3 CHj CH 2 o C 2 H 5 C 3 H 7 5108 CH 2 CH 3 CH 3 CH 2 CH 2 o C 2 H 5 C 4 H 9 5109 CH j CH 3 CH 3 CH 2 CH 2 o C 3 H 7 C 3 H 7 5110 CH J CH 3 CH 3 CH 2 CH 2 o CH 3 C 3 H 7 5111 CH 2 H Cl 0 C=0 NH c-C 3 H 5 c-C 3 H 5 5112 CH 2 H Cl 0 C=0 NH H 4-(CH 3 0)-C 6 H 4 5113 CH 2 H Cl 0 C=0 NH CH 3 c-C 3 H 5 5114 CHj H Cl 0 C=0 NH C 2 H 5 c-C 3 H 5 5115 CH J H Cl 0 C=0 NH C 3 H 7 c-C 3 H 5 5116 CH J H Cl 0 C=0 NH C 4 H 9 c-C 3 H 5 5117 CH J H Cl 0 C=0 NH C 2 H 5 C 3 H 7 5118 CH J H Cl 0 C=0 NH C 2 H 5 CH 9 5119 CH J H Cl 0 C=0 NH C 3 H 7 C 3 H 7 Os ro -— ^ .! 00 Os CΛ m a a a a a a a a a a a a X 2 2 2 2 2 s M M M M a 2* M M M M M M M 2* o o o o o o o o o o o II II II II II II a a a a a a a a a a o o o o o CJ CJ II II o II o II o II o II o II o II o II o II o II o II u J CJ CJ u u u CJ υ CJ u J u CJ u υ II II II II o o υ υ CJ υ u CJ J u υ υ CJ CJ CJ CJ CJ CJ U CJ u u U J J CJ CJ CJ rH rH rH CJ J CJ CJ J CJ CJ u J J J u o U CJ CJ CJ CJ CJ CJ CJ u a a X X X X X a a X X X X X X X X X a a a a a a a a a a a a a a a X a a a a a a a a X X X X a CJ CJ CJ CJ J CJ CJ CJ CJ u CJ u o CJ CJ CJ CJ υ u CJ CJ CJ CJ CJ CJ CJ CJ J CJ u u CJ J J u CJ CJ u σs o ro r- o ro r σs o ro r o ro co CN cn ro ro ro ro ro ro ro ro ro "tf in o LO LO LO LO LO σs ro so σs X υ CJ u C X X X X X X X X x x a „ a a X .-. a a CJ CJ X O CJ u u u X X X u a X X X CJ J CJ i υ I CJ u u I i CJ u CJ J o U a ' I I J U u u CJ I I I υ υ J υ I "tf a a a a X a u a a X x_ X X X X X X X X X X X X X rs X X CJ X X J I u o O J cT u u CJ u CJ u CJ C J CJ CJ υ υ J u CJ CJ u u a o o o o o o o o o o a a a a a £ £ £ £ o o X X X X X X a X X X o o o o o o o o o o X X X a a a X X X X X X X X X CJ CJ J CJ J J J J J J CJ J CJ CJ CJ CJ CJ J CJ CJ J CJ CJ J CJ u o CJ X X X X X a a X X X CJ CJ CJ CJ u CJ CJ CJ u J X X X a a a X X X X X X X X X J υ J CJ CJ CJ υ u CJ J u o CJ CJ CJ u CJ CJ CJ υ υ υ υ CJ υ o X X X X u u u u u u u u u u u u u u u u ϋ u ϋ u u u u u u υ u u ϋ υ ϋ u u u u υ α ^ x a a a a a a a a a x x x x x x a a a a a x x x x x x a a a a a a a a a a a a a a a a X X X X X a a a a X X X X X a a a a a a a a a a X a a a X X X X X CJ CJ u CJ u u CJ CJ CJ o u o u CJ u CJ u u CJ CJ u CJ o o CJ u CJ CJ CJ CJ o CJ CJ u o CJ CJ CJ © σs σs o ro "tf r σs ro "tf co r- σs o ro "tf r σs o ro "tf in σs co r r r- r- r r- r- r r σs σs σs σs σs σs O 5196 CH j H Cl 0 CH 2 CH 2 NCH 3 4 H 9 c-C 3 H 5 5197 CH 2 H Cl 0 CH 2 CH NCH 3 C 2 H 5 C 3 H 7 5198 CH 2 H Cl 0 CH 2 CH 2 NCH 3 C 2 H 5 C 4 H 9 5199 CH 2 H Cl 0 CH 2 CH 2 NCH 3 C 3 H 7 C 3 H 7 5200 CH j H Cl 0 CHjCHj NCH 3 CH 3 C 3 H 7 5201 CH 2 H CH 3 CH CH 0 c-C 3 H 5 c-C 3 H 5 139-141 5202 CH 2 H CH 3 CH CH 0 H 4-(CH 3 0)-C 6 H 4 5203 CH 2 H CH 3 CH CH 0 CH 3 c-C 3 H 5 5204 CH 2 H CH 3 CH CH 0 C 2 H 5 c-C 3 H 5 5205 CH 2 H CH 3 CH CH 0 C 3 H 7 c-C 3 H 5 5206 CH 2 H CH 3 CH CH 0 C 4 H 9 c-C 3 H 5 5207 CHj H CH 3 CH CH 0 C 2 H 5 C 3 H 7 5208 CH 2 H CH 3 CH CH 0 C 2 H 5 C 4 H 9 5209 CH 2 H CH 3 CH CH 0 C 3 H 7 C 3 H 7 - 5210 CH 2 H CH 3 CH CH 0 CH 3 C 3 H 7 5211 CH 2 H Cl CH CH 0 c-C 3 H 5 c-C 3 H 5 5212 CH 2 H Cl CH CH 0 H 4-(CH 3 0)-C 6 H 4 5213 CH 2 H Cl CH CH 0 CH 3 c-C 3 H 5 5214 CH 2 H Cl CH CH 0 C 2 H 5 c-C 3 H 5 5215 CH 2 H Cl CH CH 0 C 3 H 7 c-C 3 H 5 5216 CH 2 H Cl CH CH 0 C 4 H 9 c-C 3 H 5 5217 CH 2 H Cl CH CH 0 C 2 H 5 C 3 H 7 5218 CH j H Cl CH CH 0 C 2 H 5 C 4 H 9 5219 CH 2 H Cl CH CH 0 C 3 H 7 C 3 H 7 5220 CH 2 H Cl CH CH 0 CH 3 C 3 H 7 5221 CH 2 H CH 3 CH CHCH CH c-C 3 H 5 c-C 3 H 5 5222 CH 2 H CH 3 CH CHCH CH H 4-(CH 3 0)-C«H 4 5223 CH 2 H CH 3 CH CHCH CH CH 3 c-C 3 H 5 5224 CH 2 H CH 3 CH CHCH CH C 2 H 5 c-C 3 H 5 5225 CHj H CH 3 CH CHCH CH C 3 H 7 c-C 3 H 5 5226 CH J H CH 3 CH CHCH CH C 4 H 9 c-C 3 H 5 5227 CH 2 H CH 3 CH CHCH CH C 2 H 5 C 3 H 7 5228 CH 2 H CH 3 CH CHCH CH C 2 H 5 C 4 H 9 5229 CHj H CH 3 CH CHCH CH C 3 H 7 C 3 H 7 5230 CH 2 H CH 3 CH CHCH CH CH 3 C 3 H 7 5231 CH 2 H CH 3 CH CBr 0 c-C 3 H 5 c-C 3 H 5 177-178 5232 CH 2 H CH 3 CH 2 CH 2 0 c-C 3 H 5 c-C 3 H 5 179-180 5233 CH 2 H CH 3 CH CCH 3 0 c-C 3 H 5 c-C 3 H 5 5234 CH 2 H CH 3 CH 2 CH 2 0 c-C 3 H 5 c-C 3 H 5 5235 CH 2 H CH 3 CH CSCH 3 0 c-C 3 H 5 c-C 3 H 5 5236 CH 2 H CH 3 CH, CH 2 0 c-C 3 H 5 c-C 3 H 5 TABLE 5A (A) (B) (C) Ex. X R 12 a b c R la R lb m.p. , No. °C 5232 CH 2 Br CH 2 CH 2 0 c-C 3 H 5 c-C 3 H 5 179-180 5234 CH 2 CN CH 2 CH 2 0 c-C 3 H 5 c-C 3 H 5 - 5236 CH 2 SCH 3 CHj CH 2 0 c-C 3 H 5 c-C 3 H 5 - The methods used in the preparation of the compounds of Table 1 may be used for the compounds of Structure A of Table 6. For example, replacing variously-substituted pentaatomic heteroaryl boronic acids for benzeneboronic acids in the palladium-catalyzed aryl cross-coupling method (see Examples 35 or 831) will afford the desired 6-heteroarylpurine compounds . The methods of Schemes 13 and 14 may be used to prepare many of the examples of Structure B and Structure C contained in Table 6, with minor procedural modifications where necessary and use of reagents of the appropriate structure. TABLE 6 ( A) ( B ) ( C ) Ex . No . X R 3 a b c d R l « R lb m. p . °C " 6001 CH 2 H CCH 3 N O CCH 3 c-C 3 H 5 c-C 3 H 5 oil 6002 CH 2 H CCH 3 N 0 CCH 3 CH 3 c-C 3 H 5 - 6003 CH j H CCH 3 N o CCH 3 C 2 H 5 c-C 3 H 5 - 6004 CH J H CCH 3 N 0 CCH 3 C 3 H 7 c-C 3 H 5 - 6005 CHJ H CCH 3 N 0 CCH 3 C 4 H 9 c-C 3 H 5 - 6006 CH 2 H CCH 3 N 0 CCH 3 CH 3 C 3 H 7 - 6007 CH J H CCH 3 N 0 CCH 3 C 2 H 5 C 3 H 7 - 6008 CH J H CCH 3 N 0 CCH 3 C 3 H 7 C 3 H 7 - 6009 CH J H CCH 3 N 0 CCH 3 C 2 H 5 C H 9 - 6010 CH 2 H CCH 3 N 0 CCH 3 H 4 -CH 3 0-C 6 H 4 - 6011 O H CCH 3 N 0 CCH 3 c -C 3 H 5 c-C 3 H 5 - 6012 0 H CCH 3 N 0 CCH 3 CH 3 c-C 3 H 5 - 6013 0 H CCH 3 N 0 CCH 3 C 2 H 5 c-C 3 H 5 - 6014 0 H CCH 3 N 0 CCH 3 C 3 H 7 c-C 3 H 5 6015 0 H CCH 3 N 0 CCH 3 C H 9 c-C 3 H 5 6016 0 H CCH 3 N 0 CCH 3 CH 3 C 3 H 7 6017 0 H CCH 3 N 0 CCH 3 C 2 H 5 C 3 H 7 6018 0 H CCH 3 N 0 CCH 3 C 3 H 7 C 3 H 7 6019 0 H CCH 3 N 0 CCH 3 C 2 H 5 C 4 H 9 6020 0 H CCH 3 N 0 CCH 3 H 4 -CH 3 0-C 6 H 4 6021 CH 2 CH 3 CCH 3 N 0 CCH 3 c-C 3 H 5 c-C 3 H 5 6022 CH 2 CH 3 CCH 3 N 0 CCH 3 CH 3 c-C 3 H 5 6023 CH j CH 3 CCH 3 N 0 CCH 3 C 2 H 5 c-C 3 H 5 6024 CH 2 CH 3 CCH 3 N 0 CCH 3 C 3 H 7 c -C 3 H 5 6025 CH 2 CH 3 CCH 3 N 0 CCH 3 C 4 H 9 C-C 3 H 5 6026 CH j CH 3 CCH 3 N 0 CCH 3 CH 3 C 3 H 7 6027 CH j CH 3 CCH 3 N 0 CCH 3 C 2 H 5 C 3 H 7 6028 CHJ CH 3 CCH 3 N 0 CCH 3 C 3 H 7 C 3 H 7 6029 CH 2 CH 3 CCH 3 N 0 CCH 3 C 2 H 5 C 4 H 9 6030 CH 2 CH 3 CCH 3 N 0 CCH 3 H 4 -CH 3 0-C 6 H 4 6031 CH 2 H CCH 3 N NCH 3 CCH 3 c-C 3 H 5 c-C 3 H 5 6032 CH 2 H CCH 3 N NCH 3 CCH 3 CH 3 c-C 3 H 5 6033 CH 2 H CCH 3 N NCH 3 CCH 3 C 2 H 5 c-C 3 H 5 6034 CH j H CCH 3 N NCH 3 CCH 3 C 3 H 7 c-C 3 H 5 6035 CH j H CCH 3 N NCH 3 CCH 3 C 4 H 9 c-C 3 H 5 6036 CH j H CCH 3 N NCH 3 CCH 3 CH 3 C 3 H 7 6037 CH j H CCH 3 N NCH 3 CCH 3 C 2 H 5 C 3 H 7 6038 CHJ H CCH 3 N NCH 3 CCH 3 C 3 H 7 C 3 H 7 6039 CH j H CCH 3 N NCH 3 CCH 3 C 2 H 5 C 4 H 9 6040 CHJ H CCH 3 N NCH 3 CCH 3 H 4 -CH 3 0-C 6 H 4 6041 0 H CCH 3 N NCH 3 CCH 3 c -C 3 H 5 c-C 3 H 5 6042 0 H CCH 3 N NCH 3 CCH 3 CH 3 c-C 3 H 5 6043 0 H CCH 3 N NCH 3 CCH 3 C 2 H 5 c-C 3 H 5 6044 0 H CCH 3 N NCH 3 CCH 3 C 3 H 7 c-C 3 H 5 6045 0 H CCH 3 N NCH 3 CCH 3 C 4 H 9 c-C 3 H 5 6046 0 H CCH 3 N NCH 3 CCH 3 CH 3 C 3 H 7 6047 0 H CCH 3 N NCH 3 CCH 3 C H 5 C 3 H 7 6048 0 H CCH 3 N NCH 3 CCH 3 C 3 H 7 C 3 H 7 6049 0 H CCH 3 N NCH 3 CCH 3 C 2 H 5 C 4 H 9 6050 0 H CCH 3 N NCH 3 CCH 3 H 4 -CH 3 0-C 6 H 4 6051 CH j CH 3 CCH 3 N NCH 3 CCH 3 c -C 3 H 5 c-C 3 H 5 6052 CH 2 CH 3 CCH 3 N NCH 3 CCH 3 CH 3 c-C 3 H 5 6053 CH 2 CH 3 CCH 3 N NCH 3 CCH 3 C 2 H 5 c-C 3 H 5 6054 CH 2 CH 3 CCH 3 N NCH 3 CCH 3 C 3 H 7 c-C 3 H 5 6055 CH j CH 3 CCH 3 N NCH 3 CCH 3 C 4 H 9 c-C 3 H 5 6056 CHJ CH 3 CCH 3 N NCH 3 CCH 3 CH 3 C 3 H 7 6057 CH j CH 3 CCH 3 N NCH 3 CCH 3 C 2 H 5 C 3 H 7 6058 CH j CH 3 CCH 3 N NCH 3 CCH 3 C 3 H 7 C 3 H 7 6059 CHj CH 3 CCH 3 N NCH 3 CCH 3 C 2 H 5 C 4 H 9 6060 CH 2 CH 3 CCH 3 N NCH 3 CCH 3 H 4 -CH 3 0-C 6 H 4 6061 CH 2 H CCH 3 N NC 2 H 5 CCH 3 c -C 3 H 5 c-C 3 H 5 6062 CH 2 H CCH 3 N NC 2 H 5 CCH 3 CH 3 c-C 3 H 5 6063 CH 2 H CCH 3 N NC 2 H 5 CCH 3 C 2 H 5 c-C 3 H 5 6064 CH 2 H CCH 3 N NC 2 H 5 CCH 3 C 3 H 7 c-C 3 H 5 6065 CH 2 H CCH 3 N NC j H 5 CCH 3 C 4 H 9 c-C 3 H 5 6066 CH 2 H CCH 3 N NC j H 5 CCH 3 CH 3 C 3 H 7 6067 CH 2 H CCH 3 N NC 2 H 5 CCH 3 C 2 H 5 C 3 H 7 6068 CH j H CCH 3 N NC 2 H 5 CCH 3 C 3 H 7 C 3 H 7 6069 CH 2 H CCH 3 N NC 2 H 5 CCH 3 C 2 H 5 C 4 H 9 6070 CH 2 H CCH 3 N NC 2 H 5 CCH 3 H 4 -CH 3 0-C 6 H 4 6071 0 H CCH 3 N NC 2 H 5 CCH 3 c -C 3 H 5 c-C 3 H 5 6072 0 H CCH 3 N NC 2 H 5 CCH 3 CH 3 c-C 3 H s 6073 0 H CCH 3 N NC 2 H 5 CCH 3 C H 5 c-C 3 H 5 6074 0 H CCH 3 N NC 2 H 5 CCH 3 C 3 H 7 c-C 3 H 5 6075 0 H CCH 3 N NC j H 5 CCH 3 C H 9 c-C 3 H 5 6076 0 H CCH 3 N NCjH 5 CCH 3 CH 3 C 3 H 7 6077 0 H CCH 3 N NC 2 H 5 CCH 3 C H 5 C 3 H 7 6078 0 H CCH 3 N NC 2 H 5 CCH 3 C 3 H 7 C 3 H 7 6079 0 H CCH 3 N NC 2 H 5 CCH 3 C 2 H 5 C 4 H 9 6080 0 H CCH 3 N NCjH 5 CCH 3 H 4 -CH 3 0-C 6 H 4 6081 CH 2 CH 3 CCH 3 N NC j H 5 CCH 3 c-C 3 H 5 c-C 3 H 5 6082 CH 2 CH 3 CCH 3 N NC j H 5 CCH 3 CH 3 c-C 3 H 5 6083 CH 2 CH 3 CCH 3 N NC j H 5 CCH 3 C 2 H 5 c-C 3 H 5 6084 CH 2 CH 3 CCH 3 N NC j H 5 CCH 3 C 3 H 7 c-C 3 H 5 6085 CH j CH 3 CCH 3 N NCjH 5 CCH 3 C 4 H 9 c-C 3 H 5 6086 CH 2 CH 3 CCH 3 N NC 2 H 5 CCH 3 CH 3 C 3 H 7 6087 CH 2 CH 3 CCH 3 N NC 2 H 5 CCH 3 C 2 H 5 C 3 H 7 6088 CH 2 CH 3 CCH 3 N NC 2 H 5 CCH 3 C 3 H 7 C 3 H 7 6089 CH 2 CH 3 CCH 3 N NC 2 H 5 CCH 3 C 2 H 5 C H 9 6090 CH j CH 3 CCH 3 N NC 2 H 5 CCH 3 H 4 -CH 3 0-C 6 H 4 6091 CH j H CCH 3 N CCH 3 NCH 3 c-C 3 H 5 c-C 3 H 5 6092 CHj H CCH 3 N CCH 3 NCH 3 CH 3 c-C 3 H 5 6093 CH 2 H CCH 3 N CCH 3 NCH 3 C 2 H 5 c-C 3 H 5 6094 CH 2 H CCH 3 N CCH 3 NCH 3 C 3 H 7 c-C 3 H 5 6095 CH 2 H CCH 3 N CCH 3 NCH 3 C 4 H 9 c-C 3 H 5 6096 CH j H CCH 3 N CCH 3 NCH 3 CH 3 C 3 H 7 6097 CHJ H CCH 3 N CCH 3 NCH 3 C j H 5 C 3 H 7 6098 CHJ H CCH 3 N CCH 3 NCH 3 C 3 H 7 C 3 H 7 6099 CH 2 H CCH 3 N CCH 3 NCH 3 C 2 H 5 C 4 H 9 6100 CHj H CCH 3 N CCH 3 NCH 3 H 4 -CH 3 0-C 6 H 4 6101 CHJ H CCH 3 N NC 6 H 5 CCH 3 c -C 3 H 5 c-C 3 H 5 6102 CHj H CCH 3 N NC 6 H 5 CCH 3 CH 3 c-C 3 H 5 6103 CH 2 H CCH 3 N NC 6 H 5 CCH 3 C 2 H 5 c-C 3 H 5 6104 CH j H CCH 3 N NC 6 H 5 CCH 3 C 3 H 7 c-C 3 H 5 6105 CHJ H CCH 3 N NC 6 H 5 CCH 3 4 H 9 c-C 3 H 5 6106 CH j H CCH 3 N NC 6 H 5 CCH 3 CH 3 C 3 H 7 6107 CHj H CCH 3 N NC 6 H 5 CCH 3 C 2 H 5 C 3 H 7 6108 CH j H CCH 3 N NC 6 H 5 CCH 3 C 3 H 7 C 3 H 7 6109 CHJ H CCH 3 N NC 6 H 5 CCH 3 C j H 5 C 4 H 9 6110 CH 2 H CCH 3 N NC 6 H 5 CCH 3 H 4 -CH 3 0-C 6 H 4 6111 0 H CCH 3 N NC 6 H 5 CCH 3 c -C 3 H 5 c-C 3 H 5 6112 0 H CCH 3 N NC 6 H 5 CCH 3 CH 3 c-C 3 H 5 6113 0 H CCH 3 N NC 6 H 5 CCH 3 C 2 H 5 c-C 3 H 5 6114 0 H CCH 3 N NC 6 H 5 CCH 3 C 3 H 7 c-C 3 H 5 6115 0 H CCH 3 N NC 6 H 5 CCH 3 C 4 H 9 c-C 3 H 5 6116 0 H CCH 3 N NC 6 H 5 CCH 3 CH 3 C 3 H 7 6117 0 H CCH 3 N NC 6 H 5 CCH 3 C 2 H 5 C 3 H 7 6118 0 H CCH 3 N NC 6 H 5 CCH 3 C 3 H 7 C 3 H 7 6119 0 H CCH 3 N NC 6 H 5 CCH 3 C j H 5 C 4 H 9 6120 0 H CCH 3 N NC 6 H 5 CCH 3 H 4 -CH 3 0-C 6 H 4 6121 CH 2 CH 3 CCH 3 N NC 6 H 5 CCH 3 c -C 3 H 5 c-C 3 H 5 6122 CH 2 CH 3 CCH 3 N NC 6 H 5 CCH 3 CH 3 c-C 3 H 5 6123 CH 2 CH 3 CCH 3 N NC 6 H 5 CCH 3 C 2 H 5 c-C 3 H 5 6124 CH 2 CH 3 CCH 3 N NC 6 H 5 CCH 3 C 3 H 7 c-C 3 H 5 6125 CH 2 CH 3 CCH 3 N NC 6 H 5 CCH 3 C H 9 c-C 3 H 5 6126 CH 2 CH 3 CCH 3 N NC 6 H 5 CCH 3 CH 3 C 3 H 7 6127 CH 2 CH 3 CCH 3 N NC 6 H 5 CCH 3 C 2 H 5 C 3 H 7 6128 CH j CH 3 CCH 3 N NC 6 H 5 CCH 3 C 3 H 7 C 3 H 7 6129 CH 2 CH 3 CCH 3 N NC 6 H 5 CCH 3 C 2 H 5 C 4 H 9 6130 CH 2 CH 3 CCH 3 N NC 6 H 5 CCH 3 H 4 - -CH 3 0-C 6 H 4 Key: a) Where the compound is indicated as an "oil*, spectral data is provided as follows: Example 6001 spectral data: MS (NH 3 -CI) : m/e 338 (M+H + , 100%) . The methods used in the preparation of the compounds of Table 1 may be used for preparation of many of the compounds of Structure A of Table 7. The preparation of those compounds derived from cycloaddition of compounds with alkynyl-bearing R 1 groups is illustrated by the following examples. The methods of Schemes 13 and 14 may be used to prepare many of the examples of Structure B and Structure C contained in Table 7, with minor procedural modifications where necessary and use of reagents of the appropriate structure. Example 7409 Preparation of 9- ri-cvclopropvl-1- (3-methvl-isoxazol-5- vllme hvl 1-6- (2 .4-rii.πhloronhpnvl -R- f.hvl -9ff-mιrin To a stirring solution of the compound of Example 7241 (90 mg, 0.24 mmol; prepared in a manner similar to that of Example 2 using 6- (2,4-dichlorophenyl) -8-ethyl-9H-purine and 3- cyclopropyl-l-propyn-3-ol) in methylene chloride (2 mL) were added chloroacetaldoxime (25 mg, 0.27 mmol) and triethylamine (0.038 mL, 0.27 mmol). (The chloroacetaldoxime used was previously prepared by reacting equimolar amounts of acetaldoxime and N-chlorosuccinimide in DMF, then extracting the product into diethyl ether and washing with water.) The cycloaddition reaction was monitored by TLC and additional amounts of chloroacetaldoxime and triethylamine were added until all the starting material was consumed. The reaction mixture was purified by adding directly to a column packed with silica gel and eluting using a gradient of 100% hexane to 25% ethyl acetate in hexane. 72 mg of a white foam was collected. MS (NH 3 -CI) 428 (M+H + ) . HRMS: m/e = 428.1037 (M+H + , C 21 H 20 C1 2 N 5 0) . Purity by reverse phase HPLC >97%. Examples 7396 and 7398 Preparation of 6- (2 , 4-dichlorophenvl) -9- n- (3-ethoxvcarbonvl- soxazo, - -vl ihut.vl 1 -8-ethvl-9f-nnrine> and 9- fl- (4-cvano-3- ethoxvcarbonvl-isoxazol-5-vl) butvll -6- (2 .4-dichlorophenvl) -8- ethyl-9fl-purine A solution of the compound of Example 7259 (120 mg, 0.321 mmol; prepared prepared in a manner similar to that of Example 2 using 6- (2,4-dichlorophenyl) -8-ethyl-9H-purine and 1-hexyn- 3-ol) , ethyl chlorooximidoacetate (146 mg, 0.963 mmol) and diisopropylethylamine (170 μL, 0.976 mmol) in toluene (2 mL) was heated to reflux for 20 hours, then cooled and diluted with 20 mL ethyl acetate. This was washed with water (2 x 20 mL) and satd. aq. brine (20 mL) , and the aqueous phases were back-extracted in sequence with ethyl acetate (20 mL) . The organic extracts were combined, dried over anhydrous sodium sulfate, filtered and evaporated. The residual material was separated by column chromatography (silica gel, 1:4 ethyl acetate-hexane) to afford, in order, unreacted starting material (about 50 mg) , then the compound of Example 7396 (58.7 mg, 0.120 mmol, 37%), and finally the compound of Example 7398 (23.8 mg, 0.046 mmol, 14%), the latter two compounds being amorphous solids. Example 7396 spectral data: TLC R p 0.27 (20:80 ethyl acetate-hexane). E NMR (300 MHz, CDC1 3 ) : δ 8.96 (IH, s) , 7.67 (IH, d, J = 8.1 Hz), 7.58 (IH, d, J = 1.8 Hz), 7.41 (IH, dd, J = 8.1, 1.8 Hz), 6.86 (IH, s) , 5.83 (IH, dd, J = 9.9, 6.2 Hz), 4.43 (2H, q, J = 7.3 Hz), 2.98 (2H, q, J = 7.7 Hz), 2.91-2.78 (IH, m) , 2.63-2.49 (IH, m) , 1.42 (3H, t, J = 7.7 Hz), 1.40 (3H, t, J = 7.3 Hz), 1.39-1.19 ^ (2H, m) , 1.00 (3H, t, J = 7.3 Hz). MS (NH 3 -CI) : m/e calc'd for ^.Cl^O, : 488.1256, found 488.1252; 493 (3), 492 (13), 491 (18), 490 (68), 489 (28), 488 (100) . Example 7398 spectral data: TLC R F 0.11 (20:80 ethyl acetate-hexane). Ε NMR (300 MHz, CDC1 3 ): δ 8.99 (IH, s) , 7.72 (IH, d, J = 8.1 Hz), 7.59 (IH, d, J = 1.8 Hz), 7.42 (IH, dd, J = 8.1, 1.8 Hz), 5.40 (IH, dd, J = 10.4, 5.0 Hz), 4.42 (2H, q, J = 7.4 Hz), 3.00-2.90 (2H, m) , 2.66-2.52 (IH, m) , 2.51-2.38 (IH, m) , 1.46 (3H, t, J = 7.4 Hz), 1.41 (3H, t, J = 7.3 Hz), 1.40-1.10 (2H, m) , 0.98 (3H, t, J = 7.2 Hz). MS (NH 3 -CI) : m/e calc'd for C 24 H 25 C1 2 N 6 0 4 : 531.1315, found 531.1315; 531 (100). TABLE 7 CH 3 Ex. No. X R 4 R 5 R 11 R δ R la L G a m, P- 7001 CH 2 CH 3 CH 3 H CH 3 CH 3 bond Gl 7002 CH 2 CH 3 CH 3 H CH 3 CjH 5 bond Gl 7003 CHj CH 3 CH 3 H CH 3 C 3 H 7 bond Gl 7004 CHj CH 3 CH 3 H CH 3 c-C 3 H 5 bond Gl 7005 CH 2 CH 3 CH 3 H CH 3 CH 3 bond G2 7006 CH 2 CH 3 CH 3 H CH 3 C 2 H 5 bond G2 7007 CH 2 CH 3 CH 3 H CH 3 C 3 H 7 bond G2 7008 CH 2 CH 3 CH 3 H CH 3 c-C 3 H 5 bond G2 7009 CH 2 CH 3 CH 3 H CH 3 CH 3 bond G3 7010 CHj CH 3 CH 3 H CH 3 C 2 H 5 bond G3 7011 CH J CH 3 CH 3 H CH 3 C 3 H 7 bond G3 7012 CH 2 CH 3 CH 3 H CH 3 c-C 3 H 5 bond G3 7013 CH 2 CH 3 CH 3 H CH 3 CH 3 CH 2 G4 7014 CH 2 CH 3 CH 3 H CH 3 C 2 H 5 CH 2 G4 7015 CH 2 CH 3 CH 3 H CH 3 C 3 H 7 CH 2 G4 7016 CH 2 CH 3 CH 3 H CH 3 c-C 3 H 5 CH 2 G4 7017 CH 2 CH 3 CH 3 H CH 3 CH 3 CH 2 G5 7018 CH 2 CH 3 CH 3 H CH 3 C 2 H 5 CHj G5 7019 CH 2 CH 3 CH 3 H CH 3 C 3 H 7 CH J G5 7020 CH 2 CH 3 CH 3 H CH 3 c-C 3 H 5 CH J G5 7021 CH 2 CH 3 CH 3 H CH 3 CH 3 bond G6 7022 CH 2 CH 3 CH 3 H CH 3 C 2 H 5 bond G6 7023 CHj CH 3 CH 3 H CH 3 C 3 H 7 bond G6 7024 CH J CH 3 CH 3 H CH 3 c-C 3 H 5 bond G6 7025 CH 2 CH 3 CH 3 H CH 3 CH 2 =CH bond G7 7026 CH 2 CH 3 CH 3 H CH 3 CH 3 bond G8 7027 CH 2 CH 3 CH 3 H CH 3 C 2 H 5 CHj Gl 7028 CH 2 CH 3 CH 3 H CH 3 C 3 H 7 CH J Gl 7029 CH 2 CH 3 CH 3 H CH 3 C 2 H 5 CH J G2 7030 CH 2 CH 3 CH 3 H CH 3 C 3 H 7 CHj G2 7031 CH 2 Cl Cl H H CH 3 bond Gl 7032 CH 2 Cl Cl H H C 2 H 5 bond Gl 7033 CH 2 Cl Cl H H C 3 H 7 bond Gl 7034 CH 2 Cl Cl H H c-C 3 H 5 bond Gl 7035 CH 2 Cl Cl H H CH 3 bond G2 7036 CH 2 Cl Cl H H C 2 H 5 bond G2 7037 CH 2 Cl Cl H H C 3 H 7 bond G2 7038 CH 2 Cl Cl H H c-C 3 H 5 bond G2 7039 CHj Cl Cl H H CH 3 bond G3 7040 CH 2 Cl Cl H H C 2 H 5 bond G3 7041 CHj Cl Cl H H C 3 H 7 bond G3 7042 CH 2 Cl Cl H H c-C 3 H 5 bond G3 7043 CH 2 Cl Cl H H CH 3 CHj G4 7044 CH 2 Cl Cl H H C 2 H 5 CH J G4 7045 CHj Cl Cl H H C 3 H 7 CH J G4 7046 CH 2 Cl Cl H H c-C 3 H 5 CH J G4 7047 CH 2 Cl Cl H H CH 3 CH J G5 7048 CH 2 Cl Cl H H C 2 H 5 CH 2 G5 7049 CH 2 Cl Cl H H C 3 H 7 CH 2 G5 7050 CH 2 Cl Cl H H c-C 3 H 5 CH 2 G5 7051 CH 2 Cl Cl H H CH 3 bond G6 7052 CH 2 Cl Cl H H C 2 H 5 bond G6 7053 CH 2 Cl Cl H H C 3 H 7 bond G6 7054 CH 2 Cl Cl H H c-C 3 H 5 bond G6 7055 CH 2 Cl Cl H H CH 2 =CH bond G7 7056 CH 2 Cl Cl H H CH 3 bond G8 7057 CH 2 Cl Cl H H C 2 H 5 CH 2 Gl 7058 CHj Cl Cl H H C 3 H 7 CHj Gl 7059 CH 2 Cl Cl H H C 2 H 5 CH 2 G2 7060 CH 2 Cl Cl H H C 3 H 7 CH 2 G2 7061 CH 2 CH 3 OCH 3 H H CH 3 bond Gl 7062 CH 2 CH 3 OCH 3 H H C 2 H 5 bond Gl 7063 CH 2 CH 3 OCH 3 H H C 3 H 7 bond Gl 7064 CH 2 CH 3 OCH 3 H H c-C 3 H 5 bond Gl 7065 CH 2 CH 3 OCH 3 H H CH 3 bond G2 7066 CH 2 CH 3 OCH 3 H H C 2 H 5 bond G2 7067 CH 2 CH 3 OCH 3 H H C 3 H 7 bond G2 7068 CH 2 CH 3 OCH 3 H H c-C 3 H 5 bond G2 7069 CH 2 CH 3 OCH 3 H H CH 3 bond G3 7070 CH 2 CH 3 OCH 3 H H C 2 H 5 bond G3 7071 CH 2 CH 3 OCH 3 H H C 3 H 7 bond G3 7072 CH 2 CH 3 OCH 3 H H C-C 3 H 5 bond G3 7073 CH 2 CH 3 OCH 3 H H CH 3 CH 2 G4 7074 CH 2 CH 3 OCH 3 H H C 2 H 5 CH 2 G4 7075 CH 2 CH 3 OCH 3 H H C 3 H 7 CH 2 G4 7076 CH 2 CH 3 OCH 3 H H c-C 3 H 5 CH 2 G4 7077 CHj CH 3 OCH 3 H H CH 3 CH 2 G5 7078 CHJ CH 3 OCH 3 H H C 2 H 5 CHj G5 7079 CH J CH 3 OCH 3 H H C 3 H 7 CHj G5 7080 CH J CH 3 OCH 3 H H c-C 3 H 5 CH J G5 7081 CH J CH 3 OCH 3 H H CH 3 bond G6 7082 CH J CH 3 OCH 3 H H C 2 H 5 bond G6 7083 CHJ CH 3 OCH 3 H H C 3 H 7 bond G6 7084 CH J CH 3 OCH 3 H H c-C 3 H 5 bond G6 7085 CH 2 CH 3 OCH 3 H H CH 2 =CH bond G7 7086 CH 2 CH 3 OCH 3 H H CH 3 bond G8 oil 7087 CH 2 CH 3 OCH 3 H H C 2 H 5 CHJ Gl 7088 CH 2 CH 3 OCH 3 H H C 3 H 7 CH j Gl 7089 CH J CH 3 OCH 3 H H C 2 H 5 CH 2 G2 7090 CH J CH 3 OCH 3 H H C 3 H 7 CHj G2 7091 CH 2 Cl OCH 3 H H CH 3 bond Gl 7092 CHj Cl OCH 3 H H C 2 H 5 bond Gl 7093 CH 2 Cl OCH 3 H H C 3 H 7 bond Gl 7094 CH 2 Cl OCH 3 H H c-C 3 H 5 bond Gl 7095 CH 2 Cl OCH 3 H H CH 3 bond G2 7096 CH 2 Cl OCH 3 H H C 2 H 5 bond G2 7097 CH 2 Cl OCH 3 H H C 3 H 7 bond G2 7098 CH 2 Cl OCH 3 H H c-C 3 H 5 bond G2 7099 CH 2 Cl OCH 3 H H CH 3 bond G3 7100 CH 2 Cl OCH 3 H H C 2 H 5 bond G3 7101 CH j Cl OCH 3 H H C 3 H 7 bond G3 7102 CH 2 Cl OCH 3 H H c-C 3 H 5 bond G3 7103 CH 2 Cl OCH 3 H H CH 3 CH 2 G4 7104 CH 2 Cl OCH 3 H H C 2 H 5 CH 2 G4 7105 CH 2 Cl OCH 3 H H C 3 H 7 CH 2 G4 7106 CH 2 Cl OCH 3 H H c-C 3 H 5 CH 2 G4 7107 CH 2 Cl OCH 3 H H CH 3 CH 2 G5 7108 CH 2 Cl OCH 3 H H C 2 H 5 CH 2 G5 7109 CH 2 Cl OCH 3 H H C 3 H 7 CH 2 G5 7110 CH 2 Cl OCH 3 H H c-C 3 H 5 CH 2 G5 7111 CH j Cl OCH 3 H H CH 3 bond G6 7112 CH 2 Cl OCH 3 H H C 2 H 5 bond G6 7113 CH 2 Cl OCH 3 H H C 3 H 7 bond G6 7114 CH 2 Cl OCH 3 H H C-C 3 H 5 bond G6 7115 CHj Cl OCH 3 H H CH 2 =CH bond G7 7116 CH 2 Cl OCH 3 H H CH 3 bond G8 oil 7117 CH j Cl OCH 3 H H C 2 H 5 CH 2 Gl 7118 CHJ Cl OCH 3 H H C 3 H 7 CH 2 Gl 7119 CH 2 Cl OCH 3 H H C 2 H 5 CH 2 G2 7120 CH 2 Cl OCH 3 H H C 3 H 7 CH 2 G2 7121 CH 2 Cl CF 3 H H CH 3 bond Gl 7122 CH 2 Cl CF 3 H H C H 5 bond Gl 7123 CHj Cl CF 3 H H C 3 H 7 bond Gl 7124 CHJ Cl CF 3 H H c-C 3 H 5 bond Gl 7125 CH J Cl CF 3 H H CH 3 bond G2 7126 CH 2 Cl CF 3 H H C 2 H 5 bond G2 7127 CH 2 Cl CF 3 H H C 3 H 7 bond G2 7128 CH 2 Cl CF 3 H H c -C 3 H 5 bond G2 7129 CH 2 Cl CF 3 H H CH 3 bond G3 7130 CH 2 Cl CF 3 H H C 2 H 5 bond G3 7131 CH 2 Cl CF 3 H H C 3 H 7 bond G3 7132 CH 2 Cl CF 3 H H c-C 3 H 5 bond G3 7133 CH 2 Cl CF 3 H H CH 3 CHj G4 7134 CH 2 Cl CF 3 H H C 2 H 5 CH J G4 7135 CH 2 Cl CF 3 H H C 3 H 7 CHJ G4 7136 CHj Cl CF 3 H H c-C 3 H 5 CH 2 G4 7137 CH J Cl CF 3 H H CH 3 CH 2 G5 7138 CH 2 Cl CF 3 H H C 2 H 5 CH 2 G5 7139 CH 2 Cl CF 3 H H C 3 H 7 CH 2 G5 7140 CH 2 Cl CF 3 H H c-C 3 H 5 CH 2 G5 7141 CH 2 Cl CF 3 H H CH 3 bond G6 7142 CH 2 Cl CF 3 H H C 2 H 5 bond G6 7143 CH 2 Cl CF 3 H H C 3 H 7 bond G6 7144 CH 2 Cl CF 3 H H c-C 3 H 5 bond G6 7145 CH 2 Cl CF 3 H H CH 2 =CH bond G7 7146 CH 2 Cl CF 3 H H CH 3 bond G8 oil 7147 CHj Cl CF 3 H H C 2 H 5 CH 2 Gl 7148 CH J Cl CF 3 H H C 3 H 7 CH 2 Gl 7149 CH 2 Cl CF 3 H H C 2 H 5 CH 2 G2 7150 CH 2 Cl CF 3 H H C 3 H 7 CH 2 G2 7151 CH 2 CF 3 Cl H H CH 3 bond Gl 7152 CH 2 CF 3 Cl H H C 2 H 5 bond Gl 7153 CHj CF 3 Cl H H C 3 H bond Gl 7154 CH J CF 3 Cl H H c-C 3 H 5 bond Gl 7155 CHJ CF 3 Cl H H CH 3 bond G2 7156 CH J CF 3 Cl H H C 2 H 5 bond G2 7157 CHJ CF 3 Cl H H C 3 H 7 bond G2 7158 CH 2 CF 3 Cl H H c-C 3 H 5 bond G2 7159 CH 2 CF 3 Cl H H CH 3 bond G3 7160 CH 2 CF 3 Cl H H C 2 H 5 bond G3 7161 CHj CF 3 Cl H H C 3 H 7 bond G3 7162 CH J CF 3 Cl H H c-C 3 H 5 bond G3 7163 CH J CF 3 Cl H H CH 3 CHj G4 7164 CH 2 CF 3 Cl H H C 2 H 5 CHj G4 7165 CH 2 CF 3 Cl H H C 3 H 7 CH J G4 7166 CH 2 CF 3 Cl H H c-C 3 H 5 CH J G4 7167 CH 2 CF 3 Cl H H CH 3 CH J G5 7168 CH 2 CF 3 Cl H H C 2 H 5 CH J G5 7169 CH 2 CF 3 Cl H H C 3 H 7 CH J G5 7170 CH 2 CF 3 Cl H H c-C 3 H 5 CHJ G5 7171 CH 2 CF 3 Cl H H CH 3 bond G6 7172 CH 2 CF 3 Cl H H C 2 H 5 bond G6 7173 CH 2 CF 3 Cl H H C 3 H 7 bond G6 7174 CH 2 CF 3 Cl H H c-C 3 H 5 bond G6 7175 CH 2 CF 3 Cl H H CH 2 =CH bond G7 7176 CH 2 CF 3 Cl H H CH 3 bond G8 7177 CH 2 CF 3 Cl H H C 2 H 5 CHj Gl 7178 CH 2 CF 3 Cl H H C 3 H 7 CH J Gl 7179 CH 2 CF 3 Cl H H C 2 H 5 CHJ G2 7180 CH 2 CF 3 Cl H H C 3 H 7 CH J G2 7181 CH 2 CH 3 OCH 3 CH 3 H CH 3 bond Gl 7182 CH 2 CH 3 OCH 3 CH 3 H C 2 H 5 bond Gl 7183 CH 2 CH 3 OCH 3 CH 3 H C 3 H 7 bond Gl 7184 CH 2 CH 3 OCH 3 CH 3 H c-C 3 H 5 bond Gl 7185 CH 2 CH 3 OCH 3 CH 3 H CH 3 bond G2 7186 CHj CH 3 OCH 3 CH 3 H C H 5 bond G2 7187 CH J CH 3 OCH 3 CH 3 H C 3 H 7 bond G2 7188 CHj CH 3 OCH 3 CH 3 H c-C 3 H 5 bond G2 7189 CH j CH 3 OCH 3 CH 3 H CH 3 bond G3 7190 CH J CH 3 OCH 3 CH 3 H CjH 5 bond G3 7191 CH J CH 3 OCH 3 CH 3 H C 3 H 7 bond G3 7192 CH J CH 3 OCH 3 CH 3 H c-C 3 H 5 bond G3 7193 CH J CH 3 OCH 3 CH 3 H CH 3 CHj G4 7194 CH J CH 3 OCH 3 CH 3 H C 2 H 5 CH J G4 7195 CH 2 CH 3 OCH 3 CH 3 H C 3 H 7 CH 2 G4 7196 CHj CH 3 OCH 3 CH 3 H c-C 3 H 5 CH 2 G4 7197 CH 2 CH 3 OCH 3 CH 3 H CH 3 CH 2 G5 7198 CH 2 CH 3 OCH 3 CH 3 H C 2 H 5 CH 2 G5 7199 CH 2 CH 3 OCH 3 CH 3 H C 3 H 7 CH 2 G5 7200 CH 2 CH 3 OCH 3 CH 3 H c-C 3 H 5 CH 2 G5 7201 CH 2 CH 3 OCH 3 CH 3 H CH 3 bond G6 7202 CHj CH 3 OCH 3 CH 3 H C 2 H 5 bond G6 7203 CH j CH 3 OCH 3 CH 3 H C 3 H 7 bond G6 7204 CH j CH 3 OCH 3 CH 3 H c-C 3 H 5 bond G6 7205 CH j CH 3 OCH 3 CH 3 H CH 2 =CH bond G7 7206 CHj CH 3 OCH 3 CH 3 H CH 3 bond G8 7207 CHj CH 3 OCH 3 CH 3 H C 2 H 5 CHj Gl 7208 CHj CH 3 OCH 3 CH 3 H C 3 H 7 CH 2 Gl 7209 CHj CH 3 OCH 3 CH 3 H C 2 H 5 CH 2 G2 7210 CHj CH 3 OCH 3 CH 3 H C 3 H 7 CH 2 G2 7211 0 Cl CF 3 H H C 2 H 5 CH 2 Gl 7212 O Cl CF 3 H H C 3 H 7 CH 2 Gl 7213 0 Cl CF 3 H H C 2 H 5 bond G2 7214 0 Cl CF 3 H H C 3 H 7 bond G2 7215 0 Cl CF 3 H H C 2 H 5 CH 2 G4 7216 CHj Cl CF 3 H H C 2 H 5 CH 2 Gl 7217 CHj Cl CF 3 H H C 3 H 7 CH 2 Gl 7218 CHj Cl CF 3 H H C 2 H 5 bond G2 7219 CH j Cl CF 3 H H C 3 H 7 bond G2 7220 CHj Cl CF 3 H H C 2 H 5 CH 2 G4 7221 0 CF 3 Cl H H C 2 H 5 CH 2 Gl 7222 O CF 3 Cl H H C 3 H 7 CH 2 Gl 7223 O CF 3 Cl H H C 2 H 5 bond G2 7224 0 CF 3 Cl H H C 3 H 7 bond G2 7225 O CF 3 Cl H H C 2 H 5 CH 2 G4 7226 CHj CF 3 Cl H H C 2 H 5 CH 2 Gl 7227 CHj CF 3 Cl H H C 3 H 7 CH 2 Gl 7228 CHj CF 3 Cl H H C 2 H 5 bond G2 7229 CH 2 CF 3 Cl H H C 3 H 7 bond G2 7230 CHj CF 3 Cl H H CjH 5 CH 2 G4 7231 CH j CH 3 CH 3 H CH 3 C 2 H 5 CH 2 0 G3 oil 7232 CHj Cl Cl H H c-C 3 H 5 bond G9 7233 O Cl Cl H H c-C 3 H 5 bond G9 7234 CHj Cl CF 3 H H c-C 3 H 5 bond G9 oil 7235 O Cl CF 3 H H c-C 3 H 5 bond G9 7236 CHj Cl OCH 3 H H c-C 3 H 5 bond G9 7237 CH 2 Cl OCF 3 H H c-C 3 H 5 bond G9 7238 CH 2 CH 3 OCH 3 Cl H c-C 3 H 5 bond G9 7239 CH 2 Cl Cl H CH 3 c-C 3 H 5 bond G9 7240 CH 2 CF 3 OCH 3 H H c-C 3 H 5 bond G9 - 7241 CH 2 Cl Cl H H c-C 3 H 5 bond G10 oi l 7242 0 Cl Cl H H c-C 3 H 5 bond G10 - 7243 CH 2 Cl CF 3 H H c-C 3 H 5 bond G10 oil 7244 0 Cl CF 3 H H c-C 3 H 5 bond G10 - 7245 CH 2 Cl OCH 3 H H c-C 3 H 5 bond G10 - 7246 CH 2 Cl OCF 3 H H c-C 3 H 5 bond G10 - 7247 CH 2 CH 3 OCH 3 Cl H c-C 3 H 5 bond G10 - 7248 CH 2 Cl Cl H CH 3 c-C 3 H 5 bond G10 - 7249 CH 2 CF 3 OCH 3 H H c-C 3 H 5 bond G10 oil 7250 CH 2 Cl Cl H H C 2 H 5 bond G10 oil 7251 0 Cl Cl H H C 2 H 5 bond G10 - 7252 CH 2 Cl CF 3 H H C 2 H 5 bond G10 98 -9 7253 0 Cl CF 3 H H C H 5 bond G10 - 7254 CHj Cl OCH 3 H H C 2 H 5 bond G10 - 7255 CH 2 Cl OCF 3 H H C 2 H 5 bond G10 - 7256 CH 2 CH 3 OCH 3 Cl H C 2 H 5 bond G10 - 7257 CH 2 Cl Cl H CH 3 C H 5 bond G10 - 7258 CH 2 CF 3 OCH 3 H H C 2 H 5 bond G10 - 7259 CH 2 Cl Cl H H C 3 H 7 bond G10 oil 7260 0 Cl Cl H H C 3 H 7 bond G10 - 7261 CH 2 Cl CF 3 H H C 3 H 7 bond G10 oil 7262 0 Cl CF 3 H H C 3 H 7 bond G10 - 7263 CH 2 Cl OCH 3 H H C 3 H 7 bond G10 - 7264 CH 2 Cl OCF 3 H H C 3 H 7 bond G10 - 7265 CH 2 CH 3 OCH 3 Cl H C 3 H 7 bond G10 - 7266 CH 2 Cl Cl H CH 3 C 3 H-, bond G10 oil 7267 CHj CF 3 OCH 3 H H C 3 H 7 bond G10 - 7268 CH J Cl Cl H H C 5 H 11 bond G10 oil 7269 0 Cl Cl H H 5 H 11 bond G10 - 7270 CHj Cl CF 3 H H C 5 H n bond G10 oi l 7271 0 Cl CF 3 H H C 5 H 11 bond G10 - 7272 CHj Cl OCH 3 H H C 5 H 11 bond G10 - 7273 CH 2 Cl OCF 3 H H C 5 H 1 1 bond G10 - 7274 CH 2 CH 3 OCH 3 Cl H C 5 H n bond G10 - 7275 CH 2 Cl Cl H CH 3 CsHu bond G10 - 7276 CH 2 CF 3 OCH 3 H H C 5 H U bond G10 - 7277 CH 2 Cl Cl H H CH 3 CH 2 G10 - 7278 0 Cl Cl H H CH 3 CH 2 G10 - 7279 CH 2 Cl CF 3 H H CH 3 CH 2 G10 oil 7280 0 Cl CF 3 H H CH 3 CH 2 G10 - 7281 CH 2 Cl OCH 3 H H CH 3 CH 2 G10 - 7282 CH 2 Cl OCF 3 H H CH 3 CH 2 G10 - 7283 CH 2 CH 3 OCH 3 Cl H CH 3 CH 2 G10 - 7284 CH 2 Cl Cl H CH 3 CH 3 CH 2 G10 - 7285 CH 2 CF 3 OCH 3 H H CH 3 CH 2 G10 - 7286 CH 2 Cl Cl H H c-C 3 H 5 bond Gil oi l 7287 0 Cl Cl H H c-C 3 H 5 bond Gil - 7288 CH 2 Cl CF 3 H H c-C 3 H 5 bond Gi l oi l 7289 0 Cl CF 3 H H c-C 3 H 5 bond Gil - 7290 CH 2 Cl OCH 3 H H c-C 3 H 5 bond Gil - 7291 CH 2 Cl OCF 3 H H c-C 3 H 5 bond Gi l - 7292 CH 2 CH 3 OCH 3 Cl H c-C 3 H 5 bond Gil - 7293 CHj Cl Cl H CH 3 c-C 3 H 5 bond Gil - 7294 CH J CF 3 OCH 3 H H c-C 3 H 5 bond Gil - 7295 CH J Cl Cl H H C 2 H 5 bond Gil oil 7296 0 Cl Cl H H C 2 H 5 bond Gi l - 7297 CHj Cl CF 3 H H C 2 H 5 bond Gil oil 7298 0 Cl CF 3 H H C 2 H 5 bond Gil - 7299 CHj Cl OCH 3 H H C 2 H 5 bond Gil - 7300 CHj Cl OCF 3 H H C 2 H 5 bond Gil - 7301 CH J CH 3 OCH 3 Cl H C 2 H 5 bond Gi l - 7302 CH j Cl Cl H CH 3 C 2 H 5 bond Gil - 7303 CH J CF 3 OCH 3 H H C 2 H 5 bond Gil - 7304 CH J Cl Cl H H C 3 H 7 bond Gil 88-89 7305 0 Cl Cl H H C 3 H 7 bond Gil - 7306 CHj Cl CF 3 H H C 3 H 7 bond Gil oil 7307 0 Cl CF 3 H H C 3 H 7 bond Gil - 7308 CH 2 Cl OCH 3 H H C 3 H 7 bond Gil - 7309 CH 2 Cl OCF 3 H H C 3 H 7 bond Gil - 7310 CH 2 CH 3 OCH 3 Cl H C 3 H 7 bond Gil - 7311 CHj Cl Cl H CH 3 C 3 H 7 bond Gil - 7312 CH J CF 3 OCH 3 H H C 3 H 7 bond Gil - 7313 CH 2 Cl Cl H H C 6 H 5 bond Gil 156-157 7314 0 Cl Cl H H C 6 H 5 bond Gil - 7315 CH 2 Cl CF 3 H H C 6 H 5 bond Gil 150-151 7316 0 Cl CF 3 H H C 6 H 5 bond Gi l 7317 CH 2 Cl OCH 3 H H C 6 H 5 bond Gi l 7318 CH 2 Cl OCF 3 H H C 6 H 5 bond Gi l 7319 CH 2 CH 3 OCH 3 Cl H C 6 H 5 bond Gi l 7320 CH 2 Cl Cl H CH 3 C 6 H 5 bond Gil 7321 CH 2 CF 3 OCH 3 H H C 6 H 5 bond Gil 7322 CHj Cl Cl H H C 2 H 5 bond G12 7323 0 Cl Cl H H C 2 H 5 bond G12 7324 CHj Cl CF 3 H H C 2 H 5 bond G12 oil 7325 0 Cl CF 3 H H C 2 H 5 bond G12 7326 CH 2 Cl OCH 3 H H C 2 H 5 bond G12 7327 CH 2 Cl OCF 3 H H C 2 H 5 bond G12 7328 CHj CH 3 OCH 3 Cl H C 2 H 5 bond G12 7329 CH J Cl Cl H CH 3 C 2 H 5 bond G12 7330 CH J CF 3 OCH 3 H H C 2 H 5 bond G12 7331 CH J Cl Cl H H C 3 H 7 bond G12 7332 0 Cl Cl H H C 3 H 7 bond G12 7333 CH j Cl CF 3 H H C 3 H 7 bond G12 7334 0 Cl CF 3 H H C 3 H 7 bond G12 7335 CH 2 Cl OCH 3 H H C 3 H 7 bond G12 7336 CH 2 Cl OCF 3 H H C 3 H 7 bond G12 7337 CH 2 CH 3 OCH 3 Cl H C 3 H 7 bond G12 7338 CH 2 Cl Cl H CH 3 C 3 H 7 bond G12 7339 CHj CF 3 OCH 3 H H C 3 H 7 bond G12 7340 CH J Cl Cl H H c-C 3 H 5 bond G12 7341 0 Cl Cl H H c-C 3 H 5 bond G12 7342 CHj Cl CF 3 H H c-C 3 H 5 bond G12 128 -130 7343 0 Cl CF 3 H H c-C 3 H 5 bond G12 7344 CHj Cl OCH 3 H H c-C 3 H 5 bond G12 7345 CH J Cl OCF 3 H H c-C 3 H 5 bond G12 7346 CH J CH 3 OCH 3 Cl H c-C 3 H 5 bond G12 7347 CH J Cl Cl H CH 3 c-C 3 H 5 bond G12 7348 CH 2 CF 3 OCH 3 H H c-C 3 H 5 bond G12 7349 CH 2 Cl CF 3 H H c-C 3 H 5 bond G13 oil 7350 CH 2 Cl Cl H H c-C 3 H 5 bond G13 7351 CH 2 Cl CF 3 H H c-C 3 H 5 bond G7 oil 7352 CH 2 Cl Cl H H c-C 3 H 5 bond G7 oil 7353 CH 2 Cl CF 3 H H CH 3 bond G7 7354 CH 2 Cl Cl H H CH 3 bond G7 - 7355 CH 2 CH 3 OCH 3 CH 3 H CH 3 bond G7 oil 7356 CH 2 CH 3 OCH 3 CH 3 H C 3 H 7 bond G7 oil 7357 CH 2 CF 3 OCH 3 H H C 3 H 7 bond G7 oil 7358 CH 2 CH 3 OCH 3 CH 3 H C H bond G7 oil 7359 CH 2 Cl Cl H CH 3 c-C 3 H 5 bond G7 156-158 7360 CH 2 CF 3 OCH 3 H H CH 3 bond G8 oil 7361 CH 2 CH 3 OCH 3 OCH 3 H C 2 H 5 bond G10 oil 7362 0 Cl Cl H H CH 3 bond Gl - 7363 0 Cl CF 3 H H CH 3 bond Gl - 7364 CH 2 Cl OCF 3 H H CH 3 bond Gl - 7365 CH 2 CH 3 OCH 3 Cl H CH 3 bond Gl - 7366 CH 2 Cl Cl H CH 3 CH 3 bond Gl - 7367 CH 2 CF 3 OCH 3 H H CH 3 bond Gl - 7368 CHj CH 3 OCH 3 F H CH 3 bond Gl - 7369 0 Cl Cl H H C 2 H 5 bond Gl - 7370 0 Cl CF 3 H H C 2 H 5 bond Gl - 7371 CH j Cl OCF 3 H H C 2 H 5 bond Gl - 7372 CHj CH 3 OCH 3 Cl H C 2 H 5 bond Gl - 7373 CH 2 Cl Cl H CH 3 C 2 H 5 bond Gl - 7374 CH j CF 3 OCH 3 H H C 2 H 5 bond Gl - 7375 CH J CH 3 OCH 3 F H C 2 H 5 bond Gl - 7376 0 Cl Cl H H C 3 H 7 bond Gl - 7377 0 Cl CF 3 H H C 3 H 7 bond Gl - 7378 CHJ Cl OCF 3 H H C 3 H 7 bond Gl - 7379 CH 2 CH 3 OCH 3 Cl H C 3 H 7 bond Gl - 7380 CHj Cl Cl H CH 3 C 3 H 7 bond Gl - 7381 CHJ CF 3 OCH 3 H H C 3 H 7 bond Gl - 7382 CHJ CH 3 OCH 3 F H C 3 H 7 bond Gl - 7383 0 Cl Cl H H c-C 3 H 5 bond Gl - 7384 0 Cl CF 3 H H c-C 3 H 5 bond Gl - 7385 CH 2 Cl OCF 3 H H c-C 3 H 5 bond Gl - 7386 CH 2 CH 3 OCH 3 Cl H c-C 3 H 5 bond Gl - 7387 CH 2 Cl Cl H CH 3 c-C 3 H 5 bond Gl - 7388 CH 2 CF 3 OCH 3 H H c-C 3 H 5 bond Gl - 7389 CH 2 CH 3 OCH 3 F H c-C 3 H 5 bond Gl - 7390 CH 2 Cl CF 3 H H c-C 3 H 5 bond G14 oil 7391 CH 2 Cl Cl H H c-C 3 H 5 bond G14 - 7391 CH 2 Cl CF 3 H H C-C 3 H 5 bond G15 oi l 7392 CH 2 Cl Cl H H c-C 3 H 5 bond G15 - 7393 CH 2 Cl CF 3 H H c-C 3 H 5 bond G16 139 - 140 7394 CH 2 Cl Cl H H C-C 3 H 5 bond G16 - 7395 CH 2 Cl CF 3 H H c-C 3 H 5 bond G17 - 7396 CH 2 Cl Cl H H c-C 3 H 5 bond G17 oil 7397 CH 2 Cl CF 3 H H c-C 3 H 5 bond G18 - 7398 CHj Cl Cl H H c-C 3 H 5 bond G18 oi l 7399 CHj Cl ci H CH 3 CH 3 bboonndd G8 oi l 7400 CH 2 Cl CF 3 H H c-C 3 H 5 bond G19 7401 CH 2 Cl Cl H H c-C 3 H 5 bond G19 oil 7402 CH 2 Cl Cl H H c-C 3 H 5 bond G20 oi l 7403 CH 2 Cl CF 3 H H c-CjHj bond G20 7404 CH 2 Cl Cl H H C 4 H 9 bond Gl oil 7405 CH 2 Cl Cl H H C 6 H 5 C=0 C 6 H oil 5 7406 CH j Cl Cl H H C 6 H 5 C-=0 G21 oil 7407 CH J Cl Cl H H C 6 H 5 C=0 G22 oil 7408 CH 2 Cl Cl H H 4-F- C=0 CH 3 oil C 6 H 4 CH 2 7409 CH, Cl Cl H c-C 3 H 5 bond G23 oi l Key : ( a) G groups : Gl K G2 KD G7 CH=CH 2 G8 = E-CH=CH-CH 3 (b) Where a compound is indicated as an "oil", spectral data is provided as follows: Example 7056 spectral data: MS (ESI): m/e 363 (M+2) , 361 (M\ 100%). Example 7086 spectral data: TLC R P 0.25 (30:70 ethyl acetate-hexane) X H NMR (300 MHz, CDC1 3 ) : δ 8.91 (IH, s) , 7.72 (IH, d, J = 9.2 Hz), 6.90-6.84 (2H, m) , 6.08 (IH, ddq, J = 15.4 Hz, 6.6H, 1.4 Hz), 5.67 (IH, dqd, J = 15.4 Hz, 6.5H, 1.5 Hz), 5.24 (IH, br pentet, J = 7.0 Hz), 3.85 (3H, s) , 2.96 (2H, dq, J = 7.5, 1.1 Hz), 2.47 (3H, s) , 1.81 (3H, d, J = 7.0 Hz), 1.73 (3H, dt, J = 6.2, 1.3 Hz), 1.41 (3H, t, J = 7.5 Hz). MS (NH 3 -CI) : m/e 339 (3), 338 (23), 337 (100). Example 7116 spectral data: TLC R r 0.15 (30:70 ethyl acetate-hexane). *H NMR (300 MHz, CDC1 3 ) : δ 8.96 (IH, s) , 7.68 (IH, d, J = 8.4 Hz), 7.09 (IH, d, J = 2.6 Hz), 6.96 (IH, dd, J = 8.4, 2.6 Hz), 6.09 (IH, ddq, J = 15.4 Hz, 6.6H, 1.8 Hz), 5.67 (IH, dqd, J = 15.4 Hz, 6.5H, 1.4 Hz), 5.23 (IH, br pentet, J = 6.8 Hz), 3.87 (3H, s) , 2.98 (2H, q, J = 7.5 Hz), 1.82 (3H, d, J = 7.0 Hz), 1.73 (3H, dt, J = 6.6, 1.3 Hz), 1.40 (3H, t, J = 7.5 Hz). MS (NH 3 -CI): m/e 360 (7), 359 (33), 358 (23), 357 (100). Example 7145 spectral data: m.p. 78-79 °C. TLC R P 0.52 (30:70 ethyl acetate-hexane) . J H NMR (300 MHz, CDC1 3 ) : 8 9.01 (IH, s) , 7.86-7.81 (2H, m) , 7.68 (IH, d, J = 8.0 Hz), 6.38 (2H, ddd, J = 17.2 Hz, 10.6H, 5.8 Hz), 5.90-5.83 (IH, m) , 5.40 (2H, dd, J = 10.6, 1.3 Hz) , 5.29 (2H, dt, J = 17.2, 0.9 Hz) , 2.97 (2H, q, J = 7.6 Hz) , 1.41 (3H, t, J = 7.6 Hz) . MS (NHj-CI) : m/e 396 (8), 395 (36) , 394 (25) , 393 (100) . Analysis calculated for C 19 H 16 C1F 3 N 4 : C, 58.10; H, 4.12; N, 14.26; found: C, 58.14; H, 4.28; N, 13.74. Example 7146 spectral data: TLC R F 0.43 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 8.99 (IH, s) , 7.84-7.79 (2H, m) , 7.67 (IH, dd, J = 8.5, 1.1 Hz) , 6.10 (IH, ddq, J = 15.4 Hz, 6.8H, 1.8 Hz) , 5.70 (IH, dqd, J = 15.4 Hz, 6.5H, 1.1 Hz) , 5.24 (IH, pentet, J = 7.0 Hz), 2.99 (2H, q, J = 7.5 Hz), 1.83 (3H, d, J = 7.0 Hz) , 1.74 (3H, dt, J = 6.6, 1.3 Hz) , 1.40 (3H, t, J = 7.5 Hz) . MS (NH 3 -CI) : m/e 398 (7) , 397 (36) , 396 (25) , 395 (100) . Example 7231 spectral data: m.p. 78-88 °C. TLC R F 0.55 (50:50 ethyl acetate-hexane). *H NMR (300 MHz, CDC1 3 ) : Major isomer: δ 8.90 (IH, s) , 6.95 (2H, s), 4.68-3.05 (6H, m) , 3.02-2.92 (2H, m) , 2.70-2.55 (2H, m) , 2.32 (3H, s), 2.20-2.00 (2H, m) , 2.05 (3H, s) , 1.96 (3H, s) , 1.70-1.45 (4H, m) , 1.39 (3H, t, J = 7.7 Hz), 0.93 (3H, t, J = 7.3 Hz); Minor isomer: δ 8.89 (IH, s) , 6.95 (2H, s) , 4.68-3.05 (6H, m) , 3.02-2.92 (2H, m) , 2.70-2.55 (2H, m) , 2.32 (3H, s) , 2.20-2.00 (2H, m) , 2.06 (3H, s) , 2.01 (3H, s), 1.70-1.45 (4H, m) , 1.38 (3H, t, J = 7.7 Hz), 0.90 (3H, t, J = 7.3 Hz) . MS (NH 3 -CI) : m/e calc'd for C 25 H 35 N 4 0 2 : 423.2760, found 423.2748; 425 (5) , 424 (29), 423 (100) . Analysis calc'd for C 25 H 34 N 4 0 2 »H 2 0: C, 68.15; H, 8.24; N, 12.72; found: C, 67.80; H, 7.89; N, 12.24. Example 7234 spectral data: TLC R F 0.46 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 8.99 (IH, s) , 7.87 (IH, d, J = 8.0 Hz) , 7.83 (IH, s), 7.68 (IH, d, J = 8.0 Hz), 6.50 (IH, d, J = 3.0 Hz), 5.99 (IH, d, J = 3.0 Hz), 5.10 (IH, d, J = 10.6 Hz) , 2.99-2.79 (2H, m) , 2.20 (3H, s) , 2.10-2.00 (IH, m) , 1.30 (3H, t, J = 7.5 Hz), 1.00-0.90 (IH, m) , 0.71- 0.59 (2H, m) , 0.56-0.46 (IH, m) . MS (NH 3 -CI) : m/e 463 (35), 461 (100) . Example 7241 spectral data: MS (NH 3 -CI) : m/e 371 (M+H\ 100%) . Example 7243 spectral data: TLC R F 0.43 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 9.01 (IH, s) , 7.85 (IH, d, J = 8.0 Hz) , 7.83 (IH, s) , 7.69 (IH, d, J = 8.0 Hz), 5.24 (IH, dd, J = 8.4, 2.5 Hz) , 3.28 (IH, dq, J = 15.5, 7.5 Hz), 3.14 (IH, dq, J = 15.5, 7.5 Hz) , 2.56 (IH, d, J = 2.5 Hz), 1.78-1.67 (IH, m) , 1.48 (3H, t, J = 7.5 Hz) , 0.92-0.81 (2H, m) , 0.66-0.49 (2H, m) . MS (NH 3 -CI): m/e calculated for C 20 H 17 C1F 3 N 4 : 405.1094, found 405.1098; 408 (8), 407 (34), 406 (25), 405 (100) . Example 7249 spectral data: TLC R F 0.19 (30:70 ethyl acetate-hexane). *H NMR (300 MHz, CDC1 3 ) : δ 8.93 (IH, s), 7.72 (IH, d, J = 8.5 Hz), 7.37 (IH, d, J = 2.5 Hz), 7.18 (IH, dd, J = 8.5, 2.5 Hz), 5.23 (IH, dd, J = 8.1, 2.6 Hz), 3.92 (3H, s), 3.31-3.04 (2H, m) , 2.54 (IH, d, J = 2.6 Hz), 1.76-1.64 (IH, m) , 1.47 (3H, t, J = 7.5 Hz), 0.90-0.80 (2H, m) , 0.64- 0.52 (2H, m) . MS (NH 3 -CI) : m/e calc'd for C 21 H 20 F 3 N 4 O: 401.1603, found 401.1602; 403 (6), 402 (24), 401 (100). Example 7250 spectral data: TLC R F 0.17 (20:80 ethyl acetate-hexane) . * -H NMR (300 MHz, CDC1 3 ) : δ 9.01 (IH, s), 7.67 (IH, d, J = 8.5 Hz), 7.58 (IH, d, J = 1.8 Hz), 7.41 (IH, dd, J = 8.5, 1.8 Hz), 5.53 (IH, dt, J = 8.0, 2.6 Hz), 3.20 (IH, dq, J = 15.8, 7.5 Hz), 3.05 (IH, dq, J = 15.8, 7.5 Hz), 2.55 (IH, d, J = 2.6 Hz), 2.42-2.29 (IH, m) , 2.28-2.15 (IH, m) , 1.46 (3H, t, J = 7.5 Hz), 1.04 (3H, t, J = 7.5 Hz). MS (NH 3 -CI) : m/e calc'd for C 18 H 17 C1 2 N 4 : 359.0830, found 359.0835; 364 (2), 363 (12), 362 (14), 361 (67), 360 (24), 359 (100). Example 7259 spectral data: TLC R F 0.22 (20:80 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 9.01 (IH, s) , 7.67 (IH, d, J = 8.1 Hz), 7.58 (IH, d, J = 1.8 Hz), 7.40 (IH, dd, J = 8.1, 1.8 Hz), 5.63 (IH, dt, J = 7.9, 2.5 Hz), 3.20 (IH, dq, J = 15.7, 7.7 Hz), 3.05 (IH, dq, J = 15.7, 7.7 Hz), 2.54 (IH, d, J = 2.5 Hz), 2.37-2.24 (IH, m) , 2.19-2.06 (IH, m) , 1.60-1.45 (IH, m) , 1.46 (3H, t, J = 7.7 Hz), 1.39-1.25 (IH, m) , 0.99 (3H, t, J = 7.3 Hz). MS (NH 3 -CI) : m/e calc'd for C 19 H 19 C1 2 N 4 : 373.0987, found 373.0984; 378 (3), 377 (12), 376 (15), 375 (66), 374 (26), 373 (100) . Example 7261 spectral data: TLC R F 0.52 (30:70 ethyl acetate-hexane). α H NMR (300 MHz, CDCl 3 ) : δ 9.03 (IH, s) , 7.84 (2H, m) , 7.68 (IH, dd, J = 7.3, 0.7 Hz), 5.65 (IH, dt, J = 8.1, 2.6 Hz), 3.24-3.02 (2H, m) , 2.55 (IH, d, J = 2.6 Hz), 2.33-2.25 (IH, m) , 2.20-2.12 (IH, m) , 1.46 (3H, t, J = 7.5 Hz), 1.00 (3H, t, J = 7.3 Hz). MS (NH 3 -CI) : m/e calc'd for C 20 H 19 C1F 3 N 4 : 407.1250, found 407.1243; 410 (8), 409 (36), 408 (25), 407 (100) . Example 7266 spectral data: TLC R F 0.19 (20:80 ethyl acetate-hexane) . l H NMR (300 MHz, CDC1 3 ) : δ 9.01 (IH, d, J = 1.5 Hz), 7.38 (IH, d, J = 1.8 Hz), 7.24 (IH, d, J = 1.8 Hz), 5.70-5.58 (IH, m) , 3.24-3.00 (2H, m) , ^ 2.55 (IH, d, J = 2.5 Hz), 2.40-2.25 (IH, m) , 2.20-2.05 (IH, m) , 2.10 (3H, d, J = 1.8 Hz), 1.62-1.47 (IH, m) , 1.43 (3H, t, J = 7.5 Hz), 1.42- 1.27 (IH, m) , 1.00 (3H, , J = 7.3 Hz) . MS (NH 3 -CI) : m/e calc'd for C 20 H 21 C1 2 N 4 : 387.1143, found 387.1144; 392 (3) , 391 (12) , 390 (16) , 389 (66) , 388 (27) , 387 (100) . Example 7268 spectral data: TLC R F 0.29 (20:80 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 9.01 (IH, s) , 7.67 (IH, d, J = 8.5 Hz) , 7.58 (IH, d, J = 2.2 Hz) , 7.41 (IH, dd, J = 8.5, 2.2 Hz), 5.60 (IH, dt, J = 7.9, 2.6 Hz), 3.19 (IH, dq, J = 15.3, 7.3 Hz) , 3.05 (IH, dq, J = 15.3, 7.3 Hz), 2.54 (IH, d, J = 2.6 Hz) , 2.38-2.23 (IH, m) , 2.20-2.05 (IH, m) , 1.58-1.44 (IH, m) , 1.46 (3H, t, J = 7.3 Hz) , 1.40-1.23 (5H, m) , 0.87 (3H, t, J = 7.0 Hz) . MS (NH 3 -CI) : m/e calc'd for C 21 H 23 C1 2 N 4 : 401.1300, found 401.1300; 406 (3) , 405 (13) , 404 (17) , 403 (69) , 402 (28) , 401 (100) . Example 7270 spectral data: TLC R F 0.60 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 9.03 (IH, s) , 7.84 (2H, m) , 7.68 (IH, dd, J = 9.1, 0.7 Hz), 5.62 (IH, dt , J = 8.1, 2.6 Hz) , 3.24-3.02 (2H, m) , 2.55 (IH, d, J = 2.6 Hz), 2.34-2.27 (IH, m) , 2.19-2.13 (IH, m) , 1.46 (3H, t, J = 7.3 Hz) , 1.40-1.25 (6H, m) , 0.88 (3H, t, J = 7.0 Hz) . MS (NH 3 -CI) : m/e calc'd for C 22 H 23 C1F 3 N 4 : 435.1563, found 435.1566; 438 (9), 437 (36) , 436 (27) , 435 (100) . Example 7279 spectral data: TLC R F 0.31 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 8.97 (IH, s) , 7.84 (2H, m) , 7.68 (IH, d, J = 7.7 Hz) , 4.74-4.67 (IH, m) , 3.45-3.36 (IH, m) , 3.03 (2H, q, J = 7.7 Hz), 3.00-2.93 (IH, m) , 1.93 (IH, t, J = 2.7 Hz) , 1.86 (3H, d, J = 7.0 Hz), 1.43 (3H, t, J = 7.5 Hz) . MS (NH 3 -CI) : m/e 396 (7) , 395 (34), 394 (24), 393 (100) . Example 7286 spectral data: TLC R P 0.29 (20:80 ethyl acetate-hexane). H NMR (300 MHz, CDC1 3 ) : δ 8.97 (IH, s) , 7.68 (IH, d, J = 8.4 Hz), 7.58 (IH, d, J = 1.8 Hz), 7.41 (IH, dd, J = 8.4, 1.8 Hz), 5.19 (IH, dq, J = 8.4, 2.6 Hz), 3.26 (IH, dq, J = 15.7, 7.3 Hz), 3.14 (IH, dq, J = 15.7, 7.3 Hz), 1.88 (3H, d, J = 2.6 Hz), 1.70-1.60 (IH, m) , 1.47 (3H, t, J = 7.3 Hz), 0.89-0.78 (2H, m) , 0.60-0.43 (2H, m) . MS (NH 3 -CI) : m/e calc'd for C 20 H 19 C1 2 N 4 : 385.0986, found 385.0992; 390 (3), 389 (12), 388 (15), 387 (66), 386 (26), 385 (100). Example 7288 spectral data: MS (NH 3 -CI) : m/e 419 (M+H\ 100%). Example 7295 spectral data: TLC R F 0.19 (20:80 ethyl acetate-hexane). 1 H NMR (300 MHz, CDC1 3 ) : δ 8.99 (IH, s) , 7.67 (IH, d, J = 8.4 Hz), 7.57 (IH, d, J = 2.2 Hz), 7.40 (IH, dd, J = 8.4, 2.2 Hz), 5.49 (IH, tq, J = 7.7, 2.2 Hz), 3.19 (IH, dq, J = 15.3, 7.7 Hz), 3.05 (IH, dq, J = 15.3, 7.7 Hz) , 2.26 (IH, dq, J = 21.3, 7.7 Hz) , 2.13 (IH, dq, J = 21.3, 7.7 Hz) , 1.87 (3H, d, J = 2.2 Hz) , 1.45 (3H, t, J = 7.7 Hz) , 1.01 (3H, t, J = 7.7 Hz) . MS (NH 3 -CI) : m/e calc'd for C 19 H 19 C1 2 N 4 : 373.0987, found 373.0987; 378 (3) , 377 (13) , 376 (15) , 375 (68) , 374 (25) , 373 (100) . Example 7297 spectral data: TLC R F 0.48 (30:70 ethyl acetate-hexane) . X W NMR (300 MHz, CDC1 3 ) : δ 9.01 (IH, s) , 7.83 (2H, m) , 7.67 (IH, dd, J = 7.4, 0.8 Hz) , 5.51 (IH, dt, J = 8.1, 2.2 Hz) , 3.25-3.03 (2H, m) , 2.35- 2.13 (2H, m) , 1.88 (3H, d, J = 2.2 Hz), 1.45 (3H, t, J = 7.5 Hz) , 1.01 (3H, t, J = 7.3 Hz) . MS (NH 3 -CI) : m/e calc'd for C 20 H 19 C1F 3 N 4 : 407.1250, found 407.1267; 410 (8) , 409 (35) , 408 (25) , 407 (100) . Example 7306 spectral data: MS (NH 3 -CI) : m/e 421 (M+H\ 100%) . Example 7324 spectral data: TLC R F 0.38 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 8.99 (IH, s) , 7.84 (IH, d, J = 8.4 Hz) , 7.83 (IH, d, J = 1.8 Hz) , 7.68 (IH, dd, J = 8.4, 1.8 Hz), 7.36 (IH, d, J = 3 Hz) , 6.51 (IH, d, J = 5 Hz) , 6.39 (IH, dd, J = 5, 3 Hz) , 5.78 (IH, dd, J = 9, 7 Hz) , 3.00-2.85 (2H, m) , 2.75-2.52 (2H, m) , 1.37 (3H, t, J = 7.5 Hz) , 0.98 (3H, t, J = 7.5 Hz) . MS (NH 3 -CI) : m/e 439 (1) , 438 (8), 437 (34), 436 (26) , 435 (100) . Example 7349 spectral data: TLC R F 0.20 (30:70 ethyl acetate-hexane) . l K NMR (300 MHz, CDC1 3 ) : δ 9.00 (IH, s), 7.87 (IH, d, J = 8.0 Hz) , 7.83 (IH, s), 7.69 (IH, d, J = 8.0 Hz) , 5.01 (IH, d, J = 10.6 Hz) , 2.93 (IH, dq, J = 15.9, 7.5 Hz) , 2.75 (IH, dq, J = 15.9, 7.5 Hz) , 2.58 (3H, s) , 2.04- 1.94 (IH, m) , 1.93 (3H, s) , 1.33 (3H, t, J * = 7.5 Hz), 1.32-1.22 (IH, m) , 1.00-0.87 (IH, m) , 0.74-0.60 (3H, m) . MS (NH 3 -CI) : m/e calculated for C 23 H 22 C1F 3 N 5 0: 476.1465, found 476.1469; 478 (35), 476 (100) . Example 7351 spectral data: TLC R F 0.44 (30:70 ethyl acetate-hexane) . H NMR (300 MHz, CDC1 3 ) : δ 8.99 (IH, s) , 7.88-7.82 (2H, m) , 7.68 (IH, d, J = 8.0 Hz), 6.35 (IH, ddd, J = 17.2 Hz, 10.6H, 5.1 Hz), 5.33 (IH, br d, J = 10.6 Hz), 5.26 (IH, br d, J - 17.2 Hz), 4.43-4.37 (IH, m) , 3.02-2.90 (2H, m) , 1.99-1.89 (IH, m) , 1.41 (3H, t, J = 7.5 Hz), 0.94-0.84 (IH, m) , 0.62-0.52 (2H, m) , 0.40-0.30 (IH, m) . MS (NH 3 -CI) : m/e 411 (1) , 410 (7) , 409 (34) , 408 (25) , 407 (100) . Example 7352 spectral data: TLC R F 0.13 (20:80 ethyl acetate-hexane) . H NMR (300 MHz, CDCl 3 ) : δ 8.96 (IH, s) , 7.69 (IH, d, J = 8.4 Hz), 7.58 (IH, d, J = 2.2 Hz) , 7.41 (IH, dd, J = 8.8, 2.2 Hz), 6.33 (IH, ddd, J = 17.2, 10.6, 5.2 Hz), 5.35-5.20 (2H, m) , 4.42-4.35 (IH, m) , 3.03-2.88 (2H, m) , 2.00-1.89 (IH, m) , 1.40 (3H, t, J = 7.6 Hz) , 0.92-0.82 (IH, m) , 0.62- 0.52 (2H, m) , 0.40-0.30 (IH, m) . MS (NH 3 -CI) : m/e calc'd for C 19 H 19 C1 2 N 4 : 373.1000, found 373.0995; 378 (3) , 377 (12) , 376 (15) , 375 (66) , 374 (26) , 373 (100) . Example 7355 spectral data: MS (NH 3 -CI) : m/e 337 (M+H\ 100%) . Example 7356 spectral data: MS (NH 3 -CI) : m/e 365 (M+H * , 100%) . Example 7357 spectral data: TLC R F 0.19 (30:70 ethyl acetate-hexane) . Η NMR (300 MHz, CDC1 3 ) : δ 8.91 (IH, s) , 7.70 (IH, d, J = 8.4 Hz) , 7.35 (IH, d, J = 2.6 Hz), 7.19 (IH, dd, J = 8.4, 2.6 Hz) , 6.42 (IH, ddd, J = 16.9, 10.3, 6.6 Hz) , 5.27 (IH, d, J = 10.2 Hz) , 5.14 (IH, d, J = 17.3 Hz), 5.08-4.99 (IH, m) , 3.91 (3H, s) , 2.99-2.90 (2H, m) , 2.42-2.29 (IH, m) , 2.27-2.15 (IH, m) , 1.39 (3H, t, J = 7.5 Hz) , 1.38-1.10 (2H, m) , 0.95 (3H, t, J = 7.1 Hz) . MS (NHj-CI) : m/e calc'd for C 21 H 24 F 3 N 4 0: 405.1915, found 405.1923; 407 (5) , 406 (24) , 405 (100) . Analysis calc'd for C 21 H 23 F 3 N 4 0: C, 62.37; H, 5.73; N, 13.85; found: C, 62.42; H, 5.73; N, 13.48. Example 7358 spectral data: MS (NH 3 -CI) : m/e 379 (M+H + , 100%) . Example 7360 spectral data: TLC R F 0.13 (30:70 ethyl acetate-hexane) . Η NMR (300 MHz, CDC1 3 ) : δ 8.91 (IH, s), 7.68 (IH, d, J = 8.8 Hz) , 7.35 (IH, d, J = 2.6 Hz) , 7.16 (IH, dd, J = 8.8, 2.6 Hz) , 6.15-6.05 (IH, m) , 5.73- 5.63 (IH, m) , 5.28-5.18 (IH, m) , 3.91 (3H, s) , 2.96 (2H, q, J = 7.4 Hz), 1.82 (3H, d, J = 7.3 Hz) , 1.74 (3H, dt, J = 6.6, 1.3 Hz) , 1.39 (3H, t, J = 7.4 Hz) . MS (NH 3 -CI) : m/e calc'd for C 20 H 22 F 3 N 4 O: 391.1733, found 391.1736; 393 (3) , 392 (23) , 391 (100) . Example 7361 spectral data: TLC R F 0.43 (50:50 ethyl acetate-hexane) . Η NMR (300 MHz, CDC1 3 ) : δ 8.96 (IH, s) , 7.42 (IH, s) , 6.84 (IH, s) , 5.55 (IH, dt, J = 5.5, 2.2 Hz) , 3.94 (3H, s) , 3.92 (3H, s) , 3.49-2.98 (2H, m) , 2.54 (IH, d, J = 2.6 Hz), 2.45 (3H, s) , 2.35-2.16 (2H, m) , 1.48 (3H, t, J = 7.5 Hz) , 1.03 (3H, t, J = 7.5 Hz) . MS (NH 3 -CI) : m/e calc'd for C 21 H 25 N 4 0 2 : 365.1978, found 365.1966; 367 (6), 366 (24) , 365 (100) . Example 7390 spectral data: TLC R F 0.45 (30:70 ethyl acetate-hexane) . Η NMR (300 MHz, CDC1 3 ) : δ 8.99 (IH, s) , 7.88 (IH, d, J = 8.0 Hz) , 7.83 (IH, s) , 7.69 (IH, d, J = 8.0 Hz) , 7.30-7.22 (IH, m) , 7.07-7.01 (IH, m) , 6.99-6.92 (IH, m) , 5.25 (IH, d, J = 10.2 Hz) , 2.97-2.78 (2H, m) , 2.23 (IH, br) , 1.32 (3H, t, J = 7.3 Hz), 1.10-1.00 (IH, m) , 0.81-0.71 (IH, m) , 0.64-0.54 (IH, m) , 0.50-0.40 (IH, m) . MS (NH 3 -CI) : m/e calc'd for C 22 H 19 C1F 3 N 4 S: 463.0971, found 463.0960; 467 (3), 466 (10) , 465 (99) , 464 (28) , 463 (100) . Example 7392 spectral data: TLC R F 0.44 (30:70 ethyl acetate-hexane) . Η NMR (300 MHz, CDC1 3 ) : δ 8.99 (lh, s), 7.88 (IH, d, J = 8.0 Hz), 7.83 (IH, s), 7.68 (IH, d, J = 8.0 Hz), 7.30 (IH, br d, J = 4.8 Hz), 7.18 (IH, br d, J = 4.8 Hz), 6.92 (IH, m) , 5.12 (IH, d, J = 9.9 Hz), 2.92-2.67 (2H, m) , 2.13 (IH, br) , 1.28 (3H, t, J = 7.5 Hz), 1.08-0.99 (IH, m) , 0.79- 0.69 (IH, m) , 0.55-0.45 (2H, m) . MS (NH 3 -CI) : m/e calculated for C 22 H 19 C1F 3 N 4 S: 463.0971, found 463.0953; 467 (3), 466 (10), 465 (39), 464 (29) , 463 (100) . Example 7396 spectral data: TLC R F 0.27 (20:80 ethyl acetate-hexane). * Η NMR (300 MHz, CDC1 3 ) : δ 8.96 (IH, s) , 7.67 (IH, d, J = 8.1 Hz), 7.58 (IH, d, J = 1.8 Hz), 7.41 (IH, dd, J = 8.1, 1.8 Hz), 6.86 (IH, s) , 5.83 (IH, dd, J = 9.9, 6.2 Hz), 4.43 (2H, q, J = 7.3 Hz), 2.98 (2H, q, J = 7.7 Hz), 2.91-2.78 (IH, m) , 2.63-2.49 (IH, m) , 1.42 (3H, t, J = 7.7 Hz), 1.40 (3H, t, J = 7.3 Hz), 1.39-1.19 (2H, m) , 1.00 (3H, t, J = 7.3 Hz) . MS (NHj-CI) : m/e calc'd for C 23 H 24 C1 2 N 5 0 3 : 488.1256, found 488.1252; 493 (3), 492 (13), 491 (18), 490 (68), 489 (28), 488 (100). Example 7398 spectral data: TLC R F 0.11 (20:80 ethyl acetate-hexane) . Η NMR (300 MHz, CDC1 3 ) : δ 8.99 (IH, s), 7.72 (IH, d, J = 8.1 Hz), 7.59 (IH, d, J . = 1.8 Hz), 7.42 (IH, dd, J = 8.1, 1.8 Hz), 5.40 (IH, dd, J = 10.4, 5.0 Hz), 4.42 (2H, q, J = 7.4 Hz), 3.00-2.90 (2H, m) , 2.66-2.52 (IH, m) , 2.51-2.38 (IH, m) , 1.46 (3H, t, J = 7.4 Hz), 1.41 (3H, t, J = 7.3 Hz), 1.40-1.10 (2H, m) , 0.98 (3H, t, J = 7.2 Hz) . MS (NH 3 -CI) : m/e calc'd for C 24 H 25 C1 2 N 6 0 4 : 531.1315, found 531.1315; 531 (100). Example 7399 spectral data: TLC R F 0.13 (20:80 ethyl acetate-hexane). Η NMR (300 MHz, CDC1 3 ) : δ 8.98 (IH, s), 7.38 (IH, d, J = 1.8 Hz), 7.23 (IH, d, J = 1.8 Hz), 6.15-6.06 (IH, m) , 5.76-5.63 (IH, m) , 5.26-5.20 (IH, m) , 2.96 (2H, q, J = 7.4 Hz), 2.10 (3H, s) , 1.83 (3H, d, J = 7.0 Hz), 1.74 (3H, d, J = 6.6 Hz), 1.37 (3H, t, J = 7.4 Hz) . MS (NH 3 -CI) : m/e calc'd for C 19 H 21 C1 2 N 4 : 375.1117, found 375.1123; 380 (2), 379 (12), 378 (15), 377 (66), 376 (26), 375 (100). Example 7401 spectral data: TLC R F 0.20 (ethyl acetate). Η NMR (300 MHz, CDC1 3 ) : δ 8.99 (IH, s) , 7.71 (IH, d, J = 8.4 Hz), 7.58 (IH, d, J = 1.8 Hz), 7.41 (IH, dd, J = 8.4, 1.8 Hz), 7.11 (IH, d, J = 1.1 Hz), 6.87 (IH, d, J = 1.1 Hz), 5.41 (IH, d, J = 10.3 Hz), 3.34 (3H, s) , 3.08 (IH, dq, J = 15.8, 7.7 Hz), 2.89 (IH, dq, J = 15.8, 7.7 Hz), 2.39-2.25 (IH, m) , 1.14 (3H, t, J = 7.7 Hz), 1.07-0.97 (IH, m) , 0.70-0.58 (2H, m) , 0.52- 0.42 (IH, m) . MS (NH 3 -CI) : m/e calc'd for C 21 H 21 C1 2 N 6 : 427.1205, found 427.1196; 429 (66), 427 (100). Example 7402 spectral data: MS (NH 3 -CI) : m/e 424 (M+H + , 100%). Example 7404 spectral data: MS (NH 3 -CI) : m/e 419 (M+H * , 100%). Example 7405 spectral data: MS (NH 3 -CI) : m/e 487 (M+H\ 100%) . Example 7406 spectral data: MS (NH 3 -CI) : m/e 501 (M+H + , 100%) . Example 7407 spectral data: MS (NH 3 -CI) : m/e 517 (M+H\ 100%). Example 7408 spectral data: MS (NH 3 -CI) : m/e 457 (M+H\ 100%) . Example 7409 spectral data: MS (NH 3 -CI) : m/e 429 (M+H * , 100%) . Utility CRF-Rl Receptor Binding Assay for the Evaluation of Biological Activity The following is a description of the isolation of cell membranes containing cloned human CRF-Rl receptors for use in the standard binding assay as well as a description of the assay itself. Messenger RNA was isolated from human hippocampus. The mRNA was reverse transcribed using oligo (dt) 12-18 and the coding region was amplified by PCR from start to stop codons The resulting PCR fragment was cloned into the EcoRV site of pGEMV, from whence the insert was reclaimed using Xhol + Xbal and cloned into the Xhol + Xbal sites of vector pm3ar (which contains a CMV promoter, the SV40 't' splice and early poly A signals, an Epstein-Barr viral origin of replication, and a hygromycin selectable marker) . The resulting expression vector, called phchCRFR was transfected in 293EBNA cells and cells retaining the episome were selected in the presence of 400 mM hygromycin. Cells surviving 4 weeks of selection in hygromycin were pooled, adapted to growth in suspension and used to generate membranes for the binding assay described below. Individual aliquots containing approximately 1 x 10 8 of the suspended cells were then centrifuged to form a pellet and frozen. For the binding assay a frozen pellet described above containing 293EBNA cells transfected with hCRFRl receptors is homogenized in 10 mL of ice cold tissue buffer (50 mM HEPES buffer pH 7.0, containing 10 mM MgCl 2 , 2 mM EGTA, 1 mg/L aprotinin, 1 mg/mL leupeptin and 1 mg/mL pepstatin) . The homogenate is centrifuged at 40,000 x g for 12 min and the resulting pellet rehomogenized in 10 mL of tissue buffer. After another centrifugation at 40,000 x g for 12 min, the pellet is resuspended to a protein concentration of 360 mg/mL to be used in the assay. Binding assays are performed in 96 well plates; each well having a 300 mL capacity. To each well is added 50 mL of test drug dilutions (final concentration of drugs range from 10 "10 to 10 "5 M) , 100 mL of 125 I-ovine-CRF ( 125 I-o-CRF) (final concentration 150 pM) and 150 mL of the cell homogenate described above. Plates are then allowed to incubate at room temperature for 2 hours before filtering the incubate over GF/F filters (presoaked with 0.3% polyethyleneimine) using an appropriate cell harvester. Filters are rinsed 2 times with ice cold assay buffer before removing individual filters and assessing them for radioactivity on a gamma counter. Curves of the inhibition of 125 I-o-CRF binding to cell membranes at various dilutions of test drug are analyzed by the iterative curve fitting program LIGAND [P.J. Munson and D. Rodbard, Anal . Biochem. 107:220 (1980), which provides K values for inhibition which are then used to assess biological activity. Alternatively, tissues and cells which naturally express CRF receptors can be employed in binding assays analogous to those described above. A compound is considered to be active if it has a K t value of less than about 10000 nM for the inhibition of CRF. Inhibition of CRF-S imulated Adenylate Cyclase Activity Inhibition of CRF-stimulated adenylate cyclase activity can be performed as described by G. Battaglia et al. Synapse 1:572 (1987). Briefly, assays are carried out at 37 °C for 10 min in 200 mL of buffer containing 100 mM Tris-HCl (pH 7.4 at 37 °C) , 10 mM MgCl 2 , 0.4 mM EGTA, 0.1% BSA, 1 mM isobutylmethylxanthine (IBMX) , 250 units/mL phosphocreatine kinase, 5 mM creatine phosphate, 100 mM guanosine 5 '-triphosphate, 100 nM oCRF, antagonist peptides (concentration range 10 "9 to 10 "6 M) and 0.8 mg original wet weight tissue (approximately 40-60 mg protein) . Reactions are initiated by the addition of 1 mM ATP/ 32 P]ATP (approximately 2-4 mCi/tube) and terminated by the addition of 100 mL of 50 mM Tris-HCL, 45 mM ATP and 2% sodium dodecyl sulfate. In order to monitor the recovery of cAMP, 1 mL of [ 3 H]cAMP (approximately 40,000 dpm) is added to each tube prior to separation. The separation of [ 32 P]cAMP from [ 32 P]ATP is performed by sequential elution over Dowex and alumina columns. Tn vi vo Biological Assay The in vivo activity of the compounds of the present invention can be assessed using any one of the biological assays available and accepted within the art. Illustrative of these tests include the Acoustic Startle Assay, the Stair Climbing Test, and the Chronic Administration Assay. These and other models useful for the testing of compounds of the present invention have been outlined in C.W. Berridge and A.J. Dunn Brain Research Reviews 15:71 (1990). Compounds may be tested in any species of rodent or small mammal . Compounds of this invention have utility in the treatment of inbalances associated with abnormal levels of corticotropin releasing factor in patients suffering from depression, affective disorders, and/or anxiety. Compounds of this invention can be administered to treat these abnormalities by means that produce contact of the active agent with the agent ' s site of action in the body of a mammal. The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals either as individual therapeutic agent or in combination of therapeutic agents. They can be administered alone, but will generally be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The dosage administered will vary depending on the use and known factors such as pharmacodynamic character of the particular agent, and its mode and route of administration; the recipient's age, weight, and health; nature and extent of symptoms; kind of concurrent treatment; frequency of treatment; and desired effect. For use in the treatment of said diseases or conditions, the compounds of this invention can be orally administered daily at a dosage of the active ingredient of 0.002 to 200 mg/kg of body weight. Ordinarily, a dose of 0.01 to 10 mg/kg in divided doses one to four times a day, or in sustained release formulation will be effective in obtaining the desired pharmacological effect. Dosage forms (compositions) suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5 to 95% by weight based on the total weight of the composition. The active ingredient can be administered orally is solid dosage forms, such as capsules, tablets and powders; or in liquid forms such as elixirs, syrups, and/or suspensions. The compounds of this invention can also be administered parenterally in sterile liquid dose formulations. Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as but not limited to lactose, starch, magnesium stearate, steric acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract. Liquid dose forms for oral administration can contain coloring or flavoring agents to increase patient acceptance. In general, water, pharmaceutically acceptable oils, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, butter substances. Antioxidizing agents, such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, are suitable stabilizing agents. Also used are citric acid and its salts, and EDTA. In addition, ' parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol . Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences", A. Osol, a standard reference in the field. Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows: Capsules A large number of units capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg lactose, 50 mg cellulose, and 6 mg magnesium stearate. Soft Gelatin Capsules A mixture of active ingredient in a digestible oil such as soybean, cottonseed oil, or olive oil is prepared and injected by means of a positive displacement was pumped into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules were washed and dried. Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg lactose. Appropriate coatings may be applied to increase palatability or delayed adsorption. The compounds of this invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction, and disease. Although the present invention has been described and exemplified in terms of certain preferred embodiments, other embodiments will be apparent to those skilled in the art. The invention is, therefore, not limited to the particular embodiments described and exemplified, but is capable of modification or variation without departing from the spirit of the invention, the full scope of which is delineated by the appended claims.

Claims: WHAT IS CLAIMED IS: 1. A compound of formula (I) (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; provided that at least one of the groups A and B is N; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 - 10 alkenyl, C 2 - 10 alkynyl, C 3 _ 8 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl, C 1 -.4 alkoxy-Cι- 4 alkyl, -SO 2 -C 1 - 10 alkyl, -S0 2 -R l , and -S0 2 -R lb ; R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b , -C0R 13a , -C0 2 R 13 , -NR 15a C0R 13a , -N(C0R 13a ) 2 , -NR 15 C0NR 13a R 16a , -NR 15a C0 2 R 14b , -C0NR 13a R 16a , l-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C 3 - 8 cycloalkyl, wherein 0-1 carbon atoms in the C 4 - 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , Cι-6 alkyl, C 2 -s alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, Cι-4 haloalkyl, -0R 13 , -NR 13 R 16a , C1-4 alkoxy-Cι_ 4 alkyl, and C 3 - 8 cycloalkyl which is substituted with 0- gg 1 1 RR aanndd iinn wwhhiicclh 0-1 carbons of C4-8 cycloalkyl is replaced by -0-; provided that R 1 is other than: (a) a cyclohexyl- (CH ) 2 - group; (b) a 3-eyelopropyl-3-methoxypropyl group; (c) an unsubstituted- (alkoxy) methyl group; and, (d) a 1-hydroxyalkyl group; also provided that when R 1 alkyl substituted with OH, then the carbon adjacent to the ring- N is other than CH 2 ; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-1 -OR 17 and 0-5 substituents independently selected at each occurrence from the group Cχ-6 alkyl, C3-6 cycloalkyl, Br, Cl, F, I, C1-4 haloalkyl, -CN, nitro, SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a C0R 17 , -N(COR 17 ) 2 , -NRl5a CONR 17a R 19a / _ NR 15a o 2 Rl8 , _ NR 17a R 19a / and -CONR 17 R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl , benzoxazolyl , isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl , 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2,3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι-6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13a , SH, -S(0) n R 14b , -COR 13a , -OC(0)R 14b , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13 R 16a , -NR 15a C0 2 R 14b , -NR 13a R 16a , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R ,13a C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any st is optionally monooxidized or dioxidized; provided that R 1 is other than a - (CH 2 )ι_ 4 -aryl, - (CH 2 ) i- 4 -heteroaryl, or - (CH 2 ) 1- 4 -heterocycle, wherein the aryl, heteroaryl, or heterocycle group is substituted or unsubstituted; R 2 is selected from the group C1-. 4 alkyl, C 3 -. 8 cycloalkyl, C 2 _ 4 alkenyl, and C _4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 F 5 ; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, Cι_ 4 alkyl, C 3 - 8 cycloalkyl, C 1 -4 alkoxy, C 1 - 4 alkylthio, C 1 -. 4 alkylsulfinyl, C 1 -. 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl ) amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 -. 4 alkoxy, C 1 - 4 haloalkoxy, C 1 - 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, Ci-β alkylamino and (C 1 - 4 alkyl) 2 amino; provided that when R 1 is unsubstituted Cι- 10 alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 6 cycloalkyl-Cι- 4 alkyl and C 3 _ 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 -. 4 haloalkyl, C 1 - 4 alkoxy-Cι_ 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, aryl, aryKCι-4 alkyl)-, heteroaryl and heteroaryl (C1-4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C1- 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 -6 cycloalkyl- C 1 - 6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, aryl, aryKCι- 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 -. 4 haloalkoxy, and dimethylamino; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C1-4 alkoxy-Cι- 4 alkyl, C 3 -. 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 -. 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 14b is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 -. 6 cycloalkyl-Cι-6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group Cι_ 4 alkyl, Br, Cl, F, I, C 1 -. 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, and C 3 -. 6 cycloalkyl-Cι-6 alkyl; R 17 is selected at each occurrence from the group H, Cι_ 6 alkyl, C3-10 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C 1 - 2 alkoxy-Cι_ 2 alkyl, C 1 - 4 haloalkyl, R 14 S (0) n -Cι_4 alkyl, and R 17b R 19b N-C 2 _ alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, Ci-β alkyl, C 3 - 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι- 2 alkyl, and Cι_ 4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 17 and R 19 taken together form 1-pyrrolidinyl, l-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , CO 2 R 14 , COR 14 and S0 2 R 14 j alternatively, in an NR 17b R 19b moiety, R 17b and R 19b taken together form 1-pyrrolidinyl, l-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 _χo cycloalkyl, C 3 - 6 cycloalkyl-Cι_ 6 alkyl and C 1 - 4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι_ 4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 C0R 17 , -N(C0R 17 ) 2 , -NR 15 C0NR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -C0NR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group Cι_ 3 alkyl, C1- 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , Sθ 2 Me and acetyl; heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl , benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_β alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(C0R 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 14a , COR 14 and S0 2 R 14a ; and, provided that when D is imidazole or triazole, R 1 is other than unsubstituted Cι_ 6 linear or branched alkyl or C 3 - 6 cycloalkyl. 2. A compound according to Claim 1, wherein the compound is of formula la: 3. A compound according to Claim 1, wherein the compound is of formula lb: (lb). A compound according to Claim 1, wherein the compound is of formula Ic: A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of formula (I) : (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; provided that at least one of the groups A and B is N; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl, C 2 _ιo alkenyl, C _ιo alkynyl, C3-8 cycloalkyl, C3-.6 cycloalkyl-Ci-6 alkyl, C1-4 alkoxy-Cι_4 alkyl, -S0 2 -Cι_ιo alkyl, -S0 2 -R la , and -S0 2 -R lb ; 1 R is substituted with 0-1 substituents selected from the group -CN, -S(0) n R 14b / -C0R 13a , -C0 2 R 13a , -NR 15a C0R 13a , -N(C0R 13a ) 2 / -NR 15a C0NR 13 R 16a , -NR 15a C0 2 R 14b , -C0NR 13 R 16a , l-morpholinyl, 1-piperidinyl, 1-piperazinyl, and C3-8 cycloalkyl, wherein 0-1 carbon atoms in the C4-8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -/ -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 1 b -, and wherein N in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , C0R 14b and S0 2 R 14b ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C1-6 alkyl, C 2 -8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C1-4 haloalkyl, -0R 13a , -NR 13a R 16a , C1-4 alkoxy-Cι-4 alkyl, and C3-8 cycloalkyl which is substituted with 0- 1 R and in which 0-1 carbons of C4-8 cycloalkyl is replaced by -0-; provided that R 1 is other than: (a) a 3-cyclopropyl-3-methoxypropyl group; (b) an unsubstituted- (alkoxy) methyl group; and, (c) a 1-hydroxyalkyl group; also provided that when R 1 alkyl substituted with OH, then the carbon adjacent to the ring N is other than CH2; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -0C(0)R 18 , -NR 15a C0R 17 , -N(C0R 17 ) 2 , -NR 15 C0NR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17 R 19a , and -CONR 17a R 19a ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl , benzothienyl , benzothiazolyl , benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl , 2,3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι_ 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C1-6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -0R 13a , SH, -S(0) n R 1 b , -C0R 13a , -OC(0)R 1 b , -NR 15a COR 13a , -N(COR 13a ) 2 , -NR 15a CONR 13a R 16a , -NR 15a C0 2 R 14b , -NR 13a R 16 , and -CONR 13a R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b and wherein any sulfur atom is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 2 _ 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C 2 Fs; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl ) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C 1 - 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, Cχ_ 4 haloalkyl, nitro, C 1 - 4 alkoxy, Cι_ 4 haloalkoxy, Cι_ 4 alkylthio, C 1 - 4 alkyl sulfinyl, C1- 4 alkylsulfonyl, Ci-β alkylamino and (C 1 - 4 alkyl) 2 amino; provided that when R 1 is unsubstituted Cι- 10 alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 -6 cycloalkyl-Cι- 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C1- 4 alkoxy-Cι-4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι_6 alkyl, aryl, aryl (C 1 - 4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, and C 3 - 6 cycloalkyl- C 1 -6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 -4 alkoxy-Cι- 4 alkyl, C3-6 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, aryl, aryKCι-4 alkyl)-, heteroaryl and heteroaryl (C 1 - 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 -4 haloalkoxy, and dimethylamino; R 14a is selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι-4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι- 6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C1- 4 alkyl, Br, Cl, F, I, C 1 -.4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R 14b is selected from the group C 1 - 4 alkyl, C 1 -. 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C3-6 cycloalkyl, and C3-6 cycloalkyl-Cι-6 alkyl; R 15 is independently selected at each occurrence from the group H, C1-4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- C 1 - 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 -.4 alkyl, Br, Cl, F, I, C1- 4 haloalkyl, nitro, C 1 - 4 alkoxy, C1-. 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 -7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 is selected at each occurrence from the group H, Cι_ 6 alkyl, C3-10 cycloalkyl, C3-6 cycloalkyl-Cι- 6 alkyl, C 1 - 2 alkoxy-Cι-2 alkyl, C 1 - 4 haloalkyl, R 14 S (0) n ~Cι- 4 alkyl, and R 17b R 19b N-C 2 - 4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, C 1 -6 alkyl, C 3 .- 10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι- 2 alkyl, and C1-4 haloalkyl; alternatively, in an NR 17R19 moiety, R17 and R19 taken together form 1-pyrrolidinyl, l-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 alternatively, in an NR 17b R 19b moiety, R 17b and R 19b taken together form 1-pyrrolidinyl, l-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; R 17 and R 19a are independently selected at each occurrence from the group H, C 1 - 6 alkyl, C 3 - 10 cycloalkyl, C 3 -. 6 cycloalkyl-Cι- 6 alkyl and C 1 - 4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι-4 alkoxy, -OR 17 , Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -0C(0)R 18 , -NR 15 C0R 17 , -N(COR 17 ) 2 , -NR 15 C0NR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , S0 2 Me and acetyl; and, heteroaryl . is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl , benzoxazolyl , isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl , 2 , 3-dihydrobenzothienyl , 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 14a , COR 14a and S0 2 R 14a . 6. A method of treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post- traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of formula (I) : (I) or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein: A is N or C-R 7 ; B is N or C-R 8 ; provided that at least one of the groups A and B is N; D is an aryl or heteroaryl group attached through an unsaturated carbon atom; X is selected from the group CH-R 9 , N-R 10 , 0, S(0) n and a bond; n is 0, 1 or 2; R 1 is selected from the group Cι_ιo alkyl , C 2 _ιo alkenyl , C 2 -ιo alkynyl , C 3 - 8 cycloalkyl , C 3 _ 6 cycloalkyl-Cι_ 6 alkyl , C 1 - 4 alkoxy-Cι- 4 alkyl , -S0 2 -Cι_ιo alkyl , -S0 2 -R la , and -S0 2 -R lb ; R is substituted with 0-1 substituents selected from the group -CN, -S (0) n R 14b , -C0R 13 , -C0 2 R 13a , -NR 15a C0R 13a , -N (C0R 13a ) 2 / -NR 15 C0NR 13a R 16a , -NR 15a C0 2 R 14b , -C0NR 13a R 16a , l-morpholinyl , 1-piperidinyl , 1-piperazinyl, and C3-8 cycloalkyl, wherein 0-1 carbon atoms in the C4- 8 cycloalkyl is replaced by a group selected from the group -0-, -S(0) n -, -NR 13a -, -NC0 2 R 14b -, -NCOR 14b - and -NS0 2 R 14b -, and wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R is also substituted with 0-3 substituents independently selected at each occurrence from the group R la , R lb , R lc , C1-6 alkyl, C 2 -8 alkenyl, C 2 _ 8 alkynyl, Br, Cl, F, I, C1-4 haloalkyl, -OR 13a , -NR 13a R 16a , C1-4 alkoxy-Cι_ alkyl, and C3-8 cycloalkyl which is substituted with 0- 1 R and in which 0-1 carbons of C4- 8 cycloalkyl is replaced by -0-; provided that R 1 is other than: (a) a 3-cyclopropyl-3-methoxypropyl group; (b) an unsubstituted- (alkoxy) methyl group; and, (c) a 1-hydroxyalkyl group; also provided that when R 1 alkyl substituted with OH, then the carbon adjacent to the ring N is other than CH 2 ; R la is aryl and is selected from the group phenyl, naphthyl, indanyl and indenyl, each R la being substituted with 0-5 substituents independently selected at each occurrence from the group Cι_6 alkyl, C3_6 cycloalkyl, Br, Cl, F, I, C1-4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0) n R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17a R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19 ; R lb is heteroaryl and is selected from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl , 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2 , 3-dihydrobenzothienyl-S-dioxide, indolinyl , benzoxazolin-2-onyl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Cι- 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)π,R 18 , -COR 17 , -OC(0)R 18 , -NR 15a COR 17 , -N(COR 17 ) 2 , -NR 15a CONR 17 R 19a , -NR 15a C0 2 R 18 , -NR 17a R 19a , and -CONR 17a R 19a and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15a , C0 2 R 14b , COR 14b and S0 2 R 14b ; R lc is heterocyclyl and is a saturated or partially saturated heteroaryl, each heterocyclyl being substituted on 0-4 carbon atoms with a substituent independently selected at each occurrence from the group C 1 - 6 alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, -CN, nitro, -OR 13 , SH, -S(0) n R 14b / -C0R 13a , -OC(0)R 14b , -NR 15 COR 13a , -N(C0R 13a ) 2 , -NR 15 CONR 13 R 16 , -NR 15a C0 2 R 14b , -NR 13a R 16 , and -CONR 13 R 16a and each heterocyclyl being substituted on any nitrogen atom with 0-1 substituents selected from the group R a , C0R 14b , COR 14b and S0 2 R 1 b and wherein any sulfur atom is optionally monooxidized or dioxidized; R 2 is selected from the group C 1 -. 4 alkyl, C 3 - 8 cycloalkyl, C 2 _ 4 alkenyl, and C 2 _ 4 alkynyl and is substituted with 0-3 substituents selected from the group -CN, hydroxy, halo and C 1 - 4 alkoxy; alternatively R 2 , in the case where X is a bond, is selected from the group -CN, CF 3 and C Fs; R 3 , R 7 and R 8 are independently selected at each occurrence from the group H, Br, Cl, F, I, -CN, C 1 - 4 alkyl, C 3 - 8 cycloalkyl, C 1 - 4 alkoxy, C 1 - 4 alkylthio, C 1 - 4 alkylsulfinyl, C 1 - 4 alkylsulfonyl, amino, C 1 - 4 alkylamino, (C 1 - 4 alkyl) 2 amino and phenyl, each phenyl is substituted with 0-3 groups selected from the group C1- 7 alkyl, C 3 - 8 cycloalkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, C 1 - 4 alkylthio, C 1 - 4 alkyl sulfinyl, C 1 - 4 alkylsulfonyl, C 1 - 6 alkylamino and (C 1 - 4 alkyl) 2 anri.n0; provided that when R 1 is unsubstituted Cι- 10 alkyl, then R 3 is other than substituted or unsubstituted phenyl; R 9 and R 10 are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 6 cycloalkyl-Cι- 4 alkyl and C 3 - 8 cycloalkyl; R 13 is selected from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, aryl, aryl(Cι-4 alkyl)-, heteroaryl and heteroaryl (Ci- 4 alkyl)-; R 13a and R 16a are independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 1 - 4 haloalkyl, C1- 4 alkoxy-Cι_ 4 alkyl, C 3 - 6 cycloalkyl, and C3-.6 cycloalkyl- C 1 -6 alkyl; R 14 is selected from the group C 1 - 4 alkyl, Cι_4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι_6 alkyl, aryl, aryl (C1-4 alkyl)-, heteroaryl and heteroaryl (C1- 4 alkyl)- and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 -4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy C 1 - 4 haloalkoxy, and dimethylamino; R i4a is selected from the group C1- 4 alkyl, C 1 -. 4 haloalkyl, C 1 - 4 alkoxy-Cι- 4 alkyl, C 3 - 6 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl and benzyl, each benzyl being substituted on the aryl moiety with 0-1 substituents selected from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 - 4 haloalkoxy, and dimethylamino; R i4b i s selected from the group C 1 - 4 alkyl, C 1 - 4 haloalkyl, Cι_ 4 alkoxy-Cι- 4 alkyl, C 3 .- 6 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 15 is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 - 7 cycloalkyl, C 3 - 6 cycloalkyl- Cι_ 6 alkyl, phenyl and benzyl, each phenyl or benzyl being substituted on the aryl moiety with 0-3 groups chosen from the group C 1 - 4 alkyl, Br, Cl, F, I, C 1 - 4 haloalkyl, nitro, C 1 - 4 alkoxy, C 1 -. 4 haloalkoxy, and dimethylamino; R 15a is independently selected at each occurrence from the group H, C 1 - 4 alkyl, C 3 -- 7 cycloalkyl, and C 3 - 6 cycloalkyl-Cι-6 alkyl; R 17 is selected at each occurrence from the group H, Cχ- 6 alkyl, C3-10 cycloalkyl, C3-6 cycloalkyl-Cι-6 alkyl, C 1 - 2 alkoxy-Cι-2 alkyl, C 1 -4 haloalkyl, R 14 S(0) n -Cι-4 alkyl, and R 17b R 19b N-C 2 -4 alkyl; R 18 and R 19 are independently selected at each occurrence from the group H, C1- 6 alkyl, C3-10 cycloalkyl, C 3 - 6 cycloalkyl-Cι-6 alkyl, C1-2 alkoxy-Cι-2 alkyl, and C1-4 haloalkyl; alternatively, in an NR 17 R 19 moiety, R 7 and R 19 taken together form 1-pyrrolidinyl, l-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , C0 2 R 14 , COR 14 and S0 2 R 14 ; alternatively, in an NR 17b R 19b moiety, R 17b and R 19b taken together form 1-pyrrolidinyl, l-morpholinyl, 1-piperidinyl or 1-piperazinyl, wherein N 4 in 1-piperazinyl is substituted with 0-1 substituents selected from the group R 13 , CO 2 R 14 , COR 14 and S0 2 R 14 ; R 17a and R 19a are independently selected at each occurrence from the group H, Cι_ 6 alkyl, C 3 - 10 cycloalkyl, C 3 -- 6 cycloalkyl-Cι- 6 alkyl and C 1 - 4 haloalkyl; aryl is independently selected at each occurrence from the group phenyl, naphthyl, indanyl and indenyl, each aryl being substituted with 0-5 substituents independently selected at each occurrence from the group Cχ- 6 alkyl, C 3 - 6 cycloalkyl, methylenedioxy, C 1 - 4 alkoxy-Cι- 4 alkoxy, -OR 17 , Br, Cl, F, I, Cι_ 4 haloalkyl, -CN, -N0 2 , SH, -S(0) n R 18 , -COR 17 , -C0 2 R 17 , -0C(0)R 18 , -NR 15 C0R 17 , -N(COR 17 ) 2 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and up to 1 phenyl, each phenyl substituent being substituted with 0-4 substituents selected from the group C 1 - 3 alkyl, C 1 - 3 alkoxy, Br, Cl, F, I, -CN, dimethylamino, CF 3 , C 2 F 5 , OCF 3 , S0 2 Me and acetyl; and, heteroaryl is independently selected at each occurence from the group pyridyl, pyrimidinyl, triazinyl, furanyl, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl , benzothiazolyl , benzoxazolyl, isoxazolyl, triazolyl, tetrazolyl, indazolyl, 2 , 3-dihydrobenzofuranyl, 2 , 3-dihydrobenzothienyl, 2 , 3-dihydrobenzothienyl-S-oxide, 2, 3-dihydrobenzothienyl-S-dioxide, indolinyl, benzoxazolin-2-on-yl, benzodioxolanyl and benzodioxane, each heteroaryl being substituted 0-4 carbon atoms with a substituent independently selected at each occurrence from the group Ci-β alkyl, C 3 - 6 cycloalkyl, Br, Cl, F, I, Cχ_ 4 haloalkyl, -CN, nitro, -OR 17 , SH, -S(0)mR 18 , -COR 17 , -C0 2 R 17 , -OC(0)R 18 , -NR 15 COR 17 , -N(COR 17 ) 2 , -NR 15 CONR 17 R 19 , -NR 15 C0 2 R 18 , -NR 17 R 19 , and -CONR 17 R 19 and each heteroaryl being substituted on any nitrogen atom with 0-1 substituents selected from the group R 15 , C0 2 R 14a , COR 14 and S0 2 R 14a .

Inventors: ARVANITIS ARGYRIOS G, BAKTHAVATCHALAM RAJAGOPAL, BECK JAMES P, WILDE RICHARD G, ARVANITIS, ARGYRIOS, G., BAKTHAVATCHALAM, RAJAGOPAL, BECK, JAMES, P., WILDE, RICHARD, G.
Applicants: DU PONT PHARM CO, DU PONT PHARMACEUTICALS COMPANY
Application year: 1998
Main classification: C07D471
IPC codes: A61K31, A61P1, A61P9, A61P25, A61P43, C07D471, C07D473, C07D487